data_5yzk_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5yzk _Structure_validation_residue.Date_analyzed 2018-12-14 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 5.3 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.932 0.396 . . . . 73.4 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 41.3 p -123.55 168.08 13.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 74.42 111.14 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 45.8 t80 -145.23 136.38 24.89 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 73.44 110.968 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.6 m -91.73 123.09 34.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.108 -0.496 . . . . 75.43 111.116 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 60.6 mt -90.89 109.49 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.453 . . . . 74.31 111.152 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -111.24 163.51 17.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.617 0.722 . . . . 74.45 110.93 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_exo -46.16 124.58 7.71 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.718 2.278 . . . . 75.44 112.333 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 106.54 -17.96 38.86 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.777 -0.725 . . . . 70.22 112.483 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -97.31 147.03 24.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.908 0.385 . . . . 75.41 110.833 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.96 174.36 10.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 74.53 111.121 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.51 -70.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 75.24 110.905 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.92 -50.07 61.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.16 -0.473 . . . . 74.33 110.924 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.03 -66.29 0.41 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.264 -0.425 . . . . 71.34 111.11 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 43.9 mt -51.37 -32.68 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 75.43 111.077 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -66.73 -38.46 86.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 65.44 111.147 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -52.32 -69.42 0.11 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 74.04 110.882 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 9.6 ptm180 -56.28 -44.48 79.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 75.31 110.855 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -56.35 -25.03 47.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 74.34 110.841 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.82 16.55 56.21 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.736 -0.745 . . . . 72.42 112.463 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 7.7 t -119.84 -176.1 3.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.897 0.38 . . . . 73.42 111.103 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.27 165.97 17.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 75.05 111.14 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 61.3 t -55.78 -41.12 64.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 73.11 111.175 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -51.79 -36.03 46.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 73.41 110.856 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.21 -51.5 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 73.24 111.103 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 49.7 mm -51.25 -42.45 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 74.12 111.166 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -78.18 -25.4 47.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 75.25 110.909 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.7 t -78.05 -21.07 51.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 74.41 110.864 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 43.3 mt -97.05 -46.16 6.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.151 -0.477 . . . . 74.12 110.921 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -117.96 68.15 6.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.596 0.712 . . . . 73.33 110.878 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -8.51 23.78 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.657 2.238 . . . . 75.03 112.314 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -67.23 -17.59 68.34 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.733 -0.746 . . . . 74.01 112.523 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.2 t -131.14 119.67 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.909 0.385 . . . . 73.51 111.098 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -88.77 154.86 50.51 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.599 0.714 . . . . 74.5 110.902 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -19.63 35.73 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.725 2.283 . . . . 74.44 112.327 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.79 -15.98 60.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 63.34 111.112 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -170.56 115.33 0.47 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 75.33 110.852 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 47.0 mt -117.34 150.79 38.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.47 . . . . 73.03 110.933 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.0 mm100 -97.77 149.5 22.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 74.0 110.911 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.3 p -68.35 146.61 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 74.43 111.137 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.8 63.73 4.51 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 63.35 112.514 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 13.5 tt0 -119.14 121.62 40.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 71.44 110.907 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.54 124.53 40.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 74.03 111.121 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.6 pt -127.83 175.93 8.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 74.52 111.148 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -96.05 144.07 26.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 74.1 110.9 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -141.26 156.15 67.68 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.726 . . . . 73.45 111.085 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 105.52 1.5 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.675 2.25 . . . . 74.52 112.346 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.2 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 75.0 110.873 -179.972 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.1 m . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.892 0.377 . . . . 65.42 110.876 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.5 p -126.43 161.52 27.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.148 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 45.2 t80 -142.85 136.63 28.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 74.44 110.918 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 m -93.44 124.03 37.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 63.5 111.124 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.8 mt -91.05 109.58 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 65.11 111.116 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -111.58 163.52 17.3 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.579 0.704 . . . . 72.0 110.926 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_exo -46.16 120.95 4.01 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.712 2.274 . . . . 73.11 112.336 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.6 -18.86 26.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.759 . . . . 70.15 112.478 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -99.04 140.94 32.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.896 0.379 . . . . 63.44 110.852 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.77 163.8 24.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 73.22 111.134 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.99 -64.57 0.79 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 74.11 110.865 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -56.2 -50.67 70.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 74.11 110.919 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.65 -65.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 65.41 111.049 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 36.3 mt -51.73 -37.0 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 70.15 111.118 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.13 -36.1 82.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 73.44 111.085 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.9 mt-30 -51.82 -63.75 1.03 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 75.45 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 47.9 mtm180 -67.1 -39.38 86.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.41 110.89 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 8.5 mmp_? -56.41 -25.14 49.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 72.44 110.904 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 92.23 17.15 47.82 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 75.51 112.517 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 13.4 t -125.21 177.3 6.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.87 0.367 . . . . 73.5 111.13 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.1 m -125.43 164.68 19.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 72.44 111.104 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.9 t -54.68 -40.88 53.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.198 -0.455 . . . . 70.12 111.094 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -51.67 -38.51 55.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.196 -0.456 . . . . 75.44 110.877 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.9 t -78.94 -52.33 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 75.4 111.142 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 47.7 mm -52.2 -41.1 32.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 75.32 111.179 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -75.66 -25.51 56.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 65.24 110.905 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.3 t -79.41 -23.47 43.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 65.53 110.863 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.7 mt -98.92 -44.65 6.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 75.44 110.897 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -117.67 68.29 5.91 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.625 0.726 . . . . 73.33 110.874 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -7.3 20.72 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.625 2.216 . . . . 74.53 112.366 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.34 -43.75 43.84 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.747 -0.739 . . . . 43.53 112.518 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.4 m -116.46 127.24 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.802 0.334 . . . . 54.41 111.151 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -55.92 160.87 3.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.619 0.723 . . . . 63.21 110.917 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.73 24.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.266 . . . . 75.33 112.348 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -133.07 24.39 4.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.34 111.102 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 67.9 mtp85 -149.73 89.48 1.62 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 74.43 110.86 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 9.9 mt -125.16 176.23 6.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 74.53 110.943 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 24.3 mm100 -136.38 150.4 48.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.889 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.1 p -54.37 146.45 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 62.2 111.188 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.02 65.01 3.5 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.73 -0.747 . . . . 60.43 112.509 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 13.6 tt0 -119.12 122.01 41.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.816 0.341 . . . . 75.53 110.941 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.4 p -87.43 135.04 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 75.22 111.141 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.0 pt -140.74 175.82 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 75.43 111.163 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 10.0 m-20 -103.19 143.06 33.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 74.22 110.894 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.2 156.14 66.99 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 74.4 111.151 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 110.54 2.59 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.657 2.238 . . . . 73.41 112.351 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 70.3 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 62.13 110.894 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 81.8 m . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.943 0.401 . . . . 75.02 110.843 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.6 p -125.55 163.47 22.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 72.23 111.201 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -142.85 136.56 28.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.256 -0.429 . . . . 74.33 110.933 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -93.61 123.66 37.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.123 -0.489 . . . . 74.43 111.15 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 74.8 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 75.41 111.127 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.1 mm-40 -109.28 163.15 17.69 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.56 0.695 . . . . 73.15 110.896 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -46.17 124.8 7.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 64.31 112.321 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.75 -18.88 39.85 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.724 -0.751 . . . . 63.2 112.464 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -96.83 141.39 30.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.886 0.374 . . . . 74.43 110.875 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -129.73 170.26 14.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 73.25 111.164 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.39 -69.53 0.12 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 74.34 110.886 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.1 t-105 -52.3 -49.93 63.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 73.24 110.939 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.31 -65.7 0.51 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.238 -0.437 . . . . 71.4 111.076 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 46.8 mt -51.77 -37.09 19.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.264 -0.426 . . . . 75.33 111.14 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -63.64 -35.87 81.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 72.54 111.123 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -51.78 -68.18 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 72.01 110.909 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 46.6 mtt180 -61.71 -41.99 98.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 74.21 110.837 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.1 mmm180 -54.68 -27.1 37.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 64.12 110.893 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.4 18.09 50.41 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 60.3 112.451 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 12.4 t -119.36 178.39 4.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.866 0.365 . . . . 73.02 111.142 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -120.97 160.68 23.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 73.41 111.177 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.0 t -54.37 -47.17 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 55.42 111.172 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -52.24 -29.71 24.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 72.34 110.844 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.7 t -81.32 -54.19 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 73.43 111.104 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 50.0 mm -52.59 -39.65 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 71.23 111.12 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -25.35 47.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 73.55 110.926 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 t -80.64 -21.01 41.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.187 -0.46 . . . . 75.24 110.847 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 6.6 mt -102.59 -42.13 6.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.104 -0.498 . . . . 74.21 110.928 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -117.64 68.34 5.87 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.644 0.735 . . . . 75.3 110.894 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -7.29 20.69 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.681 2.254 . . . . 74.52 112.357 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.29 -43.5 43.17 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.749 -0.739 . . . . 75.05 112.477 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.2 m -116.43 128.04 73.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.883 0.373 . . . . 74.35 111.167 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -58.45 161.49 7.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 73.33 110.885 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -8.48 23.72 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.699 2.266 . . . . 71.34 112.324 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.13 18.87 4.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.091 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -142.67 87.28 1.99 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 74.42 110.866 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 7.9 mt -124.23 167.94 13.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.478 . . . . 72.53 110.885 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -135.42 153.31 51.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 74.54 110.875 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.9 p -52.81 147.76 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 71.2 111.12 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.69 66.72 2.38 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.688 -0.767 . . . . 75.25 112.474 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 7.0 tt0 -114.31 120.9 41.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.867 0.365 . . . . 71.14 110.889 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.99 124.98 42.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 74.24 111.163 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.4 pt -135.06 175.92 9.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 73.43 111.17 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -104.59 148.94 25.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 53.51 110.874 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -133.29 156.12 80.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.565 0.698 . . . . 74.3 111.163 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 110.16 2.49 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.693 2.262 . . . . 62.43 112.278 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 88.6 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 74.53 110.9 179.932 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 6.8 m . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.906 0.384 . . . . 74.23 110.891 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.6 p -123.6 160.75 26.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 75.23 111.119 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -143.42 136.56 27.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 74.34 110.93 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.7 m -94.91 123.27 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 60.04 111.172 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 57.0 mt -90.99 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.235 -0.438 . . . . 73.12 111.13 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -116.21 163.36 21.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.568 0.699 . . . . 72.41 110.95 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -46.52 107.79 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 73.44 112.337 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 126.63 -18.51 6.35 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.714 -0.755 . . . . 71.45 112.484 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -103.49 136.97 42.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 75.42 110.843 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.25 163.86 20.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 74.11 111.194 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -54.75 -67.54 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 72.31 110.911 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -52.23 -51.74 56.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 74.42 110.916 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.32 -65.6 0.53 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.264 -0.426 . . . . 74.41 111.143 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 26.3 mt -51.42 -31.68 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 72.23 111.148 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -67.47 -39.82 85.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 75.45 111.087 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -52.39 -58.77 5.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 74.55 110.936 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 3.1 mmt85 -69.31 -16.85 63.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 75.24 110.891 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 18.3 mmt180 -90.83 12.76 18.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 65.15 110.904 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.94 28.08 23.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.74 -0.743 . . . . 74.23 112.51 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 12.4 t -129.55 177.94 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.879 0.371 . . . . 74.1 111.123 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.98 163.01 26.28 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.197 -0.456 . . . . 72.33 111.15 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 62.0 t -51.85 -39.53 25.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 74.23 111.141 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -51.55 -39.35 57.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.484 . . . . 74.51 110.864 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -80.25 -50.34 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.15 -0.477 . . . . 75.2 111.111 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 47.5 mm -51.43 -41.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 74.23 111.079 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -77.65 -25.6 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 74.4 110.933 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 19.9 t -76.14 -24.5 54.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.182 -0.463 . . . . 72.04 110.843 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 20.8 mt -98.59 -44.53 6.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 71.41 110.906 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.93 67.97 6.33 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.589 0.709 . . . . 73.01 110.911 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -7.63 21.54 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.686 2.257 . . . . 74.04 112.316 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.47 -45.42 46.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.78 -0.724 . . . . 63.14 112.47 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.3 m -117.24 124.93 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 73.52 111.127 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -67.97 160.87 71.83 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.607 0.717 . . . . 65.35 110.887 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -8.46 23.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.624 2.216 . . . . 75.02 112.352 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -115.51 24.9 11.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 53.35 111.11 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.2 ptp180 -173.34 108.16 0.16 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 74.53 110.858 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 10.3 mt -136.99 146.91 45.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.174 -0.467 . . . . 71.14 110.92 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -97.75 153.0 18.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 75.0 110.89 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 12.4 p -68.12 148.07 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 74.1 111.178 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.84 61.7 6.24 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.783 -0.722 . . . . 50.34 112.481 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -119.24 121.96 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.838 0.352 . . . . 73.41 110.902 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.87 124.95 40.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 65.3 111.117 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.5 pt -123.58 175.74 5.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.185 -0.461 . . . . 73.51 111.132 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -99.16 137.26 37.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 65.34 110.85 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -117.93 156.22 50.29 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.598 0.713 . . . . 72.5 111.124 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 83.91 0.67 Allowed 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.647 2.231 . . . . 72.11 112.355 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.264 -0.426 . . . . 62.01 110.868 -179.998 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 9.2 m . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.903 0.382 . . . . 73.12 110.894 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.3 p -123.61 154.38 39.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 62.34 111.13 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 47.0 t80 -132.26 136.6 47.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.236 -0.438 . . . . 74.13 110.889 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -91.43 125.24 36.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.065 -0.516 . . . . 74.11 111.127 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 52.2 mt -93.22 110.51 23.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 74.23 111.146 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm-40 -89.45 158.87 45.3 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.55 0.69 . . . . 71.3 110.898 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -59.67 92.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.645 2.23 . . . . 63.34 112.37 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.44 -18.28 2.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.754 -0.736 . . . . 72.4 112.493 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -78.81 155.86 29.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 74.03 110.841 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -131.66 165.15 24.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 74.45 111.166 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -51.32 -51.08 57.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 74.2 110.877 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -67.85 -48.94 64.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.138 -0.483 . . . . 72.34 110.91 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.98 -29.95 58.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 71.23 111.084 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 31.2 mt -87.44 -33.43 6.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.238 -0.437 . . . . 71.23 111.142 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -65.01 -43.66 91.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 75.21 111.11 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -56.31 -44.59 80.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.21 110.841 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -65.76 -60.22 3.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 74.22 110.884 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -51.97 -30.86 26.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.456 . . . . 74.54 110.894 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 103.36 16.72 19.75 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 74.43 112.46 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 7.2 t -120.74 -174.83 2.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 71.14 111.149 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -116.23 165.22 13.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 75.43 111.12 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.8 t -55.51 -43.42 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 73.55 111.137 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -51.74 -33.39 34.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.855 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.89 -48.67 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 70.12 111.114 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 43.2 mm -51.31 -42.75 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 73.04 111.161 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -78.06 -25.41 47.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 65.4 110.928 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.1 t -76.83 -23.17 52.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 52.41 110.878 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 37.2 mt -100.59 -43.18 6.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 74.23 110.894 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -120.22 67.99 13.19 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 73.35 110.854 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.77 -8.24 23.1 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.737 2.291 . . . . 74.2 112.313 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.78 -44.79 55.36 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.685 -0.769 . . . . 71.12 112.517 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.6 m -114.56 161.76 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 74.43 111.129 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -102.73 161.39 23.36 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.659 0.742 . . . . 62.02 110.851 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -8.39 23.47 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.679 2.253 . . . . 75.55 112.395 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.49 20.79 4.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 65.31 111.072 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 60.0 mtt85 -151.63 49.68 0.81 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 75.2 110.846 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 27.9 mt -85.52 166.52 16.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 70.42 110.9 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 -115.51 153.4 31.23 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.141 -0.481 . . . . 73.52 110.896 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 12.2 p -63.9 133.94 29.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.09 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.88 63.28 4.89 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.695 -0.764 . . . . 63.3 112.511 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -114.74 123.5 49.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 75.42 110.942 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.37 126.81 40.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 71.53 111.133 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.1 pt -127.23 175.91 8.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.149 -0.478 . . . . 75.44 111.151 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -94.97 153.9 17.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 74.14 110.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.5 m -141.23 156.03 67.81 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.643 0.735 . . . . 71.24 111.155 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 87.84 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.675 2.25 . . . . 73.23 112.352 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 71.52 110.854 179.997 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.939 0.4 . . . . 73.23 110.842 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 46.4 p -124.24 157.33 35.1 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.146 -0.479 . . . . 65.0 111.167 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -130.36 136.72 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.214 -0.448 . . . . 74.55 110.893 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -91.12 122.42 33.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 64.31 111.129 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 35.2 mt -90.8 109.59 21.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 74.43 111.135 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 16.4 mt-30 -87.75 157.28 52.27 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.606 0.717 . . . . 73.32 110.884 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -58.16 94.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.675 2.25 . . . . 72.31 112.34 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.38 -20.38 2.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.694 -0.765 . . . . 75.53 112.456 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -87.43 137.51 32.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.867 0.365 . . . . 64.42 110.913 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.48 171.48 7.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 74.11 111.186 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -53.92 -64.36 0.85 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 75.24 110.927 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -53.08 -51.95 60.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 74.21 110.929 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.66 -63.77 1.03 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 62.03 111.091 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 46.7 mt -51.69 -34.13 15.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 75.3 111.133 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -68.16 -35.72 78.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 75.01 111.114 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.4 mt-30 -51.66 -73.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 72.24 110.904 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 36.4 mmm-85 -54.62 -45.27 73.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 75.55 110.903 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -54.54 -27.2 36.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 74.42 110.907 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 91.54 16.09 53.41 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.775 -0.726 . . . . 74.52 112.469 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 9.6 t -122.26 -177.71 3.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.843 0.354 . . . . 75.4 111.113 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -121.12 164.27 17.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 71.14 111.145 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.6 t -55.71 -43.06 72.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 75.34 111.066 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -51.8 -33.51 35.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 70.41 110.852 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.0 t -81.86 -52.04 14.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 72.41 111.138 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 47.6 mm -51.64 -42.21 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 71.13 111.151 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -77.89 -25.4 48.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.874 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.6 t -77.08 -23.86 51.91 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 73.31 110.88 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.7 mt -99.45 -44.7 6.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 75.13 110.945 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.69 67.61 7.74 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.63 0.728 . . . . 63.4 110.897 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -8.22 23.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.659 2.239 . . . . 63.2 112.395 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.6 -44.09 53.74 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 73.33 112.472 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.5 m -115.21 156.71 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.881 0.372 . . . . 74.14 111.098 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -97.94 161.8 24.38 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.635 0.731 . . . . 75.34 110.849 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -7.82 22.05 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 73.33 112.36 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.42 18.89 4.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 74.51 111.063 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -143.32 40.82 1.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.215 -0.448 . . . . 73.32 110.897 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 59.9 mt -85.59 149.77 25.11 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.214 -0.448 . . . . 74.42 110.893 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . 0.459 ' H ' ' NE2' ' A' ' 125' ' ' GLN . 80.7 mm-40 -104.66 153.53 21.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 63.31 110.905 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.9 p -56.45 134.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.467 . . . . 54.44 111.122 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.25 63.21 5.04 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 72.2 112.509 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . 0.459 ' NE2' ' H ' ' A' ' 122' ' ' GLN . 5.6 tt0 -109.55 123.01 48.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 73.32 110.884 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 8.4 p -85.66 136.87 21.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 75.02 111.112 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 10.3 pt -142.56 175.94 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.123 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -97.67 153.44 18.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 60.42 110.905 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -146.24 156.16 50.27 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.594 0.712 . . . . 70.15 111.149 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 91.0 0.52 Allowed 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.684 2.256 . . . . 75.23 112.33 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 65.34 110.926 179.991 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.915 0.388 . . . . 72.11 110.909 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 72.7 p -124.96 150.48 46.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 71.45 111.15 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.1 t80 -123.86 135.97 54.07 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.54 110.936 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -89.66 123.38 33.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 54.54 111.177 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.4 mt -90.93 109.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 73.25 111.179 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -91.99 158.82 39.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.566 0.698 . . . . 75.54 110.936 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -59.41 92.88 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.687 2.258 . . . . 74.33 112.374 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.82 -19.04 2.56 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.751 . . . . 75.33 112.528 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -80.97 154.17 27.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.906 0.384 . . . . 74.33 110.841 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 152.46 45.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 75.05 111.152 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -53.4 -55.6 23.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.34 110.861 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -57.95 -55.76 30.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 74.35 110.871 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.26 -61.04 2.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.259 -0.428 . . . . 71.23 111.106 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 41.0 mt -51.37 -38.24 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 72.4 111.134 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.68 -38.32 90.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 71.35 111.151 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -51.93 -72.77 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 63.14 110.898 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -53.97 -41.67 68.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 74.52 110.879 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 6.9 mmp_? -57.05 -24.17 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 73.44 110.876 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.46 15.34 60.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.771 -0.728 . . . . 74.12 112.484 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 8.0 t -115.24 -175.48 2.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.931 0.396 . . . . 73.14 111.109 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -124.45 154.94 39.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 73.04 111.169 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 74.1 t -54.14 -42.94 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 75.13 111.152 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -51.72 -39.54 58.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.139 -0.482 . . . . 74.12 110.875 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.1 t -75.14 -54.18 14.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 75.34 111.145 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 43.4 mm -51.58 -42.08 29.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 74.44 111.144 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -76.78 -25.54 53.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 75.31 110.885 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.8 t -76.18 -25.22 54.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.6 mt -96.89 -45.47 6.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 75.31 110.939 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.03 67.85 6.48 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.73 . . . . 75.23 110.939 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.49 21.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.696 2.264 . . . . 72.11 112.356 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.45 -44.46 45.62 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 72.02 112.483 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.4 m -117.2 130.93 71.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.86 0.362 . . . . 73.44 111.077 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 16.5 m-20 -76.78 160.9 75.73 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.626 0.727 . . . . 75.45 110.883 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -8.6 24.01 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.635 2.223 . . . . 74.12 112.35 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -113.65 24.93 11.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 72.43 111.112 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.7 ptm180 -178.36 104.17 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 75.22 110.88 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 63.8 mt -122.31 167.48 13.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.446 . . . . 75.21 110.882 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -109.57 153.38 24.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 71.02 110.898 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.3 p -70.44 136.19 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 74.44 111.094 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.0 63.82 4.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.733 -0.746 . . . . 65.31 112.515 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 12.1 tt0 -117.66 122.74 44.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.873 0.368 . . . . 73.34 110.892 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -88.18 125.34 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.464 . . . . 75.42 111.157 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.1 pt -125.84 175.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 71.43 111.142 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -97.76 137.43 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 71.01 110.859 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -138.95 156.19 72.65 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.609 0.718 . . . . 74.54 111.142 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 109.55 2.34 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.721 2.281 . . . . 73.34 112.345 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 75.45 110.9 -179.982 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 97.8 m . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.925 0.393 . . . . 74.53 110.853 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.4 p -123.51 168.52 12.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.133 -0.485 . . . . 74.14 111.158 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -136.82 136.59 38.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 72.24 110.891 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.1 m -89.18 122.76 32.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 73.2 111.171 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -91.07 109.5 21.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 75.23 111.149 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.56 163.7 16.38 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 74.22 110.928 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -46.1 111.11 0.31 Allowed 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.708 2.272 . . . . 71.51 112.341 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 113.21 -1.64 25.35 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 74.52 112.52 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -113.17 113.82 25.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 74.44 110.87 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -101.37 157.84 16.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 75.51 111.104 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -51.5 -43.04 62.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 74.15 110.911 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.15 -47.66 27.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.111 -0.495 . . . . 74.43 110.906 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.54 -26.86 62.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 74.24 111.064 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 28.2 mt -88.31 -45.1 15.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 74.44 111.133 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -55.27 -46.15 76.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.46 . . . . 74.13 111.123 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -52.0 -44.97 64.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 72.42 110.89 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 74.8 mtt-85 -71.88 -52.7 16.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.881 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.8 mmm180 -54.12 -27.6 34.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 75.4 110.886 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.85 17.57 18.36 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.768 -0.73 . . . . 71.14 112.523 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 12.0 t -124.1 179.02 5.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.848 0.356 . . . . 73.21 111.162 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.41 164.47 17.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.198 -0.455 . . . . 73.12 111.163 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 46.8 t -55.23 -41.02 58.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.262 -0.426 . . . . 73.01 111.123 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -51.67 -38.89 56.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 75.23 110.886 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.3 t -78.38 -51.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 75.14 111.143 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 47.6 mm -51.54 -43.97 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 74.41 111.148 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -73.55 -25.54 60.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 72.42 110.931 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.5 t -78.91 -23.07 44.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 74.15 110.885 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.5 mt -98.27 -44.53 6.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 74.34 110.921 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.83 67.89 6.09 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.603 0.716 . . . . 74.2 110.909 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -7.25 20.58 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.701 2.267 . . . . 72.45 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.06 -42.03 38.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 72.32 112.435 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.37 125.13 74.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.858 0.361 . . . . 74.45 111.132 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -57.58 161.14 6.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.619 0.724 . . . . 71.54 110.835 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 -8.59 23.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.653 2.235 . . . . 55.43 112.322 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -126.59 14.9 7.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 73.33 111.1 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 63.0 mtt180 -141.55 93.76 2.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 74.42 110.881 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 10.0 mt -132.73 163.84 28.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 74.13 110.902 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -125.04 150.68 46.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 74.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.5 p -52.81 146.86 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.441 . . . . 74.43 111.112 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.61 65.91 2.88 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 71.3 112.536 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.2 tt0 -119.15 121.61 40.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 75.51 110.921 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 15.0 p -89.03 136.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 74.2 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 2.4 pt -138.68 174.23 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 75.13 111.166 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -100.25 139.39 35.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 75.45 110.931 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -141.19 156.12 67.9 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.645 0.736 . . . . 73.33 111.131 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 110.59 2.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.677 2.251 . . . . 74.23 112.334 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 74.11 110.921 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 19.4 m . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.878 0.37 . . . . 75.35 110.907 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.0 p -123.59 166.72 14.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.151 -0.477 . . . . 74.05 111.164 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.4 t80 -142.97 136.59 28.65 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.25 -0.432 . . . . 73.05 110.982 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -89.79 121.91 32.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 73.15 111.143 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.8 mt -90.94 109.61 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 72.23 111.156 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -86.86 158.62 53.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 75.55 110.935 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -58.54 93.61 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.639 2.226 . . . . 71.22 112.345 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.8 -18.87 2.38 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 75.43 112.482 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -84.67 138.23 32.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.361 . . . . 65.32 110.867 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.05 155.21 26.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 62.42 111.156 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -53.13 -47.52 68.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 74.42 110.878 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -71.56 -47.32 55.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 75.45 110.933 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.82 -30.44 63.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.229 -0.441 . . . . 64.15 111.144 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 38.5 mt -88.29 -33.64 6.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 74.41 111.098 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -65.0 -41.86 95.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 64.22 111.116 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -58.68 -44.64 90.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 74.13 110.904 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -78.67 -18.42 54.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 73.44 110.873 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -92.83 16.33 12.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 64.45 110.857 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.56 28.35 21.37 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.798 -0.715 . . . . 72.32 112.469 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 9.9 t -129.8 -177.24 4.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.863 0.363 . . . . 75.13 111.131 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.85 157.86 34.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 72.44 111.145 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 60.3 t -55.58 -42.26 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 74.42 111.106 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -51.82 -37.26 51.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 75.2 110.836 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.0 t -78.18 -52.99 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.11 111.138 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 49.2 mm -51.33 -43.23 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.138 -0.483 . . . . 73.35 111.125 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -76.62 -25.54 53.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 72.14 110.904 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -75.28 -25.46 57.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.201 -0.454 . . . . 65.2 110.844 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.9 mt -94.93 -46.46 6.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 72.2 110.948 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -118.5 67.33 7.2 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.628 0.727 . . . . 73.55 110.897 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.674 2.25 . . . . 65.23 112.32 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.36 -42.05 49.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 65.34 112.523 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.2 m -119.43 139.91 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.864 0.364 . . . . 74.04 111.108 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.1 161.25 66.25 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.596 0.712 . . . . 74.45 110.924 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -8.32 23.3 Favored 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.697 2.265 . . . . 74.25 112.4 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.76 20.58 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 74.13 111.106 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -144.07 43.62 1.44 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 75.55 110.863 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 71.9 mt -85.61 173.82 9.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 73.42 110.9 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -129.52 150.38 50.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 75.54 110.857 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 14.0 p -52.0 133.63 13.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 74.21 111.137 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 53.03 63.35 5.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.783 -0.722 . . . . 73.2 112.471 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -110.62 122.73 48.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 70.41 110.922 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 30.7 t -84.45 140.75 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 71.42 111.142 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.1 pt -143.73 175.24 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 53.42 111.121 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -99.78 130.82 46.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 74.01 110.92 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -123.32 156.22 63.96 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.716 . . . . 75.5 111.132 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 91.61 0.52 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.689 2.259 . . . . 70.42 112.372 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 73.14 110.877 -179.974 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.3 m . . . . . 0 N--CA 1.457 -0.104 0 CA-C-O 120.932 0.396 . . . . 64.23 110.865 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.8 p -123.58 163.92 20.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 72.43 111.134 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 46.7 t80 -145.12 136.68 25.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 73.34 110.938 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.75 125.23 37.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 70.12 111.13 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 79.2 mt -90.93 109.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 74.42 111.112 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -109.17 163.27 17.39 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.548 0.689 . . . . 75.44 110.933 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -46.31 121.9 5.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.638 2.225 . . . . 74.3 112.34 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.27 -4.2 54.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.778 -0.725 . . . . 73.23 112.464 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.13 116.7 32.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.937 0.399 . . . . 73.34 110.884 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.96 -179.5 3.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 73.01 111.135 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -54.64 -70.02 0.11 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 73.02 110.909 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.88 -50.52 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 75.12 110.889 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.13 -65.89 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 75.24 111.138 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 47.0 mt -51.22 -35.78 16.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 75.42 111.131 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.5 -37.34 87.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 71.12 111.06 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 19.1 mt-30 -51.92 -70.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 70.34 110.93 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.5 ptm180 -57.01 -43.04 81.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 74.44 110.847 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.6 -24.81 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 75.45 110.858 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.07 17.13 56.68 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 63.23 112.463 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 7.3 t -121.71 -174.65 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.838 0.351 . . . . 72.32 111.174 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -125.46 165.34 18.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 75.12 111.174 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 41.4 t -55.8 -44.69 78.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.264 -0.426 . . . . 71.4 111.067 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -51.92 -30.11 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 72.32 110.849 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.88 -52.19 13.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 73.43 111.139 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 48.7 mm -51.29 -43.08 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 75.14 111.11 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -76.2 -25.42 55.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 73.23 110.924 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.9 m -80.02 -20.31 45.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.854 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.9 mt -94.94 -47.86 6.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.121 -0.49 . . . . 73.32 110.906 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -118.51 67.28 7.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.634 0.73 . . . . 74.42 110.897 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -8.48 23.71 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.737 2.291 . . . . 75.42 112.39 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -69.76 -17.6 73.31 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.75 -0.738 . . . . 73.42 112.478 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.1 t -125.89 112.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.845 0.355 . . . . 75.44 111.133 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.19 160.29 1.72 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.591 0.71 . . . . 73.03 110.912 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -45.63 1.53 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.691 2.261 . . . . 71.21 112.368 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.24 -29.84 24.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 74.34 111.13 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -83.41 68.5 9.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 74.44 110.895 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 53.7 mt -121.3 137.89 54.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 61.13 110.941 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -110.34 153.57 24.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 70.33 110.913 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -51.56 147.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 71.14 111.107 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.73 66.9 2.28 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 74.51 112.505 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 3.8 tt0 -116.47 122.4 44.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 75.12 110.941 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.8 t -86.26 130.56 36.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 75.33 111.102 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 12.1 pt -141.12 175.79 5.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 71.41 111.139 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -99.18 152.18 20.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 65.35 110.872 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.61 156.18 80.12 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.603 0.716 . . . . 73.24 111.132 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 110.33 2.53 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.664 2.242 . . . . 74.12 112.36 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 75.03 110.912 179.982 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.7 m . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.953 0.406 . . . . 73.21 110.838 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.4 p -123.59 157.58 33.39 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.132 -0.485 . . . . 53.5 111.109 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -141.89 136.69 30.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.962 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -93.45 126.88 38.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 75.42 111.14 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 63.5 mt -91.0 109.52 21.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 73.45 111.089 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -92.02 159.25 38.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.537 0.684 . . . . 75.21 110.914 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -57.95 94.47 0.07 OUTLIER 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.686 2.257 . . . . 74.45 112.306 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.79 -18.1 2.59 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.781 -0.723 . . . . 74.02 112.513 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -91.22 157.09 17.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.909 0.385 . . . . 75.31 110.837 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -141.4 178.28 7.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 73.44 111.125 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -54.49 -66.43 0.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 73.1 110.858 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -54.79 -52.15 63.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.157 -0.474 . . . . 75.41 110.909 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -50.57 -66.09 0.45 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 74.42 111.089 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 54.8 mt -51.15 -33.96 13.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 75.24 111.116 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.94 -39.53 93.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 73.14 111.086 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 21.0 mt-30 -52.12 -69.39 0.11 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 74.22 110.874 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -55.3 -50.34 69.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 74.43 110.92 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 6.3 mmp_? -51.96 -29.97 22.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 72.12 110.866 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 94.56 12.27 56.02 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.81 -0.71 . . . . 71.24 112.524 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.7 t -114.11 -172.47 2.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.811 0.338 . . . . 71.34 111.163 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.7 m -124.87 162.56 24.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 74.54 111.167 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 69.2 t -53.38 -43.87 53.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 70.44 111.133 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -51.68 -37.3 50.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 70.21 110.848 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.2 t -76.83 -47.18 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 72.15 111.141 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 41.6 mm -50.84 -45.36 28.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 75.24 111.128 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -77.37 -25.46 50.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.142 -0.481 . . . . 70.54 110.965 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.7 t -76.69 -21.02 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 74.21 110.832 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.5 mt -97.72 -45.33 6.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 75.44 110.932 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.18 67.84 6.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.637 0.732 . . . . 74.13 110.892 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -8.41 23.53 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.656 2.237 . . . . 73.42 112.351 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -68.75 -19.57 73.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 71.3 112.43 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.6 t -127.3 139.71 51.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 65.41 111.115 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -79.82 160.33 69.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.631 0.729 . . . . 71.03 110.926 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -15.03 36.73 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.69 2.26 . . . . 62.43 112.342 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -116.42 -23.28 8.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 75.53 111.065 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -91.83 55.02 2.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 74.54 110.893 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 75.2 mt -107.98 131.93 54.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.459 . . . . 63.25 110.909 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -97.65 153.55 18.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 72.5 110.904 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.6 p -54.71 144.36 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 71.45 111.092 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.98 66.34 2.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.764 -0.731 . . . . 72.44 112.478 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -118.72 122.07 41.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.83 0.347 . . . . 75.32 110.898 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.4 t -84.51 126.94 40.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 74.52 111.191 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.45 175.86 10.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 73.23 111.17 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -96.08 159.76 14.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 72.45 110.885 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.1 m -144.07 156.33 58.33 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.63 0.729 . . . . 73.15 111.134 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 90.87 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.655 2.237 . . . . 73.01 112.326 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 74.43 110.873 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.4 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.951 0.405 . . . . 75.54 110.894 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 18.2 p -125.5 163.06 23.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 65.23 111.128 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -139.19 136.31 34.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 64.31 110.917 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 m -92.26 123.26 35.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 74.45 111.123 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 85.3 mt -90.9 109.47 21.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 75.24 111.162 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -112.6 162.63 20.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.55 0.69 . . . . 74.21 110.963 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -47.33 101.07 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.685 2.257 . . . . 63.21 112.378 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 124.75 0.47 8.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 74.02 112.519 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -115.22 116.91 29.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.869 0.366 . . . . 70.32 110.877 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.08 169.57 8.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 63.04 111.145 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -53.68 -66.03 0.46 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.187 -0.461 . . . . 74.33 110.897 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -55.94 -49.6 73.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 74.15 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -50.22 -55.21 16.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.24 -0.436 . . . . 63.11 111.091 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 35.4 mt -62.69 -31.93 53.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 73.35 111.127 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -69.65 -29.93 67.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 75.43 111.083 179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -52.59 -74.11 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.914 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -57.38 -38.79 74.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 74.12 110.87 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 8.2 mmp_? -57.78 -23.47 52.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 74.24 110.857 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 82.84 18.83 64.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.755 -0.736 . . . . 74.24 112.456 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 11.8 t -116.68 -179.88 3.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.846 0.355 . . . . 54.22 111.11 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -122.58 161.28 24.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 64.42 111.149 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.3 t -55.11 -47.3 77.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 74.5 111.117 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 40.4 m-20 -51.88 -30.03 22.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 75.44 110.812 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 47.0 t -80.83 -54.15 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 71.21 111.177 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 51.2 mm -52.5 -41.79 37.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.148 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.06 -25.36 58.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 61.12 110.902 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.8 t -81.15 -21.46 39.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.214 -0.448 . . . . 62.4 110.843 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.2 mt -99.48 -44.52 6.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 72.31 110.915 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.37 68.58 5.37 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.602 0.715 . . . . 73.32 110.86 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -7.5 21.2 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.69 2.26 . . . . 73.12 112.35 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.26 -40.28 37.13 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 74.53 112.506 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.3 m -118.05 127.32 75.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.826 0.346 . . . . 72.32 111.122 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.1 m-20 -56.76 161.63 4.36 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.618 0.723 . . . . 72.2 110.92 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -8.16 22.89 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.686 2.257 . . . . 64.42 112.323 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.9 21.96 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 72.12 111.119 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -144.0 101.37 3.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 73.14 110.866 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 53.1 mt -139.3 150.85 45.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 74.41 110.926 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -117.86 150.61 38.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 70.15 110.883 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 12.6 p -51.77 148.22 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 73.32 111.121 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.36 66.53 2.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.732 -0.747 . . . . 74.33 112.448 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -117.84 121.25 40.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.822 0.344 . . . . 74.3 110.927 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.95 125.01 42.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 73.21 111.158 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 pt -132.31 175.79 10.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 75.4 111.121 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.39 149.19 23.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 75.13 110.878 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -135.12 156.17 78.43 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.635 0.731 . . . . 71.14 111.15 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 110.66 2.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.679 2.253 . . . . 61.04 112.334 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 92.3 m . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 75.24 110.928 179.969 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 4.5 m . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.925 0.393 . . . . 74.13 110.84 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 76.5 p -126.19 154.89 42.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 72.32 111.137 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 47.8 t80 -132.37 136.66 46.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 73.45 110.929 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.3 m -92.87 125.58 37.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 75.52 111.147 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.12 110.0 21.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.262 -0.426 . . . . 73.34 111.122 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -112.21 162.44 21.38 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.57 0.7 . . . . 74.53 110.935 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -46.14 101.53 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.685 2.256 . . . . 72.23 112.379 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 121.37 2.5 10.8 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 71.52 112.496 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -105.24 113.95 27.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.897 0.38 . . . . 64.13 110.885 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.12 166.21 10.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 74.32 111.152 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -51.02 -46.13 61.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 72.35 110.902 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.35 -49.63 21.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 74.34 110.977 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.11 -27.94 36.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 75.02 111.114 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 42.9 mt -89.1 -41.47 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 73.3 111.16 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.1 -42.69 81.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 63.33 111.111 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -57.19 -45.02 84.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 63.24 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -65.6 -59.98 3.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 72.41 110.882 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.2 mmm180 -52.12 -29.87 23.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.138 -0.483 . . . . 74.24 110.876 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.58 13.53 29.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 61.14 112.474 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.9 t -115.35 -174.18 2.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.853 0.359 . . . . 73.4 111.128 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.92 163.47 16.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 74.14 111.172 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.7 t -54.55 -44.43 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.261 -0.427 . . . . 74.32 111.129 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -51.68 -33.61 34.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 75.11 110.829 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.9 t -80.57 -48.08 20.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 71.5 111.156 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 45.2 mm -51.19 -43.52 27.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 63.5 111.159 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -77.76 -25.48 49.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 75.04 110.934 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t -76.17 -23.53 54.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 75.45 110.805 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -99.16 -45.37 5.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 74.3 110.908 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.83 68.29 6.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.653 0.74 . . . . 72.43 110.852 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -8.17 22.93 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.656 2.237 . . . . 74.35 112.389 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.55 -43.39 52.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.69 -0.767 . . . . 61.43 112.53 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.1 m -116.42 163.04 13.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.884 0.373 . . . . 75.22 111.078 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -104.31 161.1 23.88 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.59 0.71 . . . . 75.14 110.864 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.71 -8.52 23.81 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.693 2.262 . . . . 74.01 112.372 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -128.76 12.02 6.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 74.01 111.124 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.9 mmt85 -143.77 49.67 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 74.55 110.863 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 22.9 mt -85.64 166.95 15.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.227 -0.442 . . . . 74.31 110.918 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -120.59 139.39 53.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 74.41 110.897 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.3 p -54.05 140.6 10.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 74.12 111.104 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.31 61.62 6.11 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.779 -0.724 . . . . 73.35 112.462 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -119.17 122.27 41.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.811 0.339 . . . . 72.44 110.882 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.1 p -84.43 134.61 26.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 74.24 111.106 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.8 pt -134.98 175.93 9.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 75.13 111.132 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -95.91 143.25 27.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 63.34 110.859 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -131.87 156.22 80.38 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.612 0.72 . . . . 72.3 111.12 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 86.58 0.58 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.652 2.235 . . . . 70.54 112.357 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.26 -0.427 . . . . 74.21 110.876 -179.999 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 73.4 m . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.928 0.394 . . . . 71.03 110.848 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 35.7 p -124.47 156.22 37.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 73.11 111.124 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 44.3 t80 -132.35 136.54 46.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.274 -0.421 . . . . 74.42 110.891 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -92.54 122.97 35.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 72.35 111.168 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 83.0 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 75.21 111.124 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.8 mm100 -112.29 162.45 21.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.58 0.705 . . . . 75.02 110.925 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -47.28 101.22 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.663 2.242 . . . . 75.33 112.335 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 123.8 1.36 8.97 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.73 -0.748 . . . . 72.5 112.478 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -118.46 111.58 18.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.901 0.381 . . . . 74.33 110.872 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.53 159.84 14.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 74.43 111.151 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -51.33 -44.13 61.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 74.23 110.854 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.19 -48.0 25.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.922 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.22 -28.03 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 72.41 111.112 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.76 -45.38 16.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 72.41 111.107 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -53.97 -47.28 71.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 70.05 111.061 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -51.93 -44.96 64.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.199 -0.455 . . . . 73.03 110.914 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 77.4 mtp180 -68.78 -53.94 18.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.196 -0.456 . . . . 74.22 110.872 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -55.27 -26.29 39.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 73.5 110.897 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 101.91 16.27 24.17 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.727 -0.749 . . . . 73.42 112.491 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 10.1 t -120.29 -177.87 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.86 0.362 . . . . 64.13 111.129 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.64 165.09 19.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 72.22 111.145 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 91.7 t -55.16 -40.55 55.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 74.12 111.12 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -51.7 -40.13 59.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.01 110.884 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -77.35 -51.72 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 75.3 111.153 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 50.5 mm -51.64 -44.43 34.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 72.12 111.129 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -72.86 -25.53 61.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 74.05 110.937 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t -79.98 -22.11 42.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 73.02 110.834 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 10.7 mt -98.12 -44.79 6.47 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 62.23 110.88 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.66 68.06 5.8 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.717 . . . . 73.35 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -7.13 20.26 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.669 2.246 . . . . 73.4 112.387 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.84 -40.19 33.73 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.723 -0.751 . . . . 75.54 112.473 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.5 m -118.29 127.96 75.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.795 0.331 . . . . 74.35 111.142 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -56.61 161.25 4.54 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.623 0.725 . . . . 63.3 110.913 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -8.47 23.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.644 2.229 . . . . 75.42 112.352 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.1 23.21 5.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 75.22 111.119 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.3 mmt180 -146.47 102.52 3.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.453 . . . . 72.41 110.838 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 67.2 mt -136.51 175.59 9.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 74.42 110.867 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -140.72 147.77 39.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.475 . . . . 73.05 110.913 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.5 p -52.35 147.57 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 71.31 111.094 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.63 65.2 3.32 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.697 -0.763 . . . . 55.33 112.538 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 15.2 tt0 -119.14 120.69 37.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.826 0.346 . . . . 72.44 110.925 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.36 125.11 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 74.2 111.122 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.3 pt -129.22 175.87 9.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 74.43 111.128 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -98.84 137.98 36.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 75.14 110.869 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -123.91 156.23 65.91 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.618 0.723 . . . . 71.15 111.144 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 110.52 2.59 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.698 2.265 . . . . 70.44 112.337 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.205 -0.452 . . . . 73.41 110.878 -179.954 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.9 0.381 . . . . 72.15 110.903 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.5 p -123.37 161.83 23.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 71.15 111.149 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 36.2 t80 -127.32 136.79 52.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 72.33 110.925 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 55.3 m -88.68 122.88 32.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.098 -0.501 . . . . 60.25 111.144 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.2 mt -90.83 109.52 21.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 72.53 111.153 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -111.32 162.65 19.97 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.568 0.699 . . . . 75.43 110.948 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -46.78 101.27 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.696 2.264 . . . . 72.31 112.337 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 125.95 -1.99 7.9 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 74.31 112.455 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -105.77 129.39 53.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 74.25 110.87 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.06 164.5 15.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 72.21 111.128 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -50.94 -48.28 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 74.24 110.875 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.08 -49.01 25.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 74.35 110.944 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -53.81 -27.17 27.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.11 111.124 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 39.1 mt -91.26 -39.41 11.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 74.32 111.131 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.3 -41.04 83.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.149 -0.478 . . . . 74.2 111.092 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -57.13 -44.55 83.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.439 . . . . 75.22 110.905 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -69.26 -25.96 64.54 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 75.34 110.852 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 3.0 mmp_? -94.39 17.99 11.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 72.05 110.888 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.83 27.76 21.6 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.699 -0.762 . . . . 71.33 112.538 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 8.5 t -126.73 -177.22 3.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.916 0.389 . . . . 72.23 111.116 -179.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.41 167.88 14.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 65.41 111.123 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 45.9 t -56.47 -38.98 58.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 74.34 111.167 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 68.5 m-20 -51.71 -38.56 55.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 73.01 110.855 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -81.05 -50.64 16.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 64.15 111.108 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 49.7 mm -51.29 -41.02 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 73.11 111.125 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -78.58 -25.57 45.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 74.22 110.928 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 10.3 t -76.38 -24.13 54.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 75.31 110.839 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.1 mt -98.48 -44.67 6.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 75.01 110.903 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.97 67.96 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.637 0.732 . . . . 73.5 110.907 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.72 21.77 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.66 2.24 . . . . 73.23 112.36 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.78 -44.33 48.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.764 -0.731 . . . . 73.42 112.48 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.6 m -118.82 161.06 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.829 0.347 . . . . 74.42 111.121 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -108.34 160.96 25.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.634 0.731 . . . . 71.44 110.854 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -8.22 23.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.682 2.255 . . . . 73.33 112.362 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.21 -21.63 13.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 75.1 111.109 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 6.5 ptp180 -134.87 96.22 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 74.24 110.929 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 89.5 mt -117.55 161.81 19.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.181 -0.463 . . . . 72.23 110.903 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -107.67 148.81 28.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 74.54 110.932 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 14.0 p -68.89 143.75 14.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 74.23 111.118 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.2 60.85 6.75 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.715 -0.755 . . . . 74.22 112.496 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.0 tt0 -119.21 121.18 39.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.824 0.345 . . . . 64.33 110.97 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 26.2 t -88.92 132.27 34.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 74.41 111.134 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 2.4 pt -134.04 175.97 9.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.459 . . . . 73.45 111.132 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 60.0 m-20 -92.51 136.56 33.11 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.457 . . . . 74.05 110.907 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.4 m -143.76 155.99 59.5 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.547 0.689 . . . . 75.43 111.15 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.83 110.53 2.59 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.65 2.233 . . . . 74.41 112.308 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 74.41 110.873 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.2 m . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.877 0.37 . . . . 61.34 110.931 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 22.2 p -129.65 150.31 51.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 75.03 111.127 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -122.4 136.63 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.159 -0.473 . . . . 75.5 110.897 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -89.25 122.1 32.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 74.34 111.102 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 69.7 mt -91.03 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 74.01 111.137 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.61 163.55 16.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.6 0.715 . . . . 75.25 110.945 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -45.86 105.15 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.636 2.224 . . . . 74.32 112.374 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 118.65 1.11 15.43 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.726 -0.75 . . . . 70.34 112.491 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -105.09 144.2 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.908 0.385 . . . . 74.0 110.851 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.07 158.78 43.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 74.3 111.166 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -50.9 -47.92 60.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 72.51 110.858 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -72.97 -47.68 43.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 73.55 110.918 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -55.6 -26.56 44.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 75.41 111.114 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 21.1 mt -90.91 -38.78 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 74.24 111.158 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -61.53 -40.4 94.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 72.24 111.086 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -56.38 -44.69 80.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 74.44 110.896 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 -75.52 -49.38 18.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.451 . . . . 70.12 110.837 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 21.5 mmm180 -56.98 -24.39 52.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 75.14 110.852 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.19 23.64 37.01 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 62.54 112.478 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.6 t -114.76 -171.66 1.97 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 75.1 111.149 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.15 149.13 43.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.217 -0.447 . . . . 73.43 111.111 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 83.4 t -55.5 -46.91 79.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 65.31 111.12 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -51.85 -30.69 24.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 74.42 110.826 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 72.7 t -80.08 -54.09 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 72.32 111.154 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 41.3 mm -52.57 -42.51 40.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.166 -0.47 . . . . 74.23 111.187 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.83 -25.48 59.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.108 -0.496 . . . . 75.22 110.894 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t -79.23 -22.95 44.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 53.34 110.88 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 11.9 mt -96.5 -45.54 6.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 74.25 110.919 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.72 67.86 5.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.608 0.718 . . . . 72.11 110.924 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -7.36 20.84 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.656 2.237 . . . . 75.13 112.35 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.1 -39.48 34.29 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.778 -0.725 . . . . 72.51 112.46 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -121.76 163.02 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.844 0.354 . . . . 74.11 111.14 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 33.0 m-20 -102.99 161.21 23.8 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.615 0.722 . . . . 73.15 110.877 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.67 26.68 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.685 2.256 . . . . 73.34 112.319 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -117.44 -18.83 9.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.25 -0.432 . . . . 74.14 111.124 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -122.04 90.0 3.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 75.23 110.891 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 73.0 mt -119.39 160.38 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 73.42 110.92 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -105.49 148.55 27.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 72.33 110.919 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.2 p -61.7 139.45 20.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 74.12 111.186 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.78 62.49 5.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 63.12 112.503 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -119.28 121.9 40.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.83 0.348 . . . . 73.44 110.916 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 11.3 p -86.45 134.68 26.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 74.05 111.144 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 1.3 pp -129.45 172.76 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 74.33 111.08 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -100.33 142.95 31.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 64.2 110.9 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -136.09 156.2 77.11 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.594 0.711 . . . . 74.24 111.126 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 110.11 2.48 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.679 2.253 . . . . 74.51 112.363 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 98.9 m . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 74.21 110.905 179.992 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 71.2 m . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.885 0.374 . . . . 72.25 110.869 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 44.8 p -124.96 150.26 46.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 72.32 111.153 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 42.1 t80 -122.48 136.68 54.94 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.212 -0.449 . . . . 74.11 110.932 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 m -91.41 120.19 32.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 74.54 111.109 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.4 mt -90.85 109.59 21.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.45 . . . . 74.25 111.132 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 22.9 mm-40 -97.29 159.45 31.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.612 0.72 . . . . 73.53 110.893 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.81 93.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.698 2.265 . . . . 75.13 112.358 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.48 -17.46 2.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 63.45 112.514 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.92 167.26 16.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.913 0.387 . . . . 75.13 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.2 151.77 45.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.192 -0.458 . . . . 75.41 111.154 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -51.03 -47.38 61.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.251 -0.431 . . . . 75.23 110.885 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -71.6 -47.16 56.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 73.13 110.895 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.73 -23.88 54.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 72.54 111.068 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 35.2 mt -95.46 -31.99 4.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.445 . . . . 74.22 111.129 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -72.18 -29.5 64.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 72.12 111.123 179.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 1.5 pp0? -65.7 -44.46 86.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.929 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.5 -13.73 53.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 74.41 110.908 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -93.03 16.56 12.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 74.33 110.922 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.63 28.1 21.12 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 61.0 112.494 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 11.8 t -129.0 -179.96 5.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.842 0.353 . . . . 73.02 111.152 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -123.28 159.77 28.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 54.45 111.152 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 52.6 t -55.07 -42.38 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 72.04 111.106 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -51.85 -38.09 54.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 71.5 110.828 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.2 -54.19 13.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 74.13 111.132 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 50.2 mm -51.42 -39.95 23.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 75.11 111.108 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -77.98 -25.56 48.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 72.12 110.9 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -76.92 -24.05 52.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 53.01 110.888 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 7.3 mt -95.18 -45.3 7.25 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.921 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.06 67.57 6.42 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.742 . . . . 74.34 110.906 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -6.96 19.86 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.693 2.262 . . . . 75.15 112.379 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.63 -39.9 31.56 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 63.51 112.484 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.1 m -118.95 160.83 18.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.827 0.346 . . . . 72.04 111.142 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -99.63 160.56 27.07 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.622 0.725 . . . . 71.44 110.888 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -22.78 31.61 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.749 2.3 . . . . 75.22 112.312 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.4 24.33 11.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 71.45 111.094 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 14.5 ptm180 -177.33 111.56 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 74.34 110.873 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 86.1 mt -127.66 -179.59 5.01 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.176 -0.466 . . . . 72.01 110.926 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -124.16 147.56 47.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 74.02 110.928 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 14.6 p -62.85 139.99 20.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 74.44 111.167 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.67 65.14 3.37 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 53.31 112.475 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 8.8 tt0 -113.69 127.72 56.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.787 0.327 . . . . 73.15 110.933 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 17.6 t -91.51 122.77 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 75.32 111.09 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.1 pt -127.84 175.84 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 72.42 111.089 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -110.87 143.36 41.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 74.32 110.919 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.93 156.23 79.38 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.631 0.729 . . . . 74.3 111.121 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 110.77 2.64 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.696 2.264 . . . . 63.32 112.334 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 73.31 110.884 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 26.0 m . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.858 0.361 . . . . 63.51 110.879 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.7 p -124.85 167.72 14.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 73.53 111.128 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.8 t80 -139.49 136.38 34.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 63.11 110.877 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.1 m -90.89 121.18 32.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.119 -0.491 . . . . 71.44 111.128 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 64.4 mt -91.04 109.29 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 75.2 111.09 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -110.39 162.86 18.82 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 63.23 110.911 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -45.89 118.77 2.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.711 2.274 . . . . 73.12 112.35 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 108.32 -23.83 23.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.797 -0.716 . . . . 54.22 112.529 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -86.67 121.98 29.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.868 0.366 . . . . 75.44 110.877 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.87 156.16 19.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 74.35 111.134 -179.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -51.61 -45.25 63.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 73.1 110.863 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -70.46 -51.4 29.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 75.12 110.9 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.63 -31.86 58.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 61.22 111.133 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 34.5 mt -84.04 -35.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.126 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -63.15 -48.32 78.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 74.14 111.133 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -52.99 -44.93 67.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.91 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 6.8 ptp85 -78.62 -18.05 55.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 71.44 110.898 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -94.11 19.74 8.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.189 -0.459 . . . . 72.14 110.923 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.78 28.12 22.32 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.735 -0.745 . . . . 73.0 112.478 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 14.5 t -134.45 174.72 10.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.844 0.354 . . . . 74.33 111.167 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.58 164.62 15.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.03 111.172 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 22.6 t -57.41 -41.44 78.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.02 111.166 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -51.82 -34.42 40.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.862 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.79 -51.72 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 73.53 111.079 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 49.0 mm -51.75 -41.71 29.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.236 -0.438 . . . . 73.43 111.135 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -78.32 -25.53 46.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 71.34 110.928 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -78.69 -20.92 49.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 75.11 110.874 -179.785 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 21.0 mt -98.29 -45.49 6.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.486 . . . . 74.1 110.896 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -118.45 67.91 7.4 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.635 0.731 . . . . 75.14 110.9 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -8.53 23.83 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.717 2.278 . . . . 74.41 112.302 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.77 -26.33 62.58 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.757 -0.735 . . . . 53.2 112.454 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.5 t -121.4 92.53 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.788 0.327 . . . . 71.54 111.151 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -51.8 159.13 1.42 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.617 0.723 . . . . 73.44 110.856 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -29.98 22.92 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.666 2.244 . . . . 74.24 112.326 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -95.13 31.99 1.8 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 62.43 111.059 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 179.88 93.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 75.53 110.865 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 45.5 mt -116.2 144.58 44.0 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 74.12 110.911 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -98.59 153.31 18.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 73.44 110.92 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.71 144.06 12.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 74.02 111.121 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.51 59.02 8.92 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.739 . . . . 51.32 112.443 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -119.26 122.64 42.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.834 0.349 . . . . 64.31 110.915 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 33.6 t -88.52 127.05 41.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 73.21 111.127 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.2 pt -123.54 175.91 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.172 -0.467 . . . . 73.32 111.15 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 6.0 m-20 -94.55 145.46 24.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.186 -0.461 . . . . 65.14 110.91 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.94 156.1 78.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.638 0.732 . . . . 64.55 111.108 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 110.64 2.61 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.733 2.288 . . . . 72.13 112.314 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 46.6 m . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 71.11 110.869 179.993 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 3.9 m . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.888 0.375 . . . . 72.53 110.871 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.4 p -123.55 154.67 38.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 53.31 111.148 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -133.5 134.99 44.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 75.34 110.926 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.6 125.98 35.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 74.34 111.175 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.8 mt -90.9 109.38 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 73.53 111.157 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 49.5 mm-40 -110.92 161.94 22.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.623 0.725 . . . . 74.44 110.89 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -45.98 121.45 4.34 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.721 2.281 . . . . 63.11 112.328 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.19 34.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.732 -0.747 . . . . 72.41 112.418 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -95.79 121.03 37.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.844 0.354 . . . . 74.14 110.845 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.0 165.33 11.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 71.13 111.123 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -53.98 -60.8 2.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 74.3 110.866 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -56.57 -52.47 64.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.152 -0.477 . . . . 75.02 110.906 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.42 -62.42 1.63 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.449 . . . . 75.22 111.13 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 34.3 mt -51.5 -38.15 20.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 71.44 111.138 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.28 -37.19 86.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 73.05 111.115 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -51.91 -72.11 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 72.25 110.928 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 10.0 ptt-85 -55.87 -40.47 72.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 74.43 110.858 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.8 mmp_? -57.9 -24.04 55.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.171 -0.468 . . . . 74.12 110.885 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 71.42 112.473 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 12.4 t -120.99 178.87 4.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 74.1 111.15 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -119.82 162.93 18.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 74.44 111.181 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 23.9 t -56.68 -40.32 69.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.24 -0.436 . . . . 71.04 111.155 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -51.76 -36.24 46.61 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 52.34 110.836 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.7 t -81.96 -50.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 63.51 111.141 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 47.7 mm -51.95 -41.12 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.149 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -79.14 -25.39 42.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 72.44 110.93 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 t -79.44 -20.14 48.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 75.43 110.872 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.5 mt -98.38 -45.72 6.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 64.22 110.927 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.95 68.05 6.41 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.563 0.697 . . . . 73.23 110.891 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -8.54 23.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.69 2.26 . . . . 73.52 112.346 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.41 -23.89 67.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.757 . . . . 73.31 112.518 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.45 104.74 15.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 60.54 111.11 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -75.09 154.68 86.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.61 0.719 . . . . 55.42 110.909 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -13.76 35.14 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.678 2.252 . . . . 75.15 112.338 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -71.29 -18.9 62.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 73.41 111.092 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -170.61 115.23 0.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 74.51 110.887 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 55.4 mt -108.2 153.45 23.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 61.01 110.882 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 53.8 mm-40 -97.84 148.78 23.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 71.43 110.942 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.9 145.03 11.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 75.42 111.156 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.33 58.13 10.42 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 72.13 112.479 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -119.33 120.69 37.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.818 0.342 . . . . 72.45 110.877 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 6.4 p -85.06 130.88 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 74.51 111.183 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.2 pt -131.06 175.85 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 73.14 111.162 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 39.3 m-20 -89.94 145.62 24.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.463 . . . . 73.54 110.842 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -147.67 156.15 45.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.627 0.727 . . . . 74.41 111.094 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.649 2.233 . . . . 75.21 112.309 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 74.44 110.895 179.955 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 2.4 m . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.919 0.39 . . . . 52.42 110.903 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 71.9 p -123.67 151.47 43.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 75.2 111.11 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -138.25 136.52 36.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.215 -0.448 . . . . 72.32 110.927 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 m -92.65 126.44 37.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 62.13 111.166 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.89 109.44 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 64.43 111.121 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.0 mm-40 -110.36 162.06 22.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.642 0.734 . . . . 73.03 110.906 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -45.93 118.39 2.31 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 74.12 112.355 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.62 -18.88 29.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.73 -0.748 . . . . 75.34 112.51 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -96.87 115.68 27.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 73.13 110.865 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.92 159.78 15.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.189 -0.46 . . . . 73.51 111.122 -179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -53.66 -55.03 29.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 72.33 110.859 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.2 t-105 -57.96 -56.21 24.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.137 -0.483 . . . . 73.52 110.875 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.36 -60.6 2.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.26 -0.427 . . . . 61.52 111.103 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 33.0 mt -51.62 -37.86 20.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 73.55 111.137 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.46 86.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.176 -0.465 . . . . 74.12 111.126 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -51.81 -65.15 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 75.33 110.915 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.2 mtt180 -63.32 -41.27 98.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 72.24 110.945 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.6 mmp_? -55.87 -25.7 43.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 74.1 110.816 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.76 17.41 51.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 72.31 112.494 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 11.5 t -119.37 179.9 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.856 0.36 . . . . 74.42 111.148 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.18 157.77 28.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 72.42 111.153 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 26.3 t -55.48 -42.83 69.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 74.15 111.131 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -51.84 -36.31 47.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 73.31 110.87 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -78.83 -53.6 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 73.24 111.127 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 44.8 mm -51.66 -40.58 26.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 74.42 111.173 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -77.75 -25.42 49.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 73.33 110.931 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.5 t -80.38 -20.35 44.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 73.14 110.835 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.1 mt -98.35 -45.53 6.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 71.44 110.872 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.96 68.17 6.48 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.641 0.734 . . . . 73.52 110.883 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -8.5 23.77 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.694 2.263 . . . . 74.55 112.33 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.04 -22.92 58.73 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.793 -0.718 . . . . 63.11 112.461 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.1 t -121.89 107.91 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.86 0.362 . . . . 74.14 111.096 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.55 155.0 81.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.636 0.732 . . . . 74.23 110.876 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.79 -16.72 37.55 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.707 2.272 . . . . 72.13 112.313 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -68.65 -19.44 64.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.261 -0.427 . . . . 74.01 111.13 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.3 ptt180 -173.48 116.63 0.26 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 73.41 110.899 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 61.7 mt -103.46 154.6 19.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 75.51 110.91 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 -97.77 143.12 28.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 73.12 110.957 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.51 145.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 55.11 111.133 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.28 59.1 8.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 72.32 112.495 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -119.3 121.57 39.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 73.44 110.909 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 22.4 t -85.27 127.11 40.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 71.13 111.141 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 10.0 pt -123.5 174.32 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 71.23 111.132 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -96.89 144.28 26.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.156 -0.475 . . . . 75.23 110.937 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.25 156.19 79.75 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.641 0.734 . . . . 73.11 111.108 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 85.47 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.658 2.239 . . . . 74.52 112.377 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.147 -0.479 . . . . 65.15 110.924 -179.981 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 15.7 mmt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.791 0.329 . . . . 73.02 110.871 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -101.89 -160.09 26.59 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 71.11 112.501 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 5.3 m -145.96 166.06 27.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.932 0.396 . . . . 73.4 110.881 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 41.3 p -123.55 168.08 13.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 74.42 111.14 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 45.8 t80 -145.23 136.38 24.89 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 73.44 110.968 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.6 m -91.73 123.09 34.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.108 -0.496 . . . . 75.43 111.116 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 60.6 mt -90.89 109.49 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.453 . . . . 74.31 111.152 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -111.24 163.51 17.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.617 0.722 . . . . 74.45 110.93 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_exo -46.16 124.58 7.71 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.718 2.278 . . . . 75.44 112.333 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 106.54 -17.96 38.86 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.777 -0.725 . . . . 70.22 112.483 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -97.31 147.03 24.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.908 0.385 . . . . 75.41 110.833 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.96 174.36 10.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 74.53 111.121 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.51 -70.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 75.24 110.905 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.92 -50.07 61.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.16 -0.473 . . . . 74.33 110.924 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.03 -66.29 0.41 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.264 -0.425 . . . . 71.34 111.11 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 43.9 mt -51.37 -32.68 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 75.43 111.077 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -66.73 -38.46 86.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 65.44 111.147 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -52.32 -69.42 0.11 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 74.04 110.882 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 9.6 ptm180 -56.28 -44.48 79.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 75.31 110.855 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -56.35 -25.03 47.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 74.34 110.841 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.82 16.55 56.21 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.736 -0.745 . . . . 72.42 112.463 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 7.7 t -119.84 -176.1 3.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.897 0.38 . . . . 73.42 111.103 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.27 165.97 17.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 75.05 111.14 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 61.3 t -55.78 -41.12 64.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 73.11 111.175 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -51.79 -36.03 46.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 73.41 110.856 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.21 -51.5 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 73.24 111.103 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 49.7 mm -51.25 -42.45 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 74.12 111.166 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -78.18 -25.4 47.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 75.25 110.909 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.7 t -78.05 -21.07 51.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 74.41 110.864 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 43.3 mt -97.05 -46.16 6.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.151 -0.477 . . . . 74.12 110.921 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -117.96 68.15 6.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.596 0.712 . . . . 73.33 110.878 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -8.51 23.78 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.657 2.238 . . . . 75.03 112.314 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -67.23 -17.59 68.34 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.733 -0.746 . . . . 74.01 112.523 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.2 t -131.14 119.67 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.909 0.385 . . . . 73.51 111.098 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -88.77 154.86 50.51 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.599 0.714 . . . . 74.5 110.902 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -19.63 35.73 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.725 2.283 . . . . 74.44 112.327 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.79 -15.98 60.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 63.34 111.112 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -170.56 115.33 0.47 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 75.33 110.852 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 47.0 mt -117.34 150.79 38.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.47 . . . . 73.03 110.933 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.0 mm100 -97.77 149.5 22.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 74.0 110.911 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.3 p -68.35 146.61 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 74.43 111.137 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.8 63.73 4.51 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 63.35 112.514 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 13.5 tt0 -119.14 121.62 40.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 71.44 110.907 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.54 124.53 40.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 74.03 111.121 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.6 pt -127.83 175.93 8.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 74.52 111.148 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -96.05 144.07 26.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 74.1 110.9 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -141.26 156.15 67.68 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.726 . . . . 73.45 111.085 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 105.52 1.5 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.675 2.25 . . . . 74.52 112.346 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.2 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 75.0 110.873 -179.972 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 7.9 mtp . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.819 0.342 . . . . 74.01 110.9 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 129.21 -126.56 5.24 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.752 -0.737 . . . . 52.43 112.514 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.1 m -129.85 136.68 49.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.892 0.377 . . . . 65.42 110.876 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.5 p -126.43 161.52 27.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.148 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 45.2 t80 -142.85 136.63 28.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 74.44 110.918 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 m -93.44 124.03 37.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 63.5 111.124 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.8 mt -91.05 109.58 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 65.11 111.116 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -111.58 163.52 17.3 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.579 0.704 . . . . 72.0 110.926 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_exo -46.16 120.95 4.01 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.712 2.274 . . . . 73.11 112.336 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.6 -18.86 26.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.759 . . . . 70.15 112.478 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -99.04 140.94 32.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.896 0.379 . . . . 63.44 110.852 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.77 163.8 24.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 73.22 111.134 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.99 -64.57 0.79 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 74.11 110.865 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -56.2 -50.67 70.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 74.11 110.919 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.65 -65.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 65.41 111.049 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 36.3 mt -51.73 -37.0 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 70.15 111.118 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.13 -36.1 82.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 73.44 111.085 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.9 mt-30 -51.82 -63.75 1.03 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 75.45 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 47.9 mtm180 -67.1 -39.38 86.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.41 110.89 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 8.5 mmp_? -56.41 -25.14 49.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 72.44 110.904 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 92.23 17.15 47.82 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 75.51 112.517 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 13.4 t -125.21 177.3 6.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.87 0.367 . . . . 73.5 111.13 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.1 m -125.43 164.68 19.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 72.44 111.104 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.9 t -54.68 -40.88 53.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.198 -0.455 . . . . 70.12 111.094 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -51.67 -38.51 55.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.196 -0.456 . . . . 75.44 110.877 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 24.9 t -78.94 -52.33 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 75.4 111.142 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 47.7 mm -52.2 -41.1 32.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 75.32 111.179 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -75.66 -25.51 56.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 65.24 110.905 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.3 t -79.41 -23.47 43.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 65.53 110.863 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.7 mt -98.92 -44.65 6.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 75.44 110.897 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -117.67 68.29 5.91 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.625 0.726 . . . . 73.33 110.874 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -7.3 20.72 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.625 2.216 . . . . 74.53 112.366 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.34 -43.75 43.84 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.747 -0.739 . . . . 43.53 112.518 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.4 m -116.46 127.24 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.802 0.334 . . . . 54.41 111.151 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -55.92 160.87 3.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.619 0.723 . . . . 63.21 110.917 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.73 24.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.266 . . . . 75.33 112.348 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -133.07 24.39 4.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.34 111.102 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 67.9 mtp85 -149.73 89.48 1.62 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 74.43 110.86 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 9.9 mt -125.16 176.23 6.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 74.53 110.943 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 24.3 mm100 -136.38 150.4 48.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.889 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.1 p -54.37 146.45 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 62.2 111.188 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.02 65.01 3.5 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.73 -0.747 . . . . 60.43 112.509 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 13.6 tt0 -119.12 122.01 41.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.816 0.341 . . . . 75.53 110.941 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.4 p -87.43 135.04 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 75.22 111.141 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.0 pt -140.74 175.82 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 75.43 111.163 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 10.0 m-20 -103.19 143.06 33.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 74.22 110.894 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.2 156.14 66.99 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 74.4 111.151 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 110.54 2.59 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.657 2.238 . . . . 73.41 112.351 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 70.3 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 62.13 110.894 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 10.8 mtt . . . . . 0 N--CA 1.458 -0.074 0 CA-C-O 120.78 0.324 . . . . 65.35 110.899 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.47 -144.56 7.28 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.722 -0.752 . . . . 71.25 112.496 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 81.8 m -113.68 141.18 47.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.943 0.401 . . . . 75.02 110.843 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.6 p -125.55 163.47 22.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 72.23 111.201 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -142.85 136.56 28.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.256 -0.429 . . . . 74.33 110.933 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -93.61 123.66 37.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.123 -0.489 . . . . 74.43 111.15 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 74.8 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 75.41 111.127 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.1 mm-40 -109.28 163.15 17.69 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.56 0.695 . . . . 73.15 110.896 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -46.17 124.8 7.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 64.31 112.321 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.75 -18.88 39.85 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.724 -0.751 . . . . 63.2 112.464 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -96.83 141.39 30.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.886 0.374 . . . . 74.43 110.875 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -129.73 170.26 14.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 73.25 111.164 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -54.39 -69.53 0.12 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 74.34 110.886 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.1 t-105 -52.3 -49.93 63.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 73.24 110.939 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.31 -65.7 0.51 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.238 -0.437 . . . . 71.4 111.076 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 46.8 mt -51.77 -37.09 19.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.264 -0.426 . . . . 75.33 111.14 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -63.64 -35.87 81.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 72.54 111.123 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -51.78 -68.18 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 72.01 110.909 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 46.6 mtt180 -61.71 -41.99 98.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 74.21 110.837 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.1 mmm180 -54.68 -27.1 37.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 64.12 110.893 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.4 18.09 50.41 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 60.3 112.451 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 12.4 t -119.36 178.39 4.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.866 0.365 . . . . 73.02 111.142 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -120.97 160.68 23.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 73.41 111.177 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.0 t -54.37 -47.17 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 55.42 111.172 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -52.24 -29.71 24.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 72.34 110.844 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 61.7 t -81.32 -54.19 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 73.43 111.104 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 50.0 mm -52.59 -39.65 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 71.23 111.12 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -25.35 47.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 73.55 110.926 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 t -80.64 -21.01 41.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.187 -0.46 . . . . 75.24 110.847 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 6.6 mt -102.59 -42.13 6.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.104 -0.498 . . . . 74.21 110.928 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -117.64 68.34 5.87 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.644 0.735 . . . . 75.3 110.894 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -7.29 20.69 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.681 2.254 . . . . 74.52 112.357 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.29 -43.5 43.17 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.749 -0.739 . . . . 75.05 112.477 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.2 m -116.43 128.04 73.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.883 0.373 . . . . 74.35 111.167 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -58.45 161.49 7.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 73.33 110.885 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -8.48 23.72 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.699 2.266 . . . . 71.34 112.324 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.13 18.87 4.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.091 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -142.67 87.28 1.99 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 74.42 110.866 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 7.9 mt -124.23 167.94 13.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.478 . . . . 72.53 110.885 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -135.42 153.31 51.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 74.54 110.875 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.9 p -52.81 147.76 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 71.2 111.12 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.69 66.72 2.38 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.688 -0.767 . . . . 75.25 112.474 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 7.0 tt0 -114.31 120.9 41.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.867 0.365 . . . . 71.14 110.889 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.99 124.98 42.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 74.24 111.163 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.4 pt -135.06 175.92 9.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 73.43 111.17 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -104.59 148.94 25.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 53.51 110.874 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -133.29 156.12 80.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.565 0.698 . . . . 74.3 111.163 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 110.16 2.49 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.693 2.262 . . . . 62.43 112.278 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 88.6 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 74.53 110.9 179.932 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 21.4 ttp . . . . . 0 C--O 1.23 0.06 0 CA-C-O 120.81 0.338 . . . . 73.0 110.866 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.69 -156.05 15.8 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.742 -0.742 . . . . 74.43 112.504 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 6.8 m -112.27 146.31 38.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.906 0.384 . . . . 74.23 110.891 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.6 p -123.6 160.75 26.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 75.23 111.119 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -143.42 136.56 27.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 74.34 110.93 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.7 m -94.91 123.27 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 60.04 111.172 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 57.0 mt -90.99 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.235 -0.438 . . . . 73.12 111.13 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -116.21 163.36 21.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.568 0.699 . . . . 72.41 110.95 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -46.52 107.79 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 73.44 112.337 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 126.63 -18.51 6.35 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.714 -0.755 . . . . 71.45 112.484 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -103.49 136.97 42.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 75.42 110.843 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.25 163.86 20.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 74.11 111.194 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -54.75 -67.54 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 72.31 110.911 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -52.23 -51.74 56.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 74.42 110.916 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.32 -65.6 0.53 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.264 -0.426 . . . . 74.41 111.143 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 26.3 mt -51.42 -31.68 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 72.23 111.148 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -67.47 -39.82 85.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 75.45 111.087 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -52.39 -58.77 5.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 74.55 110.936 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 3.1 mmt85 -69.31 -16.85 63.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 75.24 110.891 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 18.3 mmt180 -90.83 12.76 18.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 65.15 110.904 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.94 28.08 23.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.74 -0.743 . . . . 74.23 112.51 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 12.4 t -129.55 177.94 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.879 0.371 . . . . 74.1 111.123 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.98 163.01 26.28 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.197 -0.456 . . . . 72.33 111.15 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 62.0 t -51.85 -39.53 25.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 74.23 111.141 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -51.55 -39.35 57.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.484 . . . . 74.51 110.864 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -80.25 -50.34 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.15 -0.477 . . . . 75.2 111.111 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 47.5 mm -51.43 -41.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 74.23 111.079 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -77.65 -25.6 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 74.4 110.933 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 19.9 t -76.14 -24.5 54.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.182 -0.463 . . . . 72.04 110.843 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 20.8 mt -98.59 -44.53 6.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 71.41 110.906 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.93 67.97 6.33 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.589 0.709 . . . . 73.01 110.911 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -7.63 21.54 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.686 2.257 . . . . 74.04 112.316 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.47 -45.42 46.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.78 -0.724 . . . . 63.14 112.47 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.3 m -117.24 124.93 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 73.52 111.127 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -67.97 160.87 71.83 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.607 0.717 . . . . 65.35 110.887 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -8.46 23.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.624 2.216 . . . . 75.02 112.352 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -115.51 24.9 11.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 53.35 111.11 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.2 ptp180 -173.34 108.16 0.16 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 74.53 110.858 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 10.3 mt -136.99 146.91 45.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.174 -0.467 . . . . 71.14 110.92 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -97.75 153.0 18.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 75.0 110.89 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 12.4 p -68.12 148.07 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 74.1 111.178 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.84 61.7 6.24 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.783 -0.722 . . . . 50.34 112.481 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -119.24 121.96 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.838 0.352 . . . . 73.41 110.902 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.87 124.95 40.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 65.3 111.117 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.5 pt -123.58 175.74 5.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.185 -0.461 . . . . 73.51 111.132 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -99.16 137.26 37.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 65.34 110.85 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -117.93 156.22 50.29 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.598 0.713 . . . . 72.5 111.124 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 83.91 0.67 Allowed 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.647 2.231 . . . . 72.11 112.355 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.264 -0.426 . . . . 62.01 110.868 -179.998 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 9.2 mmt . . . . . 0 CA--C 1.526 0.051 0 CA-C-O 120.778 0.323 . . . . 74.24 110.904 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.81 169.68 28.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.745 -0.74 . . . . 63.02 112.5 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 9.2 m -131.85 143.8 50.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.903 0.382 . . . . 73.12 110.894 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.3 p -123.61 154.38 39.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 62.34 111.13 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 47.0 t80 -132.26 136.6 47.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.236 -0.438 . . . . 74.13 110.889 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -91.43 125.24 36.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.065 -0.516 . . . . 74.11 111.127 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 52.2 mt -93.22 110.51 23.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 74.23 111.146 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm-40 -89.45 158.87 45.3 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.55 0.69 . . . . 71.3 110.898 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -59.67 92.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.645 2.23 . . . . 63.34 112.37 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.44 -18.28 2.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.754 -0.736 . . . . 72.4 112.493 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -78.81 155.86 29.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 74.03 110.841 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -131.66 165.15 24.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 74.45 111.166 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -51.32 -51.08 57.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 74.2 110.877 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -67.85 -48.94 64.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.138 -0.483 . . . . 72.34 110.91 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.98 -29.95 58.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 71.23 111.084 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 31.2 mt -87.44 -33.43 6.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.238 -0.437 . . . . 71.23 111.142 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -65.01 -43.66 91.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 75.21 111.11 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -56.31 -44.59 80.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.21 110.841 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -65.76 -60.22 3.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 74.22 110.884 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -51.97 -30.86 26.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.456 . . . . 74.54 110.894 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 103.36 16.72 19.75 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 74.43 112.46 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 7.2 t -120.74 -174.83 2.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 71.14 111.149 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -116.23 165.22 13.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 75.43 111.12 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.8 t -55.51 -43.42 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 73.55 111.137 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -51.74 -33.39 34.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.855 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.89 -48.67 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 70.12 111.114 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 43.2 mm -51.31 -42.75 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 73.04 111.161 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -78.06 -25.41 47.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 65.4 110.928 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.1 t -76.83 -23.17 52.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 52.41 110.878 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 37.2 mt -100.59 -43.18 6.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 74.23 110.894 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -120.22 67.99 13.19 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 73.35 110.854 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.77 -8.24 23.1 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.737 2.291 . . . . 74.2 112.313 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.78 -44.79 55.36 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.685 -0.769 . . . . 71.12 112.517 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.6 m -114.56 161.76 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 74.43 111.129 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -102.73 161.39 23.36 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.659 0.742 . . . . 62.02 110.851 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -8.39 23.47 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.679 2.253 . . . . 75.55 112.395 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.49 20.79 4.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 65.31 111.072 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 60.0 mtt85 -151.63 49.68 0.81 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 75.2 110.846 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 27.9 mt -85.52 166.52 16.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 70.42 110.9 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 -115.51 153.4 31.23 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.141 -0.481 . . . . 73.52 110.896 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 12.2 p -63.9 133.94 29.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.09 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.88 63.28 4.89 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.695 -0.764 . . . . 63.3 112.511 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -114.74 123.5 49.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 75.42 110.942 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.37 126.81 40.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 71.53 111.133 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.1 pt -127.23 175.91 8.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.149 -0.478 . . . . 75.44 111.151 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -94.97 153.9 17.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 74.14 110.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.5 m -141.23 156.03 67.81 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.643 0.735 . . . . 71.24 111.155 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 87.84 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.675 2.25 . . . . 73.23 112.352 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 71.52 110.854 179.997 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 87.7 mtp . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.817 0.341 . . . . 72.21 110.878 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.74 -167.22 31.53 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.726 -0.749 . . . . 70.3 112.484 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.5 m -117.75 163.33 16.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.939 0.4 . . . . 73.23 110.842 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 46.4 p -124.24 157.33 35.1 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.146 -0.479 . . . . 65.0 111.167 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -130.36 136.72 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.214 -0.448 . . . . 74.55 110.893 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -91.12 122.42 33.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 64.31 111.129 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 35.2 mt -90.8 109.59 21.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 74.43 111.135 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 16.4 mt-30 -87.75 157.28 52.27 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.606 0.717 . . . . 73.32 110.884 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -58.16 94.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.675 2.25 . . . . 72.31 112.34 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.38 -20.38 2.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.694 -0.765 . . . . 75.53 112.456 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -87.43 137.51 32.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.867 0.365 . . . . 64.42 110.913 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.48 171.48 7.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 74.11 111.186 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -53.92 -64.36 0.85 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 75.24 110.927 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -53.08 -51.95 60.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 74.21 110.929 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.66 -63.77 1.03 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 62.03 111.091 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 46.7 mt -51.69 -34.13 15.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 75.3 111.133 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -68.16 -35.72 78.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 75.01 111.114 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.4 mt-30 -51.66 -73.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 72.24 110.904 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 36.4 mmm-85 -54.62 -45.27 73.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 75.55 110.903 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -54.54 -27.2 36.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 74.42 110.907 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 91.54 16.09 53.41 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.775 -0.726 . . . . 74.52 112.469 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 9.6 t -122.26 -177.71 3.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.843 0.354 . . . . 75.4 111.113 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -121.12 164.27 17.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 71.14 111.145 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.6 t -55.71 -43.06 72.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 75.34 111.066 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -51.8 -33.51 35.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 70.41 110.852 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.0 t -81.86 -52.04 14.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 72.41 111.138 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 47.6 mm -51.64 -42.21 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 71.13 111.151 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -77.89 -25.4 48.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.874 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.6 t -77.08 -23.86 51.91 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 73.31 110.88 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.7 mt -99.45 -44.7 6.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 75.13 110.945 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.69 67.61 7.74 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.63 0.728 . . . . 63.4 110.897 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -8.22 23.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.659 2.239 . . . . 63.2 112.395 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.6 -44.09 53.74 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 73.33 112.472 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.5 m -115.21 156.71 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.881 0.372 . . . . 74.14 111.098 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -97.94 161.8 24.38 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.635 0.731 . . . . 75.34 110.849 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -7.82 22.05 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 73.33 112.36 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.42 18.89 4.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 74.51 111.063 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -143.32 40.82 1.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.215 -0.448 . . . . 73.32 110.897 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 59.9 mt -85.59 149.77 25.11 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.214 -0.448 . . . . 74.42 110.893 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . 0.459 ' H ' ' NE2' ' A' ' 125' ' ' GLN . 80.7 mm-40 -104.66 153.53 21.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 63.31 110.905 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.9 p -56.45 134.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.467 . . . . 54.44 111.122 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.25 63.21 5.04 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 72.2 112.509 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . 0.459 ' NE2' ' H ' ' A' ' 122' ' ' GLN . 5.6 tt0 -109.55 123.01 48.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 73.32 110.884 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 8.4 p -85.66 136.87 21.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 75.02 111.112 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 10.3 pt -142.56 175.94 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.123 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -97.67 153.44 18.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 60.42 110.905 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -146.24 156.16 50.27 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.594 0.712 . . . . 70.15 111.149 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 91.0 0.52 Allowed 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.684 2.256 . . . . 75.23 112.33 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 65.34 110.926 179.991 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 8.1 tpt . . . . . 0 C--O 1.23 0.055 0 CA-C-O 120.77 0.319 . . . . 65.11 110.874 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -76.54 -146.69 2.08 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.694 -0.765 . . . . 55.04 112.468 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 8.0 m -131.38 166.54 21.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.915 0.388 . . . . 72.11 110.909 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 72.7 p -124.96 150.48 46.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 71.45 111.15 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.1 t80 -123.86 135.97 54.07 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.54 110.936 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -89.66 123.38 33.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 54.54 111.177 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.4 mt -90.93 109.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 73.25 111.179 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -91.99 158.82 39.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.566 0.698 . . . . 75.54 110.936 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -59.41 92.88 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.687 2.258 . . . . 74.33 112.374 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.82 -19.04 2.56 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.751 . . . . 75.33 112.528 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -80.97 154.17 27.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.906 0.384 . . . . 74.33 110.841 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 152.46 45.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 75.05 111.152 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -53.4 -55.6 23.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.34 110.861 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -57.95 -55.76 30.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 74.35 110.871 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.26 -61.04 2.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.259 -0.428 . . . . 71.23 111.106 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 41.0 mt -51.37 -38.24 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 72.4 111.134 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.68 -38.32 90.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 71.35 111.151 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -51.93 -72.77 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 63.14 110.898 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -53.97 -41.67 68.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 74.52 110.879 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 6.9 mmp_? -57.05 -24.17 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 73.44 110.876 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.46 15.34 60.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.771 -0.728 . . . . 74.12 112.484 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 8.0 t -115.24 -175.48 2.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.931 0.396 . . . . 73.14 111.109 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -124.45 154.94 39.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 73.04 111.169 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 74.1 t -54.14 -42.94 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 75.13 111.152 179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -51.72 -39.54 58.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.139 -0.482 . . . . 74.12 110.875 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.1 t -75.14 -54.18 14.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 75.34 111.145 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 43.4 mm -51.58 -42.08 29.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 74.44 111.144 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -76.78 -25.54 53.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 75.31 110.885 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.8 t -76.18 -25.22 54.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.6 mt -96.89 -45.47 6.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 75.31 110.939 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.03 67.85 6.48 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.73 . . . . 75.23 110.939 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.49 21.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.696 2.264 . . . . 72.11 112.356 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.45 -44.46 45.62 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 72.02 112.483 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.4 m -117.2 130.93 71.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.86 0.362 . . . . 73.44 111.077 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 16.5 m-20 -76.78 160.9 75.73 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.626 0.727 . . . . 75.45 110.883 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -8.6 24.01 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.635 2.223 . . . . 74.12 112.35 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -113.65 24.93 11.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 72.43 111.112 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.7 ptm180 -178.36 104.17 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 75.22 110.88 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 63.8 mt -122.31 167.48 13.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.446 . . . . 75.21 110.882 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -109.57 153.38 24.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 71.02 110.898 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.3 p -70.44 136.19 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 74.44 111.094 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.0 63.82 4.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.733 -0.746 . . . . 65.31 112.515 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 12.1 tt0 -117.66 122.74 44.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.873 0.368 . . . . 73.34 110.892 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -88.18 125.34 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.464 . . . . 75.42 111.157 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.1 pt -125.84 175.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 71.43 111.142 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -97.76 137.43 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 71.01 110.859 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -138.95 156.19 72.65 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.609 0.718 . . . . 74.54 111.142 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 109.55 2.34 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.721 2.281 . . . . 73.34 112.345 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 75.45 110.9 -179.982 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 5.3 ttt . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.808 0.337 . . . . 52.2 110.879 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.21 -11.13 22.22 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.729 -0.748 . . . . 73.21 112.465 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 97.8 m -140.76 138.58 34.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.925 0.393 . . . . 74.53 110.853 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.4 p -123.51 168.52 12.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.133 -0.485 . . . . 74.14 111.158 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -136.82 136.59 38.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 72.24 110.891 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.1 m -89.18 122.76 32.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 73.2 111.171 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 38.8 mt -91.07 109.5 21.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 75.23 111.149 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.56 163.7 16.38 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 74.22 110.928 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -46.1 111.11 0.31 Allowed 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.708 2.272 . . . . 71.51 112.341 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 113.21 -1.64 25.35 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 74.52 112.52 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -113.17 113.82 25.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 74.44 110.87 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -101.37 157.84 16.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 75.51 111.104 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -51.5 -43.04 62.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 74.15 110.911 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.15 -47.66 27.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.111 -0.495 . . . . 74.43 110.906 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.54 -26.86 62.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 74.24 111.064 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 28.2 mt -88.31 -45.1 15.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 74.44 111.133 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -55.27 -46.15 76.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.46 . . . . 74.13 111.123 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -52.0 -44.97 64.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 72.42 110.89 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 74.8 mtt-85 -71.88 -52.7 16.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.881 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.8 mmm180 -54.12 -27.6 34.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 75.4 110.886 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.85 17.57 18.36 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.768 -0.73 . . . . 71.14 112.523 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 12.0 t -124.1 179.02 5.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.848 0.356 . . . . 73.21 111.162 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.41 164.47 17.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.198 -0.455 . . . . 73.12 111.163 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 46.8 t -55.23 -41.02 58.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.262 -0.426 . . . . 73.01 111.123 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -51.67 -38.89 56.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 75.23 110.886 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.3 t -78.38 -51.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 75.14 111.143 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 47.6 mm -51.54 -43.97 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 74.41 111.148 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -73.55 -25.54 60.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 72.42 110.931 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.5 t -78.91 -23.07 44.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 74.15 110.885 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.5 mt -98.27 -44.53 6.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 74.34 110.921 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.83 67.89 6.09 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.603 0.716 . . . . 74.2 110.909 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -7.25 20.58 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.701 2.267 . . . . 72.45 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.06 -42.03 38.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 72.32 112.435 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -119.37 125.13 74.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.858 0.361 . . . . 74.45 111.132 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -57.58 161.14 6.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.619 0.724 . . . . 71.54 110.835 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 -8.59 23.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.653 2.235 . . . . 55.43 112.322 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -126.59 14.9 7.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 73.33 111.1 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 63.0 mtt180 -141.55 93.76 2.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 74.42 110.881 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 10.0 mt -132.73 163.84 28.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 74.13 110.902 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -125.04 150.68 46.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 74.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.5 p -52.81 146.86 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.441 . . . . 74.43 111.112 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.61 65.91 2.88 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 71.3 112.536 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.2 tt0 -119.15 121.61 40.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 75.51 110.921 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 15.0 p -89.03 136.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 74.2 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 2.4 pt -138.68 174.23 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 75.13 111.166 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -100.25 139.39 35.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 75.45 110.931 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -141.19 156.12 67.9 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.645 0.736 . . . . 73.33 111.131 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 110.59 2.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.677 2.251 . . . . 74.23 112.334 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 74.11 110.921 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 6.0 mmt . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 120.826 0.346 . . . . 73.31 110.907 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 58.0 -165.33 7.1 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.689 -0.767 . . . . 75.33 112.543 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 19.4 m -128.04 165.81 19.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.37 . . . . 75.35 110.907 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.0 p -123.59 166.72 14.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.151 -0.477 . . . . 74.05 111.164 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.4 t80 -142.97 136.59 28.65 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.25 -0.432 . . . . 73.05 110.982 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -89.79 121.91 32.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 73.15 111.143 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.8 mt -90.94 109.61 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 72.23 111.156 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -86.86 158.62 53.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 75.55 110.935 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -58.54 93.61 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.639 2.226 . . . . 71.22 112.345 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.8 -18.87 2.38 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 75.43 112.482 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -84.67 138.23 32.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.361 . . . . 65.32 110.867 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.05 155.21 26.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 62.42 111.156 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -53.13 -47.52 68.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 74.42 110.878 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -71.56 -47.32 55.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 75.45 110.933 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.82 -30.44 63.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.229 -0.441 . . . . 64.15 111.144 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 38.5 mt -88.29 -33.64 6.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 74.41 111.098 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -65.0 -41.86 95.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 64.22 111.116 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -58.68 -44.64 90.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 74.13 110.904 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -78.67 -18.42 54.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 73.44 110.873 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -92.83 16.33 12.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 64.45 110.857 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.56 28.35 21.37 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.798 -0.715 . . . . 72.32 112.469 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 9.9 t -129.8 -177.24 4.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.863 0.363 . . . . 75.13 111.131 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.85 157.86 34.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 72.44 111.145 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 60.3 t -55.58 -42.26 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 74.42 111.106 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -51.82 -37.26 51.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 75.2 110.836 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.0 t -78.18 -52.99 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.11 111.138 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 49.2 mm -51.33 -43.23 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.138 -0.483 . . . . 73.35 111.125 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -76.62 -25.54 53.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 72.14 110.904 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -75.28 -25.46 57.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.201 -0.454 . . . . 65.2 110.844 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.9 mt -94.93 -46.46 6.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 72.2 110.948 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -118.5 67.33 7.2 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.628 0.727 . . . . 73.55 110.897 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.674 2.25 . . . . 65.23 112.32 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.36 -42.05 49.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 65.34 112.523 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.2 m -119.43 139.91 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.864 0.364 . . . . 74.04 111.108 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.1 161.25 66.25 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.596 0.712 . . . . 74.45 110.924 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -8.32 23.3 Favored 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.697 2.265 . . . . 74.25 112.4 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.76 20.58 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 74.13 111.106 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -144.07 43.62 1.44 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 75.55 110.863 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 71.9 mt -85.61 173.82 9.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 73.42 110.9 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -129.52 150.38 50.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 75.54 110.857 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 14.0 p -52.0 133.63 13.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 74.21 111.137 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 53.03 63.35 5.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.783 -0.722 . . . . 73.2 112.471 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -110.62 122.73 48.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 70.41 110.922 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 30.7 t -84.45 140.75 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 71.42 111.142 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.1 pt -143.73 175.24 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 53.42 111.121 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -99.78 130.82 46.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 74.01 110.92 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -123.32 156.22 63.96 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.716 . . . . 75.5 111.132 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 91.61 0.52 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.689 2.259 . . . . 70.42 112.372 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 73.14 110.877 -179.974 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.9 ptt? . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.872 0.368 . . . . 72.24 110.934 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -87.06 171.92 43.12 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.774 -0.726 . . . . 72.11 112.477 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.3 m -123.58 137.93 54.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.932 0.396 . . . . 64.23 110.865 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.8 p -123.58 163.92 20.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 72.43 111.134 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 46.7 t80 -145.12 136.68 25.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 73.34 110.938 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.75 125.23 37.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 70.12 111.13 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 79.2 mt -90.93 109.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 74.42 111.112 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -109.17 163.27 17.39 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.548 0.689 . . . . 75.44 110.933 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -46.31 121.9 5.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.638 2.225 . . . . 74.3 112.34 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.27 -4.2 54.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.778 -0.725 . . . . 73.23 112.464 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.13 116.7 32.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.937 0.399 . . . . 73.34 110.884 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.96 -179.5 3.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 73.01 111.135 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -54.64 -70.02 0.11 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 73.02 110.909 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.88 -50.52 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 75.12 110.889 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.13 -65.89 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 75.24 111.138 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 47.0 mt -51.22 -35.78 16.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 75.42 111.131 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.5 -37.34 87.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 71.12 111.06 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 19.1 mt-30 -51.92 -70.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 70.34 110.93 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.5 ptm180 -57.01 -43.04 81.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 74.44 110.847 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.6 -24.81 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 75.45 110.858 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.07 17.13 56.68 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 63.23 112.463 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 7.3 t -121.71 -174.65 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.838 0.351 . . . . 72.32 111.174 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -125.46 165.34 18.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 75.12 111.174 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 41.4 t -55.8 -44.69 78.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.264 -0.426 . . . . 71.4 111.067 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -51.92 -30.11 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 72.32 110.849 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.88 -52.19 13.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 73.43 111.139 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 48.7 mm -51.29 -43.08 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 75.14 111.11 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -76.2 -25.42 55.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 73.23 110.924 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.9 m -80.02 -20.31 45.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.854 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.9 mt -94.94 -47.86 6.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.121 -0.49 . . . . 73.32 110.906 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -118.51 67.28 7.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.634 0.73 . . . . 74.42 110.897 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -8.48 23.71 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.737 2.291 . . . . 75.42 112.39 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -69.76 -17.6 73.31 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.75 -0.738 . . . . 73.42 112.478 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.1 t -125.89 112.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.845 0.355 . . . . 75.44 111.133 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.19 160.29 1.72 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.591 0.71 . . . . 73.03 110.912 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -45.63 1.53 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.691 2.261 . . . . 71.21 112.368 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.24 -29.84 24.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 74.34 111.13 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -83.41 68.5 9.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 74.44 110.895 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 53.7 mt -121.3 137.89 54.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 61.13 110.941 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -110.34 153.57 24.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 70.33 110.913 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -51.56 147.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 71.14 111.107 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.73 66.9 2.28 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 74.51 112.505 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 3.8 tt0 -116.47 122.4 44.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 75.12 110.941 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.8 t -86.26 130.56 36.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 75.33 111.102 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 12.1 pt -141.12 175.79 5.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 71.41 111.139 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -99.18 152.18 20.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 65.35 110.872 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.61 156.18 80.12 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.603 0.716 . . . . 73.24 111.132 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 110.33 2.53 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.664 2.242 . . . . 74.12 112.36 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 75.03 110.912 179.982 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.6 ttt . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.836 0.35 . . . . 71.12 110.909 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -129.13 -156.53 8.92 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.752 -0.737 . . . . 74.42 112.533 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.26 146.02 42.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.953 0.406 . . . . 73.21 110.838 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.4 p -123.59 157.58 33.39 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.132 -0.485 . . . . 53.5 111.109 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -141.89 136.69 30.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.962 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -93.45 126.88 38.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 75.42 111.14 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 63.5 mt -91.0 109.52 21.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 73.45 111.089 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -92.02 159.25 38.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.537 0.684 . . . . 75.21 110.914 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -57.95 94.47 0.07 OUTLIER 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.686 2.257 . . . . 74.45 112.306 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.79 -18.1 2.59 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.781 -0.723 . . . . 74.02 112.513 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -91.22 157.09 17.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.909 0.385 . . . . 75.31 110.837 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -141.4 178.28 7.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 73.44 111.125 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -54.49 -66.43 0.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 73.1 110.858 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -54.79 -52.15 63.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.157 -0.474 . . . . 75.41 110.909 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -50.57 -66.09 0.45 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 74.42 111.089 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 54.8 mt -51.15 -33.96 13.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 75.24 111.116 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.94 -39.53 93.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 73.14 111.086 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 21.0 mt-30 -52.12 -69.39 0.11 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 74.22 110.874 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -55.3 -50.34 69.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 74.43 110.92 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 6.3 mmp_? -51.96 -29.97 22.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 72.12 110.866 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 94.56 12.27 56.02 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.81 -0.71 . . . . 71.24 112.524 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.7 t -114.11 -172.47 2.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.811 0.338 . . . . 71.34 111.163 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.7 m -124.87 162.56 24.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 74.54 111.167 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 69.2 t -53.38 -43.87 53.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 70.44 111.133 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -51.68 -37.3 50.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 70.21 110.848 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.2 t -76.83 -47.18 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 72.15 111.141 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 41.6 mm -50.84 -45.36 28.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 75.24 111.128 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -77.37 -25.46 50.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.142 -0.481 . . . . 70.54 110.965 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.7 t -76.69 -21.02 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 74.21 110.832 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.5 mt -97.72 -45.33 6.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 75.44 110.932 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.18 67.84 6.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.637 0.732 . . . . 74.13 110.892 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -8.41 23.53 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.656 2.237 . . . . 73.42 112.351 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -68.75 -19.57 73.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 71.3 112.43 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.6 t -127.3 139.71 51.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 65.41 111.115 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -79.82 160.33 69.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.631 0.729 . . . . 71.03 110.926 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -15.03 36.73 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.69 2.26 . . . . 62.43 112.342 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -116.42 -23.28 8.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 75.53 111.065 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -91.83 55.02 2.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 74.54 110.893 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 75.2 mt -107.98 131.93 54.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.459 . . . . 63.25 110.909 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -97.65 153.55 18.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 72.5 110.904 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.6 p -54.71 144.36 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 71.45 111.092 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.98 66.34 2.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.764 -0.731 . . . . 72.44 112.478 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -118.72 122.07 41.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.83 0.347 . . . . 75.32 110.898 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.4 t -84.51 126.94 40.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 74.52 111.191 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.45 175.86 10.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 73.23 111.17 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -96.08 159.76 14.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 72.45 110.885 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.1 m -144.07 156.33 58.33 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.63 0.729 . . . . 73.15 111.134 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 90.87 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.655 2.237 . . . . 73.01 112.326 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 74.43 110.873 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 9.5 mmt . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.847 0.356 . . . . 72.34 110.886 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 163.3 -115.8 0.67 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.724 -0.75 . . . . 75.13 112.5 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.4 m -130.16 139.4 50.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.951 0.405 . . . . 75.54 110.894 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 18.2 p -125.5 163.06 23.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 65.23 111.128 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -139.19 136.31 34.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 64.31 110.917 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 m -92.26 123.26 35.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 74.45 111.123 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 85.3 mt -90.9 109.47 21.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 75.24 111.162 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -112.6 162.63 20.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.55 0.69 . . . . 74.21 110.963 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -47.33 101.07 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.685 2.257 . . . . 63.21 112.378 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 124.75 0.47 8.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 74.02 112.519 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -115.22 116.91 29.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.869 0.366 . . . . 70.32 110.877 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.08 169.57 8.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 63.04 111.145 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -53.68 -66.03 0.46 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.187 -0.461 . . . . 74.33 110.897 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -55.94 -49.6 73.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 74.15 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -50.22 -55.21 16.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.24 -0.436 . . . . 63.11 111.091 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 35.4 mt -62.69 -31.93 53.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 73.35 111.127 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -69.65 -29.93 67.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 75.43 111.083 179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -52.59 -74.11 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.914 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -57.38 -38.79 74.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 74.12 110.87 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 8.2 mmp_? -57.78 -23.47 52.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 74.24 110.857 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 82.84 18.83 64.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.755 -0.736 . . . . 74.24 112.456 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 11.8 t -116.68 -179.88 3.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.846 0.355 . . . . 54.22 111.11 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -122.58 161.28 24.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 64.42 111.149 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.3 t -55.11 -47.3 77.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 74.5 111.117 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 40.4 m-20 -51.88 -30.03 22.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 75.44 110.812 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 47.0 t -80.83 -54.15 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 71.21 111.177 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 51.2 mm -52.5 -41.79 37.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.148 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.06 -25.36 58.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 61.12 110.902 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.8 t -81.15 -21.46 39.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.214 -0.448 . . . . 62.4 110.843 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.2 mt -99.48 -44.52 6.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 72.31 110.915 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.37 68.58 5.37 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.602 0.715 . . . . 73.32 110.86 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -7.5 21.2 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.69 2.26 . . . . 73.12 112.35 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.26 -40.28 37.13 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 74.53 112.506 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.3 m -118.05 127.32 75.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.826 0.346 . . . . 72.32 111.122 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.1 m-20 -56.76 161.63 4.36 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.618 0.723 . . . . 72.2 110.92 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -8.16 22.89 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.686 2.257 . . . . 64.42 112.323 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.9 21.96 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 72.12 111.119 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -144.0 101.37 3.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 73.14 110.866 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 53.1 mt -139.3 150.85 45.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 74.41 110.926 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -117.86 150.61 38.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 70.15 110.883 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 12.6 p -51.77 148.22 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 73.32 111.121 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.36 66.53 2.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.732 -0.747 . . . . 74.33 112.448 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -117.84 121.25 40.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.822 0.344 . . . . 74.3 110.927 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.95 125.01 42.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 73.21 111.158 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 pt -132.31 175.79 10.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 75.4 111.121 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.39 149.19 23.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 75.13 110.878 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -135.12 156.17 78.43 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.635 0.731 . . . . 71.14 111.15 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 110.66 2.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.679 2.253 . . . . 61.04 112.334 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 92.3 m . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 75.24 110.928 179.969 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 6.8 ptm . . . . . 0 C--O 1.23 0.05 0 CA-C-O 120.861 0.362 . . . . 63.45 110.846 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -93.83 -135.61 7.7 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.762 -0.733 . . . . 54.11 112.493 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 4.5 m -113.13 149.95 32.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.925 0.393 . . . . 74.13 110.84 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 76.5 p -126.19 154.89 42.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 72.32 111.137 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 47.8 t80 -132.37 136.66 46.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 73.45 110.929 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.3 m -92.87 125.58 37.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 75.52 111.147 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.12 110.0 21.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.262 -0.426 . . . . 73.34 111.122 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -112.21 162.44 21.38 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.57 0.7 . . . . 74.53 110.935 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_exo -46.14 101.53 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.685 2.256 . . . . 72.23 112.379 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 121.37 2.5 10.8 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 71.52 112.496 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -105.24 113.95 27.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.897 0.38 . . . . 64.13 110.885 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.12 166.21 10.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 74.32 111.152 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -51.02 -46.13 61.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 72.35 110.902 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.35 -49.63 21.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 74.34 110.977 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.11 -27.94 36.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 75.02 111.114 179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 42.9 mt -89.1 -41.47 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 73.3 111.16 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -57.1 -42.69 81.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 63.33 111.111 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -57.19 -45.02 84.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 63.24 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -65.6 -59.98 3.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 72.41 110.882 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.2 mmm180 -52.12 -29.87 23.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.138 -0.483 . . . . 74.24 110.876 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.58 13.53 29.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 61.14 112.474 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.9 t -115.35 -174.18 2.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.853 0.359 . . . . 73.4 111.128 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.92 163.47 16.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 74.14 111.172 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.7 t -54.55 -44.43 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.261 -0.427 . . . . 74.32 111.129 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -51.68 -33.61 34.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 75.11 110.829 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.9 t -80.57 -48.08 20.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 71.5 111.156 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 45.2 mm -51.19 -43.52 27.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 63.5 111.159 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -77.76 -25.48 49.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 75.04 110.934 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t -76.17 -23.53 54.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 75.45 110.805 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -99.16 -45.37 5.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 74.3 110.908 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.83 68.29 6.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.653 0.74 . . . . 72.43 110.852 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -8.17 22.93 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.656 2.237 . . . . 74.35 112.389 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.55 -43.39 52.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.69 -0.767 . . . . 61.43 112.53 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.1 m -116.42 163.04 13.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.884 0.373 . . . . 75.22 111.078 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -104.31 161.1 23.88 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.59 0.71 . . . . 75.14 110.864 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.71 -8.52 23.81 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.693 2.262 . . . . 74.01 112.372 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -128.76 12.02 6.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 74.01 111.124 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.9 mmt85 -143.77 49.67 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 74.55 110.863 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 22.9 mt -85.64 166.95 15.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.227 -0.442 . . . . 74.31 110.918 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -120.59 139.39 53.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 74.41 110.897 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.3 p -54.05 140.6 10.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 74.12 111.104 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.31 61.62 6.11 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.779 -0.724 . . . . 73.35 112.462 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -119.17 122.27 41.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.811 0.339 . . . . 72.44 110.882 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.1 p -84.43 134.61 26.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 74.24 111.106 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.8 pt -134.98 175.93 9.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 75.13 111.132 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -95.91 143.25 27.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 63.34 110.859 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -131.87 156.22 80.38 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.612 0.72 . . . . 72.3 111.12 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 86.58 0.58 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.652 2.235 . . . . 70.54 112.357 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.26 -0.427 . . . . 74.21 110.876 -179.999 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 27.6 mmm . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.821 0.344 . . . . 75.13 110.871 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -106.84 -152.26 18.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.769 -0.729 . . . . 74.05 112.516 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 73.4 m -135.69 136.62 41.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.928 0.394 . . . . 71.03 110.848 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 35.7 p -124.47 156.22 37.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 73.11 111.124 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 44.3 t80 -132.35 136.54 46.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.274 -0.421 . . . . 74.42 110.891 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -92.54 122.97 35.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 72.35 111.168 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 83.0 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 75.21 111.124 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.8 mm100 -112.29 162.45 21.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.58 0.705 . . . . 75.02 110.925 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -47.28 101.22 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.663 2.242 . . . . 75.33 112.335 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 123.8 1.36 8.97 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.73 -0.748 . . . . 72.5 112.478 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -118.46 111.58 18.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.901 0.381 . . . . 74.33 110.872 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.53 159.84 14.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 74.43 111.151 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -51.33 -44.13 61.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 74.23 110.854 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.19 -48.0 25.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.922 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.22 -28.03 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 72.41 111.112 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 32.6 mt -87.76 -45.38 16.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 72.41 111.107 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -53.97 -47.28 71.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 70.05 111.061 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -51.93 -44.96 64.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.199 -0.455 . . . . 73.03 110.914 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 77.4 mtp180 -68.78 -53.94 18.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.196 -0.456 . . . . 74.22 110.872 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -55.27 -26.29 39.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 73.5 110.897 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 101.91 16.27 24.17 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.727 -0.749 . . . . 73.42 112.491 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 10.1 t -120.29 -177.87 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.86 0.362 . . . . 64.13 111.129 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.64 165.09 19.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 72.22 111.145 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 91.7 t -55.16 -40.55 55.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 74.12 111.12 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -51.7 -40.13 59.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.01 110.884 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -77.35 -51.72 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 75.3 111.153 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 50.5 mm -51.64 -44.43 34.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 72.12 111.129 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -72.86 -25.53 61.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 74.05 110.937 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t -79.98 -22.11 42.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 73.02 110.834 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 10.7 mt -98.12 -44.79 6.47 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 62.23 110.88 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.66 68.06 5.8 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.717 . . . . 73.35 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -7.13 20.26 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.669 2.246 . . . . 73.4 112.387 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.84 -40.19 33.73 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.723 -0.751 . . . . 75.54 112.473 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.5 m -118.29 127.96 75.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.795 0.331 . . . . 74.35 111.142 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -56.61 161.25 4.54 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.623 0.725 . . . . 63.3 110.913 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -8.47 23.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.644 2.229 . . . . 75.42 112.352 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.1 23.21 5.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 75.22 111.119 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.3 mmt180 -146.47 102.52 3.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.453 . . . . 72.41 110.838 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 67.2 mt -136.51 175.59 9.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 74.42 110.867 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -140.72 147.77 39.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.475 . . . . 73.05 110.913 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.5 p -52.35 147.57 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 71.31 111.094 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.63 65.2 3.32 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.697 -0.763 . . . . 55.33 112.538 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 15.2 tt0 -119.14 120.69 37.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.826 0.346 . . . . 72.44 110.925 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.36 125.11 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 74.2 111.122 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.3 pt -129.22 175.87 9.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 74.43 111.128 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -98.84 137.98 36.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 75.14 110.869 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -123.91 156.23 65.91 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.618 0.723 . . . . 71.15 111.144 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 110.52 2.59 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.698 2.265 . . . . 70.44 112.337 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.205 -0.452 . . . . 73.41 110.878 -179.954 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 6.5 ttm . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.798 0.332 . . . . 75.33 110.859 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -170.29 153.09 20.58 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.772 -0.727 . . . . 75.21 112.507 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m -133.67 145.69 50.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.9 0.381 . . . . 72.15 110.903 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.5 p -123.37 161.83 23.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 71.15 111.149 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 36.2 t80 -127.32 136.79 52.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 72.33 110.925 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 55.3 m -88.68 122.88 32.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.098 -0.501 . . . . 60.25 111.144 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.2 mt -90.83 109.52 21.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 72.53 111.153 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -111.32 162.65 19.97 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.568 0.699 . . . . 75.43 110.948 179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -46.78 101.27 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.696 2.264 . . . . 72.31 112.337 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 125.95 -1.99 7.9 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 74.31 112.455 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -105.77 129.39 53.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 74.25 110.87 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.06 164.5 15.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 72.21 111.128 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -50.94 -48.28 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 74.24 110.875 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.08 -49.01 25.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 74.35 110.944 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -53.81 -27.17 27.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.11 111.124 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 39.1 mt -91.26 -39.41 11.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 74.32 111.131 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -58.3 -41.04 83.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.149 -0.478 . . . . 74.2 111.092 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -57.13 -44.55 83.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.439 . . . . 75.22 110.905 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -69.26 -25.96 64.54 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 75.34 110.852 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 3.0 mmp_? -94.39 17.99 11.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 72.05 110.888 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.83 27.76 21.6 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.699 -0.762 . . . . 71.33 112.538 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 8.5 t -126.73 -177.22 3.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.916 0.389 . . . . 72.23 111.116 -179.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.41 167.88 14.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 65.41 111.123 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 45.9 t -56.47 -38.98 58.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 74.34 111.167 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 68.5 m-20 -51.71 -38.56 55.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 73.01 110.855 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -81.05 -50.64 16.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 64.15 111.108 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 49.7 mm -51.29 -41.02 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 73.11 111.125 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -78.58 -25.57 45.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 74.22 110.928 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 10.3 t -76.38 -24.13 54.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 75.31 110.839 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.1 mt -98.48 -44.67 6.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 75.01 110.903 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.97 67.96 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.637 0.732 . . . . 73.5 110.907 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.72 21.77 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.66 2.24 . . . . 73.23 112.36 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.78 -44.33 48.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.764 -0.731 . . . . 73.42 112.48 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.6 m -118.82 161.06 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.829 0.347 . . . . 74.42 111.121 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -108.34 160.96 25.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.634 0.731 . . . . 71.44 110.854 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -8.22 23.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.682 2.255 . . . . 73.33 112.362 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.21 -21.63 13.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 75.1 111.109 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 6.5 ptp180 -134.87 96.22 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 74.24 110.929 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 89.5 mt -117.55 161.81 19.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.181 -0.463 . . . . 72.23 110.903 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -107.67 148.81 28.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 74.54 110.932 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 14.0 p -68.89 143.75 14.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 74.23 111.118 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.2 60.85 6.75 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.715 -0.755 . . . . 74.22 112.496 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.0 tt0 -119.21 121.18 39.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.824 0.345 . . . . 64.33 110.97 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 26.2 t -88.92 132.27 34.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 74.41 111.134 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 2.4 pt -134.04 175.97 9.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.459 . . . . 73.45 111.132 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 60.0 m-20 -92.51 136.56 33.11 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.457 . . . . 74.05 110.907 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.4 m -143.76 155.99 59.5 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.547 0.689 . . . . 75.43 111.15 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.83 110.53 2.59 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.65 2.233 . . . . 74.41 112.308 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 74.41 110.873 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.5 ptp . . . . . 0 N--CA 1.458 -0.044 0 CA-C-O 120.823 0.344 . . . . 73.41 110.88 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 170.8 -158.94 30.89 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.698 -0.763 . . . . 71.14 112.456 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.2 m -131.78 135.32 46.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.877 0.37 . . . . 61.34 110.931 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 22.2 p -129.65 150.31 51.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 75.03 111.127 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -122.4 136.63 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.159 -0.473 . . . . 75.5 110.897 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -89.25 122.1 32.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 74.34 111.102 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 69.7 mt -91.03 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 74.01 111.137 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.61 163.55 16.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.6 0.715 . . . . 75.25 110.945 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -45.86 105.15 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.636 2.224 . . . . 74.32 112.374 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 118.65 1.11 15.43 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.726 -0.75 . . . . 70.34 112.491 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -105.09 144.2 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.908 0.385 . . . . 74.0 110.851 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.07 158.78 43.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 74.3 111.166 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -50.9 -47.92 60.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 72.51 110.858 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -72.97 -47.68 43.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 73.55 110.918 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -55.6 -26.56 44.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 75.41 111.114 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 21.1 mt -90.91 -38.78 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 74.24 111.158 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -61.53 -40.4 94.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 72.24 111.086 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -56.38 -44.69 80.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 74.44 110.896 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 -75.52 -49.38 18.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.451 . . . . 70.12 110.837 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 21.5 mmm180 -56.98 -24.39 52.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 75.14 110.852 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.19 23.64 37.01 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 62.54 112.478 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.6 t -114.76 -171.66 1.97 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 75.1 111.149 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.15 149.13 43.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.217 -0.447 . . . . 73.43 111.111 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 83.4 t -55.5 -46.91 79.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 65.31 111.12 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -51.85 -30.69 24.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 74.42 110.826 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 72.7 t -80.08 -54.09 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 72.32 111.154 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 41.3 mm -52.57 -42.51 40.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.166 -0.47 . . . . 74.23 111.187 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.83 -25.48 59.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.108 -0.496 . . . . 75.22 110.894 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t -79.23 -22.95 44.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 53.34 110.88 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 11.9 mt -96.5 -45.54 6.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 74.25 110.919 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.72 67.86 5.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.608 0.718 . . . . 72.11 110.924 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -7.36 20.84 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.656 2.237 . . . . 75.13 112.35 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.1 -39.48 34.29 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.778 -0.725 . . . . 72.51 112.46 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -121.76 163.02 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.844 0.354 . . . . 74.11 111.14 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 33.0 m-20 -102.99 161.21 23.8 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.615 0.722 . . . . 73.15 110.877 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.67 26.68 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.685 2.256 . . . . 73.34 112.319 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -117.44 -18.83 9.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.25 -0.432 . . . . 74.14 111.124 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -122.04 90.0 3.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 75.23 110.891 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 73.0 mt -119.39 160.38 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 73.42 110.92 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -105.49 148.55 27.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 72.33 110.919 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.2 p -61.7 139.45 20.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 74.12 111.186 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.78 62.49 5.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 63.12 112.503 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -119.28 121.9 40.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.83 0.348 . . . . 73.44 110.916 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 11.3 p -86.45 134.68 26.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 74.05 111.144 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 1.3 pp -129.45 172.76 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 74.33 111.08 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -100.33 142.95 31.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 64.2 110.9 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -136.09 156.2 77.11 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.594 0.711 . . . . 74.24 111.126 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 110.11 2.48 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.679 2.253 . . . . 74.51 112.363 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 98.9 m . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 74.21 110.905 179.992 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 2.5 mmt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.838 0.352 . . . . 65.04 110.865 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -107.95 -160.64 20.73 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.761 -0.733 . . . . 70.11 112.497 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 71.2 m -138.65 136.0 35.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.885 0.374 . . . . 72.25 110.869 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 44.8 p -124.96 150.26 46.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 72.32 111.153 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 42.1 t80 -122.48 136.68 54.94 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.212 -0.449 . . . . 74.11 110.932 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 m -91.41 120.19 32.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 74.54 111.109 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.4 mt -90.85 109.59 21.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.45 . . . . 74.25 111.132 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 22.9 mm-40 -97.29 159.45 31.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.612 0.72 . . . . 73.53 110.893 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.81 93.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.698 2.265 . . . . 75.13 112.358 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.48 -17.46 2.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 63.45 112.514 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.92 167.26 16.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.913 0.387 . . . . 75.13 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.2 151.77 45.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.192 -0.458 . . . . 75.41 111.154 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -51.03 -47.38 61.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.251 -0.431 . . . . 75.23 110.885 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -71.6 -47.16 56.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 73.13 110.895 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.73 -23.88 54.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 72.54 111.068 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 35.2 mt -95.46 -31.99 4.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.445 . . . . 74.22 111.129 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -72.18 -29.5 64.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 72.12 111.123 179.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 1.5 pp0? -65.7 -44.46 86.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.929 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.5 -13.73 53.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 74.41 110.908 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -93.03 16.56 12.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 74.33 110.922 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.63 28.1 21.12 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 61.0 112.494 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 11.8 t -129.0 -179.96 5.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.842 0.353 . . . . 73.02 111.152 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -123.28 159.77 28.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 54.45 111.152 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 52.6 t -55.07 -42.38 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 72.04 111.106 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -51.85 -38.09 54.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 71.5 110.828 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.2 -54.19 13.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 74.13 111.132 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 50.2 mm -51.42 -39.95 23.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 75.11 111.108 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -77.98 -25.56 48.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 72.12 110.9 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -76.92 -24.05 52.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 53.01 110.888 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 7.3 mt -95.18 -45.3 7.25 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.921 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.06 67.57 6.42 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.742 . . . . 74.34 110.906 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -6.96 19.86 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.693 2.262 . . . . 75.15 112.379 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.63 -39.9 31.56 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 63.51 112.484 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.1 m -118.95 160.83 18.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.827 0.346 . . . . 72.04 111.142 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -99.63 160.56 27.07 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.622 0.725 . . . . 71.44 110.888 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -22.78 31.61 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.749 2.3 . . . . 75.22 112.312 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.4 24.33 11.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 71.45 111.094 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 14.5 ptm180 -177.33 111.56 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 74.34 110.873 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 86.1 mt -127.66 -179.59 5.01 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.176 -0.466 . . . . 72.01 110.926 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -124.16 147.56 47.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 74.02 110.928 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 14.6 p -62.85 139.99 20.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 74.44 111.167 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.67 65.14 3.37 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 53.31 112.475 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 8.8 tt0 -113.69 127.72 56.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.787 0.327 . . . . 73.15 110.933 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 17.6 t -91.51 122.77 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 75.32 111.09 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.1 pt -127.84 175.84 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 72.42 111.089 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -110.87 143.36 41.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 74.32 110.919 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.93 156.23 79.38 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.631 0.729 . . . . 74.3 111.121 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 110.77 2.64 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.696 2.264 . . . . 63.32 112.334 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 73.31 110.884 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 18.9 ttt . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.816 0.341 . . . . 73.45 110.873 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -136.79 -167.66 11.2 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.772 -0.728 . . . . 52.44 112.507 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 26.0 m -139.29 134.96 33.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.858 0.361 . . . . 63.51 110.879 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.7 p -124.85 167.72 14.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 73.53 111.128 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.8 t80 -139.49 136.38 34.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 63.11 110.877 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.1 m -90.89 121.18 32.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.119 -0.491 . . . . 71.44 111.128 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 64.4 mt -91.04 109.29 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 75.2 111.09 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -110.39 162.86 18.82 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 63.23 110.911 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -45.89 118.77 2.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.711 2.274 . . . . 73.12 112.35 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 108.32 -23.83 23.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.797 -0.716 . . . . 54.22 112.529 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -86.67 121.98 29.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.868 0.366 . . . . 75.44 110.877 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.87 156.16 19.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 74.35 111.134 -179.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -51.61 -45.25 63.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 73.1 110.863 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -70.46 -51.4 29.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 75.12 110.9 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.63 -31.86 58.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 61.22 111.133 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 34.5 mt -84.04 -35.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.126 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -63.15 -48.32 78.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 74.14 111.133 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -52.99 -44.93 67.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.91 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 6.8 ptp85 -78.62 -18.05 55.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 71.44 110.898 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -94.11 19.74 8.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.189 -0.459 . . . . 72.14 110.923 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.78 28.12 22.32 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.735 -0.745 . . . . 73.0 112.478 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 14.5 t -134.45 174.72 10.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.844 0.354 . . . . 74.33 111.167 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.58 164.62 15.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.03 111.172 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 22.6 t -57.41 -41.44 78.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.02 111.166 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -51.82 -34.42 40.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.862 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.79 -51.72 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 73.53 111.079 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 49.0 mm -51.75 -41.71 29.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.236 -0.438 . . . . 73.43 111.135 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.2 pt20 -78.32 -25.53 46.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 71.34 110.928 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -78.69 -20.92 49.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 75.11 110.874 -179.785 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 21.0 mt -98.29 -45.49 6.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.486 . . . . 74.1 110.896 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -118.45 67.91 7.4 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.635 0.731 . . . . 75.14 110.9 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -8.53 23.83 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.717 2.278 . . . . 74.41 112.302 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.77 -26.33 62.58 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.757 -0.735 . . . . 53.2 112.454 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.5 t -121.4 92.53 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.788 0.327 . . . . 71.54 111.151 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -51.8 159.13 1.42 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.617 0.723 . . . . 73.44 110.856 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -29.98 22.92 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.666 2.244 . . . . 74.24 112.326 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -95.13 31.99 1.8 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 62.43 111.059 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 179.88 93.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 75.53 110.865 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 45.5 mt -116.2 144.58 44.0 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 74.12 110.911 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -98.59 153.31 18.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 73.44 110.92 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.71 144.06 12.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 74.02 111.121 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.51 59.02 8.92 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.739 . . . . 51.32 112.443 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -119.26 122.64 42.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.834 0.349 . . . . 64.31 110.915 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 33.6 t -88.52 127.05 41.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 73.21 111.127 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.2 pt -123.54 175.91 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.172 -0.467 . . . . 73.32 111.15 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 6.0 m-20 -94.55 145.46 24.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.186 -0.461 . . . . 65.14 110.91 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.94 156.1 78.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.638 0.732 . . . . 64.55 111.108 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 110.64 2.61 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.733 2.288 . . . . 72.13 112.314 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 46.6 m . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 71.11 110.869 179.993 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 11.7 mmm . . . . . 0 N--CA 1.458 -0.066 0 CA-C-O 120.789 0.328 . . . . 71.12 110.88 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 104.09 161.23 24.56 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.702 -0.761 . . . . 74.3 112.479 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 3.9 m -136.42 166.54 23.25 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.888 0.375 . . . . 72.53 110.871 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.4 p -123.55 154.67 38.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 53.31 111.148 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -133.5 134.99 44.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 75.34 110.926 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.6 125.98 35.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 74.34 111.175 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.8 mt -90.9 109.38 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 73.53 111.157 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 49.5 mm-40 -110.92 161.94 22.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.623 0.725 . . . . 74.44 110.89 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -45.98 121.45 4.34 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.721 2.281 . . . . 63.11 112.328 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.19 34.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.732 -0.747 . . . . 72.41 112.418 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -95.79 121.03 37.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.844 0.354 . . . . 74.14 110.845 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.0 165.33 11.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 71.13 111.123 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -53.98 -60.8 2.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 74.3 110.866 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -56.57 -52.47 64.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.152 -0.477 . . . . 75.02 110.906 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.42 -62.42 1.63 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.449 . . . . 75.22 111.13 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 34.3 mt -51.5 -38.15 20.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 71.44 111.138 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.28 -37.19 86.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 73.05 111.115 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -51.91 -72.11 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 72.25 110.928 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 10.0 ptt-85 -55.87 -40.47 72.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 74.43 110.858 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.8 mmp_? -57.9 -24.04 55.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.171 -0.468 . . . . 74.12 110.885 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 71.42 112.473 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 12.4 t -120.99 178.87 4.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 74.1 111.15 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -119.82 162.93 18.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 74.44 111.181 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 23.9 t -56.68 -40.32 69.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.24 -0.436 . . . . 71.04 111.155 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -51.76 -36.24 46.61 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 52.34 110.836 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 25.7 t -81.96 -50.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 63.51 111.141 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 47.7 mm -51.95 -41.12 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.149 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -79.14 -25.39 42.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 72.44 110.93 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 t -79.44 -20.14 48.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 75.43 110.872 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.5 mt -98.38 -45.72 6.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 64.22 110.927 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.95 68.05 6.41 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.563 0.697 . . . . 73.23 110.891 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -8.54 23.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.69 2.26 . . . . 73.52 112.346 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.41 -23.89 67.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.757 . . . . 73.31 112.518 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.45 104.74 15.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 60.54 111.11 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -75.09 154.68 86.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.61 0.719 . . . . 55.42 110.909 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -13.76 35.14 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.678 2.252 . . . . 75.15 112.338 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -71.29 -18.9 62.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 73.41 111.092 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -170.61 115.23 0.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 74.51 110.887 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 55.4 mt -108.2 153.45 23.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 61.01 110.882 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 53.8 mm-40 -97.84 148.78 23.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 71.43 110.942 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.9 145.03 11.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 75.42 111.156 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.33 58.13 10.42 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 72.13 112.479 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -119.33 120.69 37.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.818 0.342 . . . . 72.45 110.877 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 6.4 p -85.06 130.88 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 74.51 111.183 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.2 pt -131.06 175.85 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 73.14 111.162 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 39.3 m-20 -89.94 145.62 24.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.463 . . . . 73.54 110.842 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -147.67 156.15 45.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.627 0.727 . . . . 74.41 111.094 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.649 2.233 . . . . 75.21 112.309 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 74.44 110.895 179.955 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 12.0 mtm . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.778 0.323 . . . . 71.31 110.921 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 63.61 -162.74 33.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.718 -0.753 . . . . 75.12 112.478 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 2.4 m -125.27 142.12 51.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.919 0.39 . . . . 52.42 110.903 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 71.9 p -123.67 151.47 43.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 75.2 111.11 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -138.25 136.52 36.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.215 -0.448 . . . . 72.32 110.927 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.4 m -92.65 126.44 37.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 62.13 111.166 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.89 109.44 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 64.43 111.121 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.0 mm-40 -110.36 162.06 22.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.642 0.734 . . . . 73.03 110.906 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -45.93 118.39 2.31 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 74.12 112.355 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.62 -18.88 29.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.73 -0.748 . . . . 75.34 112.51 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -96.87 115.68 27.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 73.13 110.865 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.92 159.78 15.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.189 -0.46 . . . . 73.51 111.122 -179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -53.66 -55.03 29.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 72.33 110.859 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.2 t-105 -57.96 -56.21 24.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.137 -0.483 . . . . 73.52 110.875 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.36 -60.6 2.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.26 -0.427 . . . . 61.52 111.103 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 33.0 mt -51.62 -37.86 20.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 73.55 111.137 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.46 86.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.176 -0.465 . . . . 74.12 111.126 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -51.81 -65.15 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 75.33 110.915 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.2 mtt180 -63.32 -41.27 98.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 72.24 110.945 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.6 mmp_? -55.87 -25.7 43.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 74.1 110.816 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.76 17.41 51.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 72.31 112.494 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 11.5 t -119.37 179.9 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.856 0.36 . . . . 74.42 111.148 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.18 157.77 28.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 72.42 111.153 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 26.3 t -55.48 -42.83 69.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 74.15 111.131 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -51.84 -36.31 47.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 73.31 110.87 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -78.83 -53.6 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 73.24 111.127 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 44.8 mm -51.66 -40.58 26.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 74.42 111.173 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -77.75 -25.42 49.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 73.33 110.931 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.5 t -80.38 -20.35 44.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 73.14 110.835 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.1 mt -98.35 -45.53 6.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 71.44 110.872 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.96 68.17 6.48 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.641 0.734 . . . . 73.52 110.883 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -8.5 23.77 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.694 2.263 . . . . 74.55 112.33 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.04 -22.92 58.73 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.793 -0.718 . . . . 63.11 112.461 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.1 t -121.89 107.91 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.86 0.362 . . . . 74.14 111.096 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.55 155.0 81.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.636 0.732 . . . . 74.23 110.876 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.79 -16.72 37.55 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.707 2.272 . . . . 72.13 112.313 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -68.65 -19.44 64.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.261 -0.427 . . . . 74.01 111.13 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.3 ptt180 -173.48 116.63 0.26 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 73.41 110.899 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 61.7 mt -103.46 154.6 19.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 75.51 110.91 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 -97.77 143.12 28.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 73.12 110.957 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.51 145.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 55.11 111.133 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.28 59.1 8.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 72.32 112.495 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -119.3 121.57 39.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 73.44 110.909 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 22.4 t -85.27 127.11 40.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 71.13 111.141 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 10.0 pt -123.5 174.32 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 71.23 111.132 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -96.89 144.28 26.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.156 -0.475 . . . . 75.23 110.937 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.25 156.19 79.75 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.641 0.734 . . . . 73.11 111.108 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 85.47 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.658 2.239 . . . . 74.52 112.377 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.147 -0.479 . . . . 65.15 110.924 -179.981 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 5.3 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.932 0.396 . . . . 63.21 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 41.3 p -123.55 168.08 13.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 53.11 111.14 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.42 ' HB2' HG21 ' A' ' 129' ' ' VAL . 45.8 t80 -145.23 136.38 24.89 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 72.13 110.968 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.6 m -91.73 123.09 34.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.108 -0.496 . . . . 75.43 111.116 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 60.6 mt -90.89 109.49 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.453 . . . . 74.31 111.152 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -111.24 163.51 17.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.617 0.722 . . . . 73.03 110.93 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_exo -46.16 124.58 7.71 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.718 2.278 . . . . 75.44 112.333 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 106.54 -17.96 38.86 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.777 -0.725 . . . . 65.03 112.483 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -97.31 147.03 24.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.908 0.385 . . . . 75.41 110.833 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.96 174.36 10.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 40.34 111.121 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.518 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.3 m-85 -54.51 -70.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 75.24 110.905 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.92 -50.07 61.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.16 -0.473 . . . . 74.33 110.924 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.03 -66.29 0.41 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.264 -0.425 . . . . 71.34 111.11 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 43.9 mt -51.37 -32.68 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 75.43 111.077 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -66.73 -38.46 86.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 65.44 111.147 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 19.4 mt-30 -52.32 -69.42 0.11 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 74.04 110.882 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 9.6 ptm180 -56.28 -44.48 79.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 75.31 110.855 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -56.35 -25.03 47.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 74.34 110.841 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.82 16.55 56.21 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.736 -0.745 . . . . 70.04 112.463 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.683 HG21 HD11 ' A' ' 109' ' ' ILE . 7.7 t -119.84 -176.1 3.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.897 0.38 . . . . 54.34 111.103 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.402 HG22 ' H ' ' A' ' 106' ' ' VAL . 0.3 OUTLIER -125.27 165.97 17.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 75.05 111.14 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.461 HG12 ' OE1' ' A' ' 110' ' ' GLN . 61.3 t -55.78 -41.12 64.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 72.41 111.175 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -51.79 -36.03 46.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 73.41 110.856 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.21 -51.5 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 73.24 111.103 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.683 HD11 HG21 ' A' ' 104' ' ' THR . 49.7 mm -51.25 -42.45 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 74.12 111.166 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.461 ' OE1' HG12 ' A' ' 106' ' ' VAL . 19.0 pt20 -78.18 -25.4 47.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 74.24 110.909 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.7 t -78.05 -21.07 51.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 74.41 110.864 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 43.3 mt -97.05 -46.16 6.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.151 -0.477 . . . . 73.24 110.921 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -117.96 68.15 6.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.596 0.712 . . . . 63.42 110.878 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -8.51 23.78 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.657 2.238 . . . . 71.54 112.314 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -67.23 -17.59 68.34 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.733 -0.746 . . . . 64.12 112.523 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.551 HG21 ' OE1' ' A' ' 125' ' ' GLN . 2.2 t -131.14 119.67 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.909 0.385 . . . . 65.0 111.098 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -88.77 154.86 50.51 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.599 0.714 . . . . 74.5 110.902 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -19.63 35.73 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.725 2.283 . . . . 74.44 112.327 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.79 -15.98 60.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 63.13 111.112 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -170.56 115.33 0.47 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 74.43 110.852 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.518 HD11 ' CD2' ' A' ' 95' ' ' PHE . 47.0 mt -117.34 150.79 38.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.47 . . . . 72.14 110.933 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.0 mm100 -97.77 149.5 22.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 74.0 110.911 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.3 p -68.35 146.61 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 63.11 111.137 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.8 63.73 4.51 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 63.32 112.514 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' GLN . . . . . 0.551 ' OE1' HG21 ' A' ' 116' ' ' VAL . 13.5 tt0 -119.14 121.62 40.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 71.44 110.907 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.54 124.53 40.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 41.52 111.121 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.6 pt -127.83 175.93 8.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 71.33 111.148 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -96.05 144.07 26.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 74.1 110.9 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.42 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -141.26 156.15 67.68 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.726 . . . . 73.45 111.085 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 105.52 1.5 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.675 2.25 . . . . 74.52 112.346 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.2 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 74.42 110.873 -179.972 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.1 m . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.892 0.377 . . . . 65.42 110.876 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.5 p -126.43 161.52 27.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.148 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.428 ' CE1' HD13 ' A' ' 98' ' ' ILE . 45.2 t80 -142.85 136.63 28.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 74.44 110.918 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 m -93.44 124.03 37.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 63.5 111.124 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.8 mt -91.05 109.58 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 65.11 111.116 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -111.58 163.52 17.3 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.579 0.704 . . . . 63.41 110.926 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_exo -46.16 120.95 4.01 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.712 2.274 . . . . 70.31 112.336 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.6 -18.86 26.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.759 . . . . 43.12 112.478 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.565 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.4 m-20 -99.04 140.94 32.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.896 0.379 . . . . 63.44 110.852 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.77 163.8 24.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 44.51 111.134 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.416 ' CE1' HG22 ' A' ' 109' ' ' ILE . 1.3 m-85 -54.99 -64.57 0.79 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 73.51 110.865 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -56.2 -50.67 70.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 74.11 110.919 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.65 -65.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 55.33 111.049 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.565 HD11 ' CB ' ' A' ' 93' ' ' ASP . 36.3 mt -51.73 -37.0 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 70.15 111.118 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.402 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -64.13 -36.1 82.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 73.44 111.085 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.9 mt-30 -51.82 -63.75 1.03 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 75.45 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 47.9 mtm180 -67.1 -39.38 86.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.41 110.89 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ARG . . . . . 0.558 ' HG3' HG22 ' A' ' 98' ' ' ILE . 8.5 mmp_? -56.41 -25.14 49.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 72.15 110.904 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 92.23 17.15 47.82 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 75.51 112.517 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.949 HG21 HD11 ' A' ' 109' ' ' ILE . 13.4 t -125.21 177.3 6.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.87 0.367 . . . . 73.5 111.13 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.401 HG22 ' H ' ' A' ' 106' ' ' VAL . 1.1 m -125.43 164.68 19.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 71.52 111.104 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.401 ' H ' HG22 ' A' ' 105' ' ' THR . 58.9 t -54.68 -40.88 53.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.198 -0.455 . . . . 70.12 111.094 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ASP . . . . . 0.617 ' OD2' HG23 ' A' ' 108' ' ' VAL . 0.6 OUTLIER -51.67 -38.51 55.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.196 -0.456 . . . . 75.44 110.877 179.884 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.617 HG23 ' OD2' ' A' ' 107' ' ' ASP . 24.9 t -78.94 -52.33 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 75.31 111.142 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.949 HD11 HG21 ' A' ' 104' ' ' THR . 47.7 mm -52.2 -41.1 32.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 61.04 111.179 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -75.66 -25.51 56.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 61.22 110.905 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.3 t -79.41 -23.47 43.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 43.44 110.863 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.7 mt -98.92 -44.65 6.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 75.44 110.897 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -117.67 68.29 5.91 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.625 0.726 . . . . 64.44 110.874 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -7.3 20.72 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.625 2.216 . . . . 74.53 112.366 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.34 -43.75 43.84 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.747 -0.739 . . . . 43.53 112.518 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.517 HG11 HE22 ' A' ' 125' ' ' GLN . 2.4 m -116.46 127.24 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.802 0.334 . . . . 54.11 111.151 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -55.92 160.87 3.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.619 0.723 . . . . 63.21 110.917 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.73 24.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.266 . . . . 75.33 112.348 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -133.07 24.39 4.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.34 111.102 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 67.9 mtp85 -149.73 89.48 1.62 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 74.43 110.86 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.487 HD23 ' HB ' ' A' ' 116' ' ' VAL . 9.9 mt -125.16 176.23 6.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 74.12 110.943 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 24.3 mm100 -136.38 150.4 48.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.889 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.1 p -54.37 146.45 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 60.4 111.188 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.02 65.01 3.5 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.73 -0.747 . . . . 44.33 112.509 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' GLN . . . . . 0.517 HE22 HG11 ' A' ' 116' ' ' VAL . 13.6 tt0 -119.12 122.01 41.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.816 0.341 . . . . 75.53 110.941 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.4 p -87.43 135.04 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 75.22 111.141 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.0 pt -140.74 175.82 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 75.43 111.163 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 10.0 m-20 -103.19 143.06 33.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 74.22 110.894 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.2 156.14 66.99 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 74.4 111.151 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 110.54 2.59 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.657 2.238 . . . . 73.05 112.351 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 70.3 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 61.3 110.894 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 81.8 m . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.943 0.401 . . . . 75.02 110.843 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.6 p -125.55 163.47 22.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 63.1 111.201 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.434 ' CE1' HD13 ' A' ' 98' ' ' ILE . 42.2 t80 -142.85 136.56 28.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.256 -0.429 . . . . 71.11 110.933 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -93.61 123.66 37.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.123 -0.489 . . . . 63.31 111.15 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.422 HD12 ' HB3' ' A' ' 125' ' ' GLN . 74.8 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 75.41 111.127 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.1 mm-40 -109.28 163.15 17.69 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.56 0.695 . . . . 73.15 110.896 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -46.17 124.8 7.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 64.31 112.321 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.75 -18.88 39.85 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.724 -0.751 . . . . 63.2 112.464 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -96.83 141.39 30.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.886 0.374 . . . . 74.43 110.875 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -129.73 170.26 14.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 73.25 111.164 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.52 ' HZ ' HG23 ' A' ' 116' ' ' VAL . 1.3 m-85 -54.39 -69.53 0.12 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 54.23 110.886 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.1 t-105 -52.3 -49.93 63.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 73.24 110.939 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.31 -65.7 0.51 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.238 -0.437 . . . . 71.4 111.076 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.434 HD13 ' CE1' ' A' ' 87' ' ' TYR . 46.8 mt -51.77 -37.09 19.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.264 -0.426 . . . . 71.32 111.14 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -63.64 -35.87 81.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 72.54 111.123 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -51.78 -68.18 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 72.01 110.909 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 46.6 mtt180 -61.71 -41.99 98.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 74.21 110.837 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.1 mmm180 -54.68 -27.1 37.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 64.12 110.893 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.4 18.09 50.41 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 50.33 112.451 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.977 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -119.36 178.39 4.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.866 0.365 . . . . 65.4 111.142 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -120.97 160.68 23.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 72.41 111.177 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.0 t -54.37 -47.17 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 51.31 111.172 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -52.24 -29.71 24.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 54.32 110.844 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.553 HG12 HD12 ' A' ' 112' ' ' LEU . 61.7 t -81.32 -54.19 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 73.43 111.104 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.977 HD11 HG21 ' A' ' 104' ' ' THR . 50.0 mm -52.59 -39.65 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 71.14 111.12 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -25.35 47.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 73.55 110.926 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 t -80.64 -21.01 41.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.187 -0.46 . . . . 71.51 110.847 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.553 HD12 HG12 ' A' ' 108' ' ' VAL . 6.6 mt -102.59 -42.13 6.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.104 -0.498 . . . . 72.43 110.928 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -117.64 68.34 5.87 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.644 0.735 . . . . 75.3 110.894 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -7.29 20.69 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.681 2.254 . . . . 74.52 112.357 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.29 -43.5 43.17 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.749 -0.739 . . . . 75.05 112.477 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.669 HG11 ' NE2' ' A' ' 125' ' ' GLN . 2.2 m -116.43 128.04 73.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.883 0.373 . . . . 74.35 111.167 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -58.45 161.49 7.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 62.4 110.885 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -8.48 23.72 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.699 2.266 . . . . 71.34 112.324 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.13 18.87 4.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.091 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -142.67 87.28 1.99 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 74.42 110.866 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 7.9 mt -124.23 167.94 13.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.478 . . . . 72.53 110.885 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -135.42 153.31 51.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 74.54 110.875 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.9 p -52.81 147.76 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 71.2 111.12 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.69 66.72 2.38 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.688 -0.767 . . . . 75.25 112.474 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' GLN . . . . . 0.669 ' NE2' HG11 ' A' ' 116' ' ' VAL . 7.0 tt0 -114.31 120.9 41.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.867 0.365 . . . . 71.14 110.889 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.99 124.98 42.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 74.24 111.163 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.4 pt -135.06 175.92 9.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 64.23 111.17 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -104.59 148.94 25.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 53.23 110.874 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -133.29 156.12 80.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.565 0.698 . . . . 73.23 111.163 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 110.16 2.49 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.693 2.262 . . . . 62.43 112.278 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 88.6 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 73.32 110.9 179.932 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 85' ' ' CYS . . . . . 0.428 ' HB3' HG23 ' A' ' 129' ' ' VAL . 6.8 m . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.906 0.384 . . . . 74.23 110.891 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.6 p -123.6 160.75 26.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 75.23 111.119 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -143.42 136.56 27.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 74.34 110.93 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.7 m -94.91 123.27 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 52.24 111.172 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 57.0 mt -90.99 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.235 -0.438 . . . . 73.12 111.13 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -116.21 163.36 21.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.568 0.699 . . . . 72.31 110.95 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -46.52 107.79 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 53.14 112.337 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 126.63 -18.51 6.35 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.714 -0.755 . . . . 71.45 112.484 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.597 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.4 m-20 -103.49 136.97 42.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 75.42 110.843 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.25 163.86 20.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 63.22 111.194 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.499 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.4 m-85 -54.75 -67.54 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 72.31 110.911 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -52.23 -51.74 56.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 74.42 110.916 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.32 -65.6 0.53 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.264 -0.426 . . . . 74.41 111.143 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.597 HD11 ' CB ' ' A' ' 93' ' ' ASP . 26.3 mt -51.42 -31.68 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 72.23 111.148 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.504 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -67.47 -39.82 85.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 72.43 111.087 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 20.6 mt-30 -52.39 -58.77 5.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 74.55 110.936 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 3.1 mmt85 -69.31 -16.85 63.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 74.02 110.891 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ARG . . . . . 0.403 ' HE ' HG11 ' A' ' 129' ' ' VAL . 18.3 mmt180 -90.83 12.76 18.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 65.15 110.904 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.94 28.08 23.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.74 -0.743 . . . . 45.32 112.51 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.894 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -129.55 177.94 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.879 0.371 . . . . 74.1 111.123 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.98 163.01 26.28 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.197 -0.456 . . . . 72.13 111.15 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.412 HG12 ' OE1' ' A' ' 110' ' ' GLN . 62.0 t -51.85 -39.53 25.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 55.13 111.141 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -51.55 -39.35 57.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.484 . . . . 64.04 110.864 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -80.25 -50.34 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.15 -0.477 . . . . 75.2 111.111 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.894 HD11 HG21 ' A' ' 104' ' ' THR . 47.5 mm -51.43 -41.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 74.21 111.079 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.412 ' OE1' HG12 ' A' ' 106' ' ' VAL . 19.0 pt20 -77.65 -25.6 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 74.4 110.933 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 19.9 t -76.14 -24.5 54.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.182 -0.463 . . . . 53.54 110.843 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 20.8 mt -98.59 -44.53 6.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 71.41 110.906 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.93 67.97 6.33 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.589 0.709 . . . . 73.01 110.911 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -7.63 21.54 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.686 2.257 . . . . 74.04 112.316 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.47 -45.42 46.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.78 -0.724 . . . . 63.14 112.47 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.561 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.3 m -117.24 124.93 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 64.44 111.127 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -67.97 160.87 71.83 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.607 0.717 . . . . 52.24 110.887 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -8.46 23.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.624 2.216 . . . . 71.55 112.352 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -115.51 24.9 11.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 53.35 111.11 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.2 ptp180 -173.34 108.16 0.16 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 74.53 110.858 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.561 HD23 ' HB ' ' A' ' 116' ' ' VAL . 10.3 mt -136.99 146.91 45.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.174 -0.467 . . . . 44.41 110.92 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -97.75 153.0 18.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 75.0 110.89 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 12.4 p -68.12 148.07 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 74.1 111.178 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.84 61.7 6.24 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.783 -0.722 . . . . 44.03 112.481 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' GLN . . . . . 0.527 HE22 HG11 ' A' ' 116' ' ' VAL . 15.6 tt0 -119.24 121.96 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.838 0.352 . . . . 73.02 110.902 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.87 124.95 40.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 50.43 111.117 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.5 pt -123.58 175.74 5.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.185 -0.461 . . . . 53.24 111.132 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -99.16 137.26 37.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 52.43 110.85 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.428 HG23 ' HB3' ' A' ' 85' ' ' CYS . 3.2 m -117.93 156.22 50.29 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.598 0.713 . . . . 72.5 111.124 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 83.91 0.67 Allowed 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.647 2.231 . . . . 72.11 112.355 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.264 -0.426 . . . . 53.11 110.868 -179.998 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 9.2 m . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.903 0.382 . . . . 53.5 110.894 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.3 p -123.61 154.38 39.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 62.34 111.13 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 47.0 t80 -132.26 136.6 47.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.236 -0.438 . . . . 74.13 110.889 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -91.43 125.24 36.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.065 -0.516 . . . . 61.33 111.127 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 121' ' ' LEU . 52.2 mt -93.22 110.51 23.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 74.23 111.146 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm-40 -89.45 158.87 45.3 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.55 0.69 . . . . 71.3 110.898 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.632 ' HB3' HG23 ' A' ' 123' ' ' VAL . 20.2 Cg_endo -59.67 92.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.645 2.23 . . . . 44.33 112.37 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.44 -18.28 2.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.754 -0.736 . . . . 72.4 112.493 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -78.81 155.86 29.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 71.4 110.841 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.458 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -131.66 165.15 24.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 54.54 111.166 -179.932 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.623 ' HE2' HD21 ' A' ' 121' ' ' LEU . 1.1 m-85 -51.32 -51.08 57.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 74.2 110.877 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -67.85 -48.94 64.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.138 -0.483 . . . . 72.22 110.91 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.458 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -54.98 -29.95 58.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 71.03 111.084 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 31.2 mt -87.44 -33.43 6.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.238 -0.437 . . . . 71.23 111.142 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' A' ' 104' ' ' THR . . . -65.01 -43.66 91.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 75.21 111.11 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -56.31 -44.59 80.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.21 110.841 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -65.76 -60.22 3.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 72.41 110.884 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -51.97 -30.86 26.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.456 . . . . 73.43 110.894 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 103.36 16.72 19.75 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 74.43 112.46 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.431 ' O ' ' HB1' ' A' ' 99' ' ' ALA . 7.2 t -120.74 -174.83 2.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 71.14 111.149 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -116.23 165.22 13.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 75.43 111.12 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.8 t -55.51 -43.42 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 73.55 111.137 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -51.74 -33.39 34.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 64.35 110.855 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.89 -48.67 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 70.12 111.114 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 43.2 mm -51.31 -42.75 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 73.04 111.161 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -78.06 -25.41 47.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 65.4 110.928 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.1 t -76.83 -23.17 52.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 52.41 110.878 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 37.2 mt -100.59 -43.18 6.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 50.33 110.894 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -120.22 67.99 13.19 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 71.41 110.854 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.77 -8.24 23.1 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.737 2.291 . . . . 61.5 112.313 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.78 -44.79 55.36 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.685 -0.769 . . . . 51.42 112.517 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.579 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.6 m -114.56 161.76 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 51.24 111.129 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -102.73 161.39 23.36 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.659 0.742 . . . . 62.02 110.851 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -8.39 23.47 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.679 2.253 . . . . 75.55 112.395 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.49 20.79 4.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 62.4 111.072 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 60.0 mtt85 -151.63 49.68 0.81 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 71.0 110.846 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.623 HD21 ' HE2' ' A' ' 95' ' ' PHE . 27.9 mt -85.52 166.52 16.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 43.21 110.9 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 -115.51 153.4 31.23 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.141 -0.481 . . . . 73.52 110.896 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.632 HG23 ' HB3' ' A' ' 91' ' ' PRO . 12.2 p -63.9 133.94 29.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.09 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.88 63.28 4.89 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.695 -0.764 . . . . 60.05 112.511 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -114.74 123.5 49.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 75.42 110.942 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.37 126.81 40.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 71.53 111.133 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.1 pt -127.23 175.91 8.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.149 -0.478 . . . . 75.44 111.151 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -94.97 153.9 17.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 73.25 110.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.5 m -141.23 156.03 67.81 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.643 0.735 . . . . 62.45 111.155 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 87.84 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.675 2.25 . . . . 73.23 112.352 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 71.52 110.854 179.997 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.939 0.4 . . . . 71.03 110.842 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 46.4 p -124.24 157.33 35.1 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.146 -0.479 . . . . 60.02 111.167 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -130.36 136.72 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.214 -0.448 . . . . 74.55 110.893 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -91.12 122.42 33.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 54.3 111.129 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.574 HG23 HD11 ' A' ' 98' ' ' ILE . 35.2 mt -90.8 109.59 21.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 74.43 111.135 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 16.4 mt-30 -87.75 157.28 52.27 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.606 0.717 . . . . 73.32 110.884 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.697 ' HB3' HG23 ' A' ' 123' ' ' VAL . 17.8 Cg_endo -58.16 94.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.675 2.25 . . . . 61.23 112.34 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.38 -20.38 2.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.694 -0.765 . . . . 75.53 112.456 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.44 ' HB2' HD11 ' A' ' 98' ' ' ILE . 1.0 OUTLIER -87.43 137.51 32.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.867 0.365 . . . . 64.42 110.913 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.48 171.48 7.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 73.15 111.186 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.637 ' HE1' HD21 ' A' ' 121' ' ' LEU . 1.2 m-85 -53.92 -64.36 0.85 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 72.34 110.927 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -53.08 -51.95 60.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 74.21 110.929 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.66 -63.77 1.03 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 51.12 111.091 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.574 HD11 HG23 ' A' ' 89' ' ' ILE . 46.7 mt -51.69 -34.13 15.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 72.15 111.133 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HB1' ' O ' ' A' ' 104' ' ' THR . . . -68.16 -35.72 78.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 75.01 111.114 179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.4 mt-30 -51.66 -73.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 54.1 110.904 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 36.4 mmm-85 -54.62 -45.27 73.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 62.13 110.903 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -54.54 -27.2 36.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 73.23 110.907 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 91.54 16.09 53.41 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.775 -0.726 . . . . 72.1 112.469 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.685 HG21 HD11 ' A' ' 109' ' ' ILE . 9.6 t -122.26 -177.71 3.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.843 0.354 . . . . 75.4 111.113 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -121.12 164.27 17.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 61.03 111.145 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.6 t -55.71 -43.06 72.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 73.21 111.066 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -51.8 -33.51 35.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 70.41 110.852 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.0 t -81.86 -52.04 14.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 62.03 111.138 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.685 HD11 HG21 ' A' ' 104' ' ' THR . 47.6 mm -51.64 -42.21 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 71.13 111.151 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -77.89 -25.4 48.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.874 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.6 t -77.08 -23.86 51.91 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 73.31 110.88 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.7 mt -99.45 -44.7 6.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 75.13 110.945 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.69 67.61 7.74 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.63 0.728 . . . . 55.3 110.897 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -8.22 23.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.659 2.239 . . . . 63.2 112.395 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.6 -44.09 53.74 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 62.14 112.472 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.548 HG11 ' OE1' ' A' ' 125' ' ' GLN . 2.5 m -115.21 156.71 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.881 0.372 . . . . 72.34 111.098 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -97.94 161.8 24.38 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.635 0.731 . . . . 74.54 110.849 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -7.82 22.05 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 73.33 112.36 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.42 18.89 4.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 42.34 111.063 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -143.32 40.82 1.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.215 -0.448 . . . . 55.1 110.897 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.637 HD21 ' HE1' ' A' ' 95' ' ' PHE . 59.9 mt -85.59 149.77 25.11 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.214 -0.448 . . . . 74.42 110.893 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 80.7 mm-40 -104.66 153.53 21.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 63.13 110.905 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.697 HG23 ' HB3' ' A' ' 91' ' ' PRO . 9.9 p -56.45 134.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.467 . . . . 54.44 111.122 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.25 63.21 5.04 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 72.2 112.509 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' GLN . . . . . 0.548 ' OE1' HG11 ' A' ' 116' ' ' VAL . 11.2 tt0 -109.55 123.01 48.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 73.32 110.884 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 8.4 p -85.66 136.87 21.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 75.02 111.112 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.442 HD13 HD11 ' A' ' 89' ' ' ILE . 10.3 pt -142.56 175.94 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.123 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -97.67 153.44 18.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 60.42 110.905 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -146.24 156.16 50.27 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.594 0.712 . . . . 70.15 111.149 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 91.0 0.52 Allowed 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.684 2.256 . . . . 72.32 112.33 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 53.3 110.926 179.991 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.915 0.388 . . . . 61.23 110.909 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 72.7 p -124.96 150.48 46.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 53.3 111.15 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.547 ' HB2' HG21 ' A' ' 129' ' ' VAL . 48.1 t80 -123.86 135.97 54.07 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.32 110.936 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -89.66 123.38 33.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 54.54 111.177 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.4 mt -90.93 109.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 62.35 111.179 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -91.99 158.82 39.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.566 0.698 . . . . 74.1 110.936 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.598 ' HB3' HG23 ' A' ' 123' ' ' VAL . 19.9 Cg_endo -59.41 92.88 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.687 2.258 . . . . 74.33 112.374 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.82 -19.04 2.56 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.751 . . . . 63.54 112.528 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.606 ' CB ' HD11 ' A' ' 98' ' ' ILE . 5.8 m-20 -80.97 154.17 27.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.906 0.384 . . . . 74.33 110.841 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 152.46 45.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 75.05 111.152 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.601 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.2 m-85 -53.4 -55.6 23.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.34 110.861 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -57.95 -55.76 30.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 74.35 110.871 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.26 -61.04 2.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.259 -0.428 . . . . 52.13 111.106 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.606 HD11 ' CB ' ' A' ' 93' ' ' ASP . 41.0 mt -51.37 -38.24 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 72.2 111.134 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.403 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -64.68 -38.32 90.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 71.35 111.151 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -51.93 -72.77 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 63.02 110.898 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -53.97 -41.67 68.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 74.12 110.879 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 6.9 mmp_? -57.05 -24.17 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 44.13 110.876 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.46 15.34 60.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.771 -0.728 . . . . 63.4 112.484 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' THR . . . . . 1.047 HG21 HD11 ' A' ' 109' ' ' ILE . 8.0 t -115.24 -175.48 2.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.931 0.396 . . . . 60.13 111.109 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -124.45 154.94 39.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 73.04 111.169 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.444 HG12 ' OE1' ' A' ' 110' ' ' GLN . 74.1 t -54.14 -42.94 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 75.13 111.152 179.86 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -51.72 -39.54 58.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.139 -0.482 . . . . 74.12 110.875 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.1 t -75.14 -54.18 14.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 70.02 111.145 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 1.047 HD11 HG21 ' A' ' 104' ' ' THR . 43.4 mm -51.58 -42.08 29.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 74.44 111.144 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.444 ' OE1' HG12 ' A' ' 106' ' ' VAL . 19.0 pt20 -76.78 -25.54 53.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 75.31 110.885 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.8 t -76.18 -25.22 54.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 73.41 110.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.6 mt -96.89 -45.47 6.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 75.11 110.939 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.03 67.85 6.48 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.73 . . . . 73.31 110.939 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.49 21.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.696 2.264 . . . . 72.11 112.356 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.45 -44.46 45.62 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 72.02 112.483 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.601 HG23 ' CZ ' ' A' ' 95' ' ' PHE . 2.4 m -117.2 130.93 71.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.86 0.362 . . . . 63.45 111.077 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 16.5 m-20 -76.78 160.9 75.73 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.626 0.727 . . . . 75.45 110.883 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -8.6 24.01 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.635 2.223 . . . . 74.12 112.35 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -113.65 24.93 11.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 72.43 111.112 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.7 ptm180 -178.36 104.17 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 75.22 110.88 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 63.8 mt -122.31 167.48 13.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.446 . . . . 75.21 110.882 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -109.57 153.38 24.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 71.02 110.898 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.598 HG23 ' HB3' ' A' ' 91' ' ' PRO . 9.3 p -70.44 136.19 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 74.44 111.094 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.0 63.82 4.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.733 -0.746 . . . . 65.31 112.515 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 -117.66 122.74 44.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.873 0.368 . . . . 73.34 110.892 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -88.18 125.34 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.464 . . . . 63.44 111.157 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.1 pt -125.84 175.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 71.43 111.142 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -97.76 137.43 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 55.12 110.859 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.547 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -138.95 156.19 72.65 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.609 0.718 . . . . 73.23 111.142 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 109.55 2.34 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.721 2.281 . . . . 61.33 112.345 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 74.32 110.9 -179.982 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 97.8 m . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.925 0.393 . . . . 74.53 110.853 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.4 p -123.51 168.52 12.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.133 -0.485 . . . . 74.14 111.158 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -136.82 136.59 38.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 65.21 110.891 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.1 m -89.18 122.76 32.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 70.34 111.171 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.435 HD11 HG12 ' A' ' 127' ' ' ILE . 38.8 mt -91.07 109.5 21.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 74.13 111.149 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.56 163.7 16.38 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 74.22 110.928 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -46.1 111.11 0.31 Allowed 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.708 2.272 . . . . 71.51 112.341 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 113.21 -1.64 25.35 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 52.25 112.52 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -113.17 113.82 25.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 71.13 110.87 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -101.37 157.84 16.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 65.25 111.104 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.458 ' CE2' HD22 ' A' ' 121' ' ' LEU . 1.7 m-85 -51.5 -43.04 62.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 72.44 110.911 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.15 -47.66 27.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.111 -0.495 . . . . 74.43 110.906 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.54 -26.86 62.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 60.14 111.064 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 28.2 mt -88.31 -45.1 15.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 74.44 111.133 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.455 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -55.27 -46.15 76.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.46 . . . . 71.41 111.123 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -52.0 -44.97 64.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 63.11 110.89 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 74.8 mtt-85 -71.88 -52.7 16.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.881 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.8 mmm180 -54.12 -27.6 34.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 75.4 110.886 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.85 17.57 18.36 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.768 -0.73 . . . . 64.31 112.523 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.831 HG21 HD11 ' A' ' 109' ' ' ILE . 12.0 t -124.1 179.02 5.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.848 0.356 . . . . 73.03 111.162 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.41 164.47 17.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.198 -0.455 . . . . 65.52 111.163 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 46.8 t -55.23 -41.02 58.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.262 -0.426 . . . . 73.01 111.123 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -51.67 -38.89 56.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 65.41 110.886 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.3 t -78.38 -51.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 73.54 111.143 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.831 HD11 HG21 ' A' ' 104' ' ' THR . 47.6 mm -51.54 -43.97 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 74.41 111.148 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -73.55 -25.54 60.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 65.3 110.931 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.5 t -78.91 -23.07 44.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 44.31 110.885 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.5 mt -98.27 -44.53 6.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 61.4 110.921 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.83 67.89 6.09 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.603 0.716 . . . . 61.1 110.909 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -7.25 20.58 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.701 2.267 . . . . 62.54 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.06 -42.03 38.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 43.41 112.435 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.507 ' HB ' HD23 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -119.37 125.13 74.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.858 0.361 . . . . 74.45 111.132 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -57.58 161.14 6.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.619 0.724 . . . . 54.43 110.835 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 -8.59 23.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.653 2.235 . . . . 44.41 112.322 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -126.59 14.9 7.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 73.33 111.1 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 63.0 mtt180 -141.55 93.76 2.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 73.34 110.881 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.507 HD23 ' HB ' ' A' ' 116' ' ' VAL . 10.0 mt -132.73 163.84 28.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 74.13 110.902 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -125.04 150.68 46.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 74.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.5 p -52.81 146.86 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.441 . . . . 60.24 111.112 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.61 65.91 2.88 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 71.3 112.536 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' GLN . . . . . 0.459 HE22 HG11 ' A' ' 116' ' ' VAL . 11.2 tt0 -119.15 121.61 40.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 75.51 110.921 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 15.0 p -89.03 136.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 72.11 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.435 HG12 HD11 ' A' ' 89' ' ' ILE . 2.4 pt -138.68 174.23 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 75.13 111.166 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -100.25 139.39 35.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 75.45 110.931 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -141.19 156.12 67.9 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.645 0.736 . . . . 73.33 111.131 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 110.59 2.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.677 2.251 . . . . 74.23 112.334 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 74.11 110.921 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 19.4 m . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.878 0.37 . . . . 75.35 110.907 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.0 p -123.59 166.72 14.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.151 -0.477 . . . . 74.05 111.164 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.4 t80 -142.97 136.59 28.65 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.25 -0.432 . . . . 61.1 110.982 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -89.79 121.91 32.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 64.5 111.143 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.8 mt -90.94 109.61 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 71.53 111.156 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -86.86 158.62 53.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 75.55 110.935 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.57 ' HB3' HG23 ' A' ' 123' ' ' VAL . 17.9 Cg_endo -58.54 93.61 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.639 2.226 . . . . 71.22 112.345 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.8 -18.87 2.38 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 75.43 112.482 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.609 ' CB ' HD11 ' A' ' 98' ' ' ILE . 3.5 m-20 -84.67 138.23 32.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.361 . . . . 54.53 110.867 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.05 155.21 26.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 43.31 111.156 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.714 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -53.13 -47.52 68.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 74.42 110.878 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -71.56 -47.32 55.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 75.45 110.933 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.82 -30.44 63.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.229 -0.441 . . . . 64.15 111.144 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.609 HD11 ' CB ' ' A' ' 93' ' ' ASP . 38.5 mt -88.29 -33.64 6.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 73.05 111.098 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -65.0 -41.86 95.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 64.22 111.116 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -58.68 -44.64 90.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 74.13 110.904 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -78.67 -18.42 54.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 73.44 110.873 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -92.83 16.33 12.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 62.14 110.857 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.56 28.35 21.37 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.798 -0.715 . . . . 72.32 112.469 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' THR . . . . . 1.035 HG21 HD11 ' A' ' 109' ' ' ILE . 9.9 t -129.8 -177.24 4.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.863 0.363 . . . . 74.11 111.131 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.85 157.86 34.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 72.44 111.145 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.456 HG12 ' OE1' ' A' ' 110' ' ' GLN . 60.3 t -55.58 -42.26 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 74.31 111.106 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -51.82 -37.26 51.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 62.23 110.836 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.0 t -78.18 -52.99 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.11 111.138 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 1.035 HD11 HG21 ' A' ' 104' ' ' THR . 49.2 mm -51.33 -43.23 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.138 -0.483 . . . . 72.5 111.125 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.456 ' OE1' HG12 ' A' ' 106' ' ' VAL . 19.0 pt20 -76.62 -25.54 53.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 72.14 110.904 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -75.28 -25.46 57.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.201 -0.454 . . . . 65.2 110.844 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.9 mt -94.93 -46.46 6.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 72.2 110.948 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -118.5 67.33 7.2 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.628 0.727 . . . . 73.55 110.897 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.674 2.25 . . . . 64.41 112.32 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.36 -42.05 49.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 65.34 112.523 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.726 HG11 ' OE1' ' A' ' 125' ' ' GLN . 2.2 m -119.43 139.91 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.864 0.364 . . . . 74.04 111.108 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.1 161.25 66.25 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.596 0.712 . . . . 74.45 110.924 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -8.32 23.3 Favored 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.697 2.265 . . . . 73.45 112.4 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.76 20.58 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 61.25 111.106 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -144.07 43.62 1.44 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 75.55 110.863 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.714 HD11 ' CD2' ' A' ' 95' ' ' PHE . 71.9 mt -85.61 173.82 9.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 73.42 110.9 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -129.52 150.38 50.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 75.54 110.857 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.57 HG23 ' HB3' ' A' ' 91' ' ' PRO . 14.0 p -52.0 133.63 13.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 73.25 111.137 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 53.03 63.35 5.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.783 -0.722 . . . . 73.2 112.471 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' GLN . . . . . 0.726 ' OE1' HG11 ' A' ' 116' ' ' VAL . 8.7 tt0 -110.62 122.73 48.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 64.44 110.922 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 30.7 t -84.45 140.75 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 64.41 111.142 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.1 pt -143.73 175.24 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 53.13 111.121 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -99.78 130.82 46.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 74.01 110.92 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -123.32 156.22 63.96 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.716 . . . . 53.42 111.132 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 91.61 0.52 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.689 2.259 . . . . 43.45 112.372 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 73.14 110.877 -179.974 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.3 m . . . . . 0 N--CA 1.457 -0.104 0 CA-C-O 120.932 0.396 . . . . 62.24 110.865 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.8 p -123.58 163.92 20.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 71.12 111.134 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 46.7 t80 -145.12 136.68 25.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 73.34 110.938 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.75 125.23 37.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 41.51 111.13 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.434 HD12 ' HG2' ' A' ' 125' ' ' GLN . 79.2 mt -90.93 109.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 74.42 111.112 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -109.17 163.27 17.39 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.548 0.689 . . . . 75.44 110.933 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -46.31 121.9 5.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.638 2.225 . . . . 74.3 112.34 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.27 -4.2 54.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.778 -0.725 . . . . 73.23 112.464 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.13 116.7 32.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.937 0.399 . . . . 73.34 110.884 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.457 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -113.96 -179.5 3.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 61.23 111.135 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.686 ' CD1' HD11 ' A' ' 121' ' ' LEU . 0.9 OUTLIER -54.64 -70.02 0.11 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 73.02 110.909 -179.972 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.88 -50.52 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 75.12 110.889 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.457 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -51.13 -65.89 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 52.23 111.138 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 47.0 mt -51.22 -35.78 16.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 52.15 111.131 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.5 -37.34 87.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 71.12 111.06 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 19.1 mt-30 -51.92 -70.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 62.22 110.93 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.5 ptm180 -57.01 -43.04 81.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 74.44 110.847 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.6 -24.81 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 63.01 110.858 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.07 17.13 56.68 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 61.45 112.463 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.675 HG21 HD11 ' A' ' 109' ' ' ILE . 7.3 t -121.71 -174.65 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.838 0.351 . . . . 64.22 111.174 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -125.46 165.34 18.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 70.55 111.174 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 41.4 t -55.8 -44.69 78.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.264 -0.426 . . . . 71.4 111.067 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -51.92 -30.11 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 72.32 110.849 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.88 -52.19 13.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 70.24 111.139 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.675 HD11 HG21 ' A' ' 104' ' ' THR . 48.7 mm -51.29 -43.08 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 74.22 111.11 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -76.2 -25.42 55.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 64.42 110.924 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.9 m -80.02 -20.31 45.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.854 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.9 mt -94.94 -47.86 6.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.121 -0.49 . . . . 54.21 110.906 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -118.51 67.28 7.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.634 0.73 . . . . 74.42 110.897 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -8.48 23.71 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.737 2.291 . . . . 63.25 112.39 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -69.76 -17.6 73.31 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.75 -0.738 . . . . 72.33 112.478 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.539 HG12 HD23 ' A' ' 121' ' ' LEU . 2.1 t -125.89 112.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.845 0.355 . . . . 75.44 111.133 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.19 160.29 1.72 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.591 0.71 . . . . 73.03 110.912 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -45.63 1.53 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.691 2.261 . . . . 61.03 112.368 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.24 -29.84 24.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 74.34 111.13 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -83.41 68.5 9.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 74.12 110.895 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.686 HD11 ' CD1' ' A' ' 95' ' ' PHE . 53.7 mt -121.3 137.89 54.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 53.43 110.941 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -110.34 153.57 24.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 65.3 110.913 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -51.56 147.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 71.14 111.107 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.73 66.9 2.28 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 74.51 112.505 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' GLN . . . . . 0.52 ' NE2' HG11 ' A' ' 116' ' ' VAL . 7.9 tt0 -116.47 122.4 44.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 75.12 110.941 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.8 t -86.26 130.56 36.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 74.03 111.102 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 12.1 pt -141.12 175.79 5.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 64.23 111.139 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -99.18 152.18 20.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 65.35 110.872 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.61 156.18 80.12 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.603 0.716 . . . . 61.11 111.132 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 110.33 2.53 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.664 2.242 . . . . 74.12 112.36 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 75.03 110.912 179.982 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 85' ' ' CYS . . . . . 0.454 ' HB3' HG23 ' A' ' 129' ' ' VAL . 1.7 m . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.953 0.406 . . . . 73.21 110.838 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.4 p -123.59 157.58 33.39 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.132 -0.485 . . . . 42.02 111.109 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -141.89 136.69 30.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.962 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -93.45 126.88 38.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 54.42 111.14 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 63.5 mt -91.0 109.52 21.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 55.05 111.089 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -92.02 159.25 38.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.537 0.684 . . . . 75.21 110.914 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.423 ' HB3' HG23 ' A' ' 123' ' ' VAL . 18.7 Cg_endo -57.95 94.47 0.07 OUTLIER 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.686 2.257 . . . . 74.15 112.306 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.79 -18.1 2.59 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.781 -0.723 . . . . 43.14 112.513 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -91.22 157.09 17.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.909 0.385 . . . . 75.31 110.837 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.437 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -141.4 178.28 7.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 73.44 111.125 -179.877 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.678 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.7 m-85 -54.49 -66.43 0.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 71.51 110.858 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -54.79 -52.15 63.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.157 -0.474 . . . . 75.41 110.909 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.437 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -50.57 -66.09 0.45 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 72.14 111.089 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 54.8 mt -51.15 -33.96 13.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 75.24 111.116 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.94 -39.53 93.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 63.41 111.086 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 21.0 mt-30 -52.12 -69.39 0.11 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 63.31 110.874 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -55.3 -50.34 69.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 74.43 110.92 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ARG . . . . . 0.423 ' CD ' HG11 ' A' ' 129' ' ' VAL . 6.3 mmp_? -51.96 -29.97 22.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 72.12 110.866 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 94.56 12.27 56.02 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.81 -0.71 . . . . 71.24 112.524 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.7 t -114.11 -172.47 2.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.811 0.338 . . . . 71.34 111.163 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.7 m -124.87 162.56 24.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 74.54 111.167 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 69.2 t -53.38 -43.87 53.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 70.44 111.133 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -51.68 -37.3 50.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 70.21 110.848 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.2 t -76.83 -47.18 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 72.15 111.141 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 41.6 mm -50.84 -45.36 28.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 75.24 111.128 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -77.37 -25.46 50.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.142 -0.481 . . . . 61.34 110.965 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.7 t -76.69 -21.02 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 74.21 110.832 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.5 mt -97.72 -45.33 6.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 64.54 110.932 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.18 67.84 6.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.637 0.732 . . . . 70.45 110.892 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -8.41 23.53 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.656 2.237 . . . . 65.02 112.351 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -68.75 -19.57 73.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 61.42 112.43 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.732 HG11 HD23 ' A' ' 121' ' ' LEU . 2.6 t -127.3 139.71 51.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 65.41 111.115 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -79.82 160.33 69.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.631 0.729 . . . . 61.33 110.926 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -15.03 36.73 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.69 2.26 . . . . 53.51 112.342 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -116.42 -23.28 8.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 55.5 111.065 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -91.83 55.02 2.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 74.54 110.893 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.732 HD23 HG11 ' A' ' 116' ' ' VAL . 75.2 mt -107.98 131.93 54.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.459 . . . . 54.33 110.909 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -97.65 153.55 18.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 72.24 110.904 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.423 HG23 ' HB3' ' A' ' 91' ' ' PRO . 6.6 p -54.71 144.36 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 70.42 111.092 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.98 66.34 2.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.764 -0.731 . . . . 72.44 112.478 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -118.72 122.07 41.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.83 0.347 . . . . 71.14 110.898 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.4 t -84.51 126.94 40.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 74.52 111.191 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.45 175.86 10.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 63.23 111.17 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -96.08 159.76 14.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 54.21 110.885 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.454 HG23 ' HB3' ' A' ' 85' ' ' CYS . 3.1 m -144.07 156.33 58.33 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.63 0.729 . . . . 64.44 111.134 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 90.87 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.655 2.237 . . . . 72.13 112.326 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 74.43 110.873 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.4 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.951 0.405 . . . . 75.54 110.894 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 18.2 p -125.5 163.06 23.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 64.24 111.128 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -139.19 136.31 34.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 62.1 110.917 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 m -92.26 123.26 35.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 61.04 111.123 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.548 HD12 ' HG2' ' A' ' 125' ' ' GLN . 85.3 mt -90.9 109.47 21.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 73.3 111.162 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.499 ' HB3' ' HD2' ' A' ' 91' ' ' PRO . 25.6 mt-30 -112.6 162.63 20.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.55 0.69 . . . . 74.21 110.963 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.499 ' HD2' ' HB3' ' A' ' 90' ' ' GLN . 74.9 Cg_exo -47.33 101.07 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.685 2.257 . . . . 63.21 112.378 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 124.75 0.47 8.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 74.02 112.519 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -115.22 116.91 29.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.869 0.366 . . . . 70.32 110.877 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.443 HG22 ' H ' ' A' ' 95' ' ' PHE . 0.2 OUTLIER -107.08 169.57 8.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 63.04 111.145 -179.89 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.6 ' CD1' HD11 ' A' ' 121' ' ' LEU . 0.7 OUTLIER -53.68 -66.03 0.46 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.187 -0.461 . . . . 72.04 110.897 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -55.94 -49.6 73.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 74.15 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -50.22 -55.21 16.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.24 -0.436 . . . . 45.3 111.091 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 35.4 mt -62.69 -31.93 53.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 72.42 111.127 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.449 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -69.65 -29.93 67.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 75.43 111.083 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -52.59 -74.11 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.914 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -57.38 -38.79 74.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 73.33 110.87 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ARG . . . . . 0.432 ' HD2' HG11 ' A' ' 129' ' ' VAL . 8.2 mmp_? -57.78 -23.47 52.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 74.24 110.857 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 82.84 18.83 64.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.755 -0.736 . . . . 53.41 112.456 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.991 HG21 HD11 ' A' ' 109' ' ' ILE . 11.8 t -116.68 -179.88 3.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.846 0.355 . . . . 54.22 111.11 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -122.58 161.28 24.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 64.42 111.149 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.3 t -55.11 -47.3 77.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 74.5 111.117 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 40.4 m-20 -51.88 -30.03 22.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 73.15 110.812 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 47.0 t -80.83 -54.15 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 71.21 111.177 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.991 HD11 HG21 ' A' ' 104' ' ' THR . 51.2 mm -52.5 -41.79 37.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.148 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.06 -25.36 58.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 54.32 110.902 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.8 t -81.15 -21.46 39.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.214 -0.448 . . . . 62.4 110.843 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.2 mt -99.48 -44.52 6.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 53.0 110.915 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.37 68.58 5.37 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.602 0.715 . . . . 73.32 110.86 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -7.5 21.2 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.69 2.26 . . . . 72.55 112.35 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.26 -40.28 37.13 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 74.53 112.506 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.634 HG11 ' OE1' ' A' ' 125' ' ' GLN . 1.3 m -118.05 127.32 75.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.826 0.346 . . . . 54.3 111.122 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.1 m-20 -56.76 161.63 4.36 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.618 0.723 . . . . 72.2 110.92 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -8.16 22.89 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.686 2.257 . . . . 64.42 112.323 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.9 21.96 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 62.31 111.119 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -144.0 101.37 3.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 72.4 110.866 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.6 HD11 ' CD1' ' A' ' 95' ' ' PHE . 53.1 mt -139.3 150.85 45.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 62.13 110.926 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -117.86 150.61 38.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 70.15 110.883 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.423 HG23 ' HG3' ' A' ' 91' ' ' PRO . 12.6 p -51.77 148.22 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 73.32 111.121 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.36 66.53 2.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.732 -0.747 . . . . 74.13 112.448 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' GLN . . . . . 0.634 ' OE1' HG11 ' A' ' 116' ' ' VAL . 7.6 tt0 -117.84 121.25 40.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.822 0.344 . . . . 61.51 110.927 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.95 125.01 42.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 73.21 111.158 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 pt -132.31 175.79 10.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 70.23 111.121 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.39 149.19 23.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 63.51 110.878 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.432 HG11 ' HD2' ' A' ' 102' ' ' ARG . 3.2 m -135.12 156.17 78.43 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.635 0.731 . . . . 54.32 111.15 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 110.66 2.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.679 2.253 . . . . 42.43 112.334 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 92.3 m . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 75.24 110.928 179.969 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 4.5 m . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.925 0.393 . . . . 74.13 110.84 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 76.5 p -126.19 154.89 42.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 72.32 111.137 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.4 ' HB2' HG11 ' A' ' 129' ' ' VAL . 47.8 t80 -132.37 136.66 46.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 73.45 110.929 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.3 m -92.87 125.58 37.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 65.02 111.147 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.12 110.0 21.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.262 -0.426 . . . . 70.21 111.122 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.487 ' HB2' ' HD2' ' A' ' 91' ' ' PRO . 0.5 OUTLIER -112.21 162.44 21.38 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.57 0.7 . . . . 74.53 110.935 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.505 ' HG3' HG23 ' A' ' 123' ' ' VAL . 74.5 Cg_exo -46.14 101.53 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.685 2.256 . . . . 72.23 112.379 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 121.37 2.5 10.8 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 51.21 112.496 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -105.24 113.95 27.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.897 0.38 . . . . 43.25 110.885 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.55 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -108.12 166.21 10.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 74.32 111.152 -179.885 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.657 ' HE2' HD21 ' A' ' 121' ' ' LEU . 1.3 m-85 -51.02 -46.13 61.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 52.44 110.902 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.35 -49.63 21.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 70.52 110.977 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.55 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -54.11 -27.94 36.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 52.13 111.114 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 42.9 mt -89.1 -41.47 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 53.35 111.16 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.429 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -57.1 -42.69 81.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 54.34 111.111 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -57.19 -45.02 84.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 63.24 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -65.6 -59.98 3.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 72.41 110.882 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.2 mmm180 -52.12 -29.87 23.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.138 -0.483 . . . . 74.24 110.876 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.58 13.53 29.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 61.14 112.474 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.9 t -115.35 -174.18 2.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.853 0.359 . . . . 73.4 111.128 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.92 163.47 16.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 72.12 111.172 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.7 t -54.55 -44.43 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.261 -0.427 . . . . 74.32 111.129 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -51.68 -33.61 34.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 75.11 110.829 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.9 t -80.57 -48.08 20.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 63.42 111.156 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.429 HG13 ' HB2' ' A' ' 99' ' ' ALA . 45.2 mm -51.19 -43.52 27.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 51.11 111.159 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -77.76 -25.48 49.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 75.04 110.934 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t -76.17 -23.53 54.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 75.45 110.805 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -99.16 -45.37 5.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 74.3 110.908 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.83 68.29 6.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.653 0.74 . . . . 71.21 110.852 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -8.17 22.93 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.656 2.237 . . . . 73.43 112.389 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.55 -43.39 52.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.69 -0.767 . . . . 61.43 112.53 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.551 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.1 m -116.42 163.04 13.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.884 0.373 . . . . 75.22 111.078 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -104.31 161.1 23.88 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.59 0.71 . . . . 75.14 110.864 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.71 -8.52 23.81 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.693 2.262 . . . . 60.42 112.372 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -128.76 12.02 6.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 61.2 111.124 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.9 mmt85 -143.77 49.67 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 74.55 110.863 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.657 HD21 ' HE2' ' A' ' 95' ' ' PHE . 22.9 mt -85.64 166.95 15.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.227 -0.442 . . . . 63.53 110.918 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -120.59 139.39 53.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 74.41 110.897 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.505 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.3 p -54.05 140.6 10.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 74.12 111.104 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.31 61.62 6.11 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.779 -0.724 . . . . 73.35 112.462 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -119.17 122.27 41.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.811 0.339 . . . . 72.44 110.882 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.1 p -84.43 134.61 26.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 73.3 111.106 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.8 pt -134.98 175.93 9.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 63.33 111.132 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -95.91 143.25 27.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 63.34 110.859 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.4 HG11 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -131.87 156.22 80.38 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.612 0.72 . . . . 52.24 111.12 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 86.58 0.58 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.652 2.235 . . . . 63.21 112.357 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.26 -0.427 . . . . 74.21 110.876 -179.999 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 73.4 m . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.928 0.394 . . . . 54.33 110.848 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 35.7 p -124.47 156.22 37.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 72.11 111.124 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.452 ' CE2' HD13 ' A' ' 98' ' ' ILE . 44.3 t80 -132.35 136.54 46.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.274 -0.421 . . . . 74.42 110.891 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -92.54 122.97 35.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 72.35 111.168 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 83.0 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 75.21 111.124 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.502 ' HB3' ' HD2' ' A' ' 91' ' ' PRO . 4.8 mm100 -112.29 162.45 21.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.58 0.705 . . . . 75.02 110.925 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.502 ' HD2' ' HB3' ' A' ' 90' ' ' GLN . 74.3 Cg_exo -47.28 101.22 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.663 2.242 . . . . 75.33 112.335 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 123.8 1.36 8.97 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.73 -0.748 . . . . 72.5 112.478 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -118.46 111.58 18.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.901 0.381 . . . . 64.1 110.872 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.53 159.84 14.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 74.43 111.151 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.416 ' CD1' HD11 ' A' ' 121' ' ' LEU . 1.3 m-85 -51.33 -44.13 61.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 70.51 110.854 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.19 -48.0 25.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.922 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.22 -28.03 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 71.22 111.112 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.452 HD13 ' CE2' ' A' ' 87' ' ' TYR . 32.6 mt -87.76 -45.38 16.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 72.41 111.107 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.478 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -53.97 -47.28 71.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 70.05 111.061 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -51.93 -44.96 64.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.199 -0.455 . . . . 73.03 110.914 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 77.4 mtp180 -68.78 -53.94 18.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.196 -0.456 . . . . 73.34 110.872 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -55.27 -26.29 39.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 72.32 110.897 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 101.91 16.27 24.17 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.727 -0.749 . . . . 73.42 112.491 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.793 HG21 HD11 ' A' ' 109' ' ' ILE . 10.1 t -120.29 -177.87 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.86 0.362 . . . . 63.33 111.129 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.64 165.09 19.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 52.31 111.145 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 91.7 t -55.16 -40.55 55.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 74.12 111.12 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -51.7 -40.13 59.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.01 110.884 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -77.35 -51.72 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 75.3 111.153 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.793 HD11 HG21 ' A' ' 104' ' ' THR . 50.5 mm -51.64 -44.43 34.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 53.4 111.129 179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 19.3 pt20 -72.86 -25.53 61.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 64.41 110.937 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t -79.98 -22.11 42.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 73.02 110.834 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 10.7 mt -98.12 -44.79 6.47 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 62.23 110.88 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.66 68.06 5.8 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.717 . . . . 73.35 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -7.13 20.26 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.669 2.246 . . . . 73.4 112.387 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.84 -40.19 33.73 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.723 -0.751 . . . . 75.22 112.473 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.505 HG11 HE22 ' A' ' 125' ' ' GLN . 1.5 m -118.29 127.96 75.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.795 0.331 . . . . 55.4 111.142 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -56.61 161.25 4.54 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.623 0.725 . . . . 63.3 110.913 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -8.47 23.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.644 2.229 . . . . 75.33 112.352 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.1 23.21 5.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 75.22 111.119 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.3 mmt180 -146.47 102.52 3.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.453 . . . . 72.41 110.838 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.469 HD23 ' HB ' ' A' ' 116' ' ' VAL . 67.2 mt -136.51 175.59 9.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 74.42 110.867 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -140.72 147.77 39.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.475 . . . . 72.22 110.913 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.406 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.5 p -52.35 147.57 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 71.31 111.094 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.63 65.2 3.32 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.697 -0.763 . . . . 55.33 112.538 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' GLN . . . . . 0.505 HE22 HG11 ' A' ' 116' ' ' VAL . 15.2 tt0 -119.14 120.69 37.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.826 0.346 . . . . 72.44 110.925 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.36 125.11 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 42.15 111.122 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.3 pt -129.22 175.87 9.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 74.43 111.128 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -98.84 137.98 36.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 75.14 110.869 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -123.91 156.23 65.91 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.618 0.723 . . . . 62.24 111.144 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 110.52 2.59 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.698 2.265 . . . . 70.44 112.337 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.205 -0.452 . . . . 73.41 110.878 -179.954 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.9 0.381 . . . . 72.15 110.903 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.5 p -123.37 161.83 23.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 71.15 111.149 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.65 ' HB2' HG21 ' A' ' 129' ' ' VAL . 36.2 t80 -127.32 136.79 52.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 71.24 110.925 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 55.3 m -88.68 122.88 32.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.098 -0.501 . . . . 32.0 111.144 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.2 mt -90.83 109.52 21.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 64.31 111.153 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.483 ' HB2' ' HD2' ' A' ' 91' ' ' PRO . 0.1 OUTLIER -111.32 162.65 19.97 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.568 0.699 . . . . 71.15 110.948 179.94 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.483 ' HD2' ' HB2' ' A' ' 90' ' ' GLN . 74.0 Cg_exo -46.78 101.27 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.696 2.264 . . . . 64.51 112.337 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 125.95 -1.99 7.9 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 54.15 112.455 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.42 ' HB3' HD11 ' A' ' 98' ' ' ILE . 13.5 m-20 -105.77 129.39 53.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 74.25 110.87 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.504 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -118.06 164.5 15.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 72.21 111.128 -179.886 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.662 ' CE1' HD21 ' A' ' 121' ' ' LEU . 0.8 OUTLIER -50.94 -48.28 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 74.24 110.875 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.08 -49.01 25.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 74.35 110.944 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.504 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -53.81 -27.17 27.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.11 111.124 179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.42 HD11 ' HB3' ' A' ' 93' ' ' ASP . 39.1 mt -91.26 -39.41 11.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 74.21 111.131 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.553 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -58.3 -41.04 83.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.149 -0.478 . . . . 52.52 111.092 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -57.13 -44.55 83.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.439 . . . . 72.01 110.905 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -69.26 -25.96 64.54 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 73.34 110.852 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ARG . . . . . 0.41 ' HB2' HG22 ' A' ' 104' ' ' THR . 3.0 mmp_? -94.39 17.99 11.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 71.02 110.888 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.83 27.76 21.6 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.699 -0.762 . . . . 71.33 112.538 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.686 HG21 HD11 ' A' ' 109' ' ' ILE . 8.5 t -126.73 -177.22 3.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.916 0.389 . . . . 72.23 111.116 -179.83 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.439 HG22 ' H ' ' A' ' 106' ' ' VAL . 0.2 OUTLIER -125.41 167.88 14.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 61.44 111.123 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.439 ' H ' HG22 ' A' ' 105' ' ' THR . 45.9 t -56.47 -38.98 58.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 74.34 111.167 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 68.5 m-20 -51.71 -38.56 55.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 73.01 110.855 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -81.05 -50.64 16.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 64.15 111.108 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.686 HD11 HG21 ' A' ' 104' ' ' THR . 49.7 mm -51.29 -41.02 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 72.1 111.125 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.409 ' OE1' HG12 ' A' ' 106' ' ' VAL . 18.9 pt20 -78.58 -25.57 45.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 74.22 110.928 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 10.3 t -76.38 -24.13 54.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 75.31 110.839 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.1 mt -98.48 -44.67 6.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 64.14 110.903 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.97 67.96 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.637 0.732 . . . . 73.5 110.907 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.72 21.77 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.66 2.24 . . . . 73.23 112.36 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.78 -44.33 48.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.764 -0.731 . . . . 54.22 112.48 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.708 ' HB ' HD23 ' A' ' 121' ' ' LEU . 1.6 m -118.82 161.06 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.829 0.347 . . . . 74.42 111.121 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -108.34 160.96 25.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.634 0.731 . . . . 71.43 110.854 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -8.22 23.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.682 2.255 . . . . 73.24 112.362 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.21 -21.63 13.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 75.1 111.109 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 6.5 ptp180 -134.87 96.22 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 74.24 110.929 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.708 HD23 ' HB ' ' A' ' 116' ' ' VAL . 89.5 mt -117.55 161.81 19.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.181 -0.463 . . . . 71.55 110.903 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -107.67 148.81 28.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 74.54 110.932 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.457 HG23 ' HG3' ' A' ' 91' ' ' PRO . 14.0 p -68.89 143.75 14.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 74.23 111.118 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.2 60.85 6.75 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.715 -0.755 . . . . 74.22 112.496 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 45.5 tt0 -119.21 121.18 39.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.824 0.345 . . . . 64.33 110.97 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 26.2 t -88.92 132.27 34.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 74.3 111.134 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 2.4 pt -134.04 175.97 9.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.459 . . . . 73.45 111.132 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 60.0 m-20 -92.51 136.56 33.11 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.457 . . . . 70.51 110.907 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.65 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.4 m -143.76 155.99 59.5 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.547 0.689 . . . . 45.21 111.15 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.83 110.53 2.59 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.65 2.233 . . . . 74.41 112.308 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 73.35 110.873 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.2 m . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.877 0.37 . . . . 61.34 110.931 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 22.2 p -129.65 150.31 51.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 71.5 111.127 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -122.4 136.63 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.159 -0.473 . . . . 72.44 110.897 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -89.25 122.1 32.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 65.43 111.102 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.402 HG23 ' HB2' ' A' ' 93' ' ' ASP . 69.7 mt -91.03 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 60.22 111.137 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.61 163.55 16.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.6 0.715 . . . . 75.25 110.945 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.473 ' HG3' HG23 ' A' ' 123' ' ' VAL . 54.2 Cg_exo -45.86 105.15 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.636 2.224 . . . . 74.32 112.374 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 118.65 1.11 15.43 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.726 -0.75 . . . . 52.33 112.491 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.402 ' HB2' HG23 ' A' ' 89' ' ' ILE . 15.2 m-20 -105.09 144.2 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.908 0.385 . . . . 64.23 110.851 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.07 158.78 43.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 72.41 111.166 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.602 ' CE1' HD21 ' A' ' 121' ' ' LEU . 1.6 m-85 -50.9 -47.92 60.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 72.45 110.858 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -72.97 -47.68 43.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 73.55 110.918 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -55.6 -26.56 44.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 53.03 111.114 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 21.1 mt -90.91 -38.78 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 65.12 111.158 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 104' ' ' THR . . . -61.53 -40.4 94.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 72.24 111.086 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -56.38 -44.69 80.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 74.44 110.896 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 -75.52 -49.38 18.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.451 . . . . 65.21 110.837 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 21.5 mmm180 -56.98 -24.39 52.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 75.14 110.852 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.19 23.64 37.01 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 50.02 112.478 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.993 HG21 HD11 ' A' ' 109' ' ' ILE . 6.6 t -114.76 -171.66 1.97 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 74.4 111.149 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.15 149.13 43.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.217 -0.447 . . . . 72.43 111.111 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 83.4 t -55.5 -46.91 79.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 62.13 111.12 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -51.85 -30.69 24.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 74.42 110.826 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 72.7 t -80.08 -54.09 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 72.32 111.154 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.993 HD11 HG21 ' A' ' 104' ' ' THR . 41.3 mm -52.57 -42.51 40.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.166 -0.47 . . . . 74.23 111.187 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.83 -25.48 59.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.108 -0.496 . . . . 73.25 110.894 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t -79.23 -22.95 44.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 53.34 110.88 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 11.9 mt -96.5 -45.54 6.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 73.14 110.919 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.72 67.86 5.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.608 0.718 . . . . 72.11 110.924 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -7.36 20.84 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.656 2.237 . . . . 75.13 112.35 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.1 -39.48 34.29 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.778 -0.725 . . . . 53.22 112.46 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.667 ' HB ' HD23 ' A' ' 121' ' ' LEU . 0.5 OUTLIER -121.76 163.02 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.844 0.354 . . . . 74.11 111.14 -179.953 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 33.0 m-20 -102.99 161.21 23.8 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.615 0.722 . . . . 73.15 110.877 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.67 26.68 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.685 2.256 . . . . 73.34 112.319 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -117.44 -18.83 9.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.25 -0.432 . . . . 70.35 111.124 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -122.04 90.0 3.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 63.43 110.891 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.667 HD23 ' HB ' ' A' ' 116' ' ' VAL . 73.0 mt -119.39 160.38 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 71.15 110.92 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -105.49 148.55 27.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 72.33 110.919 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.473 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.2 p -61.7 139.45 20.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 74.12 111.186 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.78 62.49 5.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 63.12 112.503 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -119.28 121.9 40.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.83 0.348 . . . . 73.44 110.916 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 11.3 p -86.45 134.68 26.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 74.05 111.144 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 1.3 pp -129.45 172.76 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 72.43 111.08 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -100.33 142.95 31.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 63.02 110.9 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -136.09 156.2 77.11 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.594 0.711 . . . . 74.24 111.126 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 110.11 2.48 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.679 2.253 . . . . 71.31 112.363 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 98.9 m . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 64.5 110.905 179.992 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 71.2 m . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.885 0.374 . . . . 62.54 110.869 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 44.8 p -124.96 150.26 46.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 72.32 111.153 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.503 ' CE2' HD13 ' A' ' 98' ' ' ILE . 42.1 t80 -122.48 136.68 54.94 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.212 -0.449 . . . . 74.11 110.932 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 m -91.41 120.19 32.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 74.54 111.109 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.4 mt -90.85 109.59 21.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.45 . . . . 64.35 111.132 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 22.9 mm-40 -97.29 159.45 31.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.612 0.72 . . . . 63.44 110.893 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.81 93.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.698 2.265 . . . . 75.13 112.358 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.48 -17.46 2.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 61.3 112.514 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.92 167.26 16.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.913 0.387 . . . . 51.23 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.2 151.77 45.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.192 -0.458 . . . . 73.13 111.154 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' PHE . . . . . 0.521 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.3 m-85 -51.03 -47.38 61.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.251 -0.431 . . . . 75.23 110.885 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -71.6 -47.16 56.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 73.13 110.895 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.73 -23.88 54.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 72.54 111.068 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.503 HD13 ' CE2' ' A' ' 87' ' ' TYR . 35.2 mt -95.46 -31.99 4.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.445 . . . . 74.22 111.129 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.603 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -72.18 -29.5 64.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 72.12 111.123 179.793 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 1.5 pp0? -65.7 -44.46 86.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.929 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.5 -13.73 53.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 70.4 110.908 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -93.03 16.56 12.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 74.33 110.922 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.63 28.1 21.12 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 52.02 112.494 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' THR . . . . . 1.018 HG21 HD11 ' A' ' 109' ' ' ILE . 11.8 t -129.0 -179.96 5.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.842 0.353 . . . . 73.02 111.152 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -123.28 159.77 28.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 54.45 111.152 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 52.6 t -55.07 -42.38 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 72.04 111.106 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -51.85 -38.09 54.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 65.13 110.828 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.448 HG12 HD12 ' A' ' 112' ' ' LEU . 21.5 t -77.2 -54.19 13.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 53.22 111.132 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 1.018 HD11 HG21 ' A' ' 104' ' ' THR . 50.2 mm -51.42 -39.95 23.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 41.01 111.108 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -77.98 -25.56 48.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 72.12 110.9 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -76.92 -24.05 52.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 53.01 110.888 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.448 HD12 HG12 ' A' ' 108' ' ' VAL . 7.3 mt -95.18 -45.3 7.25 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.921 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.06 67.57 6.42 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.742 . . . . 60.23 110.906 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -6.96 19.86 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.693 2.262 . . . . 75.15 112.379 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.63 -39.9 31.56 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 62.0 112.484 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.622 HG11 HE22 ' A' ' 125' ' ' GLN . 2.1 m -118.95 160.83 18.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.827 0.346 . . . . 42.55 111.142 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -99.63 160.56 27.07 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.622 0.725 . . . . 62.32 110.888 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -22.78 31.61 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.749 2.3 . . . . 75.22 112.312 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.4 24.33 11.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 64.54 111.094 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 14.5 ptm180 -177.33 111.56 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 73.32 110.873 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 86.1 mt -127.66 -179.59 5.01 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.176 -0.466 . . . . 63.43 110.926 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -124.16 147.56 47.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 74.02 110.928 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 14.6 p -62.85 139.99 20.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 63.45 111.167 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.67 65.14 3.37 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 44.24 112.475 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' GLN . . . . . 0.622 HE22 HG11 ' A' ' 116' ' ' VAL . 8.8 tt0 -113.69 127.72 56.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.787 0.327 . . . . 73.15 110.933 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 17.6 t -91.51 122.77 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 75.32 111.09 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.1 pt -127.84 175.84 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 72.42 111.089 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -110.87 143.36 41.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 74.32 110.919 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.93 156.23 79.38 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.631 0.729 . . . . 32.1 111.121 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 110.77 2.64 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.696 2.264 . . . . 51.25 112.334 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 73.31 110.884 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 26.0 m . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.858 0.361 . . . . 63.51 110.879 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.7 p -124.85 167.72 14.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 73.53 111.128 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.5 ' CE2' HD13 ' A' ' 98' ' ' ILE . 41.8 t80 -139.49 136.38 34.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 63.11 110.877 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.482 HG23 HG22 ' A' ' 126' ' ' VAL . 2.1 m -90.89 121.18 32.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.119 -0.491 . . . . 71.44 111.128 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.453 HD11 HG12 ' A' ' 127' ' ' ILE . 64.4 mt -91.04 109.29 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 73.34 111.09 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -110.39 162.86 18.82 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 63.23 110.911 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -45.89 118.77 2.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.711 2.274 . . . . 73.12 112.35 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 108.32 -23.83 23.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.797 -0.716 . . . . 54.22 112.529 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -86.67 121.98 29.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.868 0.366 . . . . 75.44 110.877 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.87 156.16 19.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 74.35 111.134 -179.867 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -51.61 -45.25 63.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 73.1 110.863 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -70.46 -51.4 29.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 73.12 110.9 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.63 -31.86 58.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 61.22 111.133 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.5 HD13 ' CE2' ' A' ' 87' ' ' TYR . 34.5 mt -84.04 -35.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 53.3 111.126 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.453 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -63.15 -48.32 78.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 74.14 111.133 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -52.99 -44.93 67.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.91 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 6.8 ptp85 -78.62 -18.05 55.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 70.34 110.898 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -94.11 19.74 8.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.189 -0.459 . . . . 71.14 110.923 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.78 28.12 22.32 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.735 -0.745 . . . . 73.0 112.478 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.888 HG21 HD11 ' A' ' 109' ' ' ILE . 14.5 t -134.45 174.72 10.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.844 0.354 . . . . 63.14 111.167 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.58 164.62 15.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.03 111.172 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.408 HG12 ' OE1' ' A' ' 110' ' ' GLN . 22.6 t -57.41 -41.44 78.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.02 111.166 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -51.82 -34.42 40.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.862 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.79 -51.72 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 62.04 111.079 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.888 HD11 HG21 ' A' ' 104' ' ' THR . 49.0 mm -51.75 -41.71 29.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.236 -0.438 . . . . 64.32 111.135 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.408 ' OE1' HG12 ' A' ' 106' ' ' VAL . 18.6 pt20 -78.32 -25.53 46.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 71.34 110.928 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -78.69 -20.92 49.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 74.33 110.874 -179.785 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 21.0 mt -98.29 -45.49 6.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.486 . . . . 53.4 110.896 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -118.45 67.91 7.4 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.635 0.731 . . . . 75.14 110.9 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -8.53 23.83 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.717 2.278 . . . . 74.41 112.302 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.77 -26.33 62.58 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.757 -0.735 . . . . 21.21 112.454 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.691 HG12 HD23 ' A' ' 121' ' ' LEU . 1.5 t -121.4 92.53 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.788 0.327 . . . . 71.54 111.151 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -51.8 159.13 1.42 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.617 0.723 . . . . 72.21 110.856 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -29.98 22.92 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.666 2.244 . . . . 65.42 112.326 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -95.13 31.99 1.8 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 52.51 111.059 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 179.88 93.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 75.53 110.865 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.691 HD23 HG12 ' A' ' 116' ' ' VAL . 45.5 mt -116.2 144.58 44.0 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 74.12 110.911 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -98.59 153.31 18.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 43.52 110.92 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.71 144.06 12.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 74.02 111.121 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.51 59.02 8.92 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.739 . . . . 51.32 112.443 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -119.26 122.64 42.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.834 0.349 . . . . 64.31 110.915 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.482 HG22 HG23 ' A' ' 88' ' ' THR . 33.6 t -88.52 127.05 41.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 73.21 111.127 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.453 HG12 HD11 ' A' ' 89' ' ' ILE . 3.2 pt -123.54 175.91 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.172 -0.467 . . . . 72.12 111.15 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 6.0 m-20 -94.55 145.46 24.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.186 -0.461 . . . . 51.23 110.91 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.94 156.1 78.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.638 0.732 . . . . 63.13 111.108 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 110.64 2.61 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.733 2.288 . . . . 72.13 112.314 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 46.6 m . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 64.15 110.869 179.993 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 3.9 m . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.888 0.375 . . . . 71.3 110.871 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.4 p -123.55 154.67 38.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 53.31 111.148 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.524 ' HB2' HG21 ' A' ' 129' ' ' VAL . 38.6 t80 -133.5 134.99 44.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 75.34 110.926 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.6 125.98 35.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 63.23 111.175 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.8 mt -90.9 109.38 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 51.12 111.157 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 49.5 mm-40 -110.92 161.94 22.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.623 0.725 . . . . 74.44 110.89 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -45.98 121.45 4.34 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.721 2.281 . . . . 61.32 112.328 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.19 34.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.732 -0.747 . . . . 72.41 112.418 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -95.79 121.03 37.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.844 0.354 . . . . 74.14 110.845 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.0 165.33 11.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 65.53 111.123 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -53.98 -60.8 2.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 73.01 110.866 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -56.57 -52.47 64.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.152 -0.477 . . . . 74.4 110.906 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.42 -62.42 1.63 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.449 . . . . 73.41 111.13 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 34.3 mt -51.5 -38.15 20.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 71.44 111.138 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.446 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -64.28 -37.19 86.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 54.11 111.115 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -51.91 -72.11 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 72.25 110.928 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 10.0 ptt-85 -55.87 -40.47 72.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 72.42 110.858 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.8 mmp_? -57.9 -24.04 55.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.171 -0.468 . . . . 73.34 110.885 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 54.31 112.473 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.843 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -120.99 178.87 4.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 73.32 111.15 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -119.82 162.93 18.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 64.34 111.181 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 23.9 t -56.68 -40.32 69.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.24 -0.436 . . . . 71.01 111.155 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -51.76 -36.24 46.61 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 52.34 110.836 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.59 HG12 HD12 ' A' ' 112' ' ' LEU . 25.7 t -81.96 -50.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 63.51 111.141 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.843 HD11 HG21 ' A' ' 104' ' ' THR . 47.7 mm -51.95 -41.12 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.149 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 18.4 pt20 -79.14 -25.39 42.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 55.34 110.93 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 t -79.44 -20.14 48.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 75.43 110.872 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.59 HD12 HG12 ' A' ' 108' ' ' VAL . 8.5 mt -98.38 -45.72 6.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 50.34 110.927 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.95 68.05 6.41 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.563 0.697 . . . . 73.23 110.891 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -8.54 23.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.69 2.26 . . . . 73.52 112.346 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.41 -23.89 67.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.757 . . . . 61.4 112.518 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.542 HG12 ' CD2' ' A' ' 121' ' ' LEU . 2.2 t -122.45 104.74 15.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 60.54 111.11 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -75.09 154.68 86.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.61 0.719 . . . . 55.42 110.909 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -13.76 35.14 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.678 2.252 . . . . 75.15 112.338 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -71.29 -18.9 62.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 65.33 111.092 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -170.61 115.23 0.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 74.51 110.887 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.542 ' CD2' HG12 ' A' ' 116' ' ' VAL . 55.4 mt -108.2 153.45 23.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 61.01 110.882 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 53.8 mm-40 -97.84 148.78 23.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 65.51 110.942 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.9 145.03 11.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 71.42 111.156 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.33 58.13 10.42 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 72.13 112.479 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -119.33 120.69 37.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.818 0.342 . . . . 72.45 110.877 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 6.4 p -85.06 130.88 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 43.51 111.183 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.2 pt -131.06 175.85 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 64.35 111.162 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 39.3 m-20 -89.94 145.62 24.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.463 . . . . 73.42 110.842 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.524 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -147.67 156.15 45.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.627 0.727 . . . . 54.35 111.094 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.649 2.233 . . . . 75.21 112.309 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 61.54 110.895 179.955 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 2.4 m . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.919 0.39 . . . . 52.14 110.903 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 71.9 p -123.67 151.47 43.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 74.32 111.11 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -138.25 136.52 36.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.215 -0.448 . . . . 72.32 110.927 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.739 HG23 HG22 ' A' ' 126' ' ' VAL . 1.4 m -92.65 126.44 37.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 50.14 111.166 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.89 109.44 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 64.43 111.121 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.0 mm-40 -110.36 162.06 22.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.642 0.734 . . . . 73.03 110.906 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -45.93 118.39 2.31 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 73.41 112.355 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.62 -18.88 29.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.73 -0.748 . . . . 74.44 112.51 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.506 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.5 m-20 -96.87 115.68 27.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 73.13 110.865 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.92 159.78 15.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.189 -0.46 . . . . 73.51 111.122 -179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -53.66 -55.03 29.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 65.12 110.859 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.2 t-105 -57.96 -56.21 24.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.137 -0.483 . . . . 73.52 110.875 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.36 -60.6 2.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.26 -0.427 . . . . 61.52 111.103 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ILE . . . . . 0.506 HD11 ' CB ' ' A' ' 93' ' ' ASP . 33.0 mt -51.62 -37.86 20.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 73.55 111.137 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.429 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -65.7 -37.46 86.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.176 -0.465 . . . . 43.03 111.126 179.798 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -51.81 -65.15 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 75.33 110.915 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.2 mtt180 -63.32 -41.27 98.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 72.24 110.945 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.6 mmp_? -55.87 -25.7 43.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 73.24 110.816 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.76 17.41 51.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 60.12 112.494 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.967 HG21 HD11 ' A' ' 109' ' ' ILE . 11.5 t -119.37 179.9 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.856 0.36 . . . . 74.42 111.148 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.18 157.77 28.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 63.04 111.153 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 26.3 t -55.48 -42.83 69.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 64.31 111.131 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -51.84 -36.31 47.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.87 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -78.83 -53.6 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 61.03 111.127 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ILE . . . . . 0.967 HD11 HG21 ' A' ' 104' ' ' THR . 44.8 mm -51.66 -40.58 26.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 73.55 111.173 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -77.75 -25.42 49.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 65.44 110.931 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.5 t -80.38 -20.35 44.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 73.14 110.835 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.1 mt -98.35 -45.53 6.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 71.44 110.872 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.96 68.17 6.48 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.641 0.734 . . . . 73.14 110.883 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -8.5 23.77 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.694 2.263 . . . . 70.54 112.33 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.04 -22.92 58.73 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.793 -0.718 . . . . 63.11 112.461 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.517 HG12 HD23 ' A' ' 121' ' ' LEU . 2.1 t -121.89 107.91 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.86 0.362 . . . . 61.01 111.096 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.55 155.0 81.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.636 0.732 . . . . 43.32 110.876 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.79 -16.72 37.55 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.707 2.272 . . . . 72.13 112.313 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -68.65 -19.44 64.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.261 -0.427 . . . . 41.33 111.13 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.3 ptt180 -173.48 116.63 0.26 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 52.24 110.899 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.517 HD23 HG12 ' A' ' 116' ' ' VAL . 61.7 mt -103.46 154.6 19.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 60.24 110.91 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 -97.77 143.12 28.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 55.42 110.957 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.51 145.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 50.2 111.133 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.28 59.1 8.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 72.32 112.495 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -119.3 121.57 39.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 73.44 110.909 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' VAL . . . . . 0.739 HG22 HG23 ' A' ' 88' ' ' THR . 22.4 t -85.27 127.11 40.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 71.13 111.141 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 10.0 pt -123.5 174.32 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 61.0 111.132 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -96.89 144.28 26.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.156 -0.475 . . . . 72.41 110.937 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.25 156.19 79.75 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.641 0.734 . . . . 73.11 111.108 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 85.47 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.658 2.239 . . . . 42.11 112.377 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.147 -0.479 . . . . 65.15 110.924 -179.981 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 15.7 mmt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.791 0.329 . . . . 72.45 110.871 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -101.89 -160.09 26.59 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 71.11 112.501 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 5.3 m -145.96 166.06 27.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.932 0.396 . . . . 63.21 110.881 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 41.3 p -123.55 168.08 13.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 53.11 111.14 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.42 ' HB2' HG21 ' A' ' 129' ' ' VAL . 45.8 t80 -145.23 136.38 24.89 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 72.13 110.968 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.6 m -91.73 123.09 34.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.108 -0.496 . . . . 75.43 111.116 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 60.6 mt -90.89 109.49 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.453 . . . . 74.31 111.152 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -111.24 163.51 17.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.617 0.722 . . . . 73.03 110.93 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_exo -46.16 124.58 7.71 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.718 2.278 . . . . 75.44 112.333 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 106.54 -17.96 38.86 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.777 -0.725 . . . . 65.03 112.483 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -97.31 147.03 24.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.908 0.385 . . . . 75.41 110.833 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.96 174.36 10.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 40.34 111.121 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.518 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.3 m-85 -54.51 -70.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 75.24 110.905 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.92 -50.07 61.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.16 -0.473 . . . . 74.33 110.924 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.03 -66.29 0.41 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.264 -0.425 . . . . 71.34 111.11 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 43.9 mt -51.37 -32.68 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 75.43 111.077 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -66.73 -38.46 86.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 65.44 111.147 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 19.4 mt-30 -52.32 -69.42 0.11 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 74.04 110.882 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 9.6 ptm180 -56.28 -44.48 79.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 75.31 110.855 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -56.35 -25.03 47.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 74.34 110.841 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.82 16.55 56.21 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.736 -0.745 . . . . 70.04 112.463 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.683 HG21 HD11 ' A' ' 109' ' ' ILE . 7.7 t -119.84 -176.1 3.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.897 0.38 . . . . 54.34 111.103 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.402 HG22 ' H ' ' A' ' 106' ' ' VAL . 0.3 OUTLIER -125.27 165.97 17.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 75.05 111.14 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.461 HG12 ' OE1' ' A' ' 110' ' ' GLN . 61.3 t -55.78 -41.12 64.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 72.41 111.175 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -51.79 -36.03 46.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 73.41 110.856 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.21 -51.5 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 73.24 111.103 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.683 HD11 HG21 ' A' ' 104' ' ' THR . 49.7 mm -51.25 -42.45 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 74.12 111.166 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.461 ' OE1' HG12 ' A' ' 106' ' ' VAL . 19.0 pt20 -78.18 -25.4 47.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 74.24 110.909 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.7 t -78.05 -21.07 51.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 74.41 110.864 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 43.3 mt -97.05 -46.16 6.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.151 -0.477 . . . . 73.24 110.921 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -117.96 68.15 6.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.596 0.712 . . . . 63.42 110.878 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -8.51 23.78 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.657 2.238 . . . . 71.54 112.314 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -67.23 -17.59 68.34 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.733 -0.746 . . . . 64.12 112.523 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.551 HG21 ' OE1' ' A' ' 125' ' ' GLN . 2.2 t -131.14 119.67 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.909 0.385 . . . . 65.0 111.098 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -88.77 154.86 50.51 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.599 0.714 . . . . 74.5 110.902 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -19.63 35.73 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.725 2.283 . . . . 74.44 112.327 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.79 -15.98 60.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 63.13 111.112 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -170.56 115.33 0.47 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 74.43 110.852 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.518 HD11 ' CD2' ' A' ' 95' ' ' PHE . 47.0 mt -117.34 150.79 38.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.47 . . . . 72.14 110.933 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.0 mm100 -97.77 149.5 22.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 74.0 110.911 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.3 p -68.35 146.61 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 63.11 111.137 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.8 63.73 4.51 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 63.32 112.514 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.551 ' OE1' HG21 ' A' ' 116' ' ' VAL . 13.5 tt0 -119.14 121.62 40.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 71.44 110.907 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.54 124.53 40.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 41.52 111.121 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.6 pt -127.83 175.93 8.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 71.33 111.148 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -96.05 144.07 26.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 74.1 110.9 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.42 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -141.26 156.15 67.68 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.726 . . . . 73.45 111.085 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 105.52 1.5 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.675 2.25 . . . . 74.52 112.346 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.2 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 74.42 110.873 -179.972 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 7.9 mtp . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.819 0.342 . . . . 74.01 110.9 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 129.21 -126.56 5.24 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.752 -0.737 . . . . 41.52 112.514 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.1 m -129.85 136.68 49.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.892 0.377 . . . . 65.42 110.876 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.5 p -126.43 161.52 27.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.148 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.428 ' CE1' HD13 ' A' ' 98' ' ' ILE . 45.2 t80 -142.85 136.63 28.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 74.44 110.918 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 m -93.44 124.03 37.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 63.5 111.124 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.8 mt -91.05 109.58 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 65.11 111.116 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -111.58 163.52 17.3 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.579 0.704 . . . . 63.41 110.926 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_exo -46.16 120.95 4.01 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.712 2.274 . . . . 70.31 112.336 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.6 -18.86 26.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.759 . . . . 43.12 112.478 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.565 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.4 m-20 -99.04 140.94 32.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.896 0.379 . . . . 63.44 110.852 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.77 163.8 24.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 44.51 111.134 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.416 ' CE1' HG22 ' A' ' 109' ' ' ILE . 1.3 m-85 -54.99 -64.57 0.79 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 73.51 110.865 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -56.2 -50.67 70.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 74.11 110.919 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.65 -65.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 55.33 111.049 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.565 HD11 ' CB ' ' A' ' 93' ' ' ASP . 36.3 mt -51.73 -37.0 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 70.15 111.118 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.402 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -64.13 -36.1 82.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 73.44 111.085 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.9 mt-30 -51.82 -63.75 1.03 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 75.45 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 47.9 mtm180 -67.1 -39.38 86.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.41 110.89 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ARG . . . . . 0.558 ' HG3' HG22 ' A' ' 98' ' ' ILE . 8.5 mmp_? -56.41 -25.14 49.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 72.15 110.904 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 92.23 17.15 47.82 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 75.51 112.517 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.949 HG21 HD11 ' A' ' 109' ' ' ILE . 13.4 t -125.21 177.3 6.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.87 0.367 . . . . 73.5 111.13 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.401 HG22 ' H ' ' A' ' 106' ' ' VAL . 1.1 m -125.43 164.68 19.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 71.52 111.104 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.401 ' H ' HG22 ' A' ' 105' ' ' THR . 58.9 t -54.68 -40.88 53.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.198 -0.455 . . . . 70.12 111.094 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ASP . . . . . 0.617 ' OD2' HG23 ' A' ' 108' ' ' VAL . 0.6 OUTLIER -51.67 -38.51 55.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.196 -0.456 . . . . 75.44 110.877 179.884 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.617 HG23 ' OD2' ' A' ' 107' ' ' ASP . 24.9 t -78.94 -52.33 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 75.31 111.142 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.949 HD11 HG21 ' A' ' 104' ' ' THR . 47.7 mm -52.2 -41.1 32.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 61.04 111.179 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -75.66 -25.51 56.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 61.22 110.905 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.3 t -79.41 -23.47 43.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 43.44 110.863 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.7 mt -98.92 -44.65 6.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 75.44 110.897 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -117.67 68.29 5.91 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.625 0.726 . . . . 64.44 110.874 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -7.3 20.72 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.625 2.216 . . . . 74.53 112.366 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.34 -43.75 43.84 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.747 -0.739 . . . . 43.53 112.518 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.517 HG11 HE22 ' A' ' 125' ' ' GLN . 2.4 m -116.46 127.24 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.802 0.334 . . . . 54.11 111.151 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -55.92 160.87 3.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.619 0.723 . . . . 63.21 110.917 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.73 24.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.266 . . . . 75.33 112.348 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -133.07 24.39 4.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.34 111.102 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 67.9 mtp85 -149.73 89.48 1.62 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 74.43 110.86 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.487 HD23 ' HB ' ' A' ' 116' ' ' VAL . 9.9 mt -125.16 176.23 6.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 74.12 110.943 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 24.3 mm100 -136.38 150.4 48.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.889 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.1 p -54.37 146.45 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 60.4 111.188 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.02 65.01 3.5 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.73 -0.747 . . . . 44.33 112.509 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.517 HE22 HG11 ' A' ' 116' ' ' VAL . 13.6 tt0 -119.12 122.01 41.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.816 0.341 . . . . 75.53 110.941 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.4 p -87.43 135.04 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 75.22 111.141 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.0 pt -140.74 175.82 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 75.43 111.163 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 10.0 m-20 -103.19 143.06 33.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 74.22 110.894 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.2 156.14 66.99 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 74.4 111.151 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 110.54 2.59 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.657 2.238 . . . . 73.05 112.351 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 70.3 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 61.3 110.894 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 10.8 mtt . . . . . 0 N--CA 1.458 -0.074 0 CA-C-O 120.78 0.324 . . . . 65.35 110.899 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.47 -144.56 7.28 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.722 -0.752 . . . . 71.25 112.496 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 81.8 m -113.68 141.18 47.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.943 0.401 . . . . 75.02 110.843 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.6 p -125.55 163.47 22.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 63.1 111.201 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.434 ' CE1' HD13 ' A' ' 98' ' ' ILE . 42.2 t80 -142.85 136.56 28.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.256 -0.429 . . . . 71.11 110.933 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -93.61 123.66 37.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.123 -0.489 . . . . 63.31 111.15 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.422 HD12 ' HB3' ' A' ' 125' ' ' GLN . 74.8 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 75.41 111.127 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.1 mm-40 -109.28 163.15 17.69 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.56 0.695 . . . . 73.15 110.896 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -46.17 124.8 7.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 64.31 112.321 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.75 -18.88 39.85 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.724 -0.751 . . . . 63.2 112.464 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -96.83 141.39 30.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.886 0.374 . . . . 74.43 110.875 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -129.73 170.26 14.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 73.25 111.164 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.52 ' HZ ' HG23 ' A' ' 116' ' ' VAL . 1.3 m-85 -54.39 -69.53 0.12 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 54.23 110.886 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.1 t-105 -52.3 -49.93 63.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 73.24 110.939 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.31 -65.7 0.51 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.238 -0.437 . . . . 71.4 111.076 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.434 HD13 ' CE1' ' A' ' 87' ' ' TYR . 46.8 mt -51.77 -37.09 19.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.264 -0.426 . . . . 71.32 111.14 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -63.64 -35.87 81.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 72.54 111.123 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -51.78 -68.18 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 72.01 110.909 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 46.6 mtt180 -61.71 -41.99 98.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 74.21 110.837 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.1 mmm180 -54.68 -27.1 37.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 64.12 110.893 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.4 18.09 50.41 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 50.33 112.451 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.977 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -119.36 178.39 4.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.866 0.365 . . . . 65.4 111.142 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -120.97 160.68 23.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 72.41 111.177 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.0 t -54.37 -47.17 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 51.31 111.172 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -52.24 -29.71 24.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 54.32 110.844 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.553 HG12 HD12 ' A' ' 112' ' ' LEU . 61.7 t -81.32 -54.19 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 73.43 111.104 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.977 HD11 HG21 ' A' ' 104' ' ' THR . 50.0 mm -52.59 -39.65 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 71.14 111.12 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -25.35 47.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 73.55 110.926 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 t -80.64 -21.01 41.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.187 -0.46 . . . . 71.51 110.847 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.553 HD12 HG12 ' A' ' 108' ' ' VAL . 6.6 mt -102.59 -42.13 6.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.104 -0.498 . . . . 72.43 110.928 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -117.64 68.34 5.87 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.644 0.735 . . . . 75.3 110.894 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -7.29 20.69 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.681 2.254 . . . . 74.52 112.357 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.29 -43.5 43.17 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.749 -0.739 . . . . 75.05 112.477 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.669 HG11 ' NE2' ' A' ' 125' ' ' GLN . 2.2 m -116.43 128.04 73.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.883 0.373 . . . . 74.35 111.167 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -58.45 161.49 7.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 62.4 110.885 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -8.48 23.72 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.699 2.266 . . . . 71.34 112.324 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.13 18.87 4.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.091 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -142.67 87.28 1.99 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 74.42 110.866 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 7.9 mt -124.23 167.94 13.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.478 . . . . 72.53 110.885 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -135.42 153.31 51.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 74.54 110.875 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.9 p -52.81 147.76 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 71.2 111.12 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.69 66.72 2.38 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.688 -0.767 . . . . 75.25 112.474 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.669 ' NE2' HG11 ' A' ' 116' ' ' VAL . 7.0 tt0 -114.31 120.9 41.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.867 0.365 . . . . 71.14 110.889 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.99 124.98 42.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 74.24 111.163 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.4 pt -135.06 175.92 9.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 64.23 111.17 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -104.59 148.94 25.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 53.23 110.874 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -133.29 156.12 80.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.565 0.698 . . . . 73.23 111.163 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 110.16 2.49 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.693 2.262 . . . . 62.43 112.278 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 88.6 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 73.32 110.9 179.932 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 21.4 ttp . . . . . 0 C--O 1.23 0.06 0 CA-C-O 120.81 0.338 . . . . 64.53 110.866 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.69 -156.05 15.8 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.742 -0.742 . . . . 74.43 112.504 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' CYS . . . . . 0.428 ' HB3' HG23 ' A' ' 129' ' ' VAL . 6.8 m -112.27 146.31 38.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.906 0.384 . . . . 74.23 110.891 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.6 p -123.6 160.75 26.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 75.23 111.119 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -143.42 136.56 27.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 74.34 110.93 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.7 m -94.91 123.27 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 52.24 111.172 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 57.0 mt -90.99 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.235 -0.438 . . . . 73.12 111.13 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -116.21 163.36 21.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.568 0.699 . . . . 72.31 110.95 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -46.52 107.79 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 53.14 112.337 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 126.63 -18.51 6.35 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.714 -0.755 . . . . 71.45 112.484 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.597 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.4 m-20 -103.49 136.97 42.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 75.42 110.843 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.25 163.86 20.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 63.22 111.194 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.499 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.4 m-85 -54.75 -67.54 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 72.31 110.911 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -52.23 -51.74 56.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 74.42 110.916 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.32 -65.6 0.53 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.264 -0.426 . . . . 74.41 111.143 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.597 HD11 ' CB ' ' A' ' 93' ' ' ASP . 26.3 mt -51.42 -31.68 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 72.23 111.148 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.504 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -67.47 -39.82 85.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 72.43 111.087 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 20.6 mt-30 -52.39 -58.77 5.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 74.55 110.936 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 3.1 mmt85 -69.31 -16.85 63.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 74.02 110.891 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ARG . . . . . 0.403 ' HE ' HG11 ' A' ' 129' ' ' VAL . 18.3 mmt180 -90.83 12.76 18.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 65.15 110.904 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.94 28.08 23.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.74 -0.743 . . . . 45.32 112.51 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.894 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -129.55 177.94 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.879 0.371 . . . . 74.1 111.123 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.98 163.01 26.28 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.197 -0.456 . . . . 72.13 111.15 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.412 HG12 ' OE1' ' A' ' 110' ' ' GLN . 62.0 t -51.85 -39.53 25.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 55.13 111.141 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -51.55 -39.35 57.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.484 . . . . 64.04 110.864 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -80.25 -50.34 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.15 -0.477 . . . . 75.2 111.111 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.894 HD11 HG21 ' A' ' 104' ' ' THR . 47.5 mm -51.43 -41.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 74.21 111.079 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.412 ' OE1' HG12 ' A' ' 106' ' ' VAL . 19.0 pt20 -77.65 -25.6 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 74.4 110.933 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 19.9 t -76.14 -24.5 54.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.182 -0.463 . . . . 53.54 110.843 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 20.8 mt -98.59 -44.53 6.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 71.41 110.906 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.93 67.97 6.33 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.589 0.709 . . . . 73.01 110.911 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -7.63 21.54 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.686 2.257 . . . . 74.04 112.316 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.47 -45.42 46.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.78 -0.724 . . . . 63.14 112.47 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.561 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.3 m -117.24 124.93 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 64.44 111.127 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -67.97 160.87 71.83 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.607 0.717 . . . . 52.24 110.887 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -8.46 23.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.624 2.216 . . . . 71.55 112.352 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -115.51 24.9 11.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 53.35 111.11 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.2 ptp180 -173.34 108.16 0.16 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 74.53 110.858 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.561 HD23 ' HB ' ' A' ' 116' ' ' VAL . 10.3 mt -136.99 146.91 45.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.174 -0.467 . . . . 44.41 110.92 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -97.75 153.0 18.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 75.0 110.89 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 12.4 p -68.12 148.07 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 74.1 111.178 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.84 61.7 6.24 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.783 -0.722 . . . . 44.03 112.481 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.527 HE22 HG11 ' A' ' 116' ' ' VAL . 15.6 tt0 -119.24 121.96 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.838 0.352 . . . . 73.02 110.902 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.87 124.95 40.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 50.43 111.117 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.5 pt -123.58 175.74 5.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.185 -0.461 . . . . 53.24 111.132 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -99.16 137.26 37.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 52.43 110.85 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.428 HG23 ' HB3' ' A' ' 85' ' ' CYS . 3.2 m -117.93 156.22 50.29 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.598 0.713 . . . . 72.5 111.124 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 83.91 0.67 Allowed 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.647 2.231 . . . . 72.11 112.355 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.264 -0.426 . . . . 53.11 110.868 -179.998 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 9.2 mmt . . . . . 0 CA--C 1.526 0.051 0 CA-C-O 120.778 0.323 . . . . 63.32 110.904 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.81 169.68 28.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.745 -0.74 . . . . 60.45 112.5 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 9.2 m -131.85 143.8 50.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.903 0.382 . . . . 53.5 110.894 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.3 p -123.61 154.38 39.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 62.34 111.13 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 47.0 t80 -132.26 136.6 47.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.236 -0.438 . . . . 74.13 110.889 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -91.43 125.24 36.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.065 -0.516 . . . . 61.33 111.127 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 121' ' ' LEU . 52.2 mt -93.22 110.51 23.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 74.23 111.146 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm-40 -89.45 158.87 45.3 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.55 0.69 . . . . 71.3 110.898 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.632 ' HB3' HG23 ' A' ' 123' ' ' VAL . 20.2 Cg_endo -59.67 92.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.645 2.23 . . . . 44.33 112.37 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.44 -18.28 2.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.754 -0.736 . . . . 72.4 112.493 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -78.81 155.86 29.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 71.4 110.841 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.458 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -131.66 165.15 24.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 54.54 111.166 -179.932 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.623 ' HE2' HD21 ' A' ' 121' ' ' LEU . 1.1 m-85 -51.32 -51.08 57.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 74.2 110.877 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -67.85 -48.94 64.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.138 -0.483 . . . . 72.22 110.91 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.458 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -54.98 -29.95 58.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 71.03 111.084 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 31.2 mt -87.44 -33.43 6.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.238 -0.437 . . . . 71.23 111.142 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' A' ' 104' ' ' THR . . . -65.01 -43.66 91.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 75.21 111.11 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -56.31 -44.59 80.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.21 110.841 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -65.76 -60.22 3.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 72.41 110.884 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -51.97 -30.86 26.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.456 . . . . 73.43 110.894 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 103.36 16.72 19.75 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 74.43 112.46 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.431 ' O ' ' HB1' ' A' ' 99' ' ' ALA . 7.2 t -120.74 -174.83 2.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 71.14 111.149 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -116.23 165.22 13.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 75.43 111.12 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.8 t -55.51 -43.42 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 73.55 111.137 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -51.74 -33.39 34.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 64.35 110.855 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.89 -48.67 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 70.12 111.114 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 43.2 mm -51.31 -42.75 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 73.04 111.161 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -78.06 -25.41 47.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 65.4 110.928 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.1 t -76.83 -23.17 52.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 52.41 110.878 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 37.2 mt -100.59 -43.18 6.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 50.33 110.894 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -120.22 67.99 13.19 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 71.41 110.854 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.77 -8.24 23.1 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.737 2.291 . . . . 61.5 112.313 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.78 -44.79 55.36 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.685 -0.769 . . . . 51.42 112.517 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.579 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.6 m -114.56 161.76 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 51.24 111.129 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -102.73 161.39 23.36 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.659 0.742 . . . . 62.02 110.851 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -8.39 23.47 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.679 2.253 . . . . 75.55 112.395 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.49 20.79 4.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 62.4 111.072 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 60.0 mtt85 -151.63 49.68 0.81 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 71.0 110.846 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.623 HD21 ' HE2' ' A' ' 95' ' ' PHE . 27.9 mt -85.52 166.52 16.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 43.21 110.9 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 -115.51 153.4 31.23 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.141 -0.481 . . . . 73.52 110.896 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.632 HG23 ' HB3' ' A' ' 91' ' ' PRO . 12.2 p -63.9 133.94 29.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.09 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.88 63.28 4.89 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.695 -0.764 . . . . 60.05 112.511 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -114.74 123.5 49.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 75.42 110.942 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.37 126.81 40.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 71.53 111.133 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.1 pt -127.23 175.91 8.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.149 -0.478 . . . . 75.44 111.151 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -94.97 153.9 17.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 73.25 110.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.5 m -141.23 156.03 67.81 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.643 0.735 . . . . 62.45 111.155 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 87.84 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.675 2.25 . . . . 73.23 112.352 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 71.52 110.854 179.997 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 87.7 mtp . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.817 0.341 . . . . 70.13 110.878 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.74 -167.22 31.53 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.726 -0.749 . . . . 60.03 112.484 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.5 m -117.75 163.33 16.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.939 0.4 . . . . 71.03 110.842 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 46.4 p -124.24 157.33 35.1 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.146 -0.479 . . . . 60.02 111.167 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -130.36 136.72 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.214 -0.448 . . . . 74.55 110.893 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -91.12 122.42 33.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 54.3 111.129 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.574 HG23 HD11 ' A' ' 98' ' ' ILE . 35.2 mt -90.8 109.59 21.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 74.43 111.135 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 16.4 mt-30 -87.75 157.28 52.27 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.606 0.717 . . . . 73.32 110.884 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.697 ' HB3' HG23 ' A' ' 123' ' ' VAL . 17.8 Cg_endo -58.16 94.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.675 2.25 . . . . 61.23 112.34 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.38 -20.38 2.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.694 -0.765 . . . . 75.53 112.456 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.44 ' HB2' HD11 ' A' ' 98' ' ' ILE . 1.0 OUTLIER -87.43 137.51 32.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.867 0.365 . . . . 64.42 110.913 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.48 171.48 7.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 73.15 111.186 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.637 ' HE1' HD21 ' A' ' 121' ' ' LEU . 1.2 m-85 -53.92 -64.36 0.85 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 72.34 110.927 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -53.08 -51.95 60.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 74.21 110.929 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.66 -63.77 1.03 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 51.12 111.091 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.574 HD11 HG23 ' A' ' 89' ' ' ILE . 46.7 mt -51.69 -34.13 15.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 72.15 111.133 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HB1' ' O ' ' A' ' 104' ' ' THR . . . -68.16 -35.72 78.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 75.01 111.114 179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.4 mt-30 -51.66 -73.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 54.1 110.904 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 36.4 mmm-85 -54.62 -45.27 73.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 62.13 110.903 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -54.54 -27.2 36.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 73.23 110.907 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 91.54 16.09 53.41 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.775 -0.726 . . . . 72.1 112.469 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.685 HG21 HD11 ' A' ' 109' ' ' ILE . 9.6 t -122.26 -177.71 3.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.843 0.354 . . . . 75.4 111.113 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -121.12 164.27 17.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 61.03 111.145 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.6 t -55.71 -43.06 72.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 73.21 111.066 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -51.8 -33.51 35.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 70.41 110.852 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.0 t -81.86 -52.04 14.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 62.03 111.138 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.685 HD11 HG21 ' A' ' 104' ' ' THR . 47.6 mm -51.64 -42.21 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 71.13 111.151 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -77.89 -25.4 48.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.874 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.6 t -77.08 -23.86 51.91 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 73.31 110.88 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.7 mt -99.45 -44.7 6.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 75.13 110.945 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.69 67.61 7.74 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.63 0.728 . . . . 55.3 110.897 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -8.22 23.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.659 2.239 . . . . 63.2 112.395 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.6 -44.09 53.74 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 62.14 112.472 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.548 HG11 ' OE1' ' A' ' 125' ' ' GLN . 2.5 m -115.21 156.71 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.881 0.372 . . . . 72.34 111.098 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -97.94 161.8 24.38 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.635 0.731 . . . . 74.54 110.849 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -7.82 22.05 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 73.33 112.36 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.42 18.89 4.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 42.34 111.063 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -143.32 40.82 1.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.215 -0.448 . . . . 55.1 110.897 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.637 HD21 ' HE1' ' A' ' 95' ' ' PHE . 59.9 mt -85.59 149.77 25.11 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.214 -0.448 . . . . 74.42 110.893 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 80.7 mm-40 -104.66 153.53 21.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 63.13 110.905 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.697 HG23 ' HB3' ' A' ' 91' ' ' PRO . 9.9 p -56.45 134.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.467 . . . . 54.44 111.122 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.25 63.21 5.04 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 72.2 112.509 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.548 ' OE1' HG11 ' A' ' 116' ' ' VAL . 11.2 tt0 -109.55 123.01 48.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 73.32 110.884 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 8.4 p -85.66 136.87 21.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 75.02 111.112 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.442 HD13 HD11 ' A' ' 89' ' ' ILE . 10.3 pt -142.56 175.94 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.123 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -97.67 153.44 18.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 60.42 110.905 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -146.24 156.16 50.27 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.594 0.712 . . . . 70.15 111.149 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 91.0 0.52 Allowed 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.684 2.256 . . . . 72.32 112.33 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 53.3 110.926 179.991 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 8.1 tpt . . . . . 0 C--O 1.23 0.055 0 CA-C-O 120.77 0.319 . . . . 65.11 110.874 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -76.54 -146.69 2.08 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.694 -0.765 . . . . 54.24 112.468 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 8.0 m -131.38 166.54 21.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.915 0.388 . . . . 61.23 110.909 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 72.7 p -124.96 150.48 46.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 53.3 111.15 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.547 ' HB2' HG21 ' A' ' 129' ' ' VAL . 48.1 t80 -123.86 135.97 54.07 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.32 110.936 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -89.66 123.38 33.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 54.54 111.177 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.4 mt -90.93 109.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 62.35 111.179 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -91.99 158.82 39.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.566 0.698 . . . . 74.1 110.936 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.598 ' HB3' HG23 ' A' ' 123' ' ' VAL . 19.9 Cg_endo -59.41 92.88 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.687 2.258 . . . . 74.33 112.374 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.82 -19.04 2.56 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.751 . . . . 63.54 112.528 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.606 ' CB ' HD11 ' A' ' 98' ' ' ILE . 5.8 m-20 -80.97 154.17 27.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.906 0.384 . . . . 74.33 110.841 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 152.46 45.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 75.05 111.152 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.601 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.2 m-85 -53.4 -55.6 23.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.34 110.861 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -57.95 -55.76 30.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 74.35 110.871 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.26 -61.04 2.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.259 -0.428 . . . . 52.13 111.106 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.606 HD11 ' CB ' ' A' ' 93' ' ' ASP . 41.0 mt -51.37 -38.24 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 72.2 111.134 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.403 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -64.68 -38.32 90.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 71.35 111.151 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -51.93 -72.77 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 63.02 110.898 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -53.97 -41.67 68.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 74.12 110.879 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 6.9 mmp_? -57.05 -24.17 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 44.13 110.876 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.46 15.34 60.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.771 -0.728 . . . . 63.4 112.484 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' THR . . . . . 1.047 HG21 HD11 ' A' ' 109' ' ' ILE . 8.0 t -115.24 -175.48 2.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.931 0.396 . . . . 60.13 111.109 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -124.45 154.94 39.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 73.04 111.169 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.444 HG12 ' OE1' ' A' ' 110' ' ' GLN . 74.1 t -54.14 -42.94 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 75.13 111.152 179.86 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -51.72 -39.54 58.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.139 -0.482 . . . . 74.12 110.875 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.1 t -75.14 -54.18 14.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 70.02 111.145 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 1.047 HD11 HG21 ' A' ' 104' ' ' THR . 43.4 mm -51.58 -42.08 29.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 74.44 111.144 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.444 ' OE1' HG12 ' A' ' 106' ' ' VAL . 19.0 pt20 -76.78 -25.54 53.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 75.31 110.885 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.8 t -76.18 -25.22 54.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 73.41 110.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.6 mt -96.89 -45.47 6.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 75.11 110.939 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.03 67.85 6.48 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.73 . . . . 73.31 110.939 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.49 21.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.696 2.264 . . . . 72.11 112.356 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.45 -44.46 45.62 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 72.02 112.483 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.601 HG23 ' CZ ' ' A' ' 95' ' ' PHE . 2.4 m -117.2 130.93 71.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.86 0.362 . . . . 63.45 111.077 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 16.5 m-20 -76.78 160.9 75.73 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.626 0.727 . . . . 75.45 110.883 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -8.6 24.01 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.635 2.223 . . . . 74.12 112.35 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -113.65 24.93 11.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 72.43 111.112 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.7 ptm180 -178.36 104.17 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 75.22 110.88 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 63.8 mt -122.31 167.48 13.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.446 . . . . 75.21 110.882 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -109.57 153.38 24.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 71.02 110.898 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.598 HG23 ' HB3' ' A' ' 91' ' ' PRO . 9.3 p -70.44 136.19 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 74.44 111.094 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.0 63.82 4.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.733 -0.746 . . . . 65.31 112.515 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 -117.66 122.74 44.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.873 0.368 . . . . 73.34 110.892 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -88.18 125.34 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.464 . . . . 63.44 111.157 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.1 pt -125.84 175.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 71.43 111.142 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -97.76 137.43 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 55.12 110.859 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.547 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -138.95 156.19 72.65 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.609 0.718 . . . . 73.23 111.142 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 109.55 2.34 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.721 2.281 . . . . 61.33 112.345 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 74.32 110.9 -179.982 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 5.3 ttt . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.808 0.337 . . . . 52.2 110.879 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.21 -11.13 22.22 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.729 -0.748 . . . . 73.21 112.465 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 97.8 m -140.76 138.58 34.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.925 0.393 . . . . 74.53 110.853 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.4 p -123.51 168.52 12.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.133 -0.485 . . . . 74.14 111.158 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -136.82 136.59 38.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 65.21 110.891 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.1 m -89.18 122.76 32.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 70.34 111.171 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.435 HD11 HG12 ' A' ' 127' ' ' ILE . 38.8 mt -91.07 109.5 21.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 74.13 111.149 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.56 163.7 16.38 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 74.22 110.928 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -46.1 111.11 0.31 Allowed 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.708 2.272 . . . . 71.51 112.341 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 113.21 -1.64 25.35 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 52.25 112.52 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -113.17 113.82 25.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 71.13 110.87 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -101.37 157.84 16.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 65.25 111.104 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.458 ' CE2' HD22 ' A' ' 121' ' ' LEU . 1.7 m-85 -51.5 -43.04 62.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 72.44 110.911 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.15 -47.66 27.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.111 -0.495 . . . . 74.43 110.906 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.54 -26.86 62.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 60.14 111.064 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 28.2 mt -88.31 -45.1 15.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 74.44 111.133 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.455 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -55.27 -46.15 76.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.46 . . . . 71.41 111.123 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -52.0 -44.97 64.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 63.11 110.89 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 74.8 mtt-85 -71.88 -52.7 16.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.881 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.8 mmm180 -54.12 -27.6 34.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 75.4 110.886 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.85 17.57 18.36 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.768 -0.73 . . . . 64.31 112.523 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.831 HG21 HD11 ' A' ' 109' ' ' ILE . 12.0 t -124.1 179.02 5.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.848 0.356 . . . . 73.03 111.162 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.41 164.47 17.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.198 -0.455 . . . . 65.52 111.163 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 46.8 t -55.23 -41.02 58.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.262 -0.426 . . . . 73.01 111.123 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -51.67 -38.89 56.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 65.41 110.886 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.3 t -78.38 -51.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 73.54 111.143 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.831 HD11 HG21 ' A' ' 104' ' ' THR . 47.6 mm -51.54 -43.97 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 74.41 111.148 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -73.55 -25.54 60.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 65.3 110.931 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.5 t -78.91 -23.07 44.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 44.31 110.885 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.5 mt -98.27 -44.53 6.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 61.4 110.921 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.83 67.89 6.09 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.603 0.716 . . . . 61.1 110.909 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -7.25 20.58 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.701 2.267 . . . . 62.54 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.06 -42.03 38.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 43.41 112.435 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.507 ' HB ' HD23 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -119.37 125.13 74.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.858 0.361 . . . . 74.45 111.132 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -57.58 161.14 6.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.619 0.724 . . . . 54.43 110.835 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 -8.59 23.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.653 2.235 . . . . 44.41 112.322 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -126.59 14.9 7.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 73.33 111.1 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 63.0 mtt180 -141.55 93.76 2.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 73.34 110.881 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.507 HD23 ' HB ' ' A' ' 116' ' ' VAL . 10.0 mt -132.73 163.84 28.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 74.13 110.902 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -125.04 150.68 46.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 74.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.5 p -52.81 146.86 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.441 . . . . 60.24 111.112 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.61 65.91 2.88 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 71.3 112.536 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.459 HE22 HG11 ' A' ' 116' ' ' VAL . 11.2 tt0 -119.15 121.61 40.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 75.51 110.921 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 15.0 p -89.03 136.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 72.11 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.435 HG12 HD11 ' A' ' 89' ' ' ILE . 2.4 pt -138.68 174.23 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 75.13 111.166 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -100.25 139.39 35.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 75.45 110.931 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -141.19 156.12 67.9 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.645 0.736 . . . . 73.33 111.131 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 110.59 2.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.677 2.251 . . . . 74.23 112.334 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 74.11 110.921 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 6.0 mmt . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 120.826 0.346 . . . . 63.54 110.907 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 58.0 -165.33 7.1 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.689 -0.767 . . . . 73.34 112.543 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 19.4 m -128.04 165.81 19.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.37 . . . . 75.35 110.907 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.0 p -123.59 166.72 14.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.151 -0.477 . . . . 74.05 111.164 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.4 t80 -142.97 136.59 28.65 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.25 -0.432 . . . . 61.1 110.982 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -89.79 121.91 32.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 64.5 111.143 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.8 mt -90.94 109.61 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 71.53 111.156 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -86.86 158.62 53.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 75.55 110.935 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.57 ' HB3' HG23 ' A' ' 123' ' ' VAL . 17.9 Cg_endo -58.54 93.61 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.639 2.226 . . . . 71.22 112.345 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.8 -18.87 2.38 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 75.43 112.482 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.609 ' CB ' HD11 ' A' ' 98' ' ' ILE . 3.5 m-20 -84.67 138.23 32.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.361 . . . . 54.53 110.867 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.05 155.21 26.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 43.31 111.156 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.714 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -53.13 -47.52 68.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 74.42 110.878 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -71.56 -47.32 55.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 75.45 110.933 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.82 -30.44 63.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.229 -0.441 . . . . 64.15 111.144 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.609 HD11 ' CB ' ' A' ' 93' ' ' ASP . 38.5 mt -88.29 -33.64 6.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 73.05 111.098 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -65.0 -41.86 95.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 64.22 111.116 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -58.68 -44.64 90.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 74.13 110.904 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -78.67 -18.42 54.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 73.44 110.873 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -92.83 16.33 12.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 62.14 110.857 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.56 28.35 21.37 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.798 -0.715 . . . . 72.32 112.469 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' THR . . . . . 1.035 HG21 HD11 ' A' ' 109' ' ' ILE . 9.9 t -129.8 -177.24 4.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.863 0.363 . . . . 74.11 111.131 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.85 157.86 34.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 72.44 111.145 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.456 HG12 ' OE1' ' A' ' 110' ' ' GLN . 60.3 t -55.58 -42.26 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 74.31 111.106 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -51.82 -37.26 51.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 62.23 110.836 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.0 t -78.18 -52.99 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.11 111.138 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 1.035 HD11 HG21 ' A' ' 104' ' ' THR . 49.2 mm -51.33 -43.23 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.138 -0.483 . . . . 72.5 111.125 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.456 ' OE1' HG12 ' A' ' 106' ' ' VAL . 19.0 pt20 -76.62 -25.54 53.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 72.14 110.904 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -75.28 -25.46 57.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.201 -0.454 . . . . 65.2 110.844 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.9 mt -94.93 -46.46 6.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 72.2 110.948 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -118.5 67.33 7.2 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.628 0.727 . . . . 73.55 110.897 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.674 2.25 . . . . 64.41 112.32 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.36 -42.05 49.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 65.34 112.523 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.726 HG11 ' OE1' ' A' ' 125' ' ' GLN . 2.2 m -119.43 139.91 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.864 0.364 . . . . 74.04 111.108 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.1 161.25 66.25 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.596 0.712 . . . . 74.45 110.924 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -8.32 23.3 Favored 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.697 2.265 . . . . 73.45 112.4 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.76 20.58 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 61.25 111.106 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -144.07 43.62 1.44 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 75.55 110.863 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.714 HD11 ' CD2' ' A' ' 95' ' ' PHE . 71.9 mt -85.61 173.82 9.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 73.42 110.9 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -129.52 150.38 50.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 75.54 110.857 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.57 HG23 ' HB3' ' A' ' 91' ' ' PRO . 14.0 p -52.0 133.63 13.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 73.25 111.137 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 53.03 63.35 5.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.783 -0.722 . . . . 73.2 112.471 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.726 ' OE1' HG11 ' A' ' 116' ' ' VAL . 8.7 tt0 -110.62 122.73 48.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 64.44 110.922 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 30.7 t -84.45 140.75 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 64.41 111.142 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.1 pt -143.73 175.24 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 53.13 111.121 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -99.78 130.82 46.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 74.01 110.92 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -123.32 156.22 63.96 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.716 . . . . 53.42 111.132 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 91.61 0.52 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.689 2.259 . . . . 43.45 112.372 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 73.14 110.877 -179.974 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.9 ptt? . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.872 0.368 . . . . 53.32 110.934 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -87.06 171.92 43.12 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.774 -0.726 . . . . 44.24 112.477 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.3 m -123.58 137.93 54.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.932 0.396 . . . . 62.24 110.865 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.8 p -123.58 163.92 20.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 71.12 111.134 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 46.7 t80 -145.12 136.68 25.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 73.34 110.938 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.75 125.23 37.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 41.51 111.13 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.434 HD12 ' HG2' ' A' ' 125' ' ' GLN . 79.2 mt -90.93 109.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 74.42 111.112 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -109.17 163.27 17.39 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.548 0.689 . . . . 75.44 110.933 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -46.31 121.9 5.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.638 2.225 . . . . 74.3 112.34 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.27 -4.2 54.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.778 -0.725 . . . . 73.23 112.464 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.13 116.7 32.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.937 0.399 . . . . 73.34 110.884 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.457 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -113.96 -179.5 3.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 61.23 111.135 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.686 ' CD1' HD11 ' A' ' 121' ' ' LEU . 0.9 OUTLIER -54.64 -70.02 0.11 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 73.02 110.909 -179.972 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.88 -50.52 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 75.12 110.889 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.457 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -51.13 -65.89 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 52.23 111.138 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 47.0 mt -51.22 -35.78 16.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 52.15 111.131 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.5 -37.34 87.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 71.12 111.06 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 19.1 mt-30 -51.92 -70.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 62.22 110.93 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.5 ptm180 -57.01 -43.04 81.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 74.44 110.847 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.6 -24.81 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 63.01 110.858 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.07 17.13 56.68 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 61.45 112.463 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.675 HG21 HD11 ' A' ' 109' ' ' ILE . 7.3 t -121.71 -174.65 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.838 0.351 . . . . 64.22 111.174 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -125.46 165.34 18.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 70.55 111.174 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 41.4 t -55.8 -44.69 78.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.264 -0.426 . . . . 71.4 111.067 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -51.92 -30.11 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 72.32 110.849 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.88 -52.19 13.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 70.24 111.139 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.675 HD11 HG21 ' A' ' 104' ' ' THR . 48.7 mm -51.29 -43.08 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 74.22 111.11 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -76.2 -25.42 55.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 64.42 110.924 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.9 m -80.02 -20.31 45.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.854 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.9 mt -94.94 -47.86 6.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.121 -0.49 . . . . 54.21 110.906 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -118.51 67.28 7.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.634 0.73 . . . . 74.42 110.897 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -8.48 23.71 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.737 2.291 . . . . 63.25 112.39 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -69.76 -17.6 73.31 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.75 -0.738 . . . . 72.33 112.478 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.539 HG12 HD23 ' A' ' 121' ' ' LEU . 2.1 t -125.89 112.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.845 0.355 . . . . 75.44 111.133 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.19 160.29 1.72 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.591 0.71 . . . . 73.03 110.912 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -45.63 1.53 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.691 2.261 . . . . 61.03 112.368 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.24 -29.84 24.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 74.34 111.13 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -83.41 68.5 9.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 74.12 110.895 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.686 HD11 ' CD1' ' A' ' 95' ' ' PHE . 53.7 mt -121.3 137.89 54.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 53.43 110.941 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -110.34 153.57 24.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 65.3 110.913 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -51.56 147.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 71.14 111.107 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.73 66.9 2.28 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 74.51 112.505 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.52 ' NE2' HG11 ' A' ' 116' ' ' VAL . 7.9 tt0 -116.47 122.4 44.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 75.12 110.941 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.8 t -86.26 130.56 36.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 74.03 111.102 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 12.1 pt -141.12 175.79 5.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 64.23 111.139 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -99.18 152.18 20.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 65.35 110.872 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.61 156.18 80.12 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.603 0.716 . . . . 61.11 111.132 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 110.33 2.53 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.664 2.242 . . . . 74.12 112.36 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 75.03 110.912 179.982 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.6 ttt . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.836 0.35 . . . . 64.11 110.909 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -129.13 -156.53 8.92 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.752 -0.737 . . . . 74.42 112.533 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' CYS . . . . . 0.454 ' HB3' HG23 ' A' ' 129' ' ' VAL . 1.7 m -116.26 146.02 42.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.953 0.406 . . . . 73.21 110.838 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.4 p -123.59 157.58 33.39 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.132 -0.485 . . . . 42.02 111.109 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -141.89 136.69 30.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.962 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -93.45 126.88 38.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 54.42 111.14 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 63.5 mt -91.0 109.52 21.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 55.05 111.089 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -92.02 159.25 38.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.537 0.684 . . . . 75.21 110.914 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.423 ' HB3' HG23 ' A' ' 123' ' ' VAL . 18.7 Cg_endo -57.95 94.47 0.07 OUTLIER 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.686 2.257 . . . . 74.15 112.306 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.79 -18.1 2.59 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.781 -0.723 . . . . 43.14 112.513 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -91.22 157.09 17.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.909 0.385 . . . . 75.31 110.837 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.437 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -141.4 178.28 7.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 73.44 111.125 -179.877 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.678 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.7 m-85 -54.49 -66.43 0.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 71.51 110.858 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -54.79 -52.15 63.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.157 -0.474 . . . . 75.41 110.909 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.437 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -50.57 -66.09 0.45 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 72.14 111.089 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 54.8 mt -51.15 -33.96 13.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 75.24 111.116 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.94 -39.53 93.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 63.41 111.086 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 21.0 mt-30 -52.12 -69.39 0.11 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 63.31 110.874 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -55.3 -50.34 69.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 74.43 110.92 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ARG . . . . . 0.423 ' CD ' HG11 ' A' ' 129' ' ' VAL . 6.3 mmp_? -51.96 -29.97 22.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 72.12 110.866 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 94.56 12.27 56.02 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.81 -0.71 . . . . 71.24 112.524 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.7 t -114.11 -172.47 2.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.811 0.338 . . . . 71.34 111.163 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.7 m -124.87 162.56 24.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 74.54 111.167 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 69.2 t -53.38 -43.87 53.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 70.44 111.133 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -51.68 -37.3 50.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 70.21 110.848 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.2 t -76.83 -47.18 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 72.15 111.141 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 41.6 mm -50.84 -45.36 28.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 75.24 111.128 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -77.37 -25.46 50.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.142 -0.481 . . . . 61.34 110.965 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.7 t -76.69 -21.02 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 74.21 110.832 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.5 mt -97.72 -45.33 6.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 64.54 110.932 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.18 67.84 6.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.637 0.732 . . . . 70.45 110.892 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -8.41 23.53 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.656 2.237 . . . . 65.02 112.351 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -68.75 -19.57 73.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 61.42 112.43 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.732 HG11 HD23 ' A' ' 121' ' ' LEU . 2.6 t -127.3 139.71 51.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 65.41 111.115 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -79.82 160.33 69.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.631 0.729 . . . . 61.33 110.926 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -15.03 36.73 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.69 2.26 . . . . 53.51 112.342 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -116.42 -23.28 8.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 55.5 111.065 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -91.83 55.02 2.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 74.54 110.893 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.732 HD23 HG11 ' A' ' 116' ' ' VAL . 75.2 mt -107.98 131.93 54.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.459 . . . . 54.33 110.909 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -97.65 153.55 18.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 72.24 110.904 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.423 HG23 ' HB3' ' A' ' 91' ' ' PRO . 6.6 p -54.71 144.36 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 70.42 111.092 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.98 66.34 2.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.764 -0.731 . . . . 72.44 112.478 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -118.72 122.07 41.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.83 0.347 . . . . 71.14 110.898 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.4 t -84.51 126.94 40.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 74.52 111.191 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.45 175.86 10.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 63.23 111.17 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -96.08 159.76 14.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 54.21 110.885 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.454 HG23 ' HB3' ' A' ' 85' ' ' CYS . 3.1 m -144.07 156.33 58.33 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.63 0.729 . . . . 64.44 111.134 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 90.87 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.655 2.237 . . . . 72.13 112.326 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 74.43 110.873 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 9.5 mmt . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.847 0.356 . . . . 72.34 110.886 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 163.3 -115.8 0.67 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.724 -0.75 . . . . 75.13 112.5 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.4 m -130.16 139.4 50.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.951 0.405 . . . . 75.54 110.894 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 18.2 p -125.5 163.06 23.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 64.24 111.128 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -139.19 136.31 34.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 62.1 110.917 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 m -92.26 123.26 35.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 61.04 111.123 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.548 HD12 ' HG2' ' A' ' 125' ' ' GLN . 85.3 mt -90.9 109.47 21.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 73.3 111.162 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.499 ' HB3' ' HD2' ' A' ' 91' ' ' PRO . 25.6 mt-30 -112.6 162.63 20.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.55 0.69 . . . . 74.21 110.963 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.499 ' HD2' ' HB3' ' A' ' 90' ' ' GLN . 74.9 Cg_exo -47.33 101.07 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.685 2.257 . . . . 63.21 112.378 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 124.75 0.47 8.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 74.02 112.519 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -115.22 116.91 29.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.869 0.366 . . . . 70.32 110.877 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.443 HG22 ' H ' ' A' ' 95' ' ' PHE . 0.2 OUTLIER -107.08 169.57 8.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 63.04 111.145 -179.89 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.6 ' CD1' HD11 ' A' ' 121' ' ' LEU . 0.7 OUTLIER -53.68 -66.03 0.46 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.187 -0.461 . . . . 72.04 110.897 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -55.94 -49.6 73.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 74.15 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -50.22 -55.21 16.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.24 -0.436 . . . . 45.3 111.091 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 35.4 mt -62.69 -31.93 53.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 72.42 111.127 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.449 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -69.65 -29.93 67.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 75.43 111.083 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -52.59 -74.11 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.914 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -57.38 -38.79 74.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 73.33 110.87 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ARG . . . . . 0.432 ' HD2' HG11 ' A' ' 129' ' ' VAL . 8.2 mmp_? -57.78 -23.47 52.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 74.24 110.857 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 82.84 18.83 64.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.755 -0.736 . . . . 53.41 112.456 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.991 HG21 HD11 ' A' ' 109' ' ' ILE . 11.8 t -116.68 -179.88 3.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.846 0.355 . . . . 54.22 111.11 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -122.58 161.28 24.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 64.42 111.149 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.3 t -55.11 -47.3 77.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 74.5 111.117 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 40.4 m-20 -51.88 -30.03 22.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 73.15 110.812 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 47.0 t -80.83 -54.15 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 71.21 111.177 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.991 HD11 HG21 ' A' ' 104' ' ' THR . 51.2 mm -52.5 -41.79 37.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.148 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.06 -25.36 58.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 54.32 110.902 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.8 t -81.15 -21.46 39.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.214 -0.448 . . . . 62.4 110.843 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.2 mt -99.48 -44.52 6.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 53.0 110.915 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.37 68.58 5.37 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.602 0.715 . . . . 73.32 110.86 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -7.5 21.2 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.69 2.26 . . . . 72.55 112.35 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.26 -40.28 37.13 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 74.53 112.506 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.634 HG11 ' OE1' ' A' ' 125' ' ' GLN . 1.3 m -118.05 127.32 75.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.826 0.346 . . . . 54.3 111.122 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.1 m-20 -56.76 161.63 4.36 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.618 0.723 . . . . 72.2 110.92 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -8.16 22.89 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.686 2.257 . . . . 64.42 112.323 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.9 21.96 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 62.31 111.119 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -144.0 101.37 3.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 72.4 110.866 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.6 HD11 ' CD1' ' A' ' 95' ' ' PHE . 53.1 mt -139.3 150.85 45.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 62.13 110.926 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -117.86 150.61 38.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 70.15 110.883 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.423 HG23 ' HG3' ' A' ' 91' ' ' PRO . 12.6 p -51.77 148.22 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 73.32 111.121 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.36 66.53 2.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.732 -0.747 . . . . 74.13 112.448 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.634 ' OE1' HG11 ' A' ' 116' ' ' VAL . 7.6 tt0 -117.84 121.25 40.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.822 0.344 . . . . 61.51 110.927 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.95 125.01 42.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 73.21 111.158 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 pt -132.31 175.79 10.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 70.23 111.121 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.39 149.19 23.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 63.51 110.878 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.432 HG11 ' HD2' ' A' ' 102' ' ' ARG . 3.2 m -135.12 156.17 78.43 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.635 0.731 . . . . 54.32 111.15 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 110.66 2.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.679 2.253 . . . . 42.43 112.334 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 92.3 m . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 75.24 110.928 179.969 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 6.8 ptm . . . . . 0 C--O 1.23 0.05 0 CA-C-O 120.861 0.362 . . . . 62.35 110.846 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -93.83 -135.61 7.7 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.762 -0.733 . . . . 53.53 112.493 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 4.5 m -113.13 149.95 32.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.925 0.393 . . . . 74.13 110.84 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 76.5 p -126.19 154.89 42.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 72.32 111.137 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.4 ' HB2' HG11 ' A' ' 129' ' ' VAL . 47.8 t80 -132.37 136.66 46.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 73.45 110.929 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.3 m -92.87 125.58 37.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 65.02 111.147 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.12 110.0 21.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.262 -0.426 . . . . 70.21 111.122 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.487 ' HB2' ' HD2' ' A' ' 91' ' ' PRO . 0.5 OUTLIER -112.21 162.44 21.38 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.57 0.7 . . . . 74.53 110.935 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.505 ' HG3' HG23 ' A' ' 123' ' ' VAL . 74.5 Cg_exo -46.14 101.53 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.685 2.256 . . . . 72.23 112.379 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 121.37 2.5 10.8 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 51.21 112.496 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -105.24 113.95 27.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.897 0.38 . . . . 43.25 110.885 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.55 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -108.12 166.21 10.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 74.32 111.152 -179.885 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.657 ' HE2' HD21 ' A' ' 121' ' ' LEU . 1.3 m-85 -51.02 -46.13 61.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 52.44 110.902 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.35 -49.63 21.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 70.52 110.977 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.55 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -54.11 -27.94 36.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 52.13 111.114 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 42.9 mt -89.1 -41.47 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 53.35 111.16 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.429 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -57.1 -42.69 81.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 54.34 111.111 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -57.19 -45.02 84.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 63.24 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -65.6 -59.98 3.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 72.41 110.882 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.2 mmm180 -52.12 -29.87 23.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.138 -0.483 . . . . 74.24 110.876 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.58 13.53 29.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 61.14 112.474 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.9 t -115.35 -174.18 2.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.853 0.359 . . . . 73.4 111.128 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.92 163.47 16.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 72.12 111.172 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.7 t -54.55 -44.43 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.261 -0.427 . . . . 74.32 111.129 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -51.68 -33.61 34.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 75.11 110.829 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.9 t -80.57 -48.08 20.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 63.42 111.156 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.429 HG13 ' HB2' ' A' ' 99' ' ' ALA . 45.2 mm -51.19 -43.52 27.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 51.11 111.159 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -77.76 -25.48 49.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 75.04 110.934 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t -76.17 -23.53 54.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 75.45 110.805 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -99.16 -45.37 5.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 74.3 110.908 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.83 68.29 6.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.653 0.74 . . . . 71.21 110.852 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -8.17 22.93 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.656 2.237 . . . . 73.43 112.389 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.55 -43.39 52.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.69 -0.767 . . . . 61.43 112.53 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.551 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.1 m -116.42 163.04 13.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.884 0.373 . . . . 75.22 111.078 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -104.31 161.1 23.88 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.59 0.71 . . . . 75.14 110.864 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.71 -8.52 23.81 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.693 2.262 . . . . 60.42 112.372 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -128.76 12.02 6.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 61.2 111.124 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.9 mmt85 -143.77 49.67 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 74.55 110.863 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.657 HD21 ' HE2' ' A' ' 95' ' ' PHE . 22.9 mt -85.64 166.95 15.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.227 -0.442 . . . . 63.53 110.918 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -120.59 139.39 53.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 74.41 110.897 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.505 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.3 p -54.05 140.6 10.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 74.12 111.104 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.31 61.62 6.11 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.779 -0.724 . . . . 73.35 112.462 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -119.17 122.27 41.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.811 0.339 . . . . 72.44 110.882 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.1 p -84.43 134.61 26.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 73.3 111.106 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.8 pt -134.98 175.93 9.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 63.33 111.132 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -95.91 143.25 27.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 63.34 110.859 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.4 HG11 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -131.87 156.22 80.38 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.612 0.72 . . . . 52.24 111.12 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 86.58 0.58 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.652 2.235 . . . . 63.21 112.357 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.26 -0.427 . . . . 74.21 110.876 -179.999 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 27.6 mmm . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.821 0.344 . . . . 73.23 110.871 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -106.84 -152.26 18.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.769 -0.729 . . . . 62.32 112.516 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 73.4 m -135.69 136.62 41.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.928 0.394 . . . . 54.33 110.848 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 35.7 p -124.47 156.22 37.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 72.11 111.124 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.452 ' CE2' HD13 ' A' ' 98' ' ' ILE . 44.3 t80 -132.35 136.54 46.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.274 -0.421 . . . . 74.42 110.891 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -92.54 122.97 35.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 72.35 111.168 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 83.0 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 75.21 111.124 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.502 ' HB3' ' HD2' ' A' ' 91' ' ' PRO . 4.8 mm100 -112.29 162.45 21.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.58 0.705 . . . . 75.02 110.925 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.502 ' HD2' ' HB3' ' A' ' 90' ' ' GLN . 74.3 Cg_exo -47.28 101.22 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.663 2.242 . . . . 75.33 112.335 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 123.8 1.36 8.97 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.73 -0.748 . . . . 72.5 112.478 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -118.46 111.58 18.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.901 0.381 . . . . 64.1 110.872 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.53 159.84 14.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 74.43 111.151 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.416 ' CD1' HD11 ' A' ' 121' ' ' LEU . 1.3 m-85 -51.33 -44.13 61.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 70.51 110.854 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.19 -48.0 25.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.922 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.22 -28.03 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 71.22 111.112 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.452 HD13 ' CE2' ' A' ' 87' ' ' TYR . 32.6 mt -87.76 -45.38 16.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 72.41 111.107 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.478 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -53.97 -47.28 71.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 70.05 111.061 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -51.93 -44.96 64.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.199 -0.455 . . . . 73.03 110.914 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 77.4 mtp180 -68.78 -53.94 18.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.196 -0.456 . . . . 73.34 110.872 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -55.27 -26.29 39.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 72.32 110.897 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 101.91 16.27 24.17 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.727 -0.749 . . . . 73.42 112.491 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.793 HG21 HD11 ' A' ' 109' ' ' ILE . 10.1 t -120.29 -177.87 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.86 0.362 . . . . 63.33 111.129 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.64 165.09 19.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 52.31 111.145 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 91.7 t -55.16 -40.55 55.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 74.12 111.12 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -51.7 -40.13 59.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.01 110.884 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -77.35 -51.72 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 75.3 111.153 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.793 HD11 HG21 ' A' ' 104' ' ' THR . 50.5 mm -51.64 -44.43 34.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 53.4 111.129 179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 19.3 pt20 -72.86 -25.53 61.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 64.41 110.937 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t -79.98 -22.11 42.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 73.02 110.834 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 10.7 mt -98.12 -44.79 6.47 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 62.23 110.88 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.66 68.06 5.8 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.717 . . . . 73.35 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -7.13 20.26 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.669 2.246 . . . . 73.4 112.387 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.84 -40.19 33.73 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.723 -0.751 . . . . 75.22 112.473 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.505 HG11 HE22 ' A' ' 125' ' ' GLN . 1.5 m -118.29 127.96 75.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.795 0.331 . . . . 55.4 111.142 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -56.61 161.25 4.54 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.623 0.725 . . . . 63.3 110.913 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -8.47 23.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.644 2.229 . . . . 75.33 112.352 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.1 23.21 5.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 75.22 111.119 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.3 mmt180 -146.47 102.52 3.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.453 . . . . 72.41 110.838 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.469 HD23 ' HB ' ' A' ' 116' ' ' VAL . 67.2 mt -136.51 175.59 9.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 74.42 110.867 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -140.72 147.77 39.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.475 . . . . 72.22 110.913 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.406 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.5 p -52.35 147.57 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 71.31 111.094 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.63 65.2 3.32 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.697 -0.763 . . . . 55.33 112.538 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.505 HE22 HG11 ' A' ' 116' ' ' VAL . 15.2 tt0 -119.14 120.69 37.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.826 0.346 . . . . 72.44 110.925 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.36 125.11 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 42.15 111.122 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.3 pt -129.22 175.87 9.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 74.43 111.128 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -98.84 137.98 36.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 75.14 110.869 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -123.91 156.23 65.91 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.618 0.723 . . . . 62.24 111.144 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 110.52 2.59 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.698 2.265 . . . . 70.44 112.337 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.205 -0.452 . . . . 73.41 110.878 -179.954 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 6.5 ttm . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.798 0.332 . . . . 75.33 110.859 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -170.29 153.09 20.58 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.772 -0.727 . . . . 75.21 112.507 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m -133.67 145.69 50.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.9 0.381 . . . . 72.15 110.903 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.5 p -123.37 161.83 23.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 71.15 111.149 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.65 ' HB2' HG21 ' A' ' 129' ' ' VAL . 36.2 t80 -127.32 136.79 52.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 71.24 110.925 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 55.3 m -88.68 122.88 32.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.098 -0.501 . . . . 32.0 111.144 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.2 mt -90.83 109.52 21.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 64.31 111.153 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.483 ' HB2' ' HD2' ' A' ' 91' ' ' PRO . 0.1 OUTLIER -111.32 162.65 19.97 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.568 0.699 . . . . 71.15 110.948 179.94 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.483 ' HD2' ' HB2' ' A' ' 90' ' ' GLN . 74.0 Cg_exo -46.78 101.27 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.696 2.264 . . . . 64.51 112.337 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 125.95 -1.99 7.9 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 54.15 112.455 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.42 ' HB3' HD11 ' A' ' 98' ' ' ILE . 13.5 m-20 -105.77 129.39 53.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 74.25 110.87 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.504 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -118.06 164.5 15.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 72.21 111.128 -179.886 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.662 ' CE1' HD21 ' A' ' 121' ' ' LEU . 0.8 OUTLIER -50.94 -48.28 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 74.24 110.875 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.08 -49.01 25.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 74.35 110.944 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.504 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -53.81 -27.17 27.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.11 111.124 179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.42 HD11 ' HB3' ' A' ' 93' ' ' ASP . 39.1 mt -91.26 -39.41 11.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 74.21 111.131 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.553 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -58.3 -41.04 83.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.149 -0.478 . . . . 52.52 111.092 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -57.13 -44.55 83.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.439 . . . . 72.01 110.905 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -69.26 -25.96 64.54 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 73.34 110.852 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ARG . . . . . 0.41 ' HB2' HG22 ' A' ' 104' ' ' THR . 3.0 mmp_? -94.39 17.99 11.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 71.02 110.888 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.83 27.76 21.6 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.699 -0.762 . . . . 71.33 112.538 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.686 HG21 HD11 ' A' ' 109' ' ' ILE . 8.5 t -126.73 -177.22 3.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.916 0.389 . . . . 72.23 111.116 -179.83 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.439 HG22 ' H ' ' A' ' 106' ' ' VAL . 0.2 OUTLIER -125.41 167.88 14.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 61.44 111.123 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.439 ' H ' HG22 ' A' ' 105' ' ' THR . 45.9 t -56.47 -38.98 58.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 74.34 111.167 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 68.5 m-20 -51.71 -38.56 55.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 73.01 110.855 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -81.05 -50.64 16.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 64.15 111.108 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.686 HD11 HG21 ' A' ' 104' ' ' THR . 49.7 mm -51.29 -41.02 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 72.1 111.125 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.409 ' OE1' HG12 ' A' ' 106' ' ' VAL . 18.9 pt20 -78.58 -25.57 45.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 74.22 110.928 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 10.3 t -76.38 -24.13 54.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 75.31 110.839 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.1 mt -98.48 -44.67 6.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 64.14 110.903 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.97 67.96 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.637 0.732 . . . . 73.5 110.907 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.72 21.77 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.66 2.24 . . . . 73.23 112.36 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.78 -44.33 48.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.764 -0.731 . . . . 54.22 112.48 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.708 ' HB ' HD23 ' A' ' 121' ' ' LEU . 1.6 m -118.82 161.06 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.829 0.347 . . . . 74.42 111.121 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -108.34 160.96 25.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.634 0.731 . . . . 71.43 110.854 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -8.22 23.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.682 2.255 . . . . 73.24 112.362 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.21 -21.63 13.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 75.1 111.109 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 6.5 ptp180 -134.87 96.22 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 74.24 110.929 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.708 HD23 ' HB ' ' A' ' 116' ' ' VAL . 89.5 mt -117.55 161.81 19.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.181 -0.463 . . . . 71.55 110.903 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -107.67 148.81 28.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 74.54 110.932 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.457 HG23 ' HG3' ' A' ' 91' ' ' PRO . 14.0 p -68.89 143.75 14.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 74.23 111.118 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.2 60.85 6.75 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.715 -0.755 . . . . 74.22 112.496 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 45.5 tt0 -119.21 121.18 39.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.824 0.345 . . . . 64.33 110.97 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 26.2 t -88.92 132.27 34.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 74.3 111.134 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 2.4 pt -134.04 175.97 9.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.459 . . . . 73.45 111.132 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 60.0 m-20 -92.51 136.56 33.11 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.457 . . . . 70.51 110.907 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.65 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.4 m -143.76 155.99 59.5 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.547 0.689 . . . . 45.21 111.15 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.83 110.53 2.59 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.65 2.233 . . . . 74.41 112.308 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 73.35 110.873 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.5 ptp . . . . . 0 N--CA 1.458 -0.044 0 CA-C-O 120.823 0.344 . . . . 73.41 110.88 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 170.8 -158.94 30.89 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.698 -0.763 . . . . 71.14 112.456 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.2 m -131.78 135.32 46.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.877 0.37 . . . . 61.34 110.931 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 22.2 p -129.65 150.31 51.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 71.5 111.127 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -122.4 136.63 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.159 -0.473 . . . . 72.44 110.897 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -89.25 122.1 32.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 65.43 111.102 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.402 HG23 ' HB2' ' A' ' 93' ' ' ASP . 69.7 mt -91.03 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 60.22 111.137 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.61 163.55 16.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.6 0.715 . . . . 75.25 110.945 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.473 ' HG3' HG23 ' A' ' 123' ' ' VAL . 54.2 Cg_exo -45.86 105.15 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.636 2.224 . . . . 74.32 112.374 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 118.65 1.11 15.43 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.726 -0.75 . . . . 52.33 112.491 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.402 ' HB2' HG23 ' A' ' 89' ' ' ILE . 15.2 m-20 -105.09 144.2 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.908 0.385 . . . . 64.23 110.851 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.07 158.78 43.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 72.41 111.166 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.602 ' CE1' HD21 ' A' ' 121' ' ' LEU . 1.6 m-85 -50.9 -47.92 60.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 72.45 110.858 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -72.97 -47.68 43.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 73.55 110.918 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -55.6 -26.56 44.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 53.03 111.114 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 21.1 mt -90.91 -38.78 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 65.12 111.158 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 104' ' ' THR . . . -61.53 -40.4 94.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 72.24 111.086 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -56.38 -44.69 80.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 74.44 110.896 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 -75.52 -49.38 18.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.451 . . . . 65.21 110.837 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 21.5 mmm180 -56.98 -24.39 52.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 75.14 110.852 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.19 23.64 37.01 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 50.02 112.478 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.993 HG21 HD11 ' A' ' 109' ' ' ILE . 6.6 t -114.76 -171.66 1.97 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 74.4 111.149 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.15 149.13 43.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.217 -0.447 . . . . 72.43 111.111 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 83.4 t -55.5 -46.91 79.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 62.13 111.12 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -51.85 -30.69 24.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 74.42 110.826 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 72.7 t -80.08 -54.09 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 72.32 111.154 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.993 HD11 HG21 ' A' ' 104' ' ' THR . 41.3 mm -52.57 -42.51 40.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.166 -0.47 . . . . 74.23 111.187 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.83 -25.48 59.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.108 -0.496 . . . . 73.25 110.894 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t -79.23 -22.95 44.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 53.34 110.88 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 11.9 mt -96.5 -45.54 6.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 73.14 110.919 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.72 67.86 5.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.608 0.718 . . . . 72.11 110.924 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -7.36 20.84 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.656 2.237 . . . . 75.13 112.35 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.1 -39.48 34.29 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.778 -0.725 . . . . 53.22 112.46 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.667 ' HB ' HD23 ' A' ' 121' ' ' LEU . 0.5 OUTLIER -121.76 163.02 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.844 0.354 . . . . 74.11 111.14 -179.953 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 33.0 m-20 -102.99 161.21 23.8 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.615 0.722 . . . . 73.15 110.877 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.67 26.68 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.685 2.256 . . . . 73.34 112.319 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -117.44 -18.83 9.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.25 -0.432 . . . . 70.35 111.124 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -122.04 90.0 3.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 63.43 110.891 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.667 HD23 ' HB ' ' A' ' 116' ' ' VAL . 73.0 mt -119.39 160.38 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 71.15 110.92 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -105.49 148.55 27.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 72.33 110.919 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.473 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.2 p -61.7 139.45 20.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 74.12 111.186 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.78 62.49 5.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 63.12 112.503 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -119.28 121.9 40.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.83 0.348 . . . . 73.44 110.916 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 11.3 p -86.45 134.68 26.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 74.05 111.144 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 1.3 pp -129.45 172.76 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 72.43 111.08 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -100.33 142.95 31.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 63.02 110.9 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -136.09 156.2 77.11 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.594 0.711 . . . . 74.24 111.126 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 110.11 2.48 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.679 2.253 . . . . 71.31 112.363 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 98.9 m . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 64.5 110.905 179.992 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 2.5 mmt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.838 0.352 . . . . 65.04 110.865 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -107.95 -160.64 20.73 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.761 -0.733 . . . . 61.42 112.497 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 71.2 m -138.65 136.0 35.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.885 0.374 . . . . 62.54 110.869 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 44.8 p -124.96 150.26 46.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 72.32 111.153 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.503 ' CE2' HD13 ' A' ' 98' ' ' ILE . 42.1 t80 -122.48 136.68 54.94 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.212 -0.449 . . . . 74.11 110.932 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 m -91.41 120.19 32.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 74.54 111.109 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.4 mt -90.85 109.59 21.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.45 . . . . 64.35 111.132 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 22.9 mm-40 -97.29 159.45 31.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.612 0.72 . . . . 63.44 110.893 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.81 93.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.698 2.265 . . . . 75.13 112.358 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.48 -17.46 2.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 61.3 112.514 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.92 167.26 16.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.913 0.387 . . . . 51.23 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.2 151.77 45.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.192 -0.458 . . . . 73.13 111.154 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' PHE . . . . . 0.521 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.3 m-85 -51.03 -47.38 61.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.251 -0.431 . . . . 75.23 110.885 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -71.6 -47.16 56.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 73.13 110.895 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.73 -23.88 54.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 72.54 111.068 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.503 HD13 ' CE2' ' A' ' 87' ' ' TYR . 35.2 mt -95.46 -31.99 4.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.445 . . . . 74.22 111.129 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.603 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -72.18 -29.5 64.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 72.12 111.123 179.793 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 1.5 pp0? -65.7 -44.46 86.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.929 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.5 -13.73 53.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 70.4 110.908 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -93.03 16.56 12.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 74.33 110.922 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.63 28.1 21.12 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 52.02 112.494 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' THR . . . . . 1.018 HG21 HD11 ' A' ' 109' ' ' ILE . 11.8 t -129.0 -179.96 5.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.842 0.353 . . . . 73.02 111.152 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -123.28 159.77 28.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 54.45 111.152 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 52.6 t -55.07 -42.38 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 72.04 111.106 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -51.85 -38.09 54.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 65.13 110.828 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.448 HG12 HD12 ' A' ' 112' ' ' LEU . 21.5 t -77.2 -54.19 13.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 53.22 111.132 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 1.018 HD11 HG21 ' A' ' 104' ' ' THR . 50.2 mm -51.42 -39.95 23.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 41.01 111.108 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -77.98 -25.56 48.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 72.12 110.9 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -76.92 -24.05 52.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 53.01 110.888 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.448 HD12 HG12 ' A' ' 108' ' ' VAL . 7.3 mt -95.18 -45.3 7.25 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.921 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.06 67.57 6.42 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.742 . . . . 60.23 110.906 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -6.96 19.86 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.693 2.262 . . . . 75.15 112.379 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.63 -39.9 31.56 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 62.0 112.484 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.622 HG11 HE22 ' A' ' 125' ' ' GLN . 2.1 m -118.95 160.83 18.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.827 0.346 . . . . 42.55 111.142 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -99.63 160.56 27.07 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.622 0.725 . . . . 62.32 110.888 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -22.78 31.61 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.749 2.3 . . . . 75.22 112.312 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.4 24.33 11.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 64.54 111.094 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 14.5 ptm180 -177.33 111.56 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 73.32 110.873 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 86.1 mt -127.66 -179.59 5.01 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.176 -0.466 . . . . 63.43 110.926 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -124.16 147.56 47.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 74.02 110.928 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 14.6 p -62.85 139.99 20.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 63.45 111.167 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.67 65.14 3.37 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 44.24 112.475 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' GLN . . . . . 0.622 HE22 HG11 ' A' ' 116' ' ' VAL . 8.8 tt0 -113.69 127.72 56.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.787 0.327 . . . . 73.15 110.933 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 17.6 t -91.51 122.77 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 75.32 111.09 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.1 pt -127.84 175.84 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 72.42 111.089 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -110.87 143.36 41.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 74.32 110.919 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.93 156.23 79.38 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.631 0.729 . . . . 32.1 111.121 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 110.77 2.64 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.696 2.264 . . . . 51.25 112.334 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 73.31 110.884 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 18.9 ttt . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.816 0.341 . . . . 73.45 110.873 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -136.79 -167.66 11.2 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.772 -0.728 . . . . 52.01 112.507 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 26.0 m -139.29 134.96 33.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.858 0.361 . . . . 63.51 110.879 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.7 p -124.85 167.72 14.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 73.53 111.128 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.5 ' CE2' HD13 ' A' ' 98' ' ' ILE . 41.8 t80 -139.49 136.38 34.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 63.11 110.877 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.482 HG23 HG22 ' A' ' 126' ' ' VAL . 2.1 m -90.89 121.18 32.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.119 -0.491 . . . . 71.44 111.128 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.453 HD11 HG12 ' A' ' 127' ' ' ILE . 64.4 mt -91.04 109.29 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 73.34 111.09 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -110.39 162.86 18.82 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 63.23 110.911 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -45.89 118.77 2.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.711 2.274 . . . . 73.12 112.35 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 108.32 -23.83 23.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.797 -0.716 . . . . 54.22 112.529 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -86.67 121.98 29.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.868 0.366 . . . . 75.44 110.877 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.87 156.16 19.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 74.35 111.134 -179.867 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -51.61 -45.25 63.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 73.1 110.863 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -70.46 -51.4 29.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 73.12 110.9 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.63 -31.86 58.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 61.22 111.133 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.5 HD13 ' CE2' ' A' ' 87' ' ' TYR . 34.5 mt -84.04 -35.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 53.3 111.126 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.453 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -63.15 -48.32 78.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 74.14 111.133 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -52.99 -44.93 67.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.91 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 6.8 ptp85 -78.62 -18.05 55.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 70.34 110.898 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -94.11 19.74 8.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.189 -0.459 . . . . 71.14 110.923 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.78 28.12 22.32 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.735 -0.745 . . . . 73.0 112.478 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.888 HG21 HD11 ' A' ' 109' ' ' ILE . 14.5 t -134.45 174.72 10.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.844 0.354 . . . . 63.14 111.167 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.58 164.62 15.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.03 111.172 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.408 HG12 ' OE1' ' A' ' 110' ' ' GLN . 22.6 t -57.41 -41.44 78.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.02 111.166 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -51.82 -34.42 40.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.862 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.79 -51.72 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 62.04 111.079 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.888 HD11 HG21 ' A' ' 104' ' ' THR . 49.0 mm -51.75 -41.71 29.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.236 -0.438 . . . . 64.32 111.135 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.408 ' OE1' HG12 ' A' ' 106' ' ' VAL . 18.6 pt20 -78.32 -25.53 46.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 71.34 110.928 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -78.69 -20.92 49.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 74.33 110.874 -179.785 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 21.0 mt -98.29 -45.49 6.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.486 . . . . 53.4 110.896 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -118.45 67.91 7.4 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.635 0.731 . . . . 75.14 110.9 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -8.53 23.83 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.717 2.278 . . . . 74.41 112.302 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.77 -26.33 62.58 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.757 -0.735 . . . . 21.21 112.454 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.691 HG12 HD23 ' A' ' 121' ' ' LEU . 1.5 t -121.4 92.53 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.788 0.327 . . . . 71.54 111.151 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -51.8 159.13 1.42 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.617 0.723 . . . . 72.21 110.856 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -29.98 22.92 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.666 2.244 . . . . 65.42 112.326 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -95.13 31.99 1.8 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 52.51 111.059 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 179.88 93.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 75.53 110.865 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.691 HD23 HG12 ' A' ' 116' ' ' VAL . 45.5 mt -116.2 144.58 44.0 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 74.12 110.911 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -98.59 153.31 18.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 43.52 110.92 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.71 144.06 12.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 74.02 111.121 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.51 59.02 8.92 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.739 . . . . 51.32 112.443 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -119.26 122.64 42.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.834 0.349 . . . . 64.31 110.915 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.482 HG22 HG23 ' A' ' 88' ' ' THR . 33.6 t -88.52 127.05 41.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 73.21 111.127 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.453 HG12 HD11 ' A' ' 89' ' ' ILE . 3.2 pt -123.54 175.91 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.172 -0.467 . . . . 72.12 111.15 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 6.0 m-20 -94.55 145.46 24.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.186 -0.461 . . . . 51.23 110.91 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.94 156.1 78.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.638 0.732 . . . . 63.13 111.108 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 110.64 2.61 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.733 2.288 . . . . 72.13 112.314 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 46.6 m . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 64.15 110.869 179.993 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 11.7 mmm . . . . . 0 N--CA 1.458 -0.066 0 CA-C-O 120.789 0.328 . . . . 62.24 110.88 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 104.09 161.23 24.56 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.702 -0.761 . . . . 63.1 112.479 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 3.9 m -136.42 166.54 23.25 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.888 0.375 . . . . 71.3 110.871 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.4 p -123.55 154.67 38.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 53.31 111.148 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.524 ' HB2' HG21 ' A' ' 129' ' ' VAL . 38.6 t80 -133.5 134.99 44.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 75.34 110.926 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.6 125.98 35.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 63.23 111.175 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.8 mt -90.9 109.38 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 51.12 111.157 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 49.5 mm-40 -110.92 161.94 22.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.623 0.725 . . . . 74.44 110.89 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -45.98 121.45 4.34 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.721 2.281 . . . . 61.32 112.328 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.19 34.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.732 -0.747 . . . . 72.41 112.418 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -95.79 121.03 37.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.844 0.354 . . . . 74.14 110.845 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.0 165.33 11.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 65.53 111.123 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -53.98 -60.8 2.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 73.01 110.866 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -56.57 -52.47 64.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.152 -0.477 . . . . 74.4 110.906 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.42 -62.42 1.63 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.449 . . . . 73.41 111.13 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 34.3 mt -51.5 -38.15 20.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 71.44 111.138 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.446 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -64.28 -37.19 86.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 54.11 111.115 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -51.91 -72.11 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 72.25 110.928 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 10.0 ptt-85 -55.87 -40.47 72.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 72.42 110.858 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.8 mmp_? -57.9 -24.04 55.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.171 -0.468 . . . . 73.34 110.885 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 54.31 112.473 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.843 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -120.99 178.87 4.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 73.32 111.15 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -119.82 162.93 18.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 64.34 111.181 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 23.9 t -56.68 -40.32 69.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.24 -0.436 . . . . 71.01 111.155 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -51.76 -36.24 46.61 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 52.34 110.836 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.59 HG12 HD12 ' A' ' 112' ' ' LEU . 25.7 t -81.96 -50.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 63.51 111.141 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.843 HD11 HG21 ' A' ' 104' ' ' THR . 47.7 mm -51.95 -41.12 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.149 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 18.4 pt20 -79.14 -25.39 42.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 55.34 110.93 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 t -79.44 -20.14 48.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 75.43 110.872 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.59 HD12 HG12 ' A' ' 108' ' ' VAL . 8.5 mt -98.38 -45.72 6.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 50.34 110.927 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.95 68.05 6.41 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.563 0.697 . . . . 73.23 110.891 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -8.54 23.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.69 2.26 . . . . 73.52 112.346 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.41 -23.89 67.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.757 . . . . 61.4 112.518 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.542 HG12 ' CD2' ' A' ' 121' ' ' LEU . 2.2 t -122.45 104.74 15.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 60.54 111.11 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -75.09 154.68 86.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.61 0.719 . . . . 55.42 110.909 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -13.76 35.14 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.678 2.252 . . . . 75.15 112.338 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -71.29 -18.9 62.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 65.33 111.092 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -170.61 115.23 0.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 74.51 110.887 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.542 ' CD2' HG12 ' A' ' 116' ' ' VAL . 55.4 mt -108.2 153.45 23.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 61.01 110.882 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 53.8 mm-40 -97.84 148.78 23.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 65.51 110.942 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.9 145.03 11.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 71.42 111.156 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.33 58.13 10.42 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 72.13 112.479 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -119.33 120.69 37.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.818 0.342 . . . . 72.45 110.877 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 6.4 p -85.06 130.88 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 43.51 111.183 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.2 pt -131.06 175.85 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 64.35 111.162 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 39.3 m-20 -89.94 145.62 24.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.463 . . . . 73.42 110.842 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.524 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -147.67 156.15 45.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.627 0.727 . . . . 54.35 111.094 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.649 2.233 . . . . 75.21 112.309 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 61.54 110.895 179.955 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 12.0 mtm . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.778 0.323 . . . . 71.31 110.921 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 63.61 -162.74 33.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.718 -0.753 . . . . 64.53 112.478 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 2.4 m -125.27 142.12 51.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.919 0.39 . . . . 52.14 110.903 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 71.9 p -123.67 151.47 43.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 74.32 111.11 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -138.25 136.52 36.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.215 -0.448 . . . . 72.32 110.927 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.739 HG23 HG22 ' A' ' 126' ' ' VAL . 1.4 m -92.65 126.44 37.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 50.14 111.166 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.89 109.44 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 64.43 111.121 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.0 mm-40 -110.36 162.06 22.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.642 0.734 . . . . 73.03 110.906 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -45.93 118.39 2.31 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 73.41 112.355 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.62 -18.88 29.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.73 -0.748 . . . . 74.44 112.51 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.506 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.5 m-20 -96.87 115.68 27.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 73.13 110.865 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.92 159.78 15.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.189 -0.46 . . . . 73.51 111.122 -179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -53.66 -55.03 29.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 65.12 110.859 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.2 t-105 -57.96 -56.21 24.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.137 -0.483 . . . . 73.52 110.875 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.36 -60.6 2.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.26 -0.427 . . . . 61.52 111.103 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ILE . . . . . 0.506 HD11 ' CB ' ' A' ' 93' ' ' ASP . 33.0 mt -51.62 -37.86 20.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 73.55 111.137 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.429 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -65.7 -37.46 86.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.176 -0.465 . . . . 43.03 111.126 179.798 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -51.81 -65.15 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 75.33 110.915 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.2 mtt180 -63.32 -41.27 98.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 72.24 110.945 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.6 mmp_? -55.87 -25.7 43.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 73.24 110.816 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.76 17.41 51.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 60.12 112.494 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.967 HG21 HD11 ' A' ' 109' ' ' ILE . 11.5 t -119.37 179.9 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.856 0.36 . . . . 74.42 111.148 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.18 157.77 28.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 63.04 111.153 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 26.3 t -55.48 -42.83 69.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 64.31 111.131 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -51.84 -36.31 47.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.87 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -78.83 -53.6 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 61.03 111.127 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ILE . . . . . 0.967 HD11 HG21 ' A' ' 104' ' ' THR . 44.8 mm -51.66 -40.58 26.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 73.55 111.173 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -77.75 -25.42 49.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 65.44 110.931 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.5 t -80.38 -20.35 44.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 73.14 110.835 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.1 mt -98.35 -45.53 6.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 71.44 110.872 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.96 68.17 6.48 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.641 0.734 . . . . 73.14 110.883 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -8.5 23.77 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.694 2.263 . . . . 70.54 112.33 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.04 -22.92 58.73 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.793 -0.718 . . . . 63.11 112.461 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.517 HG12 HD23 ' A' ' 121' ' ' LEU . 2.1 t -121.89 107.91 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.86 0.362 . . . . 61.01 111.096 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.55 155.0 81.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.636 0.732 . . . . 43.32 110.876 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.79 -16.72 37.55 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.707 2.272 . . . . 72.13 112.313 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -68.65 -19.44 64.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.261 -0.427 . . . . 41.33 111.13 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.3 ptt180 -173.48 116.63 0.26 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 52.24 110.899 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.517 HD23 HG12 ' A' ' 116' ' ' VAL . 61.7 mt -103.46 154.6 19.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 60.24 110.91 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 -97.77 143.12 28.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 55.42 110.957 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.51 145.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 50.2 111.133 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.28 59.1 8.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 72.32 112.495 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -119.3 121.57 39.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 73.44 110.909 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' VAL . . . . . 0.739 HG22 HG23 ' A' ' 88' ' ' THR . 22.4 t -85.27 127.11 40.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 71.13 111.141 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 10.0 pt -123.5 174.32 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 61.0 111.132 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -96.89 144.28 26.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.156 -0.475 . . . . 72.41 110.937 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.25 156.19 79.75 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.641 0.734 . . . . 73.11 111.108 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 85.47 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.658 2.239 . . . . 42.11 112.377 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.147 -0.479 . . . . 65.15 110.924 -179.981 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 5.3 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.932 0.396 . . . . 63.21 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 41.3 p -123.55 168.08 13.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 53.11 111.14 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.42 ' HB2' HG21 ' A' ' 129' ' ' VAL . 45.8 t80 -145.23 136.38 24.89 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 72.13 110.968 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.6 m -91.73 123.09 34.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.108 -0.496 . . . . 75.43 111.116 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 60.6 mt -90.89 109.49 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.453 . . . . 74.31 111.152 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -111.24 163.51 17.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.617 0.722 . . . . 73.03 110.93 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_exo -46.16 124.58 7.71 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.718 2.278 . . . . 75.44 112.333 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 106.54 -17.96 38.86 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.777 -0.725 . . . . 65.03 112.483 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -97.31 147.03 24.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.908 0.385 . . . . 75.41 110.833 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.96 174.36 10.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 40.34 111.121 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.518 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.3 m-85 -54.51 -70.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 75.24 110.905 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.92 -50.07 61.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.16 -0.473 . . . . 74.33 110.924 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.03 -66.29 0.41 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.264 -0.425 . . . . 71.34 111.11 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 43.9 mt -51.37 -32.68 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 75.43 111.077 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -66.73 -38.46 86.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 65.44 111.147 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -52.32 -69.42 0.11 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 74.04 110.882 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 9.6 ptm180 -56.28 -44.48 79.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 75.31 110.855 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -56.35 -25.03 47.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 74.34 110.841 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.82 16.55 56.21 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.736 -0.745 . . . . 70.04 112.463 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.683 HG21 HD11 ' A' ' 109' ' ' ILE . 7.7 t -119.84 -176.1 3.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.897 0.38 . . . . 54.34 111.103 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.402 HG22 ' H ' ' A' ' 106' ' ' VAL . 0.3 OUTLIER -125.27 165.97 17.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 75.05 111.14 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.733 HG12 HE21 ' A' ' 110' ' ' GLN . 61.3 t -55.78 -41.12 64.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 72.41 111.175 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -51.79 -36.03 46.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 73.41 110.856 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.21 -51.5 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 73.24 111.103 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.683 HD11 HG21 ' A' ' 104' ' ' THR . 49.7 mm -51.25 -42.45 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 74.12 111.166 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.733 HE21 HG12 ' A' ' 106' ' ' VAL . 7.1 pt20 -78.18 -25.4 47.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 74.24 110.909 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.7 t -78.05 -21.07 51.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 74.41 110.864 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 43.3 mt -97.05 -46.16 6.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.151 -0.477 . . . . 73.24 110.921 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -117.96 68.15 6.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.596 0.712 . . . . 63.42 110.878 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -8.51 23.78 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.657 2.238 . . . . 71.54 112.314 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -67.23 -17.59 68.34 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.733 -0.746 . . . . 64.12 112.523 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.551 HG21 ' OE1' ' A' ' 125' ' ' GLN . 2.2 t -131.14 119.67 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.909 0.385 . . . . 65.0 111.098 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -88.77 154.86 50.51 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.599 0.714 . . . . 74.5 110.902 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -19.63 35.73 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.725 2.283 . . . . 74.44 112.327 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.79 -15.98 60.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 63.13 111.112 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -170.56 115.33 0.47 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 74.43 110.852 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.518 HD11 ' CD2' ' A' ' 95' ' ' PHE . 47.0 mt -117.34 150.79 38.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.47 . . . . 72.14 110.933 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.0 mm100 -97.77 149.5 22.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 74.0 110.911 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.3 p -68.35 146.61 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 63.11 111.137 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.8 63.73 4.51 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 63.32 112.514 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.551 ' OE1' HG21 ' A' ' 116' ' ' VAL . 13.5 tt0 -119.14 121.62 40.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 71.44 110.907 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.54 124.53 40.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 41.52 111.121 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.6 pt -127.83 175.93 8.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 71.33 111.148 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -96.05 144.07 26.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 74.1 110.9 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.42 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -141.26 156.15 67.68 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.726 . . . . 73.45 111.085 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 105.52 1.5 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.675 2.25 . . . . 74.52 112.346 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.2 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 74.42 110.873 -179.972 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.1 m . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.892 0.377 . . . . 65.42 110.876 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.5 p -126.43 161.52 27.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.148 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.428 ' CE1' HD13 ' A' ' 98' ' ' ILE . 45.2 t80 -142.85 136.63 28.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 74.44 110.918 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 m -93.44 124.03 37.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 63.5 111.124 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.8 mt -91.05 109.58 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 65.11 111.116 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -111.58 163.52 17.3 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.579 0.704 . . . . 63.41 110.926 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_exo -46.16 120.95 4.01 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.712 2.274 . . . . 70.31 112.336 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.6 -18.86 26.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.759 . . . . 43.12 112.478 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.565 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.4 m-20 -99.04 140.94 32.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.896 0.379 . . . . 63.44 110.852 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.77 163.8 24.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 44.51 111.134 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.416 ' CE1' HG22 ' A' ' 109' ' ' ILE . 1.3 m-85 -54.99 -64.57 0.79 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 73.51 110.865 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -56.2 -50.67 70.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 74.11 110.919 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.65 -65.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 55.33 111.049 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.565 HD11 ' CB ' ' A' ' 93' ' ' ASP . 36.3 mt -51.73 -37.0 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 70.15 111.118 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.402 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -64.13 -36.1 82.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 73.44 111.085 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.9 mt-30 -51.82 -63.75 1.03 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 75.45 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 47.9 mtm180 -67.1 -39.38 86.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.41 110.89 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . 0.558 ' HG3' HG22 ' A' ' 98' ' ' ILE . 8.5 mmp_? -56.41 -25.14 49.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 72.15 110.904 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 92.23 17.15 47.82 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 75.51 112.517 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.949 HG21 HD11 ' A' ' 109' ' ' ILE . 13.4 t -125.21 177.3 6.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.87 0.367 . . . . 73.5 111.13 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.401 HG22 ' H ' ' A' ' 106' ' ' VAL . 1.1 m -125.43 164.68 19.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 71.52 111.104 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.657 HG12 HE21 ' A' ' 110' ' ' GLN . 58.9 t -54.68 -40.88 53.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.198 -0.455 . . . . 70.12 111.094 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . 0.617 ' OD2' HG23 ' A' ' 108' ' ' VAL . 0.6 OUTLIER -51.67 -38.51 55.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.196 -0.456 . . . . 75.44 110.877 179.884 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.617 HG23 ' OD2' ' A' ' 107' ' ' ASP . 24.9 t -78.94 -52.33 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 75.31 111.142 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.949 HD11 HG21 ' A' ' 104' ' ' THR . 47.7 mm -52.2 -41.1 32.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 61.04 111.179 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.657 HE21 HG12 ' A' ' 106' ' ' VAL . 6.5 pt20 -75.66 -25.51 56.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 61.22 110.905 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.3 t -79.41 -23.47 43.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 43.44 110.863 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.7 mt -98.92 -44.65 6.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 75.44 110.897 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -117.67 68.29 5.91 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.625 0.726 . . . . 64.44 110.874 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -7.3 20.72 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.625 2.216 . . . . 74.53 112.366 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.34 -43.75 43.84 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.747 -0.739 . . . . 43.53 112.518 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.517 HG11 HE22 ' A' ' 125' ' ' GLN . 2.4 m -116.46 127.24 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.802 0.334 . . . . 54.11 111.151 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -55.92 160.87 3.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.619 0.723 . . . . 63.21 110.917 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.73 24.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.266 . . . . 75.33 112.348 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -133.07 24.39 4.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.34 111.102 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 67.9 mtp85 -149.73 89.48 1.62 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 74.43 110.86 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.487 HD23 ' HB ' ' A' ' 116' ' ' VAL . 9.9 mt -125.16 176.23 6.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 74.12 110.943 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 24.3 mm100 -136.38 150.4 48.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.889 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.1 p -54.37 146.45 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 60.4 111.188 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.02 65.01 3.5 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.73 -0.747 . . . . 44.33 112.509 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.517 HE22 HG11 ' A' ' 116' ' ' VAL . 13.6 tt0 -119.12 122.01 41.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.816 0.341 . . . . 75.53 110.941 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.4 p -87.43 135.04 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 75.22 111.141 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.0 pt -140.74 175.82 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 75.43 111.163 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 10.0 m-20 -103.19 143.06 33.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 74.22 110.894 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.2 156.14 66.99 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 74.4 111.151 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 110.54 2.59 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.657 2.238 . . . . 73.05 112.351 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 70.3 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 61.3 110.894 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 81.8 m . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.943 0.401 . . . . 75.02 110.843 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.6 p -125.55 163.47 22.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 63.1 111.201 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.434 ' CE1' HD13 ' A' ' 98' ' ' ILE . 42.2 t80 -142.85 136.56 28.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.256 -0.429 . . . . 71.11 110.933 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -93.61 123.66 37.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.123 -0.489 . . . . 63.31 111.15 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.422 HD12 ' HB3' ' A' ' 125' ' ' GLN . 74.8 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 75.41 111.127 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.1 mm-40 -109.28 163.15 17.69 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.56 0.695 . . . . 73.15 110.896 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -46.17 124.8 7.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 64.31 112.321 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.75 -18.88 39.85 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.724 -0.751 . . . . 63.2 112.464 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -96.83 141.39 30.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.886 0.374 . . . . 74.43 110.875 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -129.73 170.26 14.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 73.25 111.164 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.52 ' HZ ' HG23 ' A' ' 116' ' ' VAL . 1.3 m-85 -54.39 -69.53 0.12 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 54.23 110.886 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.1 t-105 -52.3 -49.93 63.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 73.24 110.939 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.31 -65.7 0.51 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.238 -0.437 . . . . 71.4 111.076 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.434 HD13 ' CE1' ' A' ' 87' ' ' TYR . 46.8 mt -51.77 -37.09 19.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.264 -0.426 . . . . 71.32 111.14 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -63.64 -35.87 81.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 72.54 111.123 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -51.78 -68.18 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 72.01 110.909 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 46.6 mtt180 -61.71 -41.99 98.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 74.21 110.837 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.1 mmm180 -54.68 -27.1 37.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 64.12 110.893 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.4 18.09 50.41 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 50.33 112.451 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.977 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -119.36 178.39 4.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.866 0.365 . . . . 65.4 111.142 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -120.97 160.68 23.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 72.41 111.177 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.0 t -54.37 -47.17 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 51.31 111.172 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -52.24 -29.71 24.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 54.32 110.844 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.553 HG12 HD12 ' A' ' 112' ' ' LEU . 61.7 t -81.32 -54.19 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 73.43 111.104 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.977 HD11 HG21 ' A' ' 104' ' ' THR . 50.0 mm -52.59 -39.65 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 71.14 111.12 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -25.35 47.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 73.55 110.926 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 t -80.64 -21.01 41.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.187 -0.46 . . . . 71.51 110.847 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.553 HD12 HG12 ' A' ' 108' ' ' VAL . 6.6 mt -102.59 -42.13 6.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.104 -0.498 . . . . 72.43 110.928 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -117.64 68.34 5.87 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.644 0.735 . . . . 75.3 110.894 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -7.29 20.69 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.681 2.254 . . . . 74.52 112.357 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.29 -43.5 43.17 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.749 -0.739 . . . . 75.05 112.477 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.669 HG11 ' NE2' ' A' ' 125' ' ' GLN . 2.2 m -116.43 128.04 73.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.883 0.373 . . . . 74.35 111.167 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -58.45 161.49 7.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 62.4 110.885 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -8.48 23.72 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.699 2.266 . . . . 71.34 112.324 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.13 18.87 4.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.091 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -142.67 87.28 1.99 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 74.42 110.866 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 7.9 mt -124.23 167.94 13.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.478 . . . . 72.53 110.885 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -135.42 153.31 51.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 74.54 110.875 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.9 p -52.81 147.76 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 71.2 111.12 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.69 66.72 2.38 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.688 -0.767 . . . . 75.25 112.474 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.669 ' NE2' HG11 ' A' ' 116' ' ' VAL . 7.0 tt0 -114.31 120.9 41.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.867 0.365 . . . . 71.14 110.889 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.99 124.98 42.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 74.24 111.163 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.4 pt -135.06 175.92 9.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 64.23 111.17 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -104.59 148.94 25.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 53.23 110.874 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -133.29 156.12 80.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.565 0.698 . . . . 73.23 111.163 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 110.16 2.49 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.693 2.262 . . . . 62.43 112.278 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 88.6 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 73.32 110.9 179.932 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . 0.428 ' HB3' HG23 ' A' ' 129' ' ' VAL . 6.8 m . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.906 0.384 . . . . 74.23 110.891 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.6 p -123.6 160.75 26.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 75.23 111.119 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -143.42 136.56 27.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 74.34 110.93 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.7 m -94.91 123.27 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 52.24 111.172 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 57.0 mt -90.99 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.235 -0.438 . . . . 73.12 111.13 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -116.21 163.36 21.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.568 0.699 . . . . 72.31 110.95 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -46.52 107.79 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 53.14 112.337 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 126.63 -18.51 6.35 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.714 -0.755 . . . . 71.45 112.484 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.597 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.4 m-20 -103.49 136.97 42.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 75.42 110.843 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.25 163.86 20.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 63.22 111.194 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.499 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.4 m-85 -54.75 -67.54 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 72.31 110.911 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -52.23 -51.74 56.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 74.42 110.916 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.32 -65.6 0.53 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.264 -0.426 . . . . 74.41 111.143 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.597 HD11 ' CB ' ' A' ' 93' ' ' ASP . 26.3 mt -51.42 -31.68 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 72.23 111.148 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.504 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -67.47 -39.82 85.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 72.43 111.087 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -52.39 -58.77 5.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 74.55 110.936 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 3.1 mmt85 -69.31 -16.85 63.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 74.02 110.891 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . 0.403 ' HE ' HG11 ' A' ' 129' ' ' VAL . 18.3 mmt180 -90.83 12.76 18.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 65.15 110.904 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.94 28.08 23.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.74 -0.743 . . . . 45.32 112.51 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.894 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -129.55 177.94 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.879 0.371 . . . . 74.1 111.123 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.98 163.01 26.28 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.197 -0.456 . . . . 72.13 111.15 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.702 HG12 HE21 ' A' ' 110' ' ' GLN . 62.0 t -51.85 -39.53 25.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 55.13 111.141 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -51.55 -39.35 57.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.484 . . . . 64.04 110.864 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -80.25 -50.34 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.15 -0.477 . . . . 75.2 111.111 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.894 HD11 HG21 ' A' ' 104' ' ' THR . 47.5 mm -51.43 -41.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 74.21 111.079 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.702 HE21 HG12 ' A' ' 106' ' ' VAL . 6.5 pt20 -77.65 -25.6 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 74.4 110.933 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 19.9 t -76.14 -24.5 54.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.182 -0.463 . . . . 53.54 110.843 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 20.8 mt -98.59 -44.53 6.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 71.41 110.906 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.93 67.97 6.33 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.589 0.709 . . . . 73.01 110.911 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -7.63 21.54 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.686 2.257 . . . . 74.04 112.316 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.47 -45.42 46.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.78 -0.724 . . . . 63.14 112.47 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.561 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.3 m -117.24 124.93 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 64.44 111.127 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -67.97 160.87 71.83 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.607 0.717 . . . . 52.24 110.887 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -8.46 23.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.624 2.216 . . . . 71.55 112.352 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -115.51 24.9 11.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 53.35 111.11 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.2 ptp180 -173.34 108.16 0.16 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 74.53 110.858 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.561 HD23 ' HB ' ' A' ' 116' ' ' VAL . 10.3 mt -136.99 146.91 45.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.174 -0.467 . . . . 44.41 110.92 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -97.75 153.0 18.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 75.0 110.89 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 12.4 p -68.12 148.07 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 74.1 111.178 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.84 61.7 6.24 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.783 -0.722 . . . . 44.03 112.481 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.527 HE22 HG11 ' A' ' 116' ' ' VAL . 15.6 tt0 -119.24 121.96 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.838 0.352 . . . . 73.02 110.902 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.87 124.95 40.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 50.43 111.117 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.5 pt -123.58 175.74 5.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.185 -0.461 . . . . 53.24 111.132 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -99.16 137.26 37.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 52.43 110.85 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.428 HG23 ' HB3' ' A' ' 85' ' ' CYS . 3.2 m -117.93 156.22 50.29 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.598 0.713 . . . . 72.5 111.124 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 83.91 0.67 Allowed 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.647 2.231 . . . . 72.11 112.355 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.264 -0.426 . . . . 53.11 110.868 -179.998 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 9.2 m . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.903 0.382 . . . . 53.5 110.894 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.3 p -123.61 154.38 39.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 62.34 111.13 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 47.0 t80 -132.26 136.6 47.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.236 -0.438 . . . . 74.13 110.889 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -91.43 125.24 36.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.065 -0.516 . . . . 61.33 111.127 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 121' ' ' LEU . 52.2 mt -93.22 110.51 23.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 74.23 111.146 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm-40 -89.45 158.87 45.3 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.55 0.69 . . . . 71.3 110.898 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.632 ' HB3' HG23 ' A' ' 123' ' ' VAL . 20.2 Cg_endo -59.67 92.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.645 2.23 . . . . 44.33 112.37 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.44 -18.28 2.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.754 -0.736 . . . . 72.4 112.493 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -78.81 155.86 29.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 71.4 110.841 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.458 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -131.66 165.15 24.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 54.54 111.166 -179.932 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.623 ' HE2' HD21 ' A' ' 121' ' ' LEU . 1.1 m-85 -51.32 -51.08 57.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 74.2 110.877 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -67.85 -48.94 64.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.138 -0.483 . . . . 72.22 110.91 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.458 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -54.98 -29.95 58.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 71.03 111.084 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 31.2 mt -87.44 -33.43 6.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.238 -0.437 . . . . 71.23 111.142 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' A' ' 104' ' ' THR . . . -65.01 -43.66 91.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 75.21 111.11 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -56.31 -44.59 80.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.21 110.841 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -65.76 -60.22 3.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 72.41 110.884 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -51.97 -30.86 26.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.456 . . . . 73.43 110.894 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 103.36 16.72 19.75 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 74.43 112.46 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.431 ' O ' ' HB1' ' A' ' 99' ' ' ALA . 7.2 t -120.74 -174.83 2.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 71.14 111.149 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -116.23 165.22 13.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 75.43 111.12 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.8 t -55.51 -43.42 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 73.55 111.137 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -51.74 -33.39 34.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 64.35 110.855 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.89 -48.67 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 70.12 111.114 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 43.2 mm -51.31 -42.75 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 73.04 111.161 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -78.06 -25.41 47.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 65.4 110.928 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.1 t -76.83 -23.17 52.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 52.41 110.878 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 37.2 mt -100.59 -43.18 6.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 50.33 110.894 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -120.22 67.99 13.19 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 71.41 110.854 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.77 -8.24 23.1 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.737 2.291 . . . . 61.5 112.313 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.78 -44.79 55.36 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.685 -0.769 . . . . 51.42 112.517 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.579 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.6 m -114.56 161.76 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 51.24 111.129 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -102.73 161.39 23.36 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.659 0.742 . . . . 62.02 110.851 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -8.39 23.47 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.679 2.253 . . . . 75.55 112.395 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.49 20.79 4.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 62.4 111.072 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 60.0 mtt85 -151.63 49.68 0.81 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 71.0 110.846 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.623 HD21 ' HE2' ' A' ' 95' ' ' PHE . 27.9 mt -85.52 166.52 16.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 43.21 110.9 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 -115.51 153.4 31.23 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.141 -0.481 . . . . 73.52 110.896 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.632 HG23 ' HB3' ' A' ' 91' ' ' PRO . 12.2 p -63.9 133.94 29.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.09 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.88 63.28 4.89 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.695 -0.764 . . . . 60.05 112.511 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -114.74 123.5 49.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 75.42 110.942 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.37 126.81 40.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 71.53 111.133 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.1 pt -127.23 175.91 8.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.149 -0.478 . . . . 75.44 111.151 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -94.97 153.9 17.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 73.25 110.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.5 m -141.23 156.03 67.81 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.643 0.735 . . . . 62.45 111.155 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 87.84 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.675 2.25 . . . . 73.23 112.352 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 71.52 110.854 179.997 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.939 0.4 . . . . 71.03 110.842 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 46.4 p -124.24 157.33 35.1 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.146 -0.479 . . . . 60.02 111.167 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -130.36 136.72 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.214 -0.448 . . . . 74.55 110.893 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -91.12 122.42 33.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 54.3 111.129 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.574 HG23 HD11 ' A' ' 98' ' ' ILE . 35.2 mt -90.8 109.59 21.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 74.43 111.135 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 16.4 mt-30 -87.75 157.28 52.27 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.606 0.717 . . . . 73.32 110.884 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.697 ' HB3' HG23 ' A' ' 123' ' ' VAL . 17.8 Cg_endo -58.16 94.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.675 2.25 . . . . 61.23 112.34 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.38 -20.38 2.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.694 -0.765 . . . . 75.53 112.456 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.44 ' HB2' HD11 ' A' ' 98' ' ' ILE . 1.0 OUTLIER -87.43 137.51 32.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.867 0.365 . . . . 64.42 110.913 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.48 171.48 7.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 73.15 111.186 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.637 ' HE1' HD21 ' A' ' 121' ' ' LEU . 1.2 m-85 -53.92 -64.36 0.85 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 72.34 110.927 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -53.08 -51.95 60.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 74.21 110.929 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.66 -63.77 1.03 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 51.12 111.091 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.574 HD11 HG23 ' A' ' 89' ' ' ILE . 46.7 mt -51.69 -34.13 15.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 72.15 111.133 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HB1' ' O ' ' A' ' 104' ' ' THR . . . -68.16 -35.72 78.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 75.01 111.114 179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.4 mt-30 -51.66 -73.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 54.1 110.904 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 36.4 mmm-85 -54.62 -45.27 73.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 62.13 110.903 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -54.54 -27.2 36.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 73.23 110.907 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 91.54 16.09 53.41 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.775 -0.726 . . . . 72.1 112.469 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.685 HG21 HD11 ' A' ' 109' ' ' ILE . 9.6 t -122.26 -177.71 3.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.843 0.354 . . . . 75.4 111.113 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -121.12 164.27 17.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 61.03 111.145 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.604 HG12 HE21 ' A' ' 110' ' ' GLN . 58.6 t -55.71 -43.06 72.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 73.21 111.066 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -51.8 -33.51 35.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 70.41 110.852 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.0 t -81.86 -52.04 14.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 62.03 111.138 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.685 HD11 HG21 ' A' ' 104' ' ' THR . 47.6 mm -51.64 -42.21 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 71.13 111.151 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.604 HE21 HG12 ' A' ' 106' ' ' VAL . 2.8 pt20 -77.89 -25.4 48.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.874 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.6 t -77.08 -23.86 51.91 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 73.31 110.88 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.7 mt -99.45 -44.7 6.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 75.13 110.945 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.69 67.61 7.74 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.63 0.728 . . . . 55.3 110.897 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -8.22 23.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.659 2.239 . . . . 63.2 112.395 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.6 -44.09 53.74 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 62.14 112.472 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.696 HG11 ' NE2' ' A' ' 125' ' ' GLN . 2.5 m -115.21 156.71 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.881 0.372 . . . . 72.34 111.098 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -97.94 161.8 24.38 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.635 0.731 . . . . 74.54 110.849 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -7.82 22.05 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 73.33 112.36 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.42 18.89 4.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 42.34 111.063 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -143.32 40.82 1.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.215 -0.448 . . . . 55.1 110.897 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.637 HD21 ' HE1' ' A' ' 95' ' ' PHE . 59.9 mt -85.59 149.77 25.11 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.214 -0.448 . . . . 74.42 110.893 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . 0.495 ' H ' ' NE2' ' A' ' 125' ' ' GLN . 80.7 mm-40 -104.66 153.53 21.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 63.13 110.905 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.697 HG23 ' HB3' ' A' ' 91' ' ' PRO . 9.9 p -56.45 134.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.467 . . . . 54.44 111.122 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.25 63.21 5.04 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 72.2 112.509 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.696 ' NE2' HG11 ' A' ' 116' ' ' VAL . 5.6 tt0 -109.55 123.01 48.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 73.32 110.884 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 8.4 p -85.66 136.87 21.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 75.02 111.112 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.442 HD13 HD11 ' A' ' 89' ' ' ILE . 10.3 pt -142.56 175.94 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.123 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -97.67 153.44 18.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 60.42 110.905 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -146.24 156.16 50.27 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.594 0.712 . . . . 70.15 111.149 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 91.0 0.52 Allowed 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.684 2.256 . . . . 72.32 112.33 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 53.3 110.926 179.991 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.915 0.388 . . . . 61.23 110.909 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 72.7 p -124.96 150.48 46.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 53.3 111.15 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.547 ' HB2' HG21 ' A' ' 129' ' ' VAL . 48.1 t80 -123.86 135.97 54.07 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.32 110.936 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -89.66 123.38 33.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 54.54 111.177 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.4 mt -90.93 109.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 62.35 111.179 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -91.99 158.82 39.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.566 0.698 . . . . 74.1 110.936 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.598 ' HB3' HG23 ' A' ' 123' ' ' VAL . 19.9 Cg_endo -59.41 92.88 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.687 2.258 . . . . 74.33 112.374 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.82 -19.04 2.56 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.751 . . . . 63.54 112.528 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.606 ' CB ' HD11 ' A' ' 98' ' ' ILE . 5.8 m-20 -80.97 154.17 27.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.906 0.384 . . . . 74.33 110.841 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 152.46 45.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 75.05 111.152 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.601 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.2 m-85 -53.4 -55.6 23.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.34 110.861 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -57.95 -55.76 30.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 74.35 110.871 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.26 -61.04 2.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.259 -0.428 . . . . 52.13 111.106 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.606 HD11 ' CB ' ' A' ' 93' ' ' ASP . 41.0 mt -51.37 -38.24 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 72.2 111.134 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.403 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -64.68 -38.32 90.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 71.35 111.151 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -51.93 -72.77 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 63.02 110.898 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -53.97 -41.67 68.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 74.12 110.879 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 6.9 mmp_? -57.05 -24.17 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 44.13 110.876 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.46 15.34 60.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.771 -0.728 . . . . 63.4 112.484 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 1.047 HG21 HD11 ' A' ' 109' ' ' ILE . 8.0 t -115.24 -175.48 2.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.931 0.396 . . . . 60.13 111.109 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -124.45 154.94 39.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 73.04 111.169 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.736 HG12 HE21 ' A' ' 110' ' ' GLN . 74.1 t -54.14 -42.94 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 75.13 111.152 179.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -51.72 -39.54 58.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.139 -0.482 . . . . 74.12 110.875 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.1 t -75.14 -54.18 14.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 70.02 111.145 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 1.047 HD11 HG21 ' A' ' 104' ' ' THR . 43.4 mm -51.58 -42.08 29.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 74.44 111.144 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.736 HE21 HG12 ' A' ' 106' ' ' VAL . 6.9 pt20 -76.78 -25.54 53.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 75.31 110.885 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.8 t -76.18 -25.22 54.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 73.41 110.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.6 mt -96.89 -45.47 6.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 75.11 110.939 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.03 67.85 6.48 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.73 . . . . 73.31 110.939 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.49 21.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.696 2.264 . . . . 72.11 112.356 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.45 -44.46 45.62 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 72.02 112.483 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.601 HG23 ' CZ ' ' A' ' 95' ' ' PHE . 2.4 m -117.2 130.93 71.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.86 0.362 . . . . 63.45 111.077 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 16.5 m-20 -76.78 160.9 75.73 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.626 0.727 . . . . 75.45 110.883 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -8.6 24.01 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.635 2.223 . . . . 74.12 112.35 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -113.65 24.93 11.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 72.43 111.112 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.7 ptm180 -178.36 104.17 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 75.22 110.88 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 63.8 mt -122.31 167.48 13.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.446 . . . . 75.21 110.882 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -109.57 153.38 24.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 71.02 110.898 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.598 HG23 ' HB3' ' A' ' 91' ' ' PRO . 9.3 p -70.44 136.19 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 74.44 111.094 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.0 63.82 4.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.733 -0.746 . . . . 65.31 112.515 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.556 HE22 HG11 ' A' ' 116' ' ' VAL . 12.1 tt0 -117.66 122.74 44.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.873 0.368 . . . . 73.34 110.892 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -88.18 125.34 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.464 . . . . 63.44 111.157 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.1 pt -125.84 175.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 71.43 111.142 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -97.76 137.43 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 55.12 110.859 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.547 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -138.95 156.19 72.65 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.609 0.718 . . . . 73.23 111.142 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 109.55 2.34 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.721 2.281 . . . . 61.33 112.345 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 74.32 110.9 -179.982 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 97.8 m . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.925 0.393 . . . . 74.53 110.853 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.4 p -123.51 168.52 12.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.133 -0.485 . . . . 74.14 111.158 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -136.82 136.59 38.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 65.21 110.891 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.1 m -89.18 122.76 32.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 70.34 111.171 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.435 HD11 HG12 ' A' ' 127' ' ' ILE . 38.8 mt -91.07 109.5 21.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 74.13 111.149 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.56 163.7 16.38 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 74.22 110.928 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -46.1 111.11 0.31 Allowed 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.708 2.272 . . . . 71.51 112.341 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 113.21 -1.64 25.35 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 52.25 112.52 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -113.17 113.82 25.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 71.13 110.87 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -101.37 157.84 16.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 65.25 111.104 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.458 ' CE2' HD22 ' A' ' 121' ' ' LEU . 1.7 m-85 -51.5 -43.04 62.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 72.44 110.911 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.15 -47.66 27.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.111 -0.495 . . . . 74.43 110.906 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.54 -26.86 62.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 60.14 111.064 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 28.2 mt -88.31 -45.1 15.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 74.44 111.133 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.455 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -55.27 -46.15 76.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.46 . . . . 71.41 111.123 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -52.0 -44.97 64.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 63.11 110.89 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 74.8 mtt-85 -71.88 -52.7 16.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.881 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.8 mmm180 -54.12 -27.6 34.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 75.4 110.886 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.85 17.57 18.36 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.768 -0.73 . . . . 64.31 112.523 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.831 HG21 HD11 ' A' ' 109' ' ' ILE . 12.0 t -124.1 179.02 5.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.848 0.356 . . . . 73.03 111.162 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.41 164.47 17.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.198 -0.455 . . . . 65.52 111.163 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.692 HG12 HE21 ' A' ' 110' ' ' GLN . 46.8 t -55.23 -41.02 58.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.262 -0.426 . . . . 73.01 111.123 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -51.67 -38.89 56.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 65.41 110.886 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.3 t -78.38 -51.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 73.54 111.143 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.831 HD11 HG21 ' A' ' 104' ' ' THR . 47.6 mm -51.54 -43.97 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 74.41 111.148 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.692 HE21 HG12 ' A' ' 106' ' ' VAL . 2.8 pt20 -73.55 -25.54 60.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 65.3 110.931 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.5 t -78.91 -23.07 44.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 44.31 110.885 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.5 mt -98.27 -44.53 6.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 61.4 110.921 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.83 67.89 6.09 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.603 0.716 . . . . 61.1 110.909 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -7.25 20.58 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.701 2.267 . . . . 62.54 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.06 -42.03 38.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 43.41 112.435 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.507 ' HB ' HD23 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -119.37 125.13 74.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.858 0.361 . . . . 74.45 111.132 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -57.58 161.14 6.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.619 0.724 . . . . 54.43 110.835 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 -8.59 23.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.653 2.235 . . . . 44.41 112.322 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -126.59 14.9 7.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 73.33 111.1 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 63.0 mtt180 -141.55 93.76 2.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 73.34 110.881 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.507 HD23 ' HB ' ' A' ' 116' ' ' VAL . 10.0 mt -132.73 163.84 28.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 74.13 110.902 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -125.04 150.68 46.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 74.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.5 p -52.81 146.86 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.441 . . . . 60.24 111.112 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.61 65.91 2.88 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 71.3 112.536 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.459 HE22 HG11 ' A' ' 116' ' ' VAL . 11.2 tt0 -119.15 121.61 40.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 75.51 110.921 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 15.0 p -89.03 136.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 72.11 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.435 HG12 HD11 ' A' ' 89' ' ' ILE . 2.4 pt -138.68 174.23 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 75.13 111.166 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -100.25 139.39 35.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 75.45 110.931 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -141.19 156.12 67.9 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.645 0.736 . . . . 73.33 111.131 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 110.59 2.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.677 2.251 . . . . 74.23 112.334 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 74.11 110.921 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 19.4 m . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.878 0.37 . . . . 75.35 110.907 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.0 p -123.59 166.72 14.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.151 -0.477 . . . . 74.05 111.164 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.4 t80 -142.97 136.59 28.65 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.25 -0.432 . . . . 61.1 110.982 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -89.79 121.91 32.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 64.5 111.143 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.8 mt -90.94 109.61 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 71.53 111.156 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -86.86 158.62 53.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 75.55 110.935 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.57 ' HB3' HG23 ' A' ' 123' ' ' VAL . 17.9 Cg_endo -58.54 93.61 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.639 2.226 . . . . 71.22 112.345 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.8 -18.87 2.38 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 75.43 112.482 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.609 ' CB ' HD11 ' A' ' 98' ' ' ILE . 3.5 m-20 -84.67 138.23 32.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.361 . . . . 54.53 110.867 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.05 155.21 26.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 43.31 111.156 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.714 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -53.13 -47.52 68.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 74.42 110.878 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -71.56 -47.32 55.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 75.45 110.933 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.82 -30.44 63.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.229 -0.441 . . . . 64.15 111.144 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.609 HD11 ' CB ' ' A' ' 93' ' ' ASP . 38.5 mt -88.29 -33.64 6.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 73.05 111.098 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -65.0 -41.86 95.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 64.22 111.116 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -58.68 -44.64 90.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 74.13 110.904 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -78.67 -18.42 54.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 73.44 110.873 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -92.83 16.33 12.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 62.14 110.857 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.56 28.35 21.37 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.798 -0.715 . . . . 72.32 112.469 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 1.035 HG21 HD11 ' A' ' 109' ' ' ILE . 9.9 t -129.8 -177.24 4.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.863 0.363 . . . . 74.11 111.131 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.85 157.86 34.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 72.44 111.145 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.733 HG12 HE21 ' A' ' 110' ' ' GLN . 60.3 t -55.58 -42.26 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 74.31 111.106 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -51.82 -37.26 51.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 62.23 110.836 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.0 t -78.18 -52.99 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.11 111.138 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 1.035 HD11 HG21 ' A' ' 104' ' ' THR . 49.2 mm -51.33 -43.23 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.138 -0.483 . . . . 72.5 111.125 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.733 HE21 HG12 ' A' ' 106' ' ' VAL . 7.0 pt20 -76.62 -25.54 53.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 72.14 110.904 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -75.28 -25.46 57.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.201 -0.454 . . . . 65.2 110.844 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.9 mt -94.93 -46.46 6.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 72.2 110.948 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -118.5 67.33 7.2 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.628 0.727 . . . . 73.55 110.897 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.674 2.25 . . . . 64.41 112.32 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.36 -42.05 49.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 65.34 112.523 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.726 HG11 ' OE1' ' A' ' 125' ' ' GLN . 2.2 m -119.43 139.91 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.864 0.364 . . . . 74.04 111.108 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.1 161.25 66.25 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.596 0.712 . . . . 74.45 110.924 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -8.32 23.3 Favored 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.697 2.265 . . . . 73.45 112.4 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.76 20.58 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 61.25 111.106 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -144.07 43.62 1.44 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 75.55 110.863 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.714 HD11 ' CD2' ' A' ' 95' ' ' PHE . 71.9 mt -85.61 173.82 9.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 73.42 110.9 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -129.52 150.38 50.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 75.54 110.857 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.57 HG23 ' HB3' ' A' ' 91' ' ' PRO . 14.0 p -52.0 133.63 13.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 73.25 111.137 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 53.03 63.35 5.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.783 -0.722 . . . . 73.2 112.471 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.726 ' OE1' HG11 ' A' ' 116' ' ' VAL . 8.7 tt0 -110.62 122.73 48.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 64.44 110.922 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 30.7 t -84.45 140.75 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 64.41 111.142 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.1 pt -143.73 175.24 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 53.13 111.121 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -99.78 130.82 46.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 74.01 110.92 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -123.32 156.22 63.96 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.716 . . . . 53.42 111.132 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 91.61 0.52 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.689 2.259 . . . . 43.45 112.372 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 73.14 110.877 -179.974 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.3 m . . . . . 0 N--CA 1.457 -0.104 0 CA-C-O 120.932 0.396 . . . . 62.24 110.865 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.8 p -123.58 163.92 20.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 71.12 111.134 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 46.7 t80 -145.12 136.68 25.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 73.34 110.938 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.75 125.23 37.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 41.51 111.13 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.434 HD12 ' HG2' ' A' ' 125' ' ' GLN . 79.2 mt -90.93 109.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 74.42 111.112 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -109.17 163.27 17.39 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.548 0.689 . . . . 75.44 110.933 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -46.31 121.9 5.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.638 2.225 . . . . 74.3 112.34 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.27 -4.2 54.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.778 -0.725 . . . . 73.23 112.464 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.13 116.7 32.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.937 0.399 . . . . 73.34 110.884 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.457 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -113.96 -179.5 3.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 61.23 111.135 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.686 ' CD1' HD11 ' A' ' 121' ' ' LEU . 0.9 OUTLIER -54.64 -70.02 0.11 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 73.02 110.909 -179.972 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.88 -50.52 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 75.12 110.889 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.457 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -51.13 -65.89 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 52.23 111.138 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 47.0 mt -51.22 -35.78 16.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 52.15 111.131 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.5 -37.34 87.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 71.12 111.06 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 19.1 mt-30 -51.92 -70.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 62.22 110.93 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.5 ptm180 -57.01 -43.04 81.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 74.44 110.847 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.6 -24.81 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 63.01 110.858 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.07 17.13 56.68 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 61.45 112.463 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.675 HG21 HD11 ' A' ' 109' ' ' ILE . 7.3 t -121.71 -174.65 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.838 0.351 . . . . 64.22 111.174 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -125.46 165.34 18.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 70.55 111.174 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.628 HG12 HE21 ' A' ' 110' ' ' GLN . 41.4 t -55.8 -44.69 78.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.264 -0.426 . . . . 71.4 111.067 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -51.92 -30.11 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 72.32 110.849 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.88 -52.19 13.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 70.24 111.139 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.675 HD11 HG21 ' A' ' 104' ' ' THR . 48.7 mm -51.29 -43.08 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 74.22 111.11 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.628 HE21 HG12 ' A' ' 106' ' ' VAL . 6.7 pt20 -76.2 -25.42 55.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 64.42 110.924 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.9 m -80.02 -20.31 45.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.854 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.9 mt -94.94 -47.86 6.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.121 -0.49 . . . . 54.21 110.906 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -118.51 67.28 7.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.634 0.73 . . . . 74.42 110.897 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -8.48 23.71 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.737 2.291 . . . . 63.25 112.39 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -69.76 -17.6 73.31 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.75 -0.738 . . . . 72.33 112.478 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.539 HG12 HD23 ' A' ' 121' ' ' LEU . 2.1 t -125.89 112.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.845 0.355 . . . . 75.44 111.133 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.19 160.29 1.72 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.591 0.71 . . . . 73.03 110.912 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -45.63 1.53 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.691 2.261 . . . . 61.03 112.368 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.24 -29.84 24.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 74.34 111.13 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -83.41 68.5 9.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 74.12 110.895 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.686 HD11 ' CD1' ' A' ' 95' ' ' PHE . 53.7 mt -121.3 137.89 54.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 53.43 110.941 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -110.34 153.57 24.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 65.3 110.913 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -51.56 147.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 71.14 111.107 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.73 66.9 2.28 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 74.51 112.505 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.434 ' HG2' HD12 ' A' ' 89' ' ' ILE . 3.8 tt0 -116.47 122.4 44.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 75.12 110.941 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.8 t -86.26 130.56 36.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 74.03 111.102 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 12.1 pt -141.12 175.79 5.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 64.23 111.139 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -99.18 152.18 20.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 65.35 110.872 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.61 156.18 80.12 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.603 0.716 . . . . 61.11 111.132 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 110.33 2.53 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.664 2.242 . . . . 74.12 112.36 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 75.03 110.912 179.982 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . 0.454 ' HB3' HG23 ' A' ' 129' ' ' VAL . 1.7 m . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.953 0.406 . . . . 73.21 110.838 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.4 p -123.59 157.58 33.39 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.132 -0.485 . . . . 42.02 111.109 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -141.89 136.69 30.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.962 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -93.45 126.88 38.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 54.42 111.14 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 63.5 mt -91.0 109.52 21.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 55.05 111.089 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -92.02 159.25 38.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.537 0.684 . . . . 75.21 110.914 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.423 ' HB3' HG23 ' A' ' 123' ' ' VAL . 18.7 Cg_endo -57.95 94.47 0.07 OUTLIER 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.686 2.257 . . . . 74.15 112.306 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.79 -18.1 2.59 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.781 -0.723 . . . . 43.14 112.513 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -91.22 157.09 17.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.909 0.385 . . . . 75.31 110.837 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.437 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -141.4 178.28 7.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 73.44 111.125 -179.877 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.678 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.7 m-85 -54.49 -66.43 0.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 71.51 110.858 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -54.79 -52.15 63.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.157 -0.474 . . . . 75.41 110.909 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.437 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -50.57 -66.09 0.45 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 72.14 111.089 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 54.8 mt -51.15 -33.96 13.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 75.24 111.116 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.94 -39.53 93.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 63.41 111.086 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 21.0 mt-30 -52.12 -69.39 0.11 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 63.31 110.874 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -55.3 -50.34 69.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 74.43 110.92 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . 0.423 ' CD ' HG11 ' A' ' 129' ' ' VAL . 6.3 mmp_? -51.96 -29.97 22.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 72.12 110.866 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 94.56 12.27 56.02 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.81 -0.71 . . . . 71.24 112.524 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.7 t -114.11 -172.47 2.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.811 0.338 . . . . 71.34 111.163 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.7 m -124.87 162.56 24.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 74.54 111.167 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 69.2 t -53.38 -43.87 53.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 70.44 111.133 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -51.68 -37.3 50.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 70.21 110.848 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.2 t -76.83 -47.18 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 72.15 111.141 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 41.6 mm -50.84 -45.36 28.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 75.24 111.128 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -77.37 -25.46 50.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.142 -0.481 . . . . 61.34 110.965 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.7 t -76.69 -21.02 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 74.21 110.832 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.5 mt -97.72 -45.33 6.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 64.54 110.932 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.18 67.84 6.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.637 0.732 . . . . 70.45 110.892 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -8.41 23.53 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.656 2.237 . . . . 65.02 112.351 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -68.75 -19.57 73.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 61.42 112.43 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.732 HG11 HD23 ' A' ' 121' ' ' LEU . 2.6 t -127.3 139.71 51.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 65.41 111.115 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -79.82 160.33 69.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.631 0.729 . . . . 61.33 110.926 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -15.03 36.73 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.69 2.26 . . . . 53.51 112.342 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -116.42 -23.28 8.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 55.5 111.065 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -91.83 55.02 2.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 74.54 110.893 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.732 HD23 HG11 ' A' ' 116' ' ' VAL . 75.2 mt -107.98 131.93 54.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.459 . . . . 54.33 110.909 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -97.65 153.55 18.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 72.24 110.904 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.423 HG23 ' HB3' ' A' ' 91' ' ' PRO . 6.6 p -54.71 144.36 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 70.42 111.092 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.98 66.34 2.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.764 -0.731 . . . . 72.44 112.478 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -118.72 122.07 41.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.83 0.347 . . . . 71.14 110.898 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.4 t -84.51 126.94 40.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 74.52 111.191 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.45 175.86 10.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 63.23 111.17 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -96.08 159.76 14.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 54.21 110.885 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.454 HG23 ' HB3' ' A' ' 85' ' ' CYS . 3.1 m -144.07 156.33 58.33 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.63 0.729 . . . . 64.44 111.134 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 90.87 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.655 2.237 . . . . 72.13 112.326 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 74.43 110.873 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.4 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.951 0.405 . . . . 75.54 110.894 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 18.2 p -125.5 163.06 23.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 64.24 111.128 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -139.19 136.31 34.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 62.1 110.917 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 m -92.26 123.26 35.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 61.04 111.123 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.548 HD12 ' HG2' ' A' ' 125' ' ' GLN . 85.3 mt -90.9 109.47 21.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 73.3 111.162 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.499 ' HB3' ' HD2' ' A' ' 91' ' ' PRO . 25.6 mt-30 -112.6 162.63 20.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.55 0.69 . . . . 74.21 110.963 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.499 ' HD2' ' HB3' ' A' ' 90' ' ' GLN . 74.9 Cg_exo -47.33 101.07 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.685 2.257 . . . . 63.21 112.378 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 124.75 0.47 8.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 74.02 112.519 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -115.22 116.91 29.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.869 0.366 . . . . 70.32 110.877 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.443 HG22 ' H ' ' A' ' 95' ' ' PHE . 0.2 OUTLIER -107.08 169.57 8.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 63.04 111.145 -179.89 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.6 ' CD1' HD11 ' A' ' 121' ' ' LEU . 0.7 OUTLIER -53.68 -66.03 0.46 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.187 -0.461 . . . . 72.04 110.897 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -55.94 -49.6 73.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 74.15 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -50.22 -55.21 16.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.24 -0.436 . . . . 45.3 111.091 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 35.4 mt -62.69 -31.93 53.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 72.42 111.127 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.449 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -69.65 -29.93 67.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 75.43 111.083 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -52.59 -74.11 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.914 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -57.38 -38.79 74.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 73.33 110.87 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . 0.432 ' HD2' HG11 ' A' ' 129' ' ' VAL . 8.2 mmp_? -57.78 -23.47 52.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 74.24 110.857 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 82.84 18.83 64.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.755 -0.736 . . . . 53.41 112.456 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.991 HG21 HD11 ' A' ' 109' ' ' ILE . 11.8 t -116.68 -179.88 3.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.846 0.355 . . . . 54.22 111.11 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -122.58 161.28 24.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 64.42 111.149 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.3 t -55.11 -47.3 77.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 74.5 111.117 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 40.4 m-20 -51.88 -30.03 22.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 73.15 110.812 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 47.0 t -80.83 -54.15 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 71.21 111.177 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.991 HD11 HG21 ' A' ' 104' ' ' THR . 51.2 mm -52.5 -41.79 37.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.148 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.06 -25.36 58.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 54.32 110.902 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.8 t -81.15 -21.46 39.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.214 -0.448 . . . . 62.4 110.843 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.2 mt -99.48 -44.52 6.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 53.0 110.915 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.37 68.58 5.37 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.602 0.715 . . . . 73.32 110.86 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -7.5 21.2 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.69 2.26 . . . . 72.55 112.35 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.26 -40.28 37.13 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 74.53 112.506 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.634 HG11 ' OE1' ' A' ' 125' ' ' GLN . 1.3 m -118.05 127.32 75.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.826 0.346 . . . . 54.3 111.122 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.1 m-20 -56.76 161.63 4.36 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.618 0.723 . . . . 72.2 110.92 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -8.16 22.89 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.686 2.257 . . . . 64.42 112.323 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.9 21.96 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 62.31 111.119 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -144.0 101.37 3.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 72.4 110.866 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.6 HD11 ' CD1' ' A' ' 95' ' ' PHE . 53.1 mt -139.3 150.85 45.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 62.13 110.926 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -117.86 150.61 38.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 70.15 110.883 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.423 HG23 ' HG3' ' A' ' 91' ' ' PRO . 12.6 p -51.77 148.22 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 73.32 111.121 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.36 66.53 2.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.732 -0.747 . . . . 74.13 112.448 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.634 ' OE1' HG11 ' A' ' 116' ' ' VAL . 7.6 tt0 -117.84 121.25 40.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.822 0.344 . . . . 61.51 110.927 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.95 125.01 42.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 73.21 111.158 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 pt -132.31 175.79 10.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 70.23 111.121 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.39 149.19 23.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 63.51 110.878 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.432 HG11 ' HD2' ' A' ' 102' ' ' ARG . 3.2 m -135.12 156.17 78.43 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.635 0.731 . . . . 54.32 111.15 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 110.66 2.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.679 2.253 . . . . 42.43 112.334 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 92.3 m . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 75.24 110.928 179.969 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 4.5 m . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.925 0.393 . . . . 74.13 110.84 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 76.5 p -126.19 154.89 42.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 72.32 111.137 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.4 ' HB2' HG11 ' A' ' 129' ' ' VAL . 47.8 t80 -132.37 136.66 46.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 73.45 110.929 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.3 m -92.87 125.58 37.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 65.02 111.147 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.12 110.0 21.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.262 -0.426 . . . . 70.21 111.122 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.487 ' HB2' ' HD2' ' A' ' 91' ' ' PRO . 0.5 OUTLIER -112.21 162.44 21.38 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.57 0.7 . . . . 74.53 110.935 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.505 ' HG3' HG23 ' A' ' 123' ' ' VAL . 74.5 Cg_exo -46.14 101.53 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.685 2.256 . . . . 72.23 112.379 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 121.37 2.5 10.8 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 51.21 112.496 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -105.24 113.95 27.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.897 0.38 . . . . 43.25 110.885 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.55 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -108.12 166.21 10.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 74.32 111.152 -179.885 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.657 ' HE2' HD21 ' A' ' 121' ' ' LEU . 1.3 m-85 -51.02 -46.13 61.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 52.44 110.902 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.35 -49.63 21.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 70.52 110.977 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.55 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -54.11 -27.94 36.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 52.13 111.114 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 42.9 mt -89.1 -41.47 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 53.35 111.16 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.429 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -57.1 -42.69 81.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 54.34 111.111 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -57.19 -45.02 84.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 63.24 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -65.6 -59.98 3.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 72.41 110.882 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.2 mmm180 -52.12 -29.87 23.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.138 -0.483 . . . . 74.24 110.876 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.58 13.53 29.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 61.14 112.474 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.9 t -115.35 -174.18 2.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.853 0.359 . . . . 73.4 111.128 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.92 163.47 16.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 72.12 111.172 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.7 t -54.55 -44.43 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.261 -0.427 . . . . 74.32 111.129 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -51.68 -33.61 34.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 75.11 110.829 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.9 t -80.57 -48.08 20.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 63.42 111.156 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.429 HG13 ' HB2' ' A' ' 99' ' ' ALA . 45.2 mm -51.19 -43.52 27.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 51.11 111.159 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -77.76 -25.48 49.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 75.04 110.934 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t -76.17 -23.53 54.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 75.45 110.805 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -99.16 -45.37 5.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 74.3 110.908 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.83 68.29 6.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.653 0.74 . . . . 71.21 110.852 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -8.17 22.93 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.656 2.237 . . . . 73.43 112.389 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.55 -43.39 52.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.69 -0.767 . . . . 61.43 112.53 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.551 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.1 m -116.42 163.04 13.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.884 0.373 . . . . 75.22 111.078 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -104.31 161.1 23.88 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.59 0.71 . . . . 75.14 110.864 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.71 -8.52 23.81 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.693 2.262 . . . . 60.42 112.372 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -128.76 12.02 6.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 61.2 111.124 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.9 mmt85 -143.77 49.67 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 74.55 110.863 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.657 HD21 ' HE2' ' A' ' 95' ' ' PHE . 22.9 mt -85.64 166.95 15.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.227 -0.442 . . . . 63.53 110.918 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -120.59 139.39 53.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 74.41 110.897 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.505 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.3 p -54.05 140.6 10.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 74.12 111.104 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.31 61.62 6.11 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.779 -0.724 . . . . 73.35 112.462 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -119.17 122.27 41.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.811 0.339 . . . . 72.44 110.882 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.1 p -84.43 134.61 26.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 73.3 111.106 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.8 pt -134.98 175.93 9.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 63.33 111.132 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -95.91 143.25 27.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 63.34 110.859 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.4 HG11 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -131.87 156.22 80.38 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.612 0.72 . . . . 52.24 111.12 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 86.58 0.58 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.652 2.235 . . . . 63.21 112.357 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.26 -0.427 . . . . 74.21 110.876 -179.999 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 73.4 m . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.928 0.394 . . . . 54.33 110.848 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 35.7 p -124.47 156.22 37.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 72.11 111.124 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.452 ' CE2' HD13 ' A' ' 98' ' ' ILE . 44.3 t80 -132.35 136.54 46.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.274 -0.421 . . . . 74.42 110.891 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -92.54 122.97 35.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 72.35 111.168 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 83.0 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 75.21 111.124 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.502 ' HB3' ' HD2' ' A' ' 91' ' ' PRO . 4.8 mm100 -112.29 162.45 21.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.58 0.705 . . . . 75.02 110.925 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.502 ' HD2' ' HB3' ' A' ' 90' ' ' GLN . 74.3 Cg_exo -47.28 101.22 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.663 2.242 . . . . 75.33 112.335 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 123.8 1.36 8.97 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.73 -0.748 . . . . 72.5 112.478 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -118.46 111.58 18.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.901 0.381 . . . . 64.1 110.872 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.53 159.84 14.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 74.43 111.151 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.416 ' CD1' HD11 ' A' ' 121' ' ' LEU . 1.3 m-85 -51.33 -44.13 61.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 70.51 110.854 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.19 -48.0 25.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.922 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.22 -28.03 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 71.22 111.112 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.452 HD13 ' CE2' ' A' ' 87' ' ' TYR . 32.6 mt -87.76 -45.38 16.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 72.41 111.107 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.478 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -53.97 -47.28 71.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 70.05 111.061 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -51.93 -44.96 64.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.199 -0.455 . . . . 73.03 110.914 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 77.4 mtp180 -68.78 -53.94 18.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.196 -0.456 . . . . 73.34 110.872 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -55.27 -26.29 39.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 72.32 110.897 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 101.91 16.27 24.17 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.727 -0.749 . . . . 73.42 112.491 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.793 HG21 HD11 ' A' ' 109' ' ' ILE . 10.1 t -120.29 -177.87 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.86 0.362 . . . . 63.33 111.129 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.64 165.09 19.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 52.31 111.145 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.715 HG12 HE21 ' A' ' 110' ' ' GLN . 91.7 t -55.16 -40.55 55.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 74.12 111.12 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -51.7 -40.13 59.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.01 110.884 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -77.35 -51.72 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 75.3 111.153 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.793 HD11 HG21 ' A' ' 104' ' ' THR . 50.5 mm -51.64 -44.43 34.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 53.4 111.129 179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.715 HE21 HG12 ' A' ' 106' ' ' VAL . 6.5 pt20 -72.86 -25.53 61.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 64.41 110.937 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t -79.98 -22.11 42.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 73.02 110.834 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 10.7 mt -98.12 -44.79 6.47 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 62.23 110.88 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.66 68.06 5.8 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.717 . . . . 73.35 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -7.13 20.26 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.669 2.246 . . . . 73.4 112.387 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.84 -40.19 33.73 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.723 -0.751 . . . . 75.22 112.473 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.505 HG11 HE22 ' A' ' 125' ' ' GLN . 1.5 m -118.29 127.96 75.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.795 0.331 . . . . 55.4 111.142 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -56.61 161.25 4.54 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.623 0.725 . . . . 63.3 110.913 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -8.47 23.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.644 2.229 . . . . 75.33 112.352 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.1 23.21 5.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 75.22 111.119 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.3 mmt180 -146.47 102.52 3.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.453 . . . . 72.41 110.838 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.469 HD23 ' HB ' ' A' ' 116' ' ' VAL . 67.2 mt -136.51 175.59 9.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 74.42 110.867 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -140.72 147.77 39.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.475 . . . . 72.22 110.913 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.406 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.5 p -52.35 147.57 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 71.31 111.094 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.63 65.2 3.32 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.697 -0.763 . . . . 55.33 112.538 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.505 HE22 HG11 ' A' ' 116' ' ' VAL . 15.2 tt0 -119.14 120.69 37.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.826 0.346 . . . . 72.44 110.925 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.36 125.11 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 42.15 111.122 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.3 pt -129.22 175.87 9.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 74.43 111.128 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -98.84 137.98 36.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 75.14 110.869 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -123.91 156.23 65.91 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.618 0.723 . . . . 62.24 111.144 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 110.52 2.59 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.698 2.265 . . . . 70.44 112.337 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.205 -0.452 . . . . 73.41 110.878 -179.954 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.9 0.381 . . . . 72.15 110.903 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.5 p -123.37 161.83 23.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 71.15 111.149 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.65 ' HB2' HG21 ' A' ' 129' ' ' VAL . 36.2 t80 -127.32 136.79 52.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 71.24 110.925 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 55.3 m -88.68 122.88 32.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.098 -0.501 . . . . 32.0 111.144 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.2 mt -90.83 109.52 21.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 64.31 111.153 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.483 ' HB2' ' HD2' ' A' ' 91' ' ' PRO . 0.1 OUTLIER -111.32 162.65 19.97 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.568 0.699 . . . . 71.15 110.948 179.94 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.483 ' HD2' ' HB2' ' A' ' 90' ' ' GLN . 74.0 Cg_exo -46.78 101.27 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.696 2.264 . . . . 64.51 112.337 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 125.95 -1.99 7.9 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 54.15 112.455 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.42 ' HB3' HD11 ' A' ' 98' ' ' ILE . 13.5 m-20 -105.77 129.39 53.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 74.25 110.87 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.504 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -118.06 164.5 15.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 72.21 111.128 -179.886 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.662 ' CE1' HD21 ' A' ' 121' ' ' LEU . 0.8 OUTLIER -50.94 -48.28 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 74.24 110.875 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.08 -49.01 25.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 74.35 110.944 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.504 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -53.81 -27.17 27.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.11 111.124 179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.42 HD11 ' HB3' ' A' ' 93' ' ' ASP . 39.1 mt -91.26 -39.41 11.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 74.21 111.131 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.553 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -58.3 -41.04 83.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.149 -0.478 . . . . 52.52 111.092 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -57.13 -44.55 83.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.439 . . . . 72.01 110.905 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -69.26 -25.96 64.54 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 73.34 110.852 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . 0.41 ' HB2' HG22 ' A' ' 104' ' ' THR . 3.0 mmp_? -94.39 17.99 11.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 71.02 110.888 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.83 27.76 21.6 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.699 -0.762 . . . . 71.33 112.538 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.686 HG21 HD11 ' A' ' 109' ' ' ILE . 8.5 t -126.73 -177.22 3.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.916 0.389 . . . . 72.23 111.116 -179.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.439 HG22 ' H ' ' A' ' 106' ' ' VAL . 0.2 OUTLIER -125.41 167.88 14.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 61.44 111.123 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.717 HG12 HE21 ' A' ' 110' ' ' GLN . 45.9 t -56.47 -38.98 58.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 74.34 111.167 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 68.5 m-20 -51.71 -38.56 55.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 73.01 110.855 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -81.05 -50.64 16.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 64.15 111.108 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.686 HD11 HG21 ' A' ' 104' ' ' THR . 49.7 mm -51.29 -41.02 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 72.1 111.125 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.717 HE21 HG12 ' A' ' 106' ' ' VAL . 6.2 pt20 -78.58 -25.57 45.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 74.22 110.928 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 10.3 t -76.38 -24.13 54.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 75.31 110.839 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.1 mt -98.48 -44.67 6.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 64.14 110.903 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.97 67.96 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.637 0.732 . . . . 73.5 110.907 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.72 21.77 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.66 2.24 . . . . 73.23 112.36 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.78 -44.33 48.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.764 -0.731 . . . . 54.22 112.48 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.708 ' HB ' HD23 ' A' ' 121' ' ' LEU . 1.6 m -118.82 161.06 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.829 0.347 . . . . 74.42 111.121 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -108.34 160.96 25.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.634 0.731 . . . . 71.43 110.854 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -8.22 23.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.682 2.255 . . . . 73.24 112.362 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.21 -21.63 13.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 75.1 111.109 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 6.5 ptp180 -134.87 96.22 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 74.24 110.929 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.708 HD23 ' HB ' ' A' ' 116' ' ' VAL . 89.5 mt -117.55 161.81 19.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.181 -0.463 . . . . 71.55 110.903 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -107.67 148.81 28.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 74.54 110.932 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.457 HG23 ' HG3' ' A' ' 91' ' ' PRO . 14.0 p -68.89 143.75 14.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 74.23 111.118 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.2 60.85 6.75 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.715 -0.755 . . . . 74.22 112.496 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.582 HE22 HG11 ' A' ' 116' ' ' VAL . 11.0 tt0 -119.21 121.18 39.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.824 0.345 . . . . 64.33 110.97 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 26.2 t -88.92 132.27 34.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 74.3 111.134 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 2.4 pt -134.04 175.97 9.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.459 . . . . 73.45 111.132 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 60.0 m-20 -92.51 136.56 33.11 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.457 . . . . 70.51 110.907 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.65 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.4 m -143.76 155.99 59.5 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.547 0.689 . . . . 45.21 111.15 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.83 110.53 2.59 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.65 2.233 . . . . 74.41 112.308 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 73.35 110.873 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.2 m . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.877 0.37 . . . . 61.34 110.931 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 22.2 p -129.65 150.31 51.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 71.5 111.127 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -122.4 136.63 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.159 -0.473 . . . . 72.44 110.897 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -89.25 122.1 32.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 65.43 111.102 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.402 HG23 ' HB2' ' A' ' 93' ' ' ASP . 69.7 mt -91.03 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 60.22 111.137 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.61 163.55 16.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.6 0.715 . . . . 75.25 110.945 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.473 ' HG3' HG23 ' A' ' 123' ' ' VAL . 54.2 Cg_exo -45.86 105.15 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.636 2.224 . . . . 74.32 112.374 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 118.65 1.11 15.43 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.726 -0.75 . . . . 52.33 112.491 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.402 ' HB2' HG23 ' A' ' 89' ' ' ILE . 15.2 m-20 -105.09 144.2 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.908 0.385 . . . . 64.23 110.851 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.07 158.78 43.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 72.41 111.166 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.602 ' CE1' HD21 ' A' ' 121' ' ' LEU . 1.6 m-85 -50.9 -47.92 60.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 72.45 110.858 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -72.97 -47.68 43.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 73.55 110.918 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -55.6 -26.56 44.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 53.03 111.114 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 21.1 mt -90.91 -38.78 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 65.12 111.158 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 104' ' ' THR . . . -61.53 -40.4 94.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 72.24 111.086 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -56.38 -44.69 80.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 74.44 110.896 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 -75.52 -49.38 18.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.451 . . . . 65.21 110.837 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 21.5 mmm180 -56.98 -24.39 52.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 75.14 110.852 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.19 23.64 37.01 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 50.02 112.478 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.993 HG21 HD11 ' A' ' 109' ' ' ILE . 6.6 t -114.76 -171.66 1.97 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 74.4 111.149 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.15 149.13 43.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.217 -0.447 . . . . 72.43 111.111 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 83.4 t -55.5 -46.91 79.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 62.13 111.12 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -51.85 -30.69 24.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 74.42 110.826 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 72.7 t -80.08 -54.09 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 72.32 111.154 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.993 HD11 HG21 ' A' ' 104' ' ' THR . 41.3 mm -52.57 -42.51 40.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.166 -0.47 . . . . 74.23 111.187 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.83 -25.48 59.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.108 -0.496 . . . . 73.25 110.894 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t -79.23 -22.95 44.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 53.34 110.88 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 11.9 mt -96.5 -45.54 6.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 73.14 110.919 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.72 67.86 5.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.608 0.718 . . . . 72.11 110.924 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -7.36 20.84 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.656 2.237 . . . . 75.13 112.35 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.1 -39.48 34.29 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.778 -0.725 . . . . 53.22 112.46 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.667 ' HB ' HD23 ' A' ' 121' ' ' LEU . 0.5 OUTLIER -121.76 163.02 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.844 0.354 . . . . 74.11 111.14 -179.953 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 33.0 m-20 -102.99 161.21 23.8 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.615 0.722 . . . . 73.15 110.877 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.67 26.68 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.685 2.256 . . . . 73.34 112.319 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -117.44 -18.83 9.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.25 -0.432 . . . . 70.35 111.124 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -122.04 90.0 3.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 63.43 110.891 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.667 HD23 ' HB ' ' A' ' 116' ' ' VAL . 73.0 mt -119.39 160.38 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 71.15 110.92 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -105.49 148.55 27.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 72.33 110.919 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.473 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.2 p -61.7 139.45 20.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 74.12 111.186 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.78 62.49 5.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 63.12 112.503 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -119.28 121.9 40.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.83 0.348 . . . . 73.44 110.916 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 11.3 p -86.45 134.68 26.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 74.05 111.144 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 1.3 pp -129.45 172.76 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 72.43 111.08 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -100.33 142.95 31.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 63.02 110.9 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -136.09 156.2 77.11 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.594 0.711 . . . . 74.24 111.126 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 110.11 2.48 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.679 2.253 . . . . 71.31 112.363 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 98.9 m . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 64.5 110.905 179.992 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 71.2 m . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.885 0.374 . . . . 62.54 110.869 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 44.8 p -124.96 150.26 46.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 72.32 111.153 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.503 ' CE2' HD13 ' A' ' 98' ' ' ILE . 42.1 t80 -122.48 136.68 54.94 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.212 -0.449 . . . . 74.11 110.932 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 m -91.41 120.19 32.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 74.54 111.109 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.4 mt -90.85 109.59 21.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.45 . . . . 64.35 111.132 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 22.9 mm-40 -97.29 159.45 31.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.612 0.72 . . . . 63.44 110.893 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.81 93.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.698 2.265 . . . . 75.13 112.358 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.48 -17.46 2.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 61.3 112.514 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.92 167.26 16.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.913 0.387 . . . . 51.23 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.2 151.77 45.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.192 -0.458 . . . . 73.13 111.154 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . 0.521 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.3 m-85 -51.03 -47.38 61.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.251 -0.431 . . . . 75.23 110.885 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -71.6 -47.16 56.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 73.13 110.895 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.73 -23.88 54.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 72.54 111.068 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.503 HD13 ' CE2' ' A' ' 87' ' ' TYR . 35.2 mt -95.46 -31.99 4.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.445 . . . . 74.22 111.129 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.603 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -72.18 -29.5 64.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 72.12 111.123 179.793 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 1.5 pp0? -65.7 -44.46 86.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.929 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.5 -13.73 53.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 70.4 110.908 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -93.03 16.56 12.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 74.33 110.922 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.63 28.1 21.12 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 52.02 112.494 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 1.018 HG21 HD11 ' A' ' 109' ' ' ILE . 11.8 t -129.0 -179.96 5.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.842 0.353 . . . . 73.02 111.152 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -123.28 159.77 28.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 54.45 111.152 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.68 HG12 HE21 ' A' ' 110' ' ' GLN . 52.6 t -55.07 -42.38 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 72.04 111.106 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -51.85 -38.09 54.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 65.13 110.828 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.448 HG12 HD12 ' A' ' 112' ' ' LEU . 21.5 t -77.2 -54.19 13.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 53.22 111.132 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 1.018 HD11 HG21 ' A' ' 104' ' ' THR . 50.2 mm -51.42 -39.95 23.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 41.01 111.108 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.68 HE21 HG12 ' A' ' 106' ' ' VAL . 2.8 pt20 -77.98 -25.56 48.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 72.12 110.9 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -76.92 -24.05 52.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 53.01 110.888 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.448 HD12 HG12 ' A' ' 108' ' ' VAL . 7.3 mt -95.18 -45.3 7.25 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.921 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.06 67.57 6.42 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.742 . . . . 60.23 110.906 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -6.96 19.86 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.693 2.262 . . . . 75.15 112.379 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.63 -39.9 31.56 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 62.0 112.484 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.622 HG11 HE22 ' A' ' 125' ' ' GLN . 2.1 m -118.95 160.83 18.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.827 0.346 . . . . 42.55 111.142 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -99.63 160.56 27.07 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.622 0.725 . . . . 62.32 110.888 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -22.78 31.61 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.749 2.3 . . . . 75.22 112.312 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.4 24.33 11.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 64.54 111.094 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 14.5 ptm180 -177.33 111.56 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 73.32 110.873 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 86.1 mt -127.66 -179.59 5.01 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.176 -0.466 . . . . 63.43 110.926 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -124.16 147.56 47.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 74.02 110.928 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 14.6 p -62.85 139.99 20.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 63.45 111.167 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.67 65.14 3.37 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 44.24 112.475 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . 0.622 HE22 HG11 ' A' ' 116' ' ' VAL . 8.8 tt0 -113.69 127.72 56.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.787 0.327 . . . . 73.15 110.933 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 17.6 t -91.51 122.77 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 75.32 111.09 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.1 pt -127.84 175.84 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 72.42 111.089 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -110.87 143.36 41.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 74.32 110.919 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.93 156.23 79.38 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.631 0.729 . . . . 32.1 111.121 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 110.77 2.64 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.696 2.264 . . . . 51.25 112.334 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 73.31 110.884 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 26.0 m . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.858 0.361 . . . . 63.51 110.879 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.7 p -124.85 167.72 14.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 73.53 111.128 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.5 ' CE2' HD13 ' A' ' 98' ' ' ILE . 41.8 t80 -139.49 136.38 34.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 63.11 110.877 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.482 HG23 HG22 ' A' ' 126' ' ' VAL . 2.1 m -90.89 121.18 32.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.119 -0.491 . . . . 71.44 111.128 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.453 HD11 HG12 ' A' ' 127' ' ' ILE . 64.4 mt -91.04 109.29 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 73.34 111.09 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -110.39 162.86 18.82 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 63.23 110.911 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -45.89 118.77 2.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.711 2.274 . . . . 73.12 112.35 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 108.32 -23.83 23.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.797 -0.716 . . . . 54.22 112.529 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -86.67 121.98 29.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.868 0.366 . . . . 75.44 110.877 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.87 156.16 19.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 74.35 111.134 -179.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -51.61 -45.25 63.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 73.1 110.863 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -70.46 -51.4 29.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 73.12 110.9 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.63 -31.86 58.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 61.22 111.133 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.5 HD13 ' CE2' ' A' ' 87' ' ' TYR . 34.5 mt -84.04 -35.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 53.3 111.126 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.453 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -63.15 -48.32 78.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 74.14 111.133 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -52.99 -44.93 67.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.91 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 6.8 ptp85 -78.62 -18.05 55.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 70.34 110.898 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -94.11 19.74 8.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.189 -0.459 . . . . 71.14 110.923 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.78 28.12 22.32 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.735 -0.745 . . . . 73.0 112.478 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.888 HG21 HD11 ' A' ' 109' ' ' ILE . 14.5 t -134.45 174.72 10.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.844 0.354 . . . . 63.14 111.167 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.58 164.62 15.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.03 111.172 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.713 HG12 HE21 ' A' ' 110' ' ' GLN . 22.6 t -57.41 -41.44 78.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.02 111.166 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -51.82 -34.42 40.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.862 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.79 -51.72 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 62.04 111.079 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.888 HD11 HG21 ' A' ' 104' ' ' THR . 49.0 mm -51.75 -41.71 29.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.236 -0.438 . . . . 64.32 111.135 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.713 HE21 HG12 ' A' ' 106' ' ' VAL . 6.2 pt20 -78.32 -25.53 46.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 71.34 110.928 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -78.69 -20.92 49.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 74.33 110.874 -179.785 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 21.0 mt -98.29 -45.49 6.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.486 . . . . 53.4 110.896 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -118.45 67.91 7.4 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.635 0.731 . . . . 75.14 110.9 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -8.53 23.83 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.717 2.278 . . . . 74.41 112.302 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.77 -26.33 62.58 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.757 -0.735 . . . . 21.21 112.454 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.691 HG12 HD23 ' A' ' 121' ' ' LEU . 1.5 t -121.4 92.53 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.788 0.327 . . . . 71.54 111.151 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -51.8 159.13 1.42 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.617 0.723 . . . . 72.21 110.856 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -29.98 22.92 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.666 2.244 . . . . 65.42 112.326 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -95.13 31.99 1.8 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 52.51 111.059 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 179.88 93.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 75.53 110.865 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.691 HD23 HG12 ' A' ' 116' ' ' VAL . 45.5 mt -116.2 144.58 44.0 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 74.12 110.911 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -98.59 153.31 18.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 43.52 110.92 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.71 144.06 12.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 74.02 111.121 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.51 59.02 8.92 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.739 . . . . 51.32 112.443 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -119.26 122.64 42.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.834 0.349 . . . . 64.31 110.915 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.482 HG22 HG23 ' A' ' 88' ' ' THR . 33.6 t -88.52 127.05 41.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 73.21 111.127 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.453 HG12 HD11 ' A' ' 89' ' ' ILE . 3.2 pt -123.54 175.91 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.172 -0.467 . . . . 72.12 111.15 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 6.0 m-20 -94.55 145.46 24.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.186 -0.461 . . . . 51.23 110.91 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.94 156.1 78.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.638 0.732 . . . . 63.13 111.108 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 110.64 2.61 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.733 2.288 . . . . 72.13 112.314 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 46.6 m . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 64.15 110.869 179.993 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 3.9 m . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.888 0.375 . . . . 71.3 110.871 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.4 p -123.55 154.67 38.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 53.31 111.148 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.524 ' HB2' HG21 ' A' ' 129' ' ' VAL . 38.6 t80 -133.5 134.99 44.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 75.34 110.926 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.6 125.98 35.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 63.23 111.175 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.8 mt -90.9 109.38 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 51.12 111.157 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 49.5 mm-40 -110.92 161.94 22.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.623 0.725 . . . . 74.44 110.89 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -45.98 121.45 4.34 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.721 2.281 . . . . 61.32 112.328 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.19 34.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.732 -0.747 . . . . 72.41 112.418 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -95.79 121.03 37.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.844 0.354 . . . . 74.14 110.845 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.0 165.33 11.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 65.53 111.123 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -53.98 -60.8 2.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 73.01 110.866 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -56.57 -52.47 64.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.152 -0.477 . . . . 74.4 110.906 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.42 -62.42 1.63 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.449 . . . . 73.41 111.13 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 34.3 mt -51.5 -38.15 20.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 71.44 111.138 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.446 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -64.28 -37.19 86.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 54.11 111.115 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -51.91 -72.11 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 72.25 110.928 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 10.0 ptt-85 -55.87 -40.47 72.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 72.42 110.858 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.8 mmp_? -57.9 -24.04 55.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.171 -0.468 . . . . 73.34 110.885 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 54.31 112.473 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.843 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -120.99 178.87 4.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 73.32 111.15 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -119.82 162.93 18.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 64.34 111.181 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 23.9 t -56.68 -40.32 69.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.24 -0.436 . . . . 71.01 111.155 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -51.76 -36.24 46.61 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 52.34 110.836 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.59 HG12 HD12 ' A' ' 112' ' ' LEU . 25.7 t -81.96 -50.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 63.51 111.141 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.843 HD11 HG21 ' A' ' 104' ' ' THR . 47.7 mm -51.95 -41.12 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.149 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -79.14 -25.39 42.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 55.34 110.93 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 t -79.44 -20.14 48.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 75.43 110.872 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.59 HD12 HG12 ' A' ' 108' ' ' VAL . 8.5 mt -98.38 -45.72 6.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 50.34 110.927 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.95 68.05 6.41 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.563 0.697 . . . . 73.23 110.891 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -8.54 23.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.69 2.26 . . . . 73.52 112.346 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.41 -23.89 67.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.757 . . . . 61.4 112.518 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.542 HG12 ' CD2' ' A' ' 121' ' ' LEU . 2.2 t -122.45 104.74 15.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 60.54 111.11 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -75.09 154.68 86.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.61 0.719 . . . . 55.42 110.909 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -13.76 35.14 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.678 2.252 . . . . 75.15 112.338 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -71.29 -18.9 62.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 65.33 111.092 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -170.61 115.23 0.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 74.51 110.887 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.542 ' CD2' HG12 ' A' ' 116' ' ' VAL . 55.4 mt -108.2 153.45 23.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 61.01 110.882 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 53.8 mm-40 -97.84 148.78 23.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 65.51 110.942 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.9 145.03 11.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 71.42 111.156 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.33 58.13 10.42 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 72.13 112.479 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -119.33 120.69 37.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.818 0.342 . . . . 72.45 110.877 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 6.4 p -85.06 130.88 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 43.51 111.183 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.2 pt -131.06 175.85 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 64.35 111.162 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 39.3 m-20 -89.94 145.62 24.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.463 . . . . 73.42 110.842 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.524 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -147.67 156.15 45.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.627 0.727 . . . . 54.35 111.094 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.649 2.233 . . . . 75.21 112.309 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 61.54 110.895 179.955 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 2.4 m . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.919 0.39 . . . . 52.14 110.903 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 71.9 p -123.67 151.47 43.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 74.32 111.11 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -138.25 136.52 36.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.215 -0.448 . . . . 72.32 110.927 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.739 HG23 HG22 ' A' ' 126' ' ' VAL . 1.4 m -92.65 126.44 37.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 50.14 111.166 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.89 109.44 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 64.43 111.121 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.0 mm-40 -110.36 162.06 22.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.642 0.734 . . . . 73.03 110.906 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -45.93 118.39 2.31 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 73.41 112.355 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.62 -18.88 29.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.73 -0.748 . . . . 74.44 112.51 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.506 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.5 m-20 -96.87 115.68 27.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 73.13 110.865 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.92 159.78 15.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.189 -0.46 . . . . 73.51 111.122 -179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -53.66 -55.03 29.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 65.12 110.859 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.2 t-105 -57.96 -56.21 24.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.137 -0.483 . . . . 73.52 110.875 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.36 -60.6 2.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.26 -0.427 . . . . 61.52 111.103 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ILE . . . . . 0.506 HD11 ' CB ' ' A' ' 93' ' ' ASP . 33.0 mt -51.62 -37.86 20.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 73.55 111.137 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.429 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -65.7 -37.46 86.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.176 -0.465 . . . . 43.03 111.126 179.798 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -51.81 -65.15 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 75.33 110.915 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.2 mtt180 -63.32 -41.27 98.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 72.24 110.945 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.6 mmp_? -55.87 -25.7 43.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 73.24 110.816 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.76 17.41 51.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 60.12 112.494 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.967 HG21 HD11 ' A' ' 109' ' ' ILE . 11.5 t -119.37 179.9 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.856 0.36 . . . . 74.42 111.148 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.18 157.77 28.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 63.04 111.153 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.711 HG12 HE21 ' A' ' 110' ' ' GLN . 26.3 t -55.48 -42.83 69.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 64.31 111.131 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -51.84 -36.31 47.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.87 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -78.83 -53.6 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 61.03 111.127 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ILE . . . . . 0.967 HD11 HG21 ' A' ' 104' ' ' THR . 44.8 mm -51.66 -40.58 26.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 73.55 111.173 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.711 HE21 HG12 ' A' ' 106' ' ' VAL . 2.8 pt20 -77.75 -25.42 49.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 65.44 110.931 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.5 t -80.38 -20.35 44.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 73.14 110.835 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.1 mt -98.35 -45.53 6.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 71.44 110.872 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.96 68.17 6.48 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.641 0.734 . . . . 73.14 110.883 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -8.5 23.77 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.694 2.263 . . . . 70.54 112.33 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.04 -22.92 58.73 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.793 -0.718 . . . . 63.11 112.461 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.517 HG12 HD23 ' A' ' 121' ' ' LEU . 2.1 t -121.89 107.91 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.86 0.362 . . . . 61.01 111.096 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.55 155.0 81.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.636 0.732 . . . . 43.32 110.876 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.79 -16.72 37.55 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.707 2.272 . . . . 72.13 112.313 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -68.65 -19.44 64.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.261 -0.427 . . . . 41.33 111.13 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.3 ptt180 -173.48 116.63 0.26 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 52.24 110.899 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.517 HD23 HG12 ' A' ' 116' ' ' VAL . 61.7 mt -103.46 154.6 19.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 60.24 110.91 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 -97.77 143.12 28.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 55.42 110.957 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.51 145.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 50.2 111.133 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.28 59.1 8.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 72.32 112.495 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -119.3 121.57 39.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 73.44 110.909 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' VAL . . . . . 0.739 HG22 HG23 ' A' ' 88' ' ' THR . 22.4 t -85.27 127.11 40.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 71.13 111.141 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 10.0 pt -123.5 174.32 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 61.0 111.132 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -96.89 144.28 26.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.156 -0.475 . . . . 72.41 110.937 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.25 156.19 79.75 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.641 0.734 . . . . 73.11 111.108 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 85.47 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.658 2.239 . . . . 42.11 112.377 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.147 -0.479 . . . . 65.15 110.924 -179.981 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 15.7 mmt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.791 0.329 . . . . 72.45 110.871 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -101.89 -160.09 26.59 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 71.11 112.501 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 5.3 m -145.96 166.06 27.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.932 0.396 . . . . 63.21 110.881 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 41.3 p -123.55 168.08 13.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 53.11 111.14 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.42 ' HB2' HG21 ' A' ' 129' ' ' VAL . 45.8 t80 -145.23 136.38 24.89 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.246 -0.434 . . . . 72.13 110.968 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.6 m -91.73 123.09 34.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.108 -0.496 . . . . 75.43 111.116 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 60.6 mt -90.89 109.49 21.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.453 . . . . 74.31 111.152 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.6 mt-30 -111.24 163.51 17.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.617 0.722 . . . . 73.03 110.93 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_exo -46.16 124.58 7.71 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.718 2.278 . . . . 75.44 112.333 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 106.54 -17.96 38.86 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.777 -0.725 . . . . 65.03 112.483 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -97.31 147.03 24.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.908 0.385 . . . . 75.41 110.833 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.96 174.36 10.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 40.34 111.121 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.518 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.3 m-85 -54.51 -70.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 75.24 110.905 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.92 -50.07 61.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.16 -0.473 . . . . 74.33 110.924 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.03 -66.29 0.41 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.264 -0.425 . . . . 71.34 111.11 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 43.9 mt -51.37 -32.68 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.456 . . . . 75.43 111.077 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -66.73 -38.46 86.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 65.44 111.147 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -52.32 -69.42 0.11 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 74.04 110.882 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 9.6 ptm180 -56.28 -44.48 79.85 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 75.31 110.855 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -56.35 -25.03 47.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 74.34 110.841 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.82 16.55 56.21 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.736 -0.745 . . . . 70.04 112.463 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.683 HG21 HD11 ' A' ' 109' ' ' ILE . 7.7 t -119.84 -176.1 3.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.897 0.38 . . . . 54.34 111.103 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.402 HG22 ' H ' ' A' ' 106' ' ' VAL . 0.3 OUTLIER -125.27 165.97 17.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 75.05 111.14 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.733 HG12 HE21 ' A' ' 110' ' ' GLN . 61.3 t -55.78 -41.12 64.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.229 -0.441 . . . . 72.41 111.175 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -51.79 -36.03 46.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 73.41 110.856 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.21 -51.5 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 73.24 111.103 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.683 HD11 HG21 ' A' ' 104' ' ' THR . 49.7 mm -51.25 -42.45 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 74.12 111.166 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.733 HE21 HG12 ' A' ' 106' ' ' VAL . 7.1 pt20 -78.18 -25.4 47.13 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 74.24 110.909 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.7 t -78.05 -21.07 51.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 74.41 110.864 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 43.3 mt -97.05 -46.16 6.29 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.151 -0.477 . . . . 73.24 110.921 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -117.96 68.15 6.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.596 0.712 . . . . 63.42 110.878 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 -8.51 23.78 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.657 2.238 . . . . 71.54 112.314 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -67.23 -17.59 68.34 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.733 -0.746 . . . . 64.12 112.523 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.551 HG21 ' OE1' ' A' ' 125' ' ' GLN . 2.2 t -131.14 119.67 44.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.909 0.385 . . . . 65.0 111.098 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -88.77 154.86 50.51 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.599 0.714 . . . . 74.5 110.902 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -19.63 35.73 Favored 'Trans proline' 0 C--O 1.231 0.131 0 C-N-CA 122.725 2.283 . . . . 74.44 112.327 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -63.79 -15.98 60.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 63.13 111.112 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -170.56 115.33 0.47 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 74.43 110.852 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.518 HD11 ' CD2' ' A' ' 95' ' ' PHE . 47.0 mt -117.34 150.79 38.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.47 . . . . 72.14 110.933 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.0 mm100 -97.77 149.5 22.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 74.0 110.911 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.3 p -68.35 146.61 12.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 63.11 111.137 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.8 63.73 4.51 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.712 -0.756 . . . . 63.32 112.514 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.551 ' OE1' HG21 ' A' ' 116' ' ' VAL . 13.5 tt0 -119.14 121.62 40.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.826 0.346 . . . . 71.44 110.907 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.3 t -87.54 124.53 40.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 41.52 111.121 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.6 pt -127.83 175.93 8.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 71.33 111.148 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 -96.05 144.07 26.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 74.1 110.9 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.42 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -141.26 156.15 67.68 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.624 0.726 . . . . 73.45 111.085 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 105.52 1.5 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.675 2.25 . . . . 74.52 112.346 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.2 t . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 74.42 110.873 -179.972 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 7.9 mtp . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.819 0.342 . . . . 74.01 110.9 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 129.21 -126.56 5.24 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.752 -0.737 . . . . 41.52 112.514 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.1 m -129.85 136.68 49.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.892 0.377 . . . . 65.42 110.876 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.5 p -126.43 161.52 27.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 74.22 111.148 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.428 ' CE1' HD13 ' A' ' 98' ' ' ILE . 45.2 t80 -142.85 136.63 28.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 74.44 110.918 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 m -93.44 124.03 37.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.108 -0.496 . . . . 63.5 111.124 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.8 mt -91.05 109.58 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.181 -0.463 . . . . 65.11 111.116 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.9 mt-30 -111.58 163.52 17.3 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.579 0.704 . . . . 63.41 110.926 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_exo -46.16 120.95 4.01 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.712 2.274 . . . . 70.31 112.336 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 110.6 -18.86 26.86 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.759 . . . . 43.12 112.478 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.565 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.4 m-20 -99.04 140.94 32.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.896 0.379 . . . . 63.44 110.852 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.77 163.8 24.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 44.51 111.134 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.416 ' CE1' HG22 ' A' ' 109' ' ' ILE . 1.3 m-85 -54.99 -64.57 0.79 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 73.51 110.865 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -56.2 -50.67 70.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.166 -0.47 . . . . 74.11 110.919 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.65 -65.01 0.63 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 55.33 111.049 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.565 HD11 ' CB ' ' A' ' 93' ' ' ASP . 36.3 mt -51.73 -37.0 19.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.257 -0.429 . . . . 70.15 111.118 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.402 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -64.13 -36.1 82.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.206 -0.452 . . . . 73.44 111.085 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.9 mt-30 -51.82 -63.75 1.03 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 75.45 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 47.9 mtm180 -67.1 -39.38 86.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 73.41 110.89 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . 0.558 ' HG3' HG22 ' A' ' 98' ' ' ILE . 8.5 mmp_? -56.41 -25.14 49.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 72.15 110.904 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 92.23 17.15 47.82 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 75.51 112.517 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.949 HG21 HD11 ' A' ' 109' ' ' ILE . 13.4 t -125.21 177.3 6.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.87 0.367 . . . . 73.5 111.13 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.401 HG22 ' H ' ' A' ' 106' ' ' VAL . 1.1 m -125.43 164.68 19.91 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 71.52 111.104 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.657 HG12 HE21 ' A' ' 110' ' ' GLN . 58.9 t -54.68 -40.88 53.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.198 -0.455 . . . . 70.12 111.094 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . 0.617 ' OD2' HG23 ' A' ' 108' ' ' VAL . 0.6 OUTLIER -51.67 -38.51 55.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.196 -0.456 . . . . 75.44 110.877 179.884 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.617 HG23 ' OD2' ' A' ' 107' ' ' ASP . 24.9 t -78.94 -52.33 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 75.31 111.142 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.949 HD11 HG21 ' A' ' 104' ' ' THR . 47.7 mm -52.2 -41.1 32.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 61.04 111.179 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.657 HE21 HG12 ' A' ' 106' ' ' VAL . 6.5 pt20 -75.66 -25.51 56.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.155 -0.475 . . . . 61.22 110.905 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.3 t -79.41 -23.47 43.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 43.44 110.863 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.7 mt -98.92 -44.65 6.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 75.44 110.897 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -117.67 68.29 5.91 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.625 0.726 . . . . 64.44 110.874 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -7.3 20.72 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.625 2.216 . . . . 74.53 112.366 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.34 -43.75 43.84 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.747 -0.739 . . . . 43.53 112.518 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.517 HG11 HE22 ' A' ' 125' ' ' GLN . 2.4 m -116.46 127.24 74.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.802 0.334 . . . . 54.11 111.151 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -55.92 160.87 3.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.619 0.723 . . . . 63.21 110.917 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.73 24.35 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.7 2.266 . . . . 75.33 112.348 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -133.07 24.39 4.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.34 111.102 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 67.9 mtp85 -149.73 89.48 1.62 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 74.43 110.86 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.487 HD23 ' HB ' ' A' ' 116' ' ' VAL . 9.9 mt -125.16 176.23 6.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 74.12 110.943 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 24.3 mm100 -136.38 150.4 48.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.889 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.1 p -54.37 146.45 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 60.4 111.188 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.02 65.01 3.5 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.73 -0.747 . . . . 44.33 112.509 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.517 HE22 HG11 ' A' ' 116' ' ' VAL . 13.6 tt0 -119.12 122.01 41.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.816 0.341 . . . . 75.53 110.941 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.4 p -87.43 135.04 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 75.22 111.141 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.0 pt -140.74 175.82 5.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 75.43 111.163 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 10.0 m-20 -103.19 143.06 33.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 74.22 110.894 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.2 156.14 66.99 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 74.4 111.151 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 110.54 2.59 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.657 2.238 . . . . 73.05 112.351 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 70.3 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 61.3 110.894 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 10.8 mtt . . . . . 0 N--CA 1.458 -0.074 0 CA-C-O 120.78 0.324 . . . . 65.35 110.899 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 175.47 -144.56 7.28 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.722 -0.752 . . . . 71.25 112.496 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 81.8 m -113.68 141.18 47.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.943 0.401 . . . . 75.02 110.843 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.6 p -125.55 163.47 22.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 63.1 111.201 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.434 ' CE1' HD13 ' A' ' 98' ' ' ILE . 42.2 t80 -142.85 136.56 28.85 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.256 -0.429 . . . . 71.11 110.933 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -93.61 123.66 37.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.123 -0.489 . . . . 63.31 111.15 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.422 HD12 ' HB3' ' A' ' 125' ' ' GLN . 74.8 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 75.41 111.127 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.1 mm-40 -109.28 163.15 17.69 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.56 0.695 . . . . 73.15 110.896 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -46.17 124.8 7.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 64.31 112.321 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 105.75 -18.88 39.85 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.724 -0.751 . . . . 63.2 112.464 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -96.83 141.39 30.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.886 0.374 . . . . 74.43 110.875 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -129.73 170.26 14.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 73.25 111.164 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.52 ' HZ ' HG23 ' A' ' 116' ' ' VAL . 1.3 m-85 -54.39 -69.53 0.12 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 54.23 110.886 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.1 t-105 -52.3 -49.93 63.2 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.103 -0.499 . . . . 73.24 110.939 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.31 -65.7 0.51 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.238 -0.437 . . . . 71.4 111.076 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.434 HD13 ' CE1' ' A' ' 87' ' ' TYR . 46.8 mt -51.77 -37.09 19.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.264 -0.426 . . . . 71.32 111.14 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -63.64 -35.87 81.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 72.54 111.123 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -51.78 -68.18 0.19 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 72.01 110.909 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 46.6 mtt180 -61.71 -41.99 98.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.247 -0.433 . . . . 74.21 110.837 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.1 mmm180 -54.68 -27.1 37.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 64.12 110.893 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.4 18.09 50.41 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.699 -0.762 . . . . 50.33 112.451 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.977 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -119.36 178.39 4.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.866 0.365 . . . . 65.4 111.142 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -120.97 160.68 23.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 72.41 111.177 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 58.0 t -54.37 -47.17 69.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 51.31 111.172 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -52.24 -29.71 24.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 54.32 110.844 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.553 HG12 HD12 ' A' ' 112' ' ' LEU . 61.7 t -81.32 -54.19 10.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 73.43 111.104 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.977 HD11 HG21 ' A' ' 104' ' ' THR . 50.0 mm -52.59 -39.65 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 71.14 111.12 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 -25.35 47.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 73.55 110.926 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.0 t -80.64 -21.01 41.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.187 -0.46 . . . . 71.51 110.847 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.553 HD12 HG12 ' A' ' 108' ' ' VAL . 6.6 mt -102.59 -42.13 6.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.104 -0.498 . . . . 72.43 110.928 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -117.64 68.34 5.87 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.644 0.735 . . . . 75.3 110.894 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 -7.29 20.69 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.681 2.254 . . . . 74.52 112.357 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.29 -43.5 43.17 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.749 -0.739 . . . . 75.05 112.477 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.669 HG11 ' NE2' ' A' ' 125' ' ' GLN . 2.2 m -116.43 128.04 73.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.883 0.373 . . . . 74.35 111.167 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -58.45 161.49 7.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 62.4 110.885 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -8.48 23.72 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.699 2.266 . . . . 71.34 112.324 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.13 18.87 4.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.091 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -142.67 87.28 1.99 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 74.42 110.866 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 7.9 mt -124.23 167.94 13.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.478 . . . . 72.53 110.885 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -135.42 153.31 51.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 74.54 110.875 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.9 p -52.81 147.76 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 71.2 111.12 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.69 66.72 2.38 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.688 -0.767 . . . . 75.25 112.474 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.669 ' NE2' HG11 ' A' ' 116' ' ' VAL . 7.0 tt0 -114.31 120.9 41.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.867 0.365 . . . . 71.14 110.889 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.99 124.98 42.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 74.24 111.163 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.4 pt -135.06 175.92 9.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 64.23 111.17 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -104.59 148.94 25.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 53.23 110.874 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -133.29 156.12 80.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.565 0.698 . . . . 73.23 111.163 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 110.16 2.49 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.693 2.262 . . . . 62.43 112.278 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 88.6 m . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 73.32 110.9 179.932 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 21.4 ttp . . . . . 0 C--O 1.23 0.06 0 CA-C-O 120.81 0.338 . . . . 64.53 110.866 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.69 -156.05 15.8 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.742 -0.742 . . . . 74.43 112.504 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . 0.428 ' HB3' HG23 ' A' ' 129' ' ' VAL . 6.8 m -112.27 146.31 38.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.906 0.384 . . . . 74.23 110.891 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.6 p -123.6 160.75 26.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.144 -0.48 . . . . 75.23 111.119 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -143.42 136.56 27.88 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.254 -0.43 . . . . 74.34 110.93 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.7 m -94.91 123.27 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.118 -0.492 . . . . 52.24 111.172 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 57.0 mt -90.99 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.235 -0.438 . . . . 73.12 111.13 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 11.6 mt-30 -116.21 163.36 21.97 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.568 0.699 . . . . 72.31 110.95 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_exo -46.52 107.79 0.13 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 53.14 112.337 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 126.63 -18.51 6.35 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.714 -0.755 . . . . 71.45 112.484 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.597 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.4 m-20 -103.49 136.97 42.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.879 0.371 . . . . 75.42 110.843 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.25 163.86 20.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 63.22 111.194 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.499 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.4 m-85 -54.75 -67.54 0.26 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 72.31 110.911 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -52.23 -51.74 56.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 74.42 110.916 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.32 -65.6 0.53 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.264 -0.426 . . . . 74.41 111.143 179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.597 HD11 ' CB ' ' A' ' 93' ' ' ASP . 26.3 mt -51.42 -31.68 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 72.23 111.148 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.504 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -67.47 -39.82 85.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 72.43 111.087 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -52.39 -58.77 5.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 74.55 110.936 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 3.1 mmt85 -69.31 -16.85 63.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 74.02 110.891 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . 0.403 ' HE ' HG11 ' A' ' 129' ' ' VAL . 18.3 mmt180 -90.83 12.76 18.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 65.15 110.904 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.94 28.08 23.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.74 -0.743 . . . . 45.32 112.51 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.894 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -129.55 177.94 6.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.879 0.371 . . . . 74.1 111.123 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.98 163.01 26.28 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.197 -0.456 . . . . 72.13 111.15 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.702 HG12 HE21 ' A' ' 110' ' ' GLN . 62.0 t -51.85 -39.53 25.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 55.13 111.141 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 -51.55 -39.35 57.6 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.484 . . . . 64.04 110.864 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -80.25 -50.34 17.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.15 -0.477 . . . . 75.2 111.111 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.894 HD11 HG21 ' A' ' 104' ' ' THR . 47.5 mm -51.43 -41.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.205 -0.452 . . . . 74.21 111.079 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.702 HE21 HG12 ' A' ' 106' ' ' VAL . 6.5 pt20 -77.65 -25.6 49.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 74.4 110.933 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 19.9 t -76.14 -24.5 54.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.182 -0.463 . . . . 53.54 110.843 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 20.8 mt -98.59 -44.53 6.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.129 -0.487 . . . . 71.41 110.906 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.93 67.97 6.33 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.589 0.709 . . . . 73.01 110.911 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -7.63 21.54 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.686 2.257 . . . . 74.04 112.316 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.47 -45.42 46.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.78 -0.724 . . . . 63.14 112.47 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.561 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.3 m -117.24 124.93 73.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 64.44 111.127 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -67.97 160.87 71.83 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.607 0.717 . . . . 52.24 110.887 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -8.46 23.66 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.624 2.216 . . . . 71.55 112.352 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -115.51 24.9 11.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 53.35 111.11 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.2 ptp180 -173.34 108.16 0.16 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 74.53 110.858 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.561 HD23 ' HB ' ' A' ' 116' ' ' VAL . 10.3 mt -136.99 146.91 45.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.174 -0.467 . . . . 44.41 110.92 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 20.6 pt20 -97.75 153.0 18.56 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 75.0 110.89 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 12.4 p -68.12 148.07 12.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 74.1 111.178 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.84 61.7 6.24 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.783 -0.722 . . . . 44.03 112.481 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.527 HE22 HG11 ' A' ' 116' ' ' VAL . 15.6 tt0 -119.24 121.96 40.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.838 0.352 . . . . 73.02 110.902 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.87 124.95 40.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 50.43 111.117 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.5 pt -123.58 175.74 5.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.185 -0.461 . . . . 53.24 111.132 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -99.16 137.26 37.94 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.166 -0.47 . . . . 52.43 110.85 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.428 HG23 ' HB3' ' A' ' 85' ' ' CYS . 3.2 m -117.93 156.22 50.29 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.598 0.713 . . . . 72.5 111.124 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 83.91 0.67 Allowed 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.647 2.231 . . . . 72.11 112.355 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.5 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.264 -0.426 . . . . 53.11 110.868 -179.998 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 9.2 mmt . . . . . 0 CA--C 1.526 0.051 0 CA-C-O 120.778 0.323 . . . . 63.32 110.904 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 164.81 169.68 28.74 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.745 -0.74 . . . . 60.45 112.5 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 9.2 m -131.85 143.8 50.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.903 0.382 . . . . 53.5 110.894 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 14.3 p -123.61 154.38 39.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 62.34 111.13 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 47.0 t80 -132.26 136.6 47.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.236 -0.438 . . . . 74.13 110.889 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -91.43 125.24 36.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.065 -0.516 . . . . 61.33 111.127 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 121' ' ' LEU . 52.2 mt -93.22 110.51 23.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 74.23 111.146 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm-40 -89.45 158.87 45.3 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.55 0.69 . . . . 71.3 110.898 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.632 ' HB3' HG23 ' A' ' 123' ' ' VAL . 20.2 Cg_endo -59.67 92.79 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.645 2.23 . . . . 44.33 112.37 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.44 -18.28 2.65 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.754 -0.736 . . . . 72.4 112.493 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -78.81 155.86 29.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.872 0.368 . . . . 71.4 110.841 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.458 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -131.66 165.15 24.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 54.54 111.166 -179.932 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.623 ' HE2' HD21 ' A' ' 121' ' ' LEU . 1.1 m-85 -51.32 -51.08 57.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 74.2 110.877 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -67.85 -48.94 64.75 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.138 -0.483 . . . . 72.22 110.91 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.458 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -54.98 -29.95 58.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 71.03 111.084 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 31.2 mt -87.44 -33.43 6.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.238 -0.437 . . . . 71.23 111.142 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' A' ' 104' ' ' THR . . . -65.01 -43.66 91.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.165 -0.47 . . . . 75.21 111.11 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -56.31 -44.59 80.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.21 110.841 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 66.5 mtt180 -65.76 -60.22 3.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.226 -0.443 . . . . 72.41 110.884 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.4 mmm180 -51.97 -30.86 26.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.456 . . . . 73.43 110.894 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 103.36 16.72 19.75 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.748 -0.739 . . . . 74.43 112.46 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.431 ' O ' ' HB1' ' A' ' 99' ' ' ALA . 7.2 t -120.74 -174.83 2.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.867 0.365 . . . . 71.14 111.149 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -116.23 165.22 13.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 75.43 111.12 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.8 t -55.51 -43.42 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 73.55 111.137 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -51.74 -33.39 34.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.168 -0.469 . . . . 64.35 110.855 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -81.89 -48.67 18.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 70.12 111.114 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 43.2 mm -51.31 -42.75 27.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 73.04 111.161 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -78.06 -25.41 47.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 65.4 110.928 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.1 t -76.83 -23.17 52.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.176 -0.466 . . . . 52.41 110.878 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 37.2 mt -100.59 -43.18 6.26 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 50.33 110.894 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -120.22 67.99 13.19 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 71.41 110.854 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.77 -8.24 23.1 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.737 2.291 . . . . 61.5 112.313 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.78 -44.79 55.36 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.685 -0.769 . . . . 51.42 112.517 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.579 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.6 m -114.56 161.76 13.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 51.24 111.129 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -102.73 161.39 23.36 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.659 0.742 . . . . 62.02 110.851 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.74 -8.39 23.47 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.679 2.253 . . . . 75.55 112.395 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.49 20.79 4.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 62.4 111.072 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 60.0 mtt85 -151.63 49.68 0.81 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 71.0 110.846 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.623 HD21 ' HE2' ' A' ' 95' ' ' PHE . 27.9 mt -85.52 166.52 16.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 43.21 110.9 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 -115.51 153.4 31.23 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.141 -0.481 . . . . 73.52 110.896 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.632 HG23 ' HB3' ' A' ' 91' ' ' PRO . 12.2 p -63.9 133.94 29.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.09 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.88 63.28 4.89 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.695 -0.764 . . . . 60.05 112.511 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 11.6 tt0 -114.74 123.5 49.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 75.42 110.942 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -86.37 126.81 40.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 71.53 111.133 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 8.1 pt -127.23 175.91 8.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.149 -0.478 . . . . 75.44 111.151 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.7 m-20 -94.97 153.9 17.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 73.25 110.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.5 m -141.23 156.03 67.81 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.643 0.735 . . . . 62.45 111.155 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 87.84 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.675 2.25 . . . . 73.23 112.352 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 71.52 110.854 179.997 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 87.7 mtp . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.817 0.341 . . . . 70.13 110.878 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 152.74 -167.22 31.53 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.726 -0.749 . . . . 60.03 112.484 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.5 m -117.75 163.33 16.66 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.939 0.4 . . . . 71.03 110.842 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 46.4 p -124.24 157.33 35.1 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.146 -0.479 . . . . 60.02 111.167 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -130.36 136.72 49.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.214 -0.448 . . . . 74.55 110.893 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -91.12 122.42 33.74 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 54.3 111.129 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.574 HG23 HD11 ' A' ' 98' ' ' ILE . 35.2 mt -90.8 109.59 21.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 74.43 111.135 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 16.4 mt-30 -87.75 157.28 52.27 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.606 0.717 . . . . 73.32 110.884 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.697 ' HB3' HG23 ' A' ' 123' ' ' VAL . 17.8 Cg_endo -58.16 94.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.675 2.25 . . . . 61.23 112.34 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.38 -20.38 2.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.694 -0.765 . . . . 75.53 112.456 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.44 ' HB2' HD11 ' A' ' 98' ' ' ILE . 1.0 OUTLIER -87.43 137.51 32.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.867 0.365 . . . . 64.42 110.913 -179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.48 171.48 7.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 73.15 111.186 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.637 ' HE1' HD21 ' A' ' 121' ' ' LEU . 1.2 m-85 -53.92 -64.36 0.85 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 72.34 110.927 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -53.08 -51.95 60.17 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 74.21 110.929 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.66 -63.77 1.03 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 51.12 111.091 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.574 HD11 HG23 ' A' ' 89' ' ' ILE . 46.7 mt -51.69 -34.13 15.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 72.15 111.133 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HB1' ' O ' ' A' ' 104' ' ' THR . . . -68.16 -35.72 78.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 75.01 111.114 179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.4 mt-30 -51.66 -73.06 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 54.1 110.904 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 36.4 mmm-85 -54.62 -45.27 73.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 62.13 110.903 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.7 mmm180 -54.54 -27.2 36.8 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.455 . . . . 73.23 110.907 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 91.54 16.09 53.41 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.775 -0.726 . . . . 72.1 112.469 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.685 HG21 HD11 ' A' ' 109' ' ' ILE . 9.6 t -122.26 -177.71 3.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.843 0.354 . . . . 75.4 111.113 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -121.12 164.27 17.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 61.03 111.145 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.604 HG12 HE21 ' A' ' 110' ' ' GLN . 58.6 t -55.71 -43.06 72.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 73.21 111.066 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -51.8 -33.51 35.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 70.41 110.852 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 22.0 t -81.86 -52.04 14.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 62.03 111.138 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.685 HD11 HG21 ' A' ' 104' ' ' THR . 47.6 mm -51.64 -42.21 30.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 71.13 111.151 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.604 HE21 HG12 ' A' ' 106' ' ' VAL . 2.8 pt20 -77.89 -25.4 48.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 74.23 110.874 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 5.6 t -77.08 -23.86 51.91 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 73.31 110.88 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.7 mt -99.45 -44.7 6.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 75.13 110.945 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.69 67.61 7.74 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.63 0.728 . . . . 55.3 110.897 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -8.22 23.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.659 2.239 . . . . 63.2 112.395 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.6 -44.09 53.74 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.721 -0.752 . . . . 62.14 112.472 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.696 HG11 ' NE2' ' A' ' 125' ' ' GLN . 2.5 m -115.21 156.71 16.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.881 0.372 . . . . 72.34 111.098 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -97.94 161.8 24.38 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.635 0.731 . . . . 74.54 110.849 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 -7.82 22.05 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.664 2.243 . . . . 73.33 112.36 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -131.42 18.89 4.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 42.34 111.063 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -143.32 40.82 1.47 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.215 -0.448 . . . . 55.1 110.897 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.637 HD21 ' HE1' ' A' ' 95' ' ' PHE . 59.9 mt -85.59 149.77 25.11 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.214 -0.448 . . . . 74.42 110.893 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . 0.495 ' H ' ' NE2' ' A' ' 125' ' ' GLN . 80.7 mm-40 -104.66 153.53 21.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 63.13 110.905 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.697 HG23 ' HB3' ' A' ' 91' ' ' PRO . 9.9 p -56.45 134.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.467 . . . . 54.44 111.122 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.25 63.21 5.04 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 72.2 112.509 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.696 ' NE2' HG11 ' A' ' 116' ' ' VAL . 5.6 tt0 -109.55 123.01 48.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.826 0.346 . . . . 73.32 110.884 -179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 8.4 p -85.66 136.87 21.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 75.02 111.112 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.442 HD13 HD11 ' A' ' 89' ' ' ILE . 10.3 pt -142.56 175.94 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.123 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -97.67 153.44 18.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.471 . . . . 60.42 110.905 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -146.24 156.16 50.27 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.594 0.712 . . . . 70.15 111.149 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 91.0 0.52 Allowed 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.684 2.256 . . . . 72.32 112.33 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 4.0 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 53.3 110.926 179.991 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 8.1 tpt . . . . . 0 C--O 1.23 0.055 0 CA-C-O 120.77 0.319 . . . . 65.11 110.874 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -76.54 -146.69 2.08 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.694 -0.765 . . . . 54.24 112.468 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 8.0 m -131.38 166.54 21.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.915 0.388 . . . . 61.23 110.909 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 72.7 p -124.96 150.48 46.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 53.3 111.15 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.547 ' HB2' HG21 ' A' ' 129' ' ' VAL . 48.1 t80 -123.86 135.97 54.07 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.32 110.936 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -89.66 123.38 33.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.104 -0.498 . . . . 54.54 111.177 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.4 mt -90.93 109.65 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 62.35 111.179 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 26.1 mm-40 -91.99 158.82 39.03 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.566 0.698 . . . . 74.1 110.936 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.598 ' HB3' HG23 ' A' ' 123' ' ' VAL . 19.9 Cg_endo -59.41 92.88 0.08 OUTLIER 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.687 2.258 . . . . 74.33 112.374 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.82 -19.04 2.56 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.751 . . . . 63.54 112.528 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.606 ' CB ' HD11 ' A' ' 98' ' ' ILE . 5.8 m-20 -80.97 154.17 27.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.906 0.384 . . . . 74.33 110.841 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 152.46 45.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 75.05 111.152 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.601 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.2 m-85 -53.4 -55.6 23.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.34 110.861 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.1 t-105 -57.95 -55.76 30.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 74.35 110.871 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.26 -61.04 2.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.259 -0.428 . . . . 52.13 111.106 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.606 HD11 ' CB ' ' A' ' 93' ' ' ASP . 41.0 mt -51.37 -38.24 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 72.2 111.134 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.403 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -64.68 -38.32 90.6 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 71.35 111.151 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -51.93 -72.77 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.449 . . . . 63.02 110.898 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -53.97 -41.67 68.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.146 -0.479 . . . . 74.12 110.879 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 6.9 mmp_? -57.05 -24.17 51.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 44.13 110.876 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.46 15.34 60.37 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.771 -0.728 . . . . 63.4 112.484 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 1.047 HG21 HD11 ' A' ' 109' ' ' ILE . 8.0 t -115.24 -175.48 2.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.931 0.396 . . . . 60.13 111.109 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -124.45 154.94 39.72 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.163 -0.471 . . . . 73.04 111.169 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.736 HG12 HE21 ' A' ' 110' ' ' GLN . 74.1 t -54.14 -42.94 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 75.13 111.152 179.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -51.72 -39.54 58.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.139 -0.482 . . . . 74.12 110.875 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.1 t -75.14 -54.18 14.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 70.02 111.145 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 1.047 HD11 HG21 ' A' ' 104' ' ' THR . 43.4 mm -51.58 -42.08 29.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.156 -0.474 . . . . 74.44 111.144 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.736 HE21 HG12 ' A' ' 106' ' ' VAL . 6.9 pt20 -76.78 -25.54 53.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.167 -0.47 . . . . 75.31 110.885 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.8 t -76.18 -25.22 54.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 73.41 110.85 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.6 mt -96.89 -45.47 6.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 75.11 110.939 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.03 67.85 6.48 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.632 0.73 . . . . 73.31 110.939 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.49 21.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.696 2.264 . . . . 72.11 112.356 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.45 -44.46 45.62 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 72.02 112.483 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.601 HG23 ' CZ ' ' A' ' 95' ' ' PHE . 2.4 m -117.2 130.93 71.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.86 0.362 . . . . 63.45 111.077 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 16.5 m-20 -76.78 160.9 75.73 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.626 0.727 . . . . 75.45 110.883 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -8.6 24.01 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.635 2.223 . . . . 74.12 112.35 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -113.65 24.93 11.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.246 -0.434 . . . . 72.43 111.112 179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 13.7 ptm180 -178.36 104.17 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.231 -0.441 . . . . 75.22 110.88 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 63.8 mt -122.31 167.48 13.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.446 . . . . 75.21 110.882 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -109.57 153.38 24.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 71.02 110.898 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.598 HG23 ' HB3' ' A' ' 91' ' ' PRO . 9.3 p -70.44 136.19 26.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 74.44 111.094 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 52.0 63.82 4.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.733 -0.746 . . . . 65.31 112.515 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.556 HE22 HG11 ' A' ' 116' ' ' VAL . 12.1 tt0 -117.66 122.74 44.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.873 0.368 . . . . 73.34 110.892 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.8 t -88.18 125.34 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.464 . . . . 63.44 111.157 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.1 pt -125.84 175.63 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 71.43 111.142 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 11.1 m-20 -97.76 137.43 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 55.12 110.859 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.547 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -138.95 156.19 72.65 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.609 0.718 . . . . 73.23 111.142 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 109.55 2.34 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.721 2.281 . . . . 61.33 112.345 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 74.32 110.9 -179.982 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 5.3 ttt . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.808 0.337 . . . . 52.2 110.879 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.21 -11.13 22.22 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.729 -0.748 . . . . 73.21 112.465 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 97.8 m -140.76 138.58 34.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.925 0.393 . . . . 74.53 110.853 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.4 p -123.51 168.52 12.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.133 -0.485 . . . . 74.14 111.158 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -136.82 136.59 38.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 65.21 110.891 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.1 m -89.18 122.76 32.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 70.34 111.171 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.435 HD11 HG12 ' A' ' 127' ' ' ILE . 38.8 mt -91.07 109.5 21.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.273 -0.421 . . . . 74.13 111.149 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.56 163.7 16.38 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.592 0.71 . . . . 74.22 110.928 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -46.1 111.11 0.31 Allowed 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.708 2.272 . . . . 71.51 112.341 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 113.21 -1.64 25.35 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.749 -0.739 . . . . 52.25 112.52 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -113.17 113.82 25.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 71.13 110.87 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -101.37 157.84 16.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 65.25 111.104 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.458 ' CE2' HD22 ' A' ' 121' ' ' LEU . 1.7 m-85 -51.5 -43.04 62.11 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 72.44 110.911 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.15 -47.66 27.42 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.111 -0.495 . . . . 74.43 110.906 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.54 -26.86 62.02 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.214 -0.448 . . . . 60.14 111.064 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 28.2 mt -88.31 -45.1 15.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 74.44 111.133 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.455 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -55.27 -46.15 76.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.46 . . . . 71.41 111.123 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -52.0 -44.97 64.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 63.11 110.89 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 74.8 mtt-85 -71.88 -52.7 16.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.881 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.8 mmm180 -54.12 -27.6 34.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 75.4 110.886 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.85 17.57 18.36 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.768 -0.73 . . . . 64.31 112.523 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.831 HG21 HD11 ' A' ' 109' ' ' ILE . 12.0 t -124.1 179.02 5.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.848 0.356 . . . . 73.03 111.162 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.41 164.47 17.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.198 -0.455 . . . . 65.52 111.163 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.692 HG12 HE21 ' A' ' 110' ' ' GLN . 46.8 t -55.23 -41.02 58.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.262 -0.426 . . . . 73.01 111.123 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -51.67 -38.89 56.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.171 -0.468 . . . . 65.41 110.886 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 27.3 t -78.38 -51.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.18 -0.464 . . . . 73.54 111.143 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.831 HD11 HG21 ' A' ' 104' ' ' THR . 47.6 mm -51.54 -43.97 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 74.41 111.148 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.692 HE21 HG12 ' A' ' 106' ' ' VAL . 2.8 pt20 -73.55 -25.54 60.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.151 -0.477 . . . . 65.3 110.931 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 40.5 t -78.91 -23.07 44.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.166 -0.47 . . . . 44.31 110.885 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.5 mt -98.27 -44.53 6.53 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 61.4 110.921 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.83 67.89 6.09 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.603 0.716 . . . . 61.1 110.909 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -7.25 20.58 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.701 2.267 . . . . 62.54 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.06 -42.03 38.91 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.796 -0.716 . . . . 43.41 112.435 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.507 ' HB ' HD23 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -119.37 125.13 74.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.858 0.361 . . . . 74.45 111.132 -179.919 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -57.58 161.14 6.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.619 0.724 . . . . 54.43 110.835 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 -8.59 23.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.653 2.235 . . . . 44.41 112.322 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -126.59 14.9 7.61 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 73.33 111.1 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 63.0 mtt180 -141.55 93.76 2.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.44 . . . . 73.34 110.881 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.507 HD23 ' HB ' ' A' ' 116' ' ' VAL . 10.0 mt -132.73 163.84 28.11 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 74.13 110.902 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -125.04 150.68 46.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 74.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.5 p -52.81 146.86 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.229 -0.441 . . . . 60.24 111.112 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.61 65.91 2.88 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.698 -0.763 . . . . 71.3 112.536 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.459 HE22 HG11 ' A' ' 116' ' ' VAL . 11.2 tt0 -119.15 121.61 40.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 75.51 110.921 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 15.0 p -89.03 136.41 23.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.444 . . . . 72.11 111.101 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.435 HG12 HD11 ' A' ' 89' ' ' ILE . 2.4 pt -138.68 174.23 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 75.13 111.166 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -100.25 139.39 35.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.207 -0.451 . . . . 75.45 110.931 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -141.19 156.12 67.9 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.645 0.736 . . . . 73.33 111.131 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 110.59 2.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.677 2.251 . . . . 74.23 112.334 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 74.11 110.921 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 6.0 mmt . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 120.826 0.346 . . . . 63.54 110.907 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 58.0 -165.33 7.1 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.689 -0.767 . . . . 73.34 112.543 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 19.4 m -128.04 165.81 19.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.37 . . . . 75.35 110.907 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.0 p -123.59 166.72 14.99 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.151 -0.477 . . . . 74.05 111.164 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 71.4 t80 -142.97 136.59 28.65 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.25 -0.432 . . . . 61.1 110.982 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.3 m -89.79 121.91 32.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 64.5 111.143 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 55.8 mt -90.94 109.61 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 71.53 111.156 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -86.86 158.62 53.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 75.55 110.935 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.57 ' HB3' HG23 ' A' ' 123' ' ' VAL . 17.9 Cg_endo -58.54 93.61 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.639 2.226 . . . . 71.22 112.345 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.8 -18.87 2.38 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 75.43 112.482 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.609 ' CB ' HD11 ' A' ' 98' ' ' ILE . 3.5 m-20 -84.67 138.23 32.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.857 0.361 . . . . 54.53 110.867 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -114.05 155.21 26.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 43.31 111.156 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.714 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -53.13 -47.52 68.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 74.42 110.878 -179.997 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -71.56 -47.32 55.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.111 -0.495 . . . . 75.45 110.933 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.82 -30.44 63.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.229 -0.441 . . . . 64.15 111.144 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.609 HD11 ' CB ' ' A' ' 93' ' ' ASP . 38.5 mt -88.29 -33.64 6.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 73.05 111.098 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -65.0 -41.86 95.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 64.22 111.116 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -58.68 -44.64 90.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 74.13 110.904 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -78.67 -18.42 54.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 73.44 110.873 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.7 mmt180 -92.83 16.33 12.7 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 62.14 110.857 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.56 28.35 21.37 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.798 -0.715 . . . . 72.32 112.469 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 1.035 HG21 HD11 ' A' ' 109' ' ' ILE . 9.9 t -129.8 -177.24 4.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.863 0.363 . . . . 74.11 111.131 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -124.85 157.86 34.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 72.44 111.145 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.733 HG12 HE21 ' A' ' 110' ' ' GLN . 60.3 t -55.58 -42.26 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 74.31 111.106 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -51.82 -37.26 51.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 62.23 110.836 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.0 t -78.18 -52.99 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 72.11 111.138 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 1.035 HD11 HG21 ' A' ' 104' ' ' THR . 49.2 mm -51.33 -43.23 28.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.138 -0.483 . . . . 72.5 111.125 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.733 HE21 HG12 ' A' ' 106' ' ' VAL . 7.0 pt20 -76.62 -25.54 53.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 72.14 110.904 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -75.28 -25.46 57.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.201 -0.454 . . . . 65.2 110.844 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 8.9 mt -94.93 -46.46 6.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 72.2 110.948 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -118.5 67.33 7.2 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.628 0.727 . . . . 73.55 110.897 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.674 2.25 . . . . 64.41 112.32 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.36 -42.05 49.29 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 65.34 112.523 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.726 HG11 ' OE1' ' A' ' 125' ' ' GLN . 2.2 m -119.43 139.91 45.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.864 0.364 . . . . 74.04 111.108 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -80.1 161.25 66.25 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.596 0.712 . . . . 74.45 110.924 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.68 -8.32 23.3 Favored 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.697 2.265 . . . . 73.45 112.4 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -132.76 20.58 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.184 -0.462 . . . . 61.25 111.106 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -144.07 43.62 1.44 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 75.55 110.863 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.714 HD11 ' CD2' ' A' ' 95' ' ' PHE . 71.9 mt -85.61 173.82 9.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 73.42 110.9 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -129.52 150.38 50.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 75.54 110.857 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.57 HG23 ' HB3' ' A' ' 91' ' ' PRO . 14.0 p -52.0 133.63 13.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 73.25 111.137 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 53.03 63.35 5.11 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.783 -0.722 . . . . 73.2 112.471 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.726 ' OE1' HG11 ' A' ' 116' ' ' VAL . 8.7 tt0 -110.62 122.73 48.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 64.44 110.922 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 30.7 t -84.45 140.75 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 64.41 111.142 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.1 pt -143.73 175.24 3.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 53.13 111.121 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -99.78 130.82 46.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 74.01 110.92 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -123.32 156.22 63.96 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.716 . . . . 53.42 111.132 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 91.61 0.52 Allowed 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.689 2.259 . . . . 43.45 112.372 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.18 -0.464 . . . . 73.14 110.877 -179.974 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.9 ptt? . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.872 0.368 . . . . 53.32 110.934 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -87.06 171.92 43.12 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.774 -0.726 . . . . 44.24 112.477 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 35.3 m -123.58 137.93 54.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.932 0.396 . . . . 62.24 110.865 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 64.8 p -123.58 163.92 20.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 71.12 111.134 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 46.7 t80 -145.12 136.68 25.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 73.34 110.938 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.75 125.23 37.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 41.51 111.13 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.434 HD12 ' HG2' ' A' ' 125' ' ' GLN . 79.2 mt -90.93 109.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 74.42 111.112 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -109.17 163.27 17.39 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.548 0.689 . . . . 75.44 110.933 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_exo -46.31 121.9 5.03 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.638 2.225 . . . . 74.3 112.34 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.27 -4.2 54.97 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.778 -0.725 . . . . 73.23 112.464 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -109.13 116.7 32.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.937 0.399 . . . . 73.34 110.884 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.457 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -113.96 -179.5 3.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 61.23 111.135 -179.874 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.686 ' CD1' HD11 ' A' ' 121' ' ' LEU . 0.9 OUTLIER -54.64 -70.02 0.11 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 73.02 110.909 -179.972 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.2 t-105 -51.88 -50.52 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 75.12 110.889 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.457 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -51.13 -65.89 0.48 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 52.23 111.138 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 47.0 mt -51.22 -35.78 16.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 52.15 111.131 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.5 -37.34 87.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 71.12 111.06 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 19.1 mt-30 -51.92 -70.74 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 62.22 110.93 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 8.5 ptm180 -57.01 -43.04 81.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 74.44 110.847 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 -56.6 -24.81 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 63.01 110.858 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 89.07 17.13 56.68 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 61.45 112.463 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.675 HG21 HD11 ' A' ' 109' ' ' ILE . 7.3 t -121.71 -174.65 2.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.838 0.351 . . . . 64.22 111.174 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -125.46 165.34 18.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 70.55 111.174 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.628 HG12 HE21 ' A' ' 110' ' ' GLN . 41.4 t -55.8 -44.69 78.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.264 -0.426 . . . . 71.4 111.067 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -51.92 -30.11 22.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.195 -0.457 . . . . 72.32 110.849 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.88 -52.19 13.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 70.24 111.139 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.675 HD11 HG21 ' A' ' 104' ' ' THR . 48.7 mm -51.29 -43.08 28.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 74.22 111.11 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.628 HE21 HG12 ' A' ' 106' ' ' VAL . 6.7 pt20 -76.2 -25.42 55.13 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.126 -0.488 . . . . 64.42 110.924 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.9 m -80.02 -20.31 45.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.208 -0.451 . . . . 74.22 110.854 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 12.9 mt -94.94 -47.86 6.24 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.121 -0.49 . . . . 54.21 110.906 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -118.51 67.28 7.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.634 0.73 . . . . 74.42 110.897 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -8.48 23.71 Favored 'Trans proline' 0 N--CA 1.465 -0.167 0 C-N-CA 122.737 2.291 . . . . 63.25 112.39 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -69.76 -17.6 73.31 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.75 -0.738 . . . . 72.33 112.478 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.539 HG12 HD23 ' A' ' 121' ' ' LEU . 2.1 t -125.89 112.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.845 0.355 . . . . 75.44 111.133 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.19 160.29 1.72 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.591 0.71 . . . . 73.03 110.912 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -45.63 1.53 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.691 2.261 . . . . 61.03 112.368 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.24 -29.84 24.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 74.34 111.13 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -83.41 68.5 9.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 74.12 110.895 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.686 HD11 ' CD1' ' A' ' 95' ' ' PHE . 53.7 mt -121.3 137.89 54.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 53.43 110.941 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -110.34 153.57 24.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 65.3 110.913 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.3 p -51.56 147.33 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 71.14 111.107 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.73 66.9 2.28 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 74.51 112.505 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.434 ' HG2' HD12 ' A' ' 89' ' ' ILE . 3.8 tt0 -116.47 122.4 44.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.833 0.349 . . . . 75.12 110.941 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.8 t -86.26 130.56 36.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 74.03 111.102 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 12.1 pt -141.12 175.79 5.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 64.23 111.139 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -99.18 152.18 20.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 65.35 110.872 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.61 156.18 80.12 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.603 0.716 . . . . 61.11 111.132 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 110.33 2.53 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.664 2.242 . . . . 74.12 112.36 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 69.1 m . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 75.03 110.912 179.982 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.6 ttt . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.836 0.35 . . . . 64.11 110.909 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -129.13 -156.53 8.92 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.752 -0.737 . . . . 74.42 112.533 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . 0.454 ' HB3' HG23 ' A' ' 129' ' ' VAL . 1.7 m -116.26 146.02 42.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.953 0.406 . . . . 73.21 110.838 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 15.4 p -123.59 157.58 33.39 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.132 -0.485 . . . . 42.02 111.109 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.4 t80 -141.89 136.69 30.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.962 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 m -93.45 126.88 38.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 54.42 111.14 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 63.5 mt -91.0 109.52 21.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.46 . . . . 55.05 111.089 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -92.02 159.25 38.14 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.537 0.684 . . . . 75.21 110.914 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.423 ' HB3' HG23 ' A' ' 123' ' ' VAL . 18.7 Cg_endo -57.95 94.47 0.07 OUTLIER 'Trans proline' 0 C--N 1.34 0.128 0 C-N-CA 122.686 2.257 . . . . 74.15 112.306 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 141.79 -18.1 2.59 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.781 -0.723 . . . . 43.14 112.513 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -91.22 157.09 17.37 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.909 0.385 . . . . 75.31 110.837 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.437 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.1 OUTLIER -141.4 178.28 7.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.164 -0.471 . . . . 73.44 111.125 -179.877 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.678 ' CD2' HD11 ' A' ' 121' ' ' LEU . 1.7 m-85 -54.49 -66.43 0.4 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 71.51 110.858 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -54.79 -52.15 63.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.157 -0.474 . . . . 75.41 110.909 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.437 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -50.57 -66.09 0.45 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.445 . . . . 72.14 111.089 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 54.8 mt -51.15 -33.96 13.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 75.24 111.116 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -64.94 -39.53 93.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 63.41 111.086 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 21.0 mt-30 -52.12 -69.39 0.11 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.251 -0.431 . . . . 63.31 110.874 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 55.5 mtm180 -55.3 -50.34 69.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.462 . . . . 74.43 110.92 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . 0.423 ' CD ' HG11 ' A' ' 129' ' ' VAL . 6.3 mmp_? -51.96 -29.97 22.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 72.12 110.866 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 94.56 12.27 56.02 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.81 -0.71 . . . . 71.24 112.524 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.7 t -114.11 -172.47 2.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.811 0.338 . . . . 71.34 111.163 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.7 m -124.87 162.56 24.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 74.54 111.167 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 69.2 t -53.38 -43.87 53.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 70.44 111.133 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -51.68 -37.3 50.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.15 -0.477 . . . . 70.21 110.848 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 23.2 t -76.83 -47.18 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 72.15 111.141 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . . . . . . . . . 41.6 mm -50.84 -45.36 28.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 75.24 111.128 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -77.37 -25.46 50.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.142 -0.481 . . . . 61.34 110.965 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 1.7 t -76.69 -21.02 55.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 74.21 110.832 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.5 mt -97.72 -45.33 6.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.116 -0.493 . . . . 64.54 110.932 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -118.18 67.84 6.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.637 0.732 . . . . 70.45 110.892 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 -8.41 23.53 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.656 2.237 . . . . 65.02 112.351 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -68.75 -19.57 73.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.773 -0.727 . . . . 61.42 112.43 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.732 HG11 HD23 ' A' ' 121' ' ' LEU . 2.6 t -127.3 139.71 51.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 65.41 111.115 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -79.82 160.33 69.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.631 0.729 . . . . 61.33 110.926 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -15.03 36.73 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.69 2.26 . . . . 53.51 112.342 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -116.42 -23.28 8.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 55.5 111.065 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 37.4 mtp180 -91.83 55.02 2.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 74.54 110.893 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.732 HD23 HG11 ' A' ' 116' ' ' VAL . 75.2 mt -107.98 131.93 54.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.459 . . . . 54.33 110.909 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -97.65 153.55 18.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 72.24 110.904 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.423 HG23 ' HB3' ' A' ' 91' ' ' PRO . 6.6 p -54.71 144.36 5.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 70.42 111.092 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.98 66.34 2.65 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.764 -0.731 . . . . 72.44 112.478 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -118.72 122.07 41.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.83 0.347 . . . . 71.14 110.898 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 23.4 t -84.51 126.94 40.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.196 -0.456 . . . . 74.52 111.191 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.0 pt -133.45 175.86 10.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 63.23 111.17 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -96.08 159.76 14.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 54.21 110.885 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.454 HG23 ' HB3' ' A' ' 85' ' ' CYS . 3.1 m -144.07 156.33 58.33 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.63 0.729 . . . . 64.44 111.134 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 90.87 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.655 2.237 . . . . 72.13 112.326 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 74.43 110.873 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 9.5 mmt . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.847 0.356 . . . . 72.34 110.886 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 163.3 -115.8 0.67 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.724 -0.75 . . . . 75.13 112.5 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.4 m -130.16 139.4 50.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.951 0.405 . . . . 75.54 110.894 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 18.2 p -125.5 163.06 23.49 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.15 -0.477 . . . . 64.24 111.128 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -139.19 136.31 34.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 62.1 110.917 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 m -92.26 123.26 35.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 61.04 111.123 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.548 HD12 ' HG2' ' A' ' 125' ' ' GLN . 85.3 mt -90.9 109.47 21.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.247 -0.433 . . . . 73.3 111.162 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.499 ' HB3' ' HD2' ' A' ' 91' ' ' PRO . 25.6 mt-30 -112.6 162.63 20.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.55 0.69 . . . . 74.21 110.963 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.499 ' HD2' ' HB3' ' A' ' 90' ' ' GLN . 74.9 Cg_exo -47.33 101.07 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.685 2.257 . . . . 63.21 112.378 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 124.75 0.47 8.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 74.02 112.519 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -115.22 116.91 29.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.869 0.366 . . . . 70.32 110.877 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.443 HG22 ' H ' ' A' ' 95' ' ' PHE . 0.2 OUTLIER -107.08 169.57 8.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 63.04 111.145 -179.89 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.6 ' CD1' HD11 ' A' ' 121' ' ' LEU . 0.7 OUTLIER -53.68 -66.03 0.46 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.187 -0.461 . . . . 72.04 110.897 -179.987 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -55.94 -49.6 73.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 74.15 110.949 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -50.22 -55.21 16.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.24 -0.436 . . . . 45.3 111.091 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 35.4 mt -62.69 -31.93 53.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.478 . . . . 72.42 111.127 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.449 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -69.65 -29.93 67.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.187 -0.461 . . . . 75.43 111.083 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 7.0 mt-30 -52.59 -74.11 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.914 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 15.7 ptp180 -57.38 -38.79 74.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 73.33 110.87 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . 0.432 ' HD2' HG11 ' A' ' 129' ' ' VAL . 8.2 mmp_? -57.78 -23.47 52.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 74.24 110.857 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 82.84 18.83 64.61 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.755 -0.736 . . . . 53.41 112.456 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.991 HG21 HD11 ' A' ' 109' ' ' ILE . 11.8 t -116.68 -179.88 3.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.846 0.355 . . . . 54.22 111.11 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -122.58 161.28 24.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 64.42 111.149 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 57.3 t -55.11 -47.3 77.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 74.5 111.117 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 40.4 m-20 -51.88 -30.03 22.27 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.171 -0.468 . . . . 73.15 110.812 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 47.0 t -80.83 -54.15 10.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 71.21 111.177 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.991 HD11 HG21 ' A' ' 104' ' ' THR . 51.2 mm -52.5 -41.79 37.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.148 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.06 -25.36 58.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 54.32 110.902 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 12.8 t -81.15 -21.46 39.73 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.214 -0.448 . . . . 62.4 110.843 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.2 mt -99.48 -44.52 6.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 53.0 110.915 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.37 68.58 5.37 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.602 0.715 . . . . 73.32 110.86 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -7.5 21.2 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.69 2.26 . . . . 72.55 112.35 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.26 -40.28 37.13 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.751 -0.738 . . . . 74.53 112.506 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.634 HG11 ' OE1' ' A' ' 125' ' ' GLN . 1.3 m -118.05 127.32 75.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.826 0.346 . . . . 54.3 111.122 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.1 m-20 -56.76 161.63 4.36 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.618 0.723 . . . . 72.2 110.92 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -8.16 22.89 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.686 2.257 . . . . 64.42 112.323 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.9 21.96 4.96 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.239 -0.437 . . . . 62.31 111.119 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 28.3 mmt85 -144.0 101.37 3.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 72.4 110.866 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.6 HD11 ' CD1' ' A' ' 95' ' ' PHE . 53.1 mt -139.3 150.85 45.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 62.13 110.926 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 41.1 mt-30 -117.86 150.61 38.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 70.15 110.883 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.423 HG23 ' HG3' ' A' ' 91' ' ' PRO . 12.6 p -51.77 148.22 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 73.32 111.121 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.36 66.53 2.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.732 -0.747 . . . . 74.13 112.448 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.634 ' OE1' HG11 ' A' ' 116' ' ' VAL . 7.6 tt0 -117.84 121.25 40.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.822 0.344 . . . . 61.51 110.927 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -88.95 125.01 42.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 73.21 111.158 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.6 pt -132.31 175.79 10.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 70.23 111.121 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.39 149.19 23.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 63.51 110.878 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.432 HG11 ' HD2' ' A' ' 102' ' ' ARG . 3.2 m -135.12 156.17 78.43 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.635 0.731 . . . . 54.32 111.15 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 110.66 2.61 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.679 2.253 . . . . 42.43 112.334 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 92.3 m . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 75.24 110.928 179.969 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 6.8 ptm . . . . . 0 C--O 1.23 0.05 0 CA-C-O 120.861 0.362 . . . . 62.35 110.846 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -93.83 -135.61 7.7 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.762 -0.733 . . . . 53.53 112.493 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 4.5 m -113.13 149.95 32.85 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.925 0.393 . . . . 74.13 110.84 -179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 76.5 p -126.19 154.89 42.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.173 -0.467 . . . . 72.32 111.137 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.4 ' HB2' HG11 ' A' ' 129' ' ' VAL . 47.8 t80 -132.37 136.66 46.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 73.45 110.929 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 87.3 m -92.87 125.58 37.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 65.02 111.147 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 76.3 mt -91.12 110.0 21.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.262 -0.426 . . . . 70.21 111.122 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.487 ' HB2' ' HD2' ' A' ' 91' ' ' PRO . 0.5 OUTLIER -112.21 162.44 21.38 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.57 0.7 . . . . 74.53 110.935 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.505 ' HG3' HG23 ' A' ' 123' ' ' VAL . 74.5 Cg_exo -46.14 101.53 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.685 2.256 . . . . 72.23 112.379 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 121.37 2.5 10.8 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.743 -0.741 . . . . 51.21 112.496 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 26.9 m-20 -105.24 113.95 27.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.897 0.38 . . . . 43.25 110.885 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.55 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.0 OUTLIER -108.12 166.21 10.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 74.32 111.152 -179.885 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.657 ' HE2' HD21 ' A' ' 121' ' ' LEU . 1.3 m-85 -51.02 -46.13 61.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 52.44 110.902 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.35 -49.63 21.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 70.52 110.977 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.55 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -54.11 -27.94 36.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.457 . . . . 52.13 111.114 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 42.9 mt -89.1 -41.47 13.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 53.35 111.16 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.429 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -57.1 -42.69 81.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.131 -0.486 . . . . 54.34 111.111 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -57.19 -45.02 84.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 63.24 110.914 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -65.6 -59.98 3.39 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 72.41 110.882 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 24.2 mmm180 -52.12 -29.87 23.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.138 -0.483 . . . . 74.24 110.876 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 102.58 13.53 29.97 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.759 -0.734 . . . . 61.14 112.474 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 6.9 t -115.35 -174.18 2.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.853 0.359 . . . . 73.4 111.128 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.92 163.47 16.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 72.12 111.172 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 68.7 t -54.55 -44.43 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.261 -0.427 . . . . 74.32 111.129 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -51.68 -33.61 34.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 75.11 110.829 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 77.9 t -80.57 -48.08 20.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 63.42 111.156 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.429 HG13 ' HB2' ' A' ' 99' ' ' ALA . 45.2 mm -51.19 -43.52 27.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 51.11 111.159 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -77.76 -25.48 49.15 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.148 -0.478 . . . . 75.04 110.934 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 8.2 t -76.17 -23.53 54.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 75.45 110.805 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -99.16 -45.37 5.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 74.3 110.908 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.83 68.29 6.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.653 0.74 . . . . 71.21 110.852 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -8.17 22.93 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.656 2.237 . . . . 73.43 112.389 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -51.55 -43.39 52.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.69 -0.767 . . . . 61.43 112.53 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.551 ' HB ' HD23 ' A' ' 121' ' ' LEU . 2.1 m -116.42 163.04 13.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.884 0.373 . . . . 75.22 111.078 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -104.31 161.1 23.88 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.59 0.71 . . . . 75.14 110.864 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.71 -8.52 23.81 Favored 'Trans proline' 0 C--N 1.341 0.136 0 C-N-CA 122.693 2.262 . . . . 60.42 112.372 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -128.76 12.02 6.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 61.2 111.124 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.9 mmt85 -143.77 49.67 1.38 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 74.55 110.863 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.657 HD21 ' HE2' ' A' ' 95' ' ' PHE . 22.9 mt -85.64 166.95 15.77 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.227 -0.442 . . . . 63.53 110.918 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -120.59 139.39 53.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.474 . . . . 74.41 110.897 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.505 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.3 p -54.05 140.6 10.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.446 . . . . 74.12 111.104 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.31 61.62 6.11 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.779 -0.724 . . . . 73.35 112.462 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -119.17 122.27 41.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.811 0.339 . . . . 72.44 110.882 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 10.1 p -84.43 134.61 26.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 73.3 111.106 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.8 pt -134.98 175.93 9.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 63.33 111.132 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -95.91 143.25 27.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.46 . . . . 63.34 110.859 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.4 HG11 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -131.87 156.22 80.38 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.612 0.72 . . . . 52.24 111.12 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 86.58 0.58 Allowed 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.652 2.235 . . . . 63.21 112.357 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.26 -0.427 . . . . 74.21 110.876 -179.999 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 27.6 mmm . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.821 0.344 . . . . 73.23 110.871 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -106.84 -152.26 18.83 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.769 -0.729 . . . . 62.32 112.516 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 73.4 m -135.69 136.62 41.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.928 0.394 . . . . 54.33 110.848 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 35.7 p -124.47 156.22 37.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.466 . . . . 72.11 111.124 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.452 ' CE2' HD13 ' A' ' 98' ' ' ILE . 44.3 t80 -132.35 136.54 46.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.274 -0.421 . . . . 74.42 110.891 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.2 m -92.54 122.97 35.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.117 -0.492 . . . . 72.35 111.168 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 83.0 mt -91.0 109.45 21.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 75.21 111.124 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.502 ' HB3' ' HD2' ' A' ' 91' ' ' PRO . 4.8 mm100 -112.29 162.45 21.4 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.58 0.705 . . . . 75.02 110.925 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.502 ' HD2' ' HB3' ' A' ' 90' ' ' GLN . 74.3 Cg_exo -47.28 101.22 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.663 2.242 . . . . 75.33 112.335 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 123.8 1.36 8.97 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.73 -0.748 . . . . 72.5 112.478 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -118.46 111.58 18.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.901 0.381 . . . . 64.1 110.872 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -100.53 159.84 14.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 74.43 111.151 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.416 ' CD1' HD11 ' A' ' 121' ' ' LEU . 1.3 m-85 -51.33 -44.13 61.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.258 -0.428 . . . . 70.51 110.854 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -75.19 -48.0 25.61 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 72.23 110.922 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -56.22 -28.03 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 71.22 111.112 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.452 HD13 ' CE2' ' A' ' 87' ' ' TYR . 32.6 mt -87.76 -45.38 16.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.248 -0.433 . . . . 72.41 111.107 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.478 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -53.97 -47.28 71.52 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 70.05 111.061 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -51.93 -44.96 64.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.199 -0.455 . . . . 73.03 110.914 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 77.4 mtp180 -68.78 -53.94 18.86 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.196 -0.456 . . . . 73.34 110.872 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -55.27 -26.29 39.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 72.32 110.897 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 101.91 16.27 24.17 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.727 -0.749 . . . . 73.42 112.491 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.793 HG21 HD11 ' A' ' 109' ' ' ILE . 10.1 t -120.29 -177.87 3.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.86 0.362 . . . . 63.33 111.129 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.64 165.09 19.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 52.31 111.145 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.715 HG12 HE21 ' A' ' 110' ' ' GLN . 91.7 t -55.16 -40.55 55.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 74.12 111.12 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 69.2 m-20 -51.7 -40.13 59.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 73.01 110.884 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.7 t -77.35 -51.72 17.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 75.3 111.153 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.793 HD11 HG21 ' A' ' 104' ' ' THR . 50.5 mm -51.64 -44.43 34.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 53.4 111.129 179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.715 HE21 HG12 ' A' ' 106' ' ' VAL . 6.5 pt20 -72.86 -25.53 61.13 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 64.41 110.937 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.4 t -79.98 -22.11 42.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 73.02 110.834 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 10.7 mt -98.12 -44.79 6.47 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 62.23 110.88 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.66 68.06 5.8 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.607 0.717 . . . . 73.35 110.866 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 -7.13 20.26 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.669 2.246 . . . . 73.4 112.387 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.84 -40.19 33.73 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.723 -0.751 . . . . 75.22 112.473 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.505 HG11 HE22 ' A' ' 125' ' ' GLN . 1.5 m -118.29 127.96 75.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.795 0.331 . . . . 55.4 111.142 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 -56.61 161.25 4.54 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.623 0.725 . . . . 63.3 110.913 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -8.47 23.67 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.644 2.229 . . . . 75.33 112.352 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -130.1 23.21 5.26 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 75.22 111.119 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 26.3 mmt180 -146.47 102.52 3.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.453 . . . . 72.41 110.838 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.469 HD23 ' HB ' ' A' ' 116' ' ' VAL . 67.2 mt -136.51 175.59 9.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 74.42 110.867 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -140.72 147.77 39.69 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.475 . . . . 72.22 110.913 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.406 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.5 p -52.35 147.57 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.227 -0.442 . . . . 71.31 111.094 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.63 65.2 3.32 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.697 -0.763 . . . . 55.33 112.538 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.505 HE22 HG11 ' A' ' 116' ' ' VAL . 15.2 tt0 -119.14 120.69 37.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.826 0.346 . . . . 72.44 110.925 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.36 125.11 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 42.15 111.122 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.3 pt -129.22 175.87 9.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.159 -0.473 . . . . 74.43 111.128 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -98.84 137.98 36.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 75.14 110.869 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -123.91 156.23 65.91 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.618 0.723 . . . . 62.24 111.144 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 110.52 2.59 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.698 2.265 . . . . 70.44 112.337 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.205 -0.452 . . . . 73.41 110.878 -179.954 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 6.5 ttm . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.798 0.332 . . . . 75.33 110.859 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -170.29 153.09 20.58 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.772 -0.727 . . . . 75.21 112.507 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m -133.67 145.69 50.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.9 0.381 . . . . 72.15 110.903 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.5 p -123.37 161.83 23.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 71.15 111.149 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.65 ' HB2' HG21 ' A' ' 129' ' ' VAL . 36.2 t80 -127.32 136.79 52.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 71.24 110.925 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 55.3 m -88.68 122.88 32.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.098 -0.501 . . . . 32.0 111.144 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 68.2 mt -90.83 109.52 21.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 64.31 111.153 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.483 ' HB2' ' HD2' ' A' ' 91' ' ' PRO . 0.1 OUTLIER -111.32 162.65 19.97 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.568 0.699 . . . . 71.15 110.948 179.94 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.483 ' HD2' ' HB2' ' A' ' 90' ' ' GLN . 74.0 Cg_exo -46.78 101.27 0.04 OUTLIER 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.696 2.264 . . . . 64.51 112.337 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 125.95 -1.99 7.9 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.717 -0.754 . . . . 54.15 112.455 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.42 ' HB3' HD11 ' A' ' 98' ' ' ILE . 13.5 m-20 -105.77 129.39 53.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.885 0.374 . . . . 74.25 110.87 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.504 ' H ' ' HB3' ' A' ' 97' ' ' ALA . 0.2 OUTLIER -118.06 164.5 15.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 72.21 111.128 -179.886 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.662 ' CE1' HD21 ' A' ' 121' ' ' LEU . 0.8 OUTLIER -50.94 -48.28 60.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 74.24 110.875 -179.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -74.08 -49.01 25.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 74.35 110.944 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.504 ' HB3' ' H ' ' A' ' 94' ' ' THR . . . -53.81 -27.17 27.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.11 111.124 179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.42 HD11 ' HB3' ' A' ' 93' ' ' ASP . 39.1 mt -91.26 -39.41 11.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 74.21 111.131 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.553 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -58.3 -41.04 83.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.149 -0.478 . . . . 52.52 111.092 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -57.13 -44.55 83.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.235 -0.439 . . . . 72.01 110.905 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -69.26 -25.96 64.54 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 73.34 110.852 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . 0.41 ' HB2' HG22 ' A' ' 104' ' ' THR . 3.0 mmp_? -94.39 17.99 11.97 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 71.02 110.888 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.83 27.76 21.6 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.699 -0.762 . . . . 71.33 112.538 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.686 HG21 HD11 ' A' ' 109' ' ' ILE . 8.5 t -126.73 -177.22 3.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.916 0.389 . . . . 72.23 111.116 -179.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.439 HG22 ' H ' ' A' ' 106' ' ' VAL . 0.2 OUTLIER -125.41 167.88 14.36 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 61.44 111.123 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.717 HG12 HE21 ' A' ' 110' ' ' GLN . 45.9 t -56.47 -38.98 58.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 74.34 111.167 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 68.5 m-20 -51.71 -38.56 55.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 73.01 110.855 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.5 t -81.05 -50.64 16.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 64.15 111.108 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.686 HD11 HG21 ' A' ' 104' ' ' THR . 49.7 mm -51.29 -41.02 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 72.1 111.125 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.717 HE21 HG12 ' A' ' 106' ' ' VAL . 6.2 pt20 -78.58 -25.57 45.33 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.471 . . . . 74.22 110.928 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 10.3 t -76.38 -24.13 54.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 75.31 110.839 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.1 mt -98.48 -44.67 6.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.137 -0.483 . . . . 64.14 110.903 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -117.97 67.96 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.637 0.732 . . . . 73.5 110.907 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -7.72 21.77 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.66 2.24 . . . . 73.23 112.36 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.78 -44.33 48.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.764 -0.731 . . . . 54.22 112.48 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.708 ' HB ' HD23 ' A' ' 121' ' ' LEU . 1.6 m -118.82 161.06 18.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.829 0.347 . . . . 74.42 111.121 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -108.34 160.96 25.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.634 0.731 . . . . 71.43 110.854 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -8.22 23.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.682 2.255 . . . . 73.24 112.362 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.21 -21.63 13.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 75.1 111.109 179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 6.5 ptp180 -134.87 96.22 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 74.24 110.929 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.708 HD23 ' HB ' ' A' ' 116' ' ' VAL . 89.5 mt -117.55 161.81 19.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.181 -0.463 . . . . 71.55 110.903 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -107.67 148.81 28.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 74.54 110.932 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.457 HG23 ' HG3' ' A' ' 91' ' ' PRO . 14.0 p -68.89 143.75 14.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 74.23 111.118 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.2 60.85 6.75 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.715 -0.755 . . . . 74.22 112.496 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.582 HE22 HG11 ' A' ' 116' ' ' VAL . 11.0 tt0 -119.21 121.18 39.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.824 0.345 . . . . 64.33 110.97 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 26.2 t -88.92 132.27 34.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 74.3 111.134 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 2.4 pt -134.04 175.97 9.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.189 -0.459 . . . . 73.45 111.132 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 60.0 m-20 -92.51 136.56 33.11 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.457 . . . . 70.51 110.907 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.65 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.4 m -143.76 155.99 59.5 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.547 0.689 . . . . 45.21 111.15 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.83 110.53 2.59 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.65 2.233 . . . . 74.41 112.308 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.253 -0.43 . . . . 73.35 110.873 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 4.5 ptp . . . . . 0 N--CA 1.458 -0.044 0 CA-C-O 120.823 0.344 . . . . 73.41 110.88 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 170.8 -158.94 30.89 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.698 -0.763 . . . . 71.14 112.456 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.2 m -131.78 135.32 46.69 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.877 0.37 . . . . 61.34 110.931 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 22.2 p -129.65 150.31 51.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 71.5 111.127 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 48.3 t80 -122.4 136.63 54.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.159 -0.473 . . . . 72.44 110.897 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 6.3 m -89.25 122.1 32.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.116 -0.493 . . . . 65.43 111.102 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.402 HG23 ' HB2' ' A' ' 93' ' ' ASP . 69.7 mt -91.03 109.55 21.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 60.22 111.137 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.4 mt-30 -108.61 163.55 16.73 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.6 0.715 . . . . 75.25 110.945 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.473 ' HG3' HG23 ' A' ' 123' ' ' VAL . 54.2 Cg_exo -45.86 105.15 0.07 OUTLIER 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.636 2.224 . . . . 74.32 112.374 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 118.65 1.11 15.43 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.726 -0.75 . . . . 52.33 112.491 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.402 ' HB2' HG23 ' A' ' 89' ' ' ILE . 15.2 m-20 -105.09 144.2 32.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.908 0.385 . . . . 64.23 110.851 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -135.07 158.78 43.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 72.41 111.166 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.602 ' CE1' HD21 ' A' ' 121' ' ' LEU . 1.6 m-85 -50.9 -47.92 60.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 72.45 110.858 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -72.97 -47.68 43.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.159 -0.473 . . . . 73.55 110.918 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -55.6 -26.56 44.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 53.03 111.114 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 21.1 mt -90.91 -38.78 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 65.12 111.158 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 104' ' ' THR . . . -61.53 -40.4 94.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 72.24 111.086 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -56.38 -44.69 80.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 74.44 110.896 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 24.0 mmm180 -75.52 -49.38 18.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.451 . . . . 65.21 110.837 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 21.5 mmm180 -56.98 -24.39 52.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 75.14 110.852 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.19 23.64 37.01 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 50.02 112.478 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.993 HG21 HD11 ' A' ' 109' ' ' ILE . 6.6 t -114.76 -171.66 1.97 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.867 0.365 . . . . 74.4 111.149 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.15 149.13 43.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.217 -0.447 . . . . 72.43 111.111 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 83.4 t -55.5 -46.91 79.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 62.13 111.12 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -51.85 -30.69 24.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 74.42 110.826 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 72.7 t -80.08 -54.09 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 72.32 111.154 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.993 HD11 HG21 ' A' ' 104' ' ' THR . 41.3 mm -52.57 -42.51 40.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.166 -0.47 . . . . 74.23 111.187 179.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -74.83 -25.48 59.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.108 -0.496 . . . . 73.25 110.894 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 13.0 t -79.23 -22.95 44.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.225 -0.443 . . . . 53.34 110.88 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 11.9 mt -96.5 -45.54 6.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 73.14 110.919 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.72 67.86 5.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.608 0.718 . . . . 72.11 110.924 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -7.36 20.84 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.656 2.237 . . . . 75.13 112.35 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -50.1 -39.48 34.29 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.778 -0.725 . . . . 53.22 112.46 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.667 ' HB ' HD23 ' A' ' 121' ' ' LEU . 0.5 OUTLIER -121.76 163.02 20.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.844 0.354 . . . . 74.11 111.14 -179.953 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 33.0 m-20 -102.99 161.21 23.8 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.615 0.722 . . . . 73.15 110.877 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.67 26.68 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.685 2.256 . . . . 73.34 112.319 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -117.44 -18.83 9.72 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.25 -0.432 . . . . 70.35 111.124 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -122.04 90.0 3.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.244 -0.434 . . . . 63.43 110.891 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.667 HD23 ' HB ' ' A' ' 116' ' ' VAL . 73.0 mt -119.39 160.38 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 71.15 110.92 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -105.49 148.55 27.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 72.33 110.919 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.473 HG23 ' HG3' ' A' ' 91' ' ' PRO . 10.2 p -61.7 139.45 20.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 74.12 111.186 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.78 62.49 5.54 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 63.12 112.503 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -119.28 121.9 40.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.83 0.348 . . . . 73.44 110.916 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 11.3 p -86.45 134.68 26.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 74.05 111.144 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 1.3 pp -129.45 172.76 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 72.43 111.08 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -100.33 142.95 31.11 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 63.02 110.9 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -136.09 156.2 77.11 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.594 0.711 . . . . 74.24 111.126 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 110.11 2.48 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.679 2.253 . . . . 71.31 112.363 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 98.9 m . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 64.5 110.905 179.992 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 2.5 mmt . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.838 0.352 . . . . 65.04 110.865 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -107.95 -160.64 20.73 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.761 -0.733 . . . . 61.42 112.497 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 71.2 m -138.65 136.0 35.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.885 0.374 . . . . 62.54 110.869 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 44.8 p -124.96 150.26 46.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.146 -0.479 . . . . 72.32 111.153 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.503 ' CE2' HD13 ' A' ' 98' ' ' ILE . 42.1 t80 -122.48 136.68 54.94 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.212 -0.449 . . . . 74.11 110.932 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 m -91.41 120.19 32.05 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 74.54 111.109 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 45.4 mt -90.85 109.59 21.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.211 -0.45 . . . . 64.35 111.132 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 22.9 mm-40 -97.29 159.45 31.22 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.612 0.72 . . . . 63.44 110.893 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -58.81 93.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.698 2.265 . . . . 75.13 112.358 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 142.48 -17.46 2.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.761 -0.733 . . . . 61.3 112.514 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -84.92 167.26 16.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.913 0.387 . . . . 51.23 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.2 151.77 45.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.192 -0.458 . . . . 73.13 111.154 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . 0.521 ' CZ ' HG23 ' A' ' 116' ' ' VAL . 1.3 m-85 -51.03 -47.38 61.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.251 -0.431 . . . . 75.23 110.885 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -71.6 -47.16 56.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 73.13 110.895 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -57.73 -23.88 54.16 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 72.54 111.068 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.503 HD13 ' CE2' ' A' ' 87' ' ' TYR . 35.2 mt -95.46 -31.99 4.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.22 -0.445 . . . . 74.22 111.129 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.603 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -72.18 -29.5 64.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 72.12 111.123 179.793 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 1.5 pp0? -65.7 -44.46 86.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 75.24 110.929 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.5 -13.73 53.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 70.4 110.908 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 18.2 mmt180 -93.03 16.56 12.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 74.33 110.922 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.63 28.1 21.12 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.714 -0.755 . . . . 52.02 112.494 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 1.018 HG21 HD11 ' A' ' 109' ' ' ILE . 11.8 t -129.0 -179.96 5.41 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.842 0.353 . . . . 73.02 111.152 -179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -123.28 159.77 28.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 54.45 111.152 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.68 HG12 HE21 ' A' ' 110' ' ' GLN . 52.6 t -55.07 -42.38 64.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.247 -0.433 . . . . 72.04 111.106 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 23.2 t0 -51.85 -38.09 54.57 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.461 . . . . 65.13 110.828 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.448 HG12 HD12 ' A' ' 112' ' ' LEU . 21.5 t -77.2 -54.19 13.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 53.22 111.132 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 1.018 HD11 HG21 ' A' ' 104' ' ' THR . 50.2 mm -51.42 -39.95 23.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 41.01 111.108 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.68 HE21 HG12 ' A' ' 106' ' ' VAL . 2.8 pt20 -77.98 -25.56 48.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 72.12 110.9 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 3.1 m -76.92 -24.05 52.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 53.01 110.888 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.448 HD12 HG12 ' A' ' 108' ' ' VAL . 7.3 mt -95.18 -45.3 7.25 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 74.21 110.921 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -118.06 67.57 6.42 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.742 . . . . 60.23 110.906 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -6.96 19.86 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.693 2.262 . . . . 75.15 112.379 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -49.63 -39.9 31.56 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 62.0 112.484 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.622 HG11 HE22 ' A' ' 125' ' ' GLN . 2.1 m -118.95 160.83 18.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.827 0.346 . . . . 42.55 111.142 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -99.63 160.56 27.07 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.622 0.725 . . . . 62.32 110.888 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -22.78 31.61 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.749 2.3 . . . . 75.22 112.312 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.4 24.33 11.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 64.54 111.094 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 14.5 ptm180 -177.33 111.56 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.237 -0.438 . . . . 73.32 110.873 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 86.1 mt -127.66 -179.59 5.01 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.176 -0.466 . . . . 63.43 110.926 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -124.16 147.56 47.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 74.02 110.928 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 14.6 p -62.85 139.99 20.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.232 -0.44 . . . . 63.45 111.167 179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.67 65.14 3.37 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.734 -0.746 . . . . 44.24 112.475 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . 0.622 HE22 HG11 ' A' ' 116' ' ' VAL . 8.8 tt0 -113.69 127.72 56.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.787 0.327 . . . . 73.15 110.933 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 17.6 t -91.51 122.77 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 75.32 111.09 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.1 pt -127.84 175.84 8.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 72.42 111.089 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 51.0 m-20 -110.87 143.36 41.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 74.32 110.919 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.93 156.23 79.38 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.631 0.729 . . . . 32.1 111.121 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 110.77 2.64 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.696 2.264 . . . . 51.25 112.334 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 73.31 110.884 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 18.9 ttt . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.816 0.341 . . . . 73.45 110.873 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -136.79 -167.66 11.2 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.772 -0.728 . . . . 52.01 112.507 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 26.0 m -139.29 134.96 33.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.858 0.361 . . . . 63.51 110.879 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 60.7 p -124.85 167.72 14.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 73.53 111.128 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.5 ' CE2' HD13 ' A' ' 98' ' ' ILE . 41.8 t80 -139.49 136.38 34.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 63.11 110.877 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.482 HG23 HG22 ' A' ' 126' ' ' VAL . 2.1 m -90.89 121.18 32.52 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.119 -0.491 . . . . 71.44 111.128 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.453 HD11 HG12 ' A' ' 127' ' ' ILE . 64.4 mt -91.04 109.29 20.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 73.34 111.09 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -110.39 162.86 18.82 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.577 0.703 . . . . 63.23 110.911 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_exo -45.89 118.77 2.47 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.711 2.274 . . . . 73.12 112.35 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 108.32 -23.83 23.96 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.797 -0.716 . . . . 54.22 112.529 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -86.67 121.98 29.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.868 0.366 . . . . 75.44 110.877 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.87 156.16 19.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 74.35 111.134 -179.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -51.61 -45.25 63.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.252 -0.431 . . . . 73.1 110.863 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.8 t-105 -70.46 -51.4 29.48 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 73.12 110.9 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -54.63 -31.86 58.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.242 -0.435 . . . . 61.22 111.133 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.5 HD13 ' CE2' ' A' ' 87' ' ' TYR . 34.5 mt -84.04 -35.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.194 -0.457 . . . . 53.3 111.126 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.453 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -63.15 -48.32 78.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 74.14 111.133 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -52.99 -44.93 67.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 75.43 110.91 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 6.8 ptp85 -78.62 -18.05 55.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 70.34 110.898 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -94.11 19.74 8.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.189 -0.459 . . . . 71.14 110.923 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.78 28.12 22.32 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.735 -0.745 . . . . 73.0 112.478 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.888 HG21 HD11 ' A' ' 109' ' ' ILE . 14.5 t -134.45 174.72 10.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.844 0.354 . . . . 63.14 111.167 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.58 164.62 15.05 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 75.03 111.172 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.713 HG12 HE21 ' A' ' 110' ' ' GLN . 22.6 t -57.41 -41.44 78.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.02 111.166 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 14.0 m-20 -51.82 -34.42 40.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 73.43 110.862 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.79 -51.72 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 62.04 111.079 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.888 HD11 HG21 ' A' ' 104' ' ' THR . 49.0 mm -51.75 -41.71 29.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.236 -0.438 . . . . 64.32 111.135 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.713 HE21 HG12 ' A' ' 106' ' ' VAL . 6.2 pt20 -78.32 -25.53 46.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 71.34 110.928 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 29.0 t -78.69 -20.92 49.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 74.33 110.874 -179.785 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 21.0 mt -98.29 -45.49 6.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.13 -0.486 . . . . 53.4 110.896 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -118.45 67.91 7.4 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.635 0.731 . . . . 75.14 110.9 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -8.53 23.83 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.717 2.278 . . . . 74.41 112.302 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -59.77 -26.33 62.58 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.757 -0.735 . . . . 21.21 112.454 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.691 HG12 HD23 ' A' ' 121' ' ' LEU . 1.5 t -121.4 92.53 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.788 0.327 . . . . 71.54 111.151 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -51.8 159.13 1.42 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.617 0.723 . . . . 72.21 110.856 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -29.98 22.92 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.666 2.244 . . . . 65.42 112.326 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -95.13 31.99 1.8 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 52.51 111.059 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 179.88 93.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 75.53 110.865 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.691 HD23 HG12 ' A' ' 116' ' ' VAL . 45.5 mt -116.2 144.58 44.0 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 74.12 110.911 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -98.59 153.31 18.76 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 43.52 110.92 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.9 p -74.71 144.06 12.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.271 -0.422 . . . . 74.02 111.121 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.51 59.02 8.92 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.739 . . . . 51.32 112.443 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -119.26 122.64 42.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.834 0.349 . . . . 64.31 110.915 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.482 HG22 HG23 ' A' ' 88' ' ' THR . 33.6 t -88.52 127.05 41.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 73.21 111.127 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.453 HG12 HD11 ' A' ' 89' ' ' ILE . 3.2 pt -123.54 175.91 5.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.172 -0.467 . . . . 72.12 111.15 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 6.0 m-20 -94.55 145.46 24.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.186 -0.461 . . . . 51.23 110.91 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.94 156.1 78.71 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.638 0.732 . . . . 63.13 111.108 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 110.64 2.61 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.733 2.288 . . . . 72.13 112.314 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 46.6 m . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.24 -0.436 . . . . 64.15 110.869 179.993 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 11.7 mmm . . . . . 0 N--CA 1.458 -0.066 0 CA-C-O 120.789 0.328 . . . . 62.24 110.88 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 104.09 161.23 24.56 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.702 -0.761 . . . . 63.1 112.479 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 3.9 m -136.42 166.54 23.25 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.888 0.375 . . . . 71.3 110.871 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 48.4 p -123.55 154.67 38.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.19 -0.459 . . . . 53.31 111.148 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.524 ' HB2' HG21 ' A' ' 129' ' ' VAL . 38.6 t80 -133.5 134.99 44.15 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 75.34 110.926 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -89.6 125.98 35.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 63.23 111.175 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 65.8 mt -90.9 109.38 20.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.237 -0.438 . . . . 51.12 111.157 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 49.5 mm-40 -110.92 161.94 22.81 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.623 0.725 . . . . 74.44 110.89 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -45.98 121.45 4.34 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.721 2.281 . . . . 61.32 112.328 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 107.46 -19.19 34.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.732 -0.747 . . . . 72.41 112.418 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -95.79 121.03 37.08 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.844 0.354 . . . . 74.14 110.845 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -108.0 165.33 11.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.208 -0.451 . . . . 65.53 111.123 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -53.98 -60.8 2.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 73.01 110.866 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 6.5 t-105 -56.57 -52.47 64.67 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.152 -0.477 . . . . 74.4 110.906 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.42 -62.42 1.63 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.211 -0.449 . . . . 73.41 111.13 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . . . . . . . . . 34.3 mt -51.5 -38.15 20.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 71.44 111.138 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.446 ' HB2' HG13 ' A' ' 109' ' ' ILE . . . -64.28 -37.19 86.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 54.11 111.115 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -51.91 -72.11 0.06 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.23 -0.441 . . . . 72.25 110.928 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 10.0 ptt-85 -55.87 -40.47 72.98 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 72.42 110.858 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.8 mmp_? -57.9 -24.04 55.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.171 -0.468 . . . . 73.34 110.885 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 88.94 17.14 56.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 54.31 112.473 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.843 HG21 HD11 ' A' ' 109' ' ' ILE . 12.4 t -120.99 178.87 4.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.839 0.352 . . . . 73.32 111.15 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -119.82 162.93 18.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 64.34 111.181 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 23.9 t -56.68 -40.32 69.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.24 -0.436 . . . . 71.01 111.155 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -51.76 -36.24 46.61 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 52.34 110.836 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.59 HG12 HD12 ' A' ' 112' ' ' LEU . 25.7 t -81.96 -50.77 15.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.2 -0.454 . . . . 63.51 111.141 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.843 HD11 HG21 ' A' ' 104' ' ' THR . 47.7 mm -51.95 -41.12 30.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 74.42 111.149 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -79.14 -25.39 42.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 55.34 110.93 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 6.2 t -79.44 -20.14 48.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 75.43 110.872 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.59 HD12 HG12 ' A' ' 108' ' ' VAL . 8.5 mt -98.38 -45.72 6.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.126 -0.488 . . . . 50.34 110.927 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.95 68.05 6.41 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.563 0.697 . . . . 73.23 110.891 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -8.54 23.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.69 2.26 . . . . 73.52 112.346 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -63.41 -23.89 67.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.757 . . . . 61.4 112.518 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.542 HG12 ' CD2' ' A' ' 121' ' ' LEU . 2.2 t -122.45 104.74 15.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.809 0.338 . . . . 60.54 111.11 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -75.09 154.68 86.53 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.61 0.719 . . . . 55.42 110.909 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -13.76 35.14 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.678 2.252 . . . . 75.15 112.338 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -71.29 -18.9 62.39 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 65.33 111.092 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -170.61 115.23 0.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.253 -0.43 . . . . 74.51 110.887 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.542 ' CD2' HG12 ' A' ' 116' ' ' VAL . 55.4 mt -108.2 153.45 23.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 61.01 110.882 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 53.8 mm-40 -97.84 148.78 23.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 65.51 110.942 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.9 145.03 11.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.45 . . . . 71.42 111.156 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.33 58.13 10.42 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 72.13 112.479 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -119.33 120.69 37.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.818 0.342 . . . . 72.45 110.877 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . . . . . . . . . 6.4 p -85.06 130.88 35.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 43.51 111.183 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.2 pt -131.06 175.85 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 64.35 111.162 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 39.3 m-20 -89.94 145.62 24.99 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.463 . . . . 73.42 110.842 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.524 HG21 ' HB2' ' A' ' 87' ' ' TYR . 3.3 m -147.67 156.15 45.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.627 0.727 . . . . 54.35 111.094 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.71 109.27 2.26 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.649 2.233 . . . . 75.21 112.309 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 61.54 110.895 179.955 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 12.0 mtm . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.778 0.323 . . . . 71.31 110.921 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 63.61 -162.74 33.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.718 -0.753 . . . . 64.53 112.478 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 2.4 m -125.27 142.12 51.69 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.919 0.39 . . . . 52.14 110.903 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 71.9 p -123.67 151.47 43.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.234 -0.439 . . . . 74.32 111.11 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 38.6 t80 -138.25 136.52 36.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.215 -0.448 . . . . 72.32 110.927 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.739 HG23 HG22 ' A' ' 126' ' ' VAL . 1.4 m -92.65 126.44 37.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 50.14 111.166 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.89 109.44 21.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 64.43 111.121 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.0 mm-40 -110.36 162.06 22.06 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.642 0.734 . . . . 73.03 110.906 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -45.93 118.39 2.31 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 73.41 112.355 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.62 -18.88 29.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.73 -0.748 . . . . 74.44 112.51 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.506 ' CB ' HD11 ' A' ' 98' ' ' ILE . 1.5 m-20 -96.87 115.68 27.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 73.13 110.865 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.92 159.78 15.06 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.189 -0.46 . . . . 73.51 111.122 -179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -53.66 -55.03 29.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 65.12 110.859 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' TRP . . . . . . . . . . . . . 7.2 t-105 -57.96 -56.21 24.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.137 -0.483 . . . . 73.52 110.875 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -51.36 -60.6 2.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.26 -0.427 . . . . 61.52 111.103 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ILE . . . . . 0.506 HD11 ' CB ' ' A' ' 93' ' ' ASP . 33.0 mt -51.62 -37.86 20.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 73.55 111.137 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.429 ' HB1' HG23 ' A' ' 104' ' ' THR . . . -65.7 -37.46 86.5 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.176 -0.465 . . . . 43.03 111.126 179.798 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -51.81 -65.15 0.61 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.191 -0.459 . . . . 75.33 110.915 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.2 mtt180 -63.32 -41.27 98.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 72.24 110.945 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ARG . . . . . . . . . . . . . 9.6 mmp_? -55.87 -25.7 43.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 73.24 110.816 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 90.76 17.41 51.99 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.78 -0.724 . . . . 60.12 112.494 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.967 HG21 HD11 ' A' ' 109' ' ' ILE . 11.5 t -119.37 179.9 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.856 0.36 . . . . 74.42 111.148 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.18 157.77 28.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 63.04 111.153 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.711 HG12 HE21 ' A' ' 110' ' ' GLN . 26.3 t -55.48 -42.83 69.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 64.31 111.131 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -51.84 -36.31 47.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.87 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 21.8 t -78.83 -53.6 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 61.03 111.127 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ILE . . . . . 0.967 HD11 HG21 ' A' ' 104' ' ' THR . 44.8 mm -51.66 -40.58 26.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 73.55 111.173 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.711 HE21 HG12 ' A' ' 106' ' ' VAL . 2.8 pt20 -77.75 -25.42 49.17 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 65.44 110.931 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 2.5 t -80.38 -20.35 44.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 73.14 110.835 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.1 mt -98.35 -45.53 6.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 71.44 110.872 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.96 68.17 6.48 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.641 0.734 . . . . 73.14 110.883 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -8.5 23.77 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.694 2.263 . . . . 70.54 112.33 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' GLY . . . . . . . . . . . . . . . -60.04 -22.92 58.73 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.793 -0.718 . . . . 63.11 112.461 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.517 HG12 HD23 ' A' ' 121' ' ' LEU . 2.1 t -121.89 107.91 20.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.86 0.362 . . . . 61.01 111.096 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.55 155.0 81.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.636 0.732 . . . . 43.32 110.876 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.79 -16.72 37.55 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.707 2.272 . . . . 72.13 112.313 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -68.65 -19.44 64.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.261 -0.427 . . . . 41.33 111.13 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ARG . . . . . . . . . . . . . 16.3 ptt180 -173.48 116.63 0.26 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 52.24 110.899 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.517 HD23 HG12 ' A' ' 116' ' ' VAL . 61.7 mt -103.46 154.6 19.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 60.24 110.91 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 -97.77 143.12 28.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 55.42 110.957 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.51 145.42 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 50.2 111.133 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 51.28 59.1 8.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 72.32 112.495 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -119.3 121.57 39.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.803 0.335 . . . . 73.44 110.909 -179.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' VAL . . . . . 0.739 HG22 HG23 ' A' ' 88' ' ' THR . 22.4 t -85.27 127.11 40.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 71.13 111.141 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 10.0 pt -123.5 174.32 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 61.0 111.132 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -96.89 144.28 26.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.156 -0.475 . . . . 72.41 110.937 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.25 156.19 79.75 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.641 0.734 . . . . 73.11 111.108 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 85.47 0.62 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.658 2.239 . . . . 42.11 112.377 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' CYS . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.147 -0.479 . . . . 65.15 110.924 -179.981 . . . . . . . . 0 0 . 1 stop_ save_